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Abstract
Chemokines display a wide range of diverse functions and MIP-1 a is no 
exception. It is not only a potent inflammatory molecule but also an inhibitor of 
primitive haemopoietic cell proliferation. The studies described in this thesis 
focus on the activity of MIP-1 a on keratinocyte proliferation. These 
experiments have shown that a pure form of MIP-1 a, derived from COS 7 
cells by transient transfection, inhibits the proliferation of clonogenic human 
epidermal keratinocytes in vitro. This activity is fully reversible by specific anti- 
MIP-1a polyclonal antibodies. Despite this, the pure bacterial recombinant 
preparation of MIP-1 a is largely inactive. In order to investigate this 
discrepancy, studies analysing the difference between these two MIP-1 a 
preparations have been carried out. These studies suggest that the activation 
of the keratinocyte inhibitory function of MIP-1 a results through a subtle 
structural modification which may involve the truncation of the amino-terminal 
amino acids. The potential role of MIP-1 a in epithelial tissues in vivo is also 
discussed.
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Statistical Analyses.
Paired t-tests have been used to test the difference between two sets of 
variables. The test has assessed the null hypothesis stating that the 
difference between the variables is zero. The significance levels have been 
quoted as p values, and were obtained using Microsoft Excel® for Windows 
95. The error bars quoted in all the result figures give an estimate of the 
standard error of the mean of all the results obtained for that experiment.
Corrections.
The figures summarise the results of at least three experiments. MIP-1 a  
concentrations were estimated using silver staining and Western blotting, and 
compared with known quantities of bacterial MIP-1 a  obtained from R&D 
systems. Since our results have suggested that the difference in the 
potencies of wildtype bactenal and COS 7 MIP-1 a  is at least several hundred 
fold, we anticipate that any potential minor inaccuracies in MIP-1 a  
concentration estimation would be unable to mask the inhibitory potential of 
the active species.
1. Introduction
Tissues which undergo constant regeneration have developed a complex and carefully 
controlled system of replication and differentiation. The maintenance and regulation of these 
tissues is ultimately controlled at the level of the stem-cell. Stem cells are the most primitive 
cells in these populations and comprise only a small subpopulation of the tissue. Stem cells 
have been described as cells capable of extensive self-maintenance, being able to maintain 
their proliferative self-renewal potential for at least one natural life-span of the organism 
(Lajtha 1979). A stem cell also has the potential to produce differentiated progeny which are 
called progenitor cells. These cells have a limited mitotic capacity, which is why they are also 
sometimes termed transit amplifying cells. These progenitor cells can also differentiate into 
mature, fully functional, terminally differentiated cells.
All continually renewing tissues by definition contain stem cells and are responsible for 
maintaining the steady-state tissue population. However not all mammalian tissues require 
this maintenance since the rate of proliferation of the cells of a particular tissue depends 
largely on the rate of turnover of the cells in that tissue. Leblond (1964) classified adult 
tissues as falling into three main types. Tissues with static cell populations and no cell 
division such as muscle and the nervous system; tissues such as liver with little cell division 
normally, but with the potential, when required, to self renew; and tissues such as the 
haemopoietic system and stratified squamous epithelia which are normally characterised by 
rapid and continuous cell turnover. Here terminally differentiated cells are being continually 
lost and replaced by an intricate and highly regulated proliferative process.
1.1. Haematopoiesis.
Most early studies of stem cells involved the haemopoietic system. The haemopoietic system 
is a complex cellular system consisting of 8 to 10 mature cell types and an overlying 
hierarchy of more immature cells which maintain the required cellularity of the system 
through proliferation, commitment and differentiation. All eight mature blood cell types 
ultimately derive from a single pluripotent stem cell which differentiates through committed 
lineage-restricted progenitors to phenotypically and functionally distinct mature cell types. 
These mature cells have a limited life-span and therefore haemopoiesis is required 
constantly even under normal physiological conditions. This process is regulated with
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precision, since circulating levels of mature cells are maintained within narrow limits of
i
f
■ variation. However cell production can be altered rapidly in response to increased or
decreased demand (Metcalf 1984).
Adult mammalian haemopoiesis occurs primarily in the bone marrow and has classically 
been viewed as being pyramidal in shape (Graham and Wright 1997) with three overlapping 
compartments comprising probably around 0.1% stem cells, approximately 3% progenitor 
cells, the remaining cells being differentiating end cells (Metcalf 1984). These terminally 
differentiated cells have remarkably diverse functions ranging from specific host defence by 
B and T lymphocytes to oxygen distribution by erythrocytes.
1.1.1. Stem cells
Historically the most conclusive evidence for the existence of stem cells first came from 
experiments in which grafting of haemopoietic tissue from normal mice into recipient mice, 
previously irradiated with lethal doses of radiotherapy, completely re-populated the recipient’s 
bone marrow. Ford et al (1956) were the first to show that transfused bone marrow cells 
would rescue mice whose haematopoietic system was completely ablated by X-ray 
irradiation. This led to the development of a clonogenic stem cell assay by Till and McCulloch 
(1961), who showed that bone marrow grafting following myeloablative doses of radiotherapy 
produced splenic nodules containing cells of both myeloid and erythroid lineage, each nodule 
apparently being the offspring of a single bone marrow cell. Moreover cells from these 
splenic colonies, when pooled and injected into a second lethally irradiated mouse, were 
capable of both generating further splenic colonies and successfully rescuing the mouse from 
bone marrow failure. They termed the cells in these nodules spleen colony forming units or 
CFU-S. Other studies were able to show that these spleen colonies were clonal (Wu 1967). 
When bone marrow with a radiation induced chromosomal abnormality was transplanted, the 
chromosomal marker was present in all the CFU-S cells. This suggested that the CFU-S 
represented a marker for mouse pluripotential haematopoietic stem cells (PHSC). The 
individual CFU-S cells appeared to have extensive proliferative capacity as demonstrated by 
the fact that the macroscopic spleen colonies frequently contained more than a million cells 
(Siminovitch 1963). The CFU-S cell therefore appeared to be a good candidate for the 
PHSC.
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It is however now well recognised that the CFU-S assay does not recognise one 
homogeneous cell type, but a heterogeneous population with respect to proliferation and 
differentiation capacity, self-renewal ability, and cell-cycle status depending on when the 
CFU-S assay is scored (Magli et al 1982). The first CFU-S colonies to appear arise on the 
spleen surface usually at days 7-8 post-transplantation and consist mainly cells of one 
haemopoietic lineage (usually erythroid), with little self-renewal potential. These colonies are 
destined to disappear within three days (Magli 1982). At day 12 post-transplant however new 
colonies become evident as the day 7 colonies start to regress. Studies of these CFU-S 
colonies involving serial transplantation have shown that these day 12 colonies have a much 
higher self renewal potential than day 7 CFU-S (Baines 1983). Other studies have shown that 
the day 7 CFU-S are very sensitive to cycle-specific cytotoxic drugs, whereas the day 12 
CFU-S cells are relatively refractory suggesting that the day 7 CFU-S cells are largely 
proliferative while the day 12 CFU-S are mainly quiescent (Hodgson 1979).
Although the origin of the day 12 CFU-S is still a matter of debate, it is clear that the CFU-S 
assay recognises a heterogeneous stem cell population. These findings led investigators to 
suggest that the stem cell compartment is organised in a hierarchical structure, with young 
stem cells that have undergone a limited number of divisions having extensive self-renewal 
capacity but a limited tendency to differentiate; while on the other hand older stem cells, that 
is cells that have undergone a relatively large number of cell-divisions, have a limited self­
renewal capacity and a greater tendency to differentiate. This hypothesis is termed the 
‘Generation Age Hypothesis’ (Rosendaal 1979).
The CFU-S, in particular day 12 CFU-S, exhibits many of the characteristics of the PHSC 
with extensive self-renewal potential, extensive proliferative potential and the ability to 
generate multiple haemopoietic lineages. Moreover most approaches that enrich for PHSC 
also enrich for day 12 CFU-S, usually to a much greater degree than other assayable 
haemopoietic progenitors (Visser 1984; Spangrude 1988). However it is now clear that the 
CFU-S is not the earliest pluripotential haematopoietic stem cell. There is in fact little 
evidence to suggest that the CFU-S are functional progenitors of the lymphoid system, 
although clonal erythroid, granulocytic, monocytic and megakaryocytic cells are found in a 
CFU-S colony (Abramson 1977). It is also clear that the frequency of PHSC in mouse bone 
marrow is considerably less than the frequency of the day 12 CFU-S cells (Jones 1987).
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There is also little correlation between the ability of bone marrow to bring about the long term 
repopulation of irradiated mice and its CFU-S content (Jones 1989). In serial bone marrow 
transplantation experiments, which are used to study the self renewal capacity of 
haematopoietic progenitors, there is little correlation between CFU-S content and long-term 
marrow repopulating ability. In serially transplanted marrow grafts that could not produce 
donor engraftment, CFU-S numbers, although reduced, were at levels that should have been 
sufficient to produce full haematopoietic reconstitution. Furthermore on the serial transplants 
that did not give donor marrow reconstitution there was an initial engraftment at 10-14 days 
post-transplant which disappeared by days 17-21. It appears that serial bone marrow 
transplantation dissociates two waves of engraftment after BMT. There is an initial but 
unsustained wave of haemopoiesis and a later sustained wave which results in long-term 
reconstitution. The CFU-S (both day 7 and day 12) appears to be responsible for the early 
unsustained engraftment while the PHSC or pre-CFU-S is responsible for the later sustained 
engraftment. The CFU-S is therefore now considered to be a primitive myeloid stem cell, 
while the more primitive pre-CFU-S cell, with both myeloid and lymphoid potential is the 
more primitive stem cell that gives rise to the CFU-S compartment (Hodgson 1979). The pre- 
CFU-S compartment can now be distinguished from day 12 CFU-S on the basis of 
rhodamine-123 dye retention (Ploemacher 1989). Marrow fractions displaying high 
rhodamine fluorescence have been shown to be day-12 CFU-S enriched while the rhodamine 
dull fraction are pre-CFU-S enriched. This was confirmed by Spangrude and Johnson (1990) 
who were also able to demonstrate that only the rhodamine dull cells were able to transfer 
long term haematopoietic reconstitution to mice upon serial BMT. Direct evidence for the role 
of the CFU-S in early transient engraftment and for the pre-CFU-S cell was derived from 
studies using counterflow centrifugal elutriation (CCE) by Jones and his colleagues in 1990. 
CCE is a procedure that sorts cells on the basis of size and density using a constant 
centrifuge rotor speed, marrow cells being selected out by changing the rate of medium flow. 
The fraction containing the largest cells was mainly enriched for CFU-GM 
(granulocyte/monocyte colony forming unit) and both day 7 and day 12 CFU-S. The 
intermediate fraction was enriched for both day 7 and day 12 CFU-S but depleted of CFU- 
GM, while the fraction containing the smallest cells contained cells that were mainly 
morphologically identified as lymphocytes and depleted of CFU-S. In order to study the
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nature of each CCE fraction male marrow cells were elutriated and then each fraction was 
transplanted into female syngeneic mice. The origin of the transplanted cells was then 
determined by southern blotting with a Y-chromosome specific probe. The large cell fraction 
was found to give rise only to early transient engraftment despite the presence of large 
numbers of CFU-S and CFU-GM. Therefore this large cell fraction is relatively depleted of 
PHSC although it is enriched for committed progenitors. The transplantation of the small cell 
fraction did not rescue mice from lethal aplasia. However when female lethally irradiated mice 
were transplanted with a female large cell fraction and a male small cell fraction, the mice 
survived. These mice had an early wave of transient engrafters derived from the female large 
cell fraction. However at two months following transplantation all the mice had male 
multilineage haemopoietic cells. Therefore the small cell fraction which was virtually depleted 
of CFU-S and committed progentors and could not rescue mice from lethal aplasia contained 
the PHSC. The CFU-S cell therefore gives rise to the transiently engrafting cells but does not 
bring about long-term bone marrow repopulation which arises from the pre-CFU-S. In long­
term bone marrow cultures the pre-CFU-S is also the cell that results in the long-term 
maintenance of the system. Therefore the pre-CFU-S is also termed the long-term 
repopulating cell or LTRC.
The CFU-S assay is therefore a useful measure of transiently engrafting stem cells, although 
it does not give an accurate quantitative measurement of the most primitive stem cell 
numbers. However it remains useful as a stem cell assay, although it is a difficult assay to 
perform and requires the use of large numbers of mice. In view of this a number of in vitro 
assays have been established and are usually preferred. As with the CFU-S assay, these 
assays also measure a heterogeneous cell population. These in-vitro assay systems include 
the cobblestone area forming cell assay (CAFC) (Ploemacher 1989), the CFU-A 
assay (Pragnell 1988; Lorimore et al 1990), the primitive haematopoietic colony forming cell 
with high proliferative potential assay (HPP-CFC) (Bradley and Hodgson 1979), blast cell 
colony forming assay (Suda 1983) and long term bone marrow cultures (Dexter 1977). These 
assays are largely dependent on the culture of bone marrow derived cells in the presence of 
the necessary growth factors, and are scored as a measure of the colony forming ability of 
these cells. These in-vitro assays have now been extensively used to investigate the stem 
cells more primitive to the CFU-S.
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Since the pre-CFU-S stem cells have been shown to be resistant to the‘ cycle-specific 
cytotoxic effects of 5-fluorouracil (5-FU) they are likely to be slow cycling cells (Lerner et al 
1990). These cells however do enter the cell-cycle some days after 5-FU treatment at which 
time they are sensitive to this drug’s cytotoxicity. Under normal conditions therefore only a 
small proportion of these long-term repopulating stem cells appear to be in active cell cycle at 
any one time, the remaining stem cells being in the quiescent or G0 phase of the cell cycle 
(Burgess and Nicola 1983). However large numbers of mature cells are required to maintain 
normal haemopoiesis, which has a turnover of hundreds of billions of cells per day in an adult 
human including 200 billion erythrocytes and 70 billion neutrophils. This is possible because 
the progenitor daughter cell that results from the division of the stem cell, can through its 
proliferative capacity, result in quite extensive amplification. For example 5-6 divisions during 
the transit of these progenitors results in a 32-64 fold amplification, while as little as 10 
divisions results in a 1024 fold amplification. Therefore the long-term repopulating cells or 
pre-CFU-S can under steady-state conditions be largely out of cycle. However it appears 
that under conditions of insult or stress to the system, for example by cytotoxic 
chemotherapy, these quiescent cells can be triggered into the cell cycle. This leads to ‘more 
mature’ actively cycling stem cells that can then replenish the system through their self­
renewal and differentiation into progenitor cells that can proliferate extensively and through 
the process of differentiation result in mature terminally differentiated cells. Once the system 
is restored to its normal state, these cells appear to return to the quiescent phase (Becker et 
al 1965). This suggests that the stem cell and the progenitor cell are under both positive and 
negative proliferative regulation. Elucidating these control mechanisms is important for our 
understanding of normal stem cell regulation and may lead to an appreciation of the 
involvement of these factors in proliferative disease (Graham and Pragnell, 1991b). This will 
be discussed in the following sections.
1.1.2. Progenitor cells.
Stem cells must maintain their numbers through the lifespan of the individual while also 
generating cells that can undergo proliferation and differentiation. To maintain a constant 
pool of stem cells, one of two alternative processes might occur. First, for every stem cell that 
divides to yield two daughter stem cells by what is described as symmetric division, another
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stem cell divides to yield two more differentiated, non-stem cells or progenitor cells whose 
purpose will be to populate the precursor pool. Alternatively, each stem cell division may 
actually be an asymmetric division. In this scenario one daughter cell from a stem cell 
division would leave the stem cell pool to become a committed progenitor, while the other 
daughter cell immediately returns to G0 and replaces the parent stem cell in the stem cell 
pool. Progenitor cells differ from stem cells in that they have an altered proliferation and 
differentiation program, with a lower self-renewal capacity and a greater tendency to 
differentiate. These cells are recognised by their ability to form colonies containing one or 
more blood cell types in in vitro assays which usually are made up of semi-solid tissue culture 
medium containing agar or methylcellulose and the appropriate growth factors. Originally, 
cells from blood forming tissues were cultured with "feeder layers" containing other cell types 
such as normal embryo fibroblasts (Sachs 1992). These were chosen as possible 
candidates for the cells which can produce the regulatory molecules required for blood cell 
formation. This work eventually led to the discovery of clonogenic cells capable of giving rise 
to colonies containing macrophages, granulocytes or both in various stages of differentiation. 
Colony assays, similar in principle to this, have now been developed for many of the other 
identified haemopoietic lineages (Metcalf 1984). The mature cell types present in the 
colonies formed in each of these assay systems have been used to name each of the 
corresponding progenitor cell types from which they were derived. For example, cells giving 
rise to colonies containing granulocytes and macrophages are called CFU-GM or colony 
forming unit granulocyte-macrophage. Cells that give rise to red cells have been termed 
erythroid colony forming units or CFU-E, while the cells that give rise to megakaryocytes are 
termed the megakaryocyte colony-forming units or CFU-MK. These assays have led to the 
discovery and then the cloning of soluble factors which may be required for the proliferation, 
differentiation and survival of these progenitor cells under in vitro conditions.
1.1.3. Mature Terminally Differentiated Cells.
Following several divisions and lineage commitment decisions, a multilineage progenitor cell 
gives rise to several progeny, each of which is committed to a single lineage. These cells are 
the terminally differentiated progeny of the stem and progenitor cells and exhibit a 
remarkable range of functions ranging from non specific and specific host defence by white
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blood cells, the control of haemostasis by platelets and the carriage of oxygen around the 
body by red blood cells. More than 8 major cell types are currently recognised. The 
functions of each of these cell types will not be discussed in detail in this text unless relevant.
1.2. The Regulation of Haemopoiesis.
Haemopoiesis therefore involves a highly complex series of cellular events in which a small 
population of stem cells continually generates large populations of maturing cells in a 
number of different lineages. Under normal conditions, this process, which involves diverse 
proliferative and differentiate events, appears to be precisely regulated. From the 
complexity of this process one would predict that the regulatory mechanisms involved in 
haemopoiesis are probably intricate and diverse. It is therefore not surprising that a large 
number of both positive and negative regulatory molecules have been identified and 
characterised. These include a number of the interleukins (IL-), erythropoietin, the 
haematopoietic colony stimulating factors (CSFs), stem cell factor (also known as kit ligand), 
thrombopoietin, transforming growth factor-p (TGF-p) and MIP-1a as well as various other 
cytokines such as the interferons and TNF-a .
1.2.1. Regulation of Haemopoiesis: The Stroma.
The bone marrow stroma is also thought to play a major role in the maintenance and 
regulation of haemopoiesis. Evidence obtained primarily from in vitro long term bone marrow 
cultures have shown that the primitive haematopoietic cells in this system are tightly bound to 
stromal cells while more differentiated cells are found as non-adherent cells (Coulombel et al 
1983). Further studies suggest that a similar relationship occurs in vivo (Funk et al 1994). 
Stromal cells are thought to provide niches for the stem cells and can secrete some of the 
factors described below that can direct stem cell proliferation and differentiation (Muller- 
Sieburg and Deryugina 1995). Also while long-term bone marrow cultures are usually unable 
to maintain the long-term repopulating cell, recent studies have shown that rare stromal cells 
are able to maintain these cells (Wineman et al 1996). The mechanism by which this is 
carried out is not as yet clear but may involve an extracellular matrix or adhesion molecule, or 
a novel cytokine (Verfaillie et al 1993).
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1.2.2. Regulation of Haemopoiesis: Growth Factors.
Growth factors are involved in the regulation of haemopoietic cell proliferation, differentiation 
and apoptosis.
1.2.2.1. Proliferation.
A considerable number of growth factors have now been characterised. Some of these 
cytokines are lineage specific and support the proliferation and the maturation of committed 
progenitors. This will be discussed in greater detail below. Examples include erythropoietin 
and thrombopoietin which are physiological regulators of erythropoiesis and 
megakaryocytopoiesis respectively, and M-CSF which is thought to be relatively specific to 
the macrophage/monocyte lineage.
However the larger proportion of these molecules are not lineage specific and can support 
the proliferation of multilineage progenitors. For example GM-CSF stimulates the proliferation 
of multipotential progenitors (Metcalf et al 1980). GM-CSF shares the same beta subunit as 
the IL-3 receptor which partly explains their overlapping functions (Kitamura et al 1991). IL-3 
can, like GM-CSF, stimulate the formation of multilineage colonies which can contain 
granulocytes, macrophages, eosinophils, mast cells, erythroid cells or megakaryocytes. The 
actions of IL-3 by itself appear to be retricted mainly to multipotential progenitors since 
studies have shown that as haematopoietic progenitors differentiate, they generally lose their 
responsiveness to this cytokine (Koike et al 1986).
A number of growth factors are able to synergize with IL-3 to increase the colony numbers 
in in vitro assays. These include IL-6 (Ikebuchi et al 1987), G-CSF (Ikebuchi et al 1988), IL- 
11 (Musashi et al 1991), stem cell factor or c-kit ligand (Tsuji et al 1991) and the ligand for 
FLT-3/FLK-2 (Hudak et al 1995). These molecules synergise with IL-3 to increase the 
proliferation of these primitive cells. It has been suggested that these factors may be 
functioning by inducing the long-term repopulating cell/stem cell into cycle (Ogawa 1993), 
however this remains difficult to prove.
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1.2.2.2. Differentiation.
It remains unclear what overall physiological role these growth factors play in the regulation 
of haemopoiesis in vivo, in vitro data suggests that they may be involved in determining 
differentiation along certain lineages e.g. granulocyte colony stimulating factor (G-CSF) in the 
differentiation of neutrophils; erythropoietin (EPO) in the production of erythrocytes; 
thrombopoietin in the generation of platelets and macrophage colony stimulating factor 
(M-CSF) for the monocyte/macrophage lineage.
However there is also evidence to suggest that in the presence of the proper permissive 
growth factors, the choice that a multipotent progenitor makes in determining which lineages 
to select upon cell division is random (Ogawa M. 1993). For example in the presence of 
granulocyte-macrophage colony stimulating factor (GM-CSF), which supports the 
differentiation along granulocytic, monocytic, eosinophilic, erythroid and megakaryocytic 
lineages, primitive haemopoietic cells commit to lineage restriction in an apparently random 
or stochastic manner (Nakahata T. et al 1982). Daughter cells arising from the single division 
of a primitive haemopoietic cell were separated by micromanipulation and then each cell was 
permitted to divide and differentiate to form secondary blast cell colonies. In a large 
proportion of the separated pairs the cells arising from each doublet daughter cell were totally 
different, with no apparent pattern connecting the two lineage compositions. Therefore at 
least within the confines of this culture system, while the presence or absence of specific 
haematopoietic growth factors appears to be important as permissive or perhaps ‘happiness 
factors’, individual cellular decisions to proceed down one or other of the permissible lineages 
seem to be stochastic or random events.
1.2.2.3. Apoptosis.
In the studies just described the growth factor appeared to be necessary in vitro as a 
permissive or ‘happiness factor’ which allows the multilineage primitive cell to commit to one 
or more lineages. There is in fact now evidence to suggest that the role of these molecules 
may be the suppression of apoptosis (Williams 1990). These cells would otherwise die by 
programmed cell death when removed from the bone marrow and the stem cell micro­
environment. Further evidence for this role comes from work on the interleukin-3 dependent 
haematopoietic multipotent cell line FDCP-Mix (Fairbairn et al 1993). FDCP-Mix cells are
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dependent on IL-3 for their continued survival and self-renewal, and upon withdrawal of this 
factor die by apoptosis. However when these cells are stably transfected with the bcl-2 gene, 
which has been shown to inhibit the apoptotic death of several factor-dependent cell lines, 
they are able to survive in the absence of IL-3 both in the serum-containing and in serum- 
deprived conditions. This survival is accompanied by multilineage differentiation in the 
absence of growth factors suggesting that the presence of a growth factor is not obligatory 
for the differentiation of stem cells although they may influence the lineage choice of 
multipotent cells. Furthermore these bcl-2 transfected FDCP-mix cells were seen to be able 
to differentiate without proliferating in single-cell experiments. This data suggests that the 
lineage commitment of the haemopoietic stem cell may be intrinsically determined by the 
cell’s genetic program and not depend on haematopoietic growth factors. The primary roles 
of some growth factors in vivo may therefore be to suppress apoptosis.
1.2.2.4 The in Vivo Evidence: Growth Factor Knockout Mice.
On the other hand however, studies involving genetically manipulated mice deficient in one or 
more growth factors suggest that the presence of these factors may still be important for the 
normal differentiation process in vivo. In fact G-CSF knockout mice have a severe 
neutropenia which Is reversible on treatment with the growth factor (Lieschke 1994a). 
However these mice still have low levels of mature neutrophils suggesting that either other 
growth factors are able to partially compensate for the loss of G-CSF, or that no growth 
factors are required for basal levels of neutrophil differentiation. To investigate this, studies 
involving transgenic mice in which two or more growth factors are knocked out have been 
pursued. Mice deficient in both GM-CSF and M-CSF have been reported. These mice have 
defects common to the GM-CSF (Stanley et al 1994) and M-CSF knockout mice, with defects 
in osteoclast and macrophage formation (as seen with the op/op M-CSF knockout mouse) 
(Yoshida 1990) and alveolar proteinosis lung pathology (as seen in the GM-CSF knockout 
mouse) (Lieschke et al 1994b). Mice lacking both G-CSF and GM-CSF have also been 
generated. These mice have a greater degree of neutropenia than mice lacking G-CSF 
alone, suggesting that the additional loss of GM-CSF in G-CSF animals further impairs 
steady-state granulopoiesis (Seymour et al 1997).
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Further evidence for the importance of haemopoietic growth factors in vivo c'ome from the 
Steel (SI) and white spotting (W) anaemic mice, which are now known to be deficient in stem 
cell factor (SCF) and c-kit, its receptor respectively (Huang et al 1990). These mice have 
similar phenotypic abnormalities including severe anaemia and a decreased activity of 
primitive haemopoietic stem cells (Matsui et al 1990). Also mice which are deficient in the 
thrombopoietin receptor c-mpl have very low platelet and megakaryocyte counts with the 
other lineages being normal, demonstrating the functional importance of this molecule in 
platelet production (Gurney 1994). These results indicate that these growth factors are 
important in the normal production of physiological levels of mature blood cells.
1.2.2.5 Functional Redundancy?
It is becoming increasingly apparent as new regulatory factors are identified that there is a 
substantial degree of overlap in the in-vitro activity of a number of these molecules, much 
more than would appear necessary. This suggests that these molecules exhibit a high 
degree of functional redundancy (Metcalf D. 1993). For example the development of 
granulocyte colonies can be stimulated by what appears to be the direct activity of G-CSF, 
GM-CSF, IL-3, SCF or IL-6. Likewise at least seven or eight factors can stimulate or 
potentiate the formation of megakaryocyte colonies of one type or another and a similar 
picture is seen for eosinophils and mast cells. As has already been described it has been 
shown that a number of these molecules with broadly similar activities eg IL-3, GM-CSF, IL-5 
share common receptor subunits. However these molecules also have discrete functions. 
This does tend to suggest true redundancy, however it does not exclude different signalling 
pathways for each regulator which may reveal important differences in the function of these 
molecules.
1.2.3. Regulation of Haemopoiesis: Inhibitors.
A number of negative regulators have been identified and proposed to be physiological 
regulators of haemopoiesis. These include y-interferon, the inhibitory tetrapeptide 
AcSDKP(acetyl-N-Serine-aspartate-lysine-proline), the inhibitory pentapeptide pEEDCK 
(pGlutamate-Glutamate-Aspartate-Cysteine-Lysine), Transforming growth factor-p and the 
chemokine Macrophage inflammatory protein-1 a (MIP-1a). These inhibitory factors will be
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discussed in turn in the following sections. However although these molecules can inhibit 
haemopoiesis in vitro and in vivo, the physiological requirement for negative regulators of 
haemopoietic stem/progenitor cells remains a matter for debate. It has been suggested that 
to maintain haemopoietic homeostasis the stem cell can be regulated by either positive or 
negative control and may not require both. Therefore up or down regulation of positive 
factors is argued to be able to give adequate bi-directional control. This would appear to 
eliminate the need for negative growth regulators. It has however been shown that antisense 
TGF-p sequence significantly increases the rate of proliferation of haematopoietic precursors 
(Hatzfeld et al 1991), as can antibodies to TGF-p in an in vitro stem cell assay, the long 
term bone marrow culture or LTBMC (Eaves et al 1991). This suggests that this molecule is 
actively involved, at least in this system, in keeping the primitive progenitors in a quiescent 
state. Also, antibodies to the tetrapeptide haemopoietic inhibitor AcSDKP, have been shown 
to result in a modest but significant increase in the cycling of haemopoietic progenitors in vivo 
(Frindel 1989). These observations suggest that these molecules may play some role in 
haemopoiesis.
It has also been postulated that during the regenerative phase after cytotoxic chemotherapy, 
when most stem cells are actively in cycle presumably in response to secreted growth factors 
(Harrison and Lerner 1991), these rapidly proliferating primitive cells can quickly be brought 
to quiescence. It has been suggested that an inhibitory molecule or molecules may be 
actively involved in this process since if this control was exerted by the downregulation of 
positive growth factors there would be a longer delay before the return to the steady-state 
proliferation rate. However a number of studies have shown that these cells can rapidly 
(within minutes) alter the function/expression of their receptors and this could control stem 
cell proliferation in the absence of a stem cell-inhibitor. The maintenance of the G0 /quiescent 
state by stem cell inhibitors may on the other hand be critical in the absence of the necessary 
"happiness" growth factors, since stem cells have been shown to undergo apoptosis in these 
conditions unless kept in G0. There is therefore both direct and indirect evidence for the role 
of these negative regulators in the physiological control of primitive haemopoietic cell 
proliferation.
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1.2.3.1. Tetrapeptide Inhibitor AcSDKP.
The tetrapeptide AcSDKP was first identified as a low molecular weight inhibitory activity from 
foetal calf bone marrow in 1977 (Frindel and Guigon). This inhibitory activity was able to 
inhibit the entry of murine bone marrow CFU-S into cycle after cytosine arabinoside 
treatment. Moreover this activity was shown to protect mice from the toxicity of high dose 
cycle-specific cytotoxic chemotherapy in the form of cytosine arabinoside The structure of 
the molecule was eventually established from amino-acid sequencing, mass spectroscopy 
and nuclear magnetic resonance (Lenfant et al 1989).
This tetrapeptide is now chemically synthesised and the synthetic molecule’s activity has 
been confirmed both in vitro and in vivo. There is some evidence to suggest that it is able to 
inhibit the entry into DNA synthesis of CFU-S after chemotherapy/radiotherapy, the cell 
cycling of murine CFU-A (Carde et al 1995), and the high proliferative potential colony 
forming cell (HPP-CFC) induced by stimulators (Robinson et al 1993). Further studies on 
long-term bone marrow cultures have shown that tetrapeptide reversibly decreases the 
proportion of high proliferative potential erythroid and granulopoietic progenitors in S-phase 
without decreasing their number (Cashman et al 1994). In vivo studies suggest that AcSDKP 
is able to significantly protect the stem cell pool from the toxicity of single-agent cytosine 
arabinoside chemotherapy (Bogden et al 1998). This molecule is therefore being further 
investigated in clinical trials.
Other studies have shown that tetrapeptide is constitutively produced in mice and that it is 
also synthesised and released by bone marrow cells in long-term bone marrow cultures 
(Grillon et al 1990). This molecule may therefore play a part in maintaining the physiologically 
quiescent state of haemopoietic stem cells.
1.2.3.2. Pentapepide Inhibitor.
The pentapeptide pyroGlu-Glu-Asp-Cys-Lys (pEEDCK) was originally isolated from normal 
human white blood cells as an inhibitor of the in vitro proliferation of murine myeloid 
progenitors (Laerum and Paukovits 1984). This small molecule is now chemically 
synthesised and its inhibitory activity has been shown to be dose dependent. It is a potent 
inhibitor resulting in 50% inhibition of colony forming unit granulocyte/macrophage (CFU-GM) 
colony formation at 10"12 M. Furthermore at high concentrations of this pentapeptide its
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inhibitory effect is no longer seen (Laerum and Paukovits 1984) since its activity follows a 
bell-shaped dose response. This molecule may also function in vivo since it has been shown 
to reduce the numbers of CFU-S and to protect the pre-CFU-S in vivo from the toxicity of 
cytotoxic chemotherapy (Paukovits et al 1993).
The presence of a thiol group in pEEDCK makes it highly oxidation sensitive. Oxidation of the 
cysteine thiol groups leads to the formation of a disulphide bridged homodimer (pEEDCK)2 
which is a powerful stimulator of haemopoiesis in vitro and in vivo (Laerum 1988). This dimer 
appears to be a potent stimulator of progenitor cells and also of LTC-IC in long-term bone 
marrow culture (Paukovits 1995). It is therefore possible that a redox equilibrium exists 
between the inhibitory pEEDCK and the stimulatory dimeric (pEEDCK)2 in the regulation of 
haemopoiesis.
The mechanism of action of this pentapeptide molecule has not yet been defined. 
Interestingly pEEDCK sequences have been identified in the Gjai chain of G proteins near the 
major phosphorylation site (Amatruda et al 1991). The significance of this is uncertain.
1.2.3.3. Tumour necrosis factor-a.
Tumour necrosis factor-a (TNF-a) is a multifunctional cytokine produced mainly by activated 
macrophages, but also by lymphocytes and endothelial cells (Kelker et al 1985; Cuturi et al 
1987). TNF-a displays a broad spectrum of activities. While it was originally shown to induce 
necrosis of tumours (Pennica et al 1984), it has also been shown to have an effect on several 
different cell types (Sugarman et al 1985; Vilcek et al 1986; Nawroth et al 1986). In 
haemopoiesis TNF-a has been shown to act as both a positive and a negative regulator. 
TNF -a either alone or in combination with interferon y has been reported to inhibit in vitro 
haemopoietic colony formation by granulocytic and monocytic (Murase et al 1987), erythroid 
(Roodman et al 1987) and multipotential progenitors (Murphy et al 1988). There has 
however been considerable variability in the results seen in these studies. This may be partly 
explained by the nature of the stimulus used in the various assays (Moore 1991). For 
example studies have shown that TNF-a can easily inhibit clonogenic assays stimulated by 
G-CSF, while colonies stimulated by GM-CSF are much more resistant to inhibition.
In contrast other studies have shown that TNF-a can, paradoxically, increase the proliferative 
response of primitive haematopoietic cells to cytokines such as IL-3 and GM-CSF (Caux et al
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1990) in short term assays (5-10 days). Further studies have however shown that in the 
same assays TNF-a is a reversible inhibitor of subsequent (after 10 days) late IL-3 
dependent granulocytic progenitor proliferation and differentiation (Caux et al 1991), 
supporting on the other hand monocytic progenitor growth.
The mechanisms of action of TNF-a in this bidirectional control are not fully understood but 
may involve a direct effect or an indirect one by regulating the production in other cells of 
haematopoetic growth factors such as G-CSF (Koeffler et al 1987), GM-CSF (Munker et al 
1986) and M-CSF (Oster et al 1987). TNF-a is also able to modulate the expression of a 
number of cell-surface cytokine receptors, including the receptors for GM-CSF (Elbaz et al
1991), M-CSF (Jacobsen et al 1992), G-CSF (Shieh et al 1991) and IL-3 (Elbaz et al 1991). 
This modulation may in part explain some of the divergent results seen with TNF-a in 
haemopoietic assays.
Further work has suggested that TNF-a may suppress haemopoiesis by inducing apoptosis 
(Selleri et al 1995). In fact TNF-a has been shown to upregulate Fas antigen (CD 95) in 
primitive CD 34+ haemopoietic cells (Maciejewski et al 1995). Fas antigen is a member of 
the TNF-a receptor family which when activated by its ligand results in the transduction of a 
signal for programmed cell death (Itoh et al 1991). Fas is not normally expressed in CD34+ 
cells, although it may be expressed in some differentiated haemopoietic cells. Since both 
TNF -a and interferon-y markedly upregulate Fas expression in CD34+ cells, some of the 
inhibitory activities previously described with these molecules may not have been transient 
inhibition of proliferation but cell death by apoptosis.
1.2.3.4. Interferons.
The interferons (IFN) are a heterogeneous family with a broad spectrum of biological 
activities which include antiviral, antiproliferative, immunomodulating, and differentiative 
effects. They have been implicated in the pathogenesis of aplastic anaemia (Zoumbos et al 
1985) which has resulted in considerable investigation into their effects on haematopoiesis. 
The interferons have been subdivided into three main classes: IFNa, IFNp, and IFNy. A 
number of studies have suggested that all the different sub-groups of interferon are able to 
inhibit the proliferation of pluripotent haematopoietic progenitors (Neumann et al 1982; 
Broxmeyer et al 1983; Rigby 1985). Although initial studies were performed with partially
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purified material, further work using bacterial recombinant preparations and specific 
neutralising antibodies has mainly confirmed the initial findings. These studies have 
confirmed that the interferons can indeed inhibit CFU-GM, CFU-GEMM, BFU-E and CFU-E 
as well as CFU-Mk (megakaryocyte) assays (Carlo-stella et al 1991; Ganser et al 1987). On 
the other hand interferon- y has also been shown to be able to potentiate the proliferation of 
immature haematopoietic progenitors (Caux et al 1992; Kawano et al 1991). In the presence 
of IL-3 and to a lesser extent GM-CSF, interferon- y stimulates progenitor proliferation, while 
IFN -a and IFN-p are inhibitory. On the other hand in the presence of G-CSF IFN-y has been 
shown to either suppress progenitor proliferation or have no effect on progenitor proliferation. 
This is not dissimilar to what has been seen with TNF-a and may also be mediated by the 
regulation of the expression of other cytokine receptors. However unlike TNF-a which 
inhibits late granulocytic progenitor development while potentiating monocytic cell generation 
(see above), IFN-y has no such effect.
Interestingly recent studies using stromal cells that were retrovirally transduced to produce 
IFN-y, have shown that in LTBMC the IFN-y secreted by these stromal cells was far more 
potent than exogenously added IFN-y (Selleri et al 1996) in inhibiting secondary colony 
formation. It has been suggested that this incongruity may be explained by the fact that this 
cytokine may require specific matrix molecules for efficient presentation to the target cell 
(Gordon et al 1987; Roberts et al 1988) or may be presented as membrane bound molecules 
(Toksoz et al 1992). The inhibition observed appeared to be mediated partly through cell- 
cycle arrest but also by the induction of apoptosis in a significant proportion of cells. It is now 
clear that IFN-y, like TNF-a, may suppress haematopoiesis by inducing programmed cell 
death in both lineage committed and non-lineage committed CD34+ cells (Selleri et al 1995). 
This may be mediated through the upregulation of Fas antigen (Maciejewski et al 1995). 
IFN-y also induces a transcription factor IFN-regulatory factor-1 (IRF-1) which has been 
shown to regulate the transcription of genes involved in apoptosis (including p53), cell-cycle 
progression, and DNA repair as well as cellular metabolism. Activation of these pathways 
may determine the cellular response to this cytokine, however this is not fully understood.
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1.2.3.5. Transforming growth factor-p (TGF-p).
The TGF-p Superfamily
The TGF-(3 family of cytokines comprises a large number of factors with very diverse 
activities, for which the structural prototype is the protein that was first isolated from human 
platelets as an activity described as TGF-p (Assoain et al 1983). This was cloned from a 
human cDNA library (Derynck et al 1985) and later named TGF-|31 (Cheifetz et al 1987). 
Further work revealed that this molecule was prototypic of a superfamily of growth, 
differentiation and morphogenesis factors including the inhibins, activins, the bone 
morphogenetic proteins, mullerian inhibitory substance as well as TGF-|32 and TGF-03 
(reviewed by Massague 1990; Sporn and Roberts 1992). Members of this family are related 
by sequence homology, the most conserved feature being the presence and position of nine 
cysteine residues in the mature carboxy terminus. The distribution of TGF-p related factors is 
widespread in organisms ranging from the fruitfly to humans and their evolutionary 
conservation is unusually strict which suggests that these molecules must play a fundamental 
role in the normal physiology of these species.
a) The TGF-p Subfamily: TGF-p Structure and Activation.
The main TGF-p subfamily consists of at least five members all of which have extensive 
sequence homology: TGF-pl, TGF-p2, TGF-p3, TGF-p4 and TGF-f55. TGF-pi is the 
structural prototype and is a 25kDa disulphide-linked homodimer comprising two identical 
chains of 112 amino-acids. Each chain is synthesised as the C-terminal domain of a 390 
amino-acid precursor that has all the characteristics of a secretory polypeptide, having an 
amino-terminal signal sequence which is necessary for transport out of the endoplasmic 
reticulum, a pro-region and the C-terminal bioactive domain (Gentry et al 1988; Wakefield et 
al 1988). This inactive 105kDa complex can be cleaved to generate the active cytokine and 
the pro-region, an 80kDa fragment which is also known as the latency associated peptide or 
LAP. Further studies have shown that association of the mature TGF-p molecule with the 
pro-region LAP can inactivate this factor (Gentry et al 1988), and that LAP is a potent 
inhibitor of TGF-p1, 2 and 3 both in vivo and in vitro (Bottinger et al 1996). Activation can be 
mediated in vitro by exposure to extreme pHs (<4 or >9), or exposure to other chaotropic 
agents such as sodium dodecyl sulphate (Lyons et al 1988) as well as the proteases
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cathepsin D and plasmin. In vivo activation may involve plasmin. The evidence for this comes 
from human apolipoprotein (a) gene transgenic mice, a species that normally lacks 
apolipoprotein (a). The activation of TGF-p is inhibited in these mice. This probably results 
via the inhibition of plasmin generation from plasminogen by apolipoprotein (a), which 
suggests that plasmin is an important activator of TGF-p in vivo (Grainger et al 1994). 
Furthermore it has been shown that TGF-p can downregulate the expression of plasminogen 
activator, while upregulating the expression of plasminogen activator inhibitor (Laiho et al 
1986a and b), which suggests that this cytokine can control its own activation. Other work 
has revealed that thrombospondin, an extracellular matrix molecule is found complexed with 
TGF-p in the a-granules of platelets (Schultz-Cherry et al 1993). Thrombospondin is able to 
activate TGF-p by forming specific complexes with TGF-p latency associated peptide in a 
reaction that does not require plasmin. Furthermore thrombospondin is also able to 
upregulate TGF-p expression. However the in vivo significance of this remains uncertain 
(Schultz-Cherry et al 1994a and 1994b).
b) TGF-p- A Multifunctional Cytokine.
The TGF-ps are multifunctional with a broad spectrum of diverse functions including both 
positive and negative effects on a number of different developmental and mature cell 
systems. Many other cytokines have been shown to have a wide range of very different 
activities (Sporn and Roberts 1988), however few have been implicated in as many different 
cellular processes as TGF-p (Sporn and Roberts 1992).
TGF-p has been shown to induce angiogenesis (Roberts et al 1986), chondrogenesis 
(Seyedin et al 1985) and osteogenesis (Seyedin et al 1987). TGF-p has also been shown to 
regulate cellular differentiation and proliferation in a number of different cell types, either 
positively or negatively - depending on the cell-type and growth conditions involved. This 
molecule is also thought to be involved in wound repair and fibrosis and can regulate the 
synthesis and degradation of extracellular matrix components (Reviewed by Noble et al
1992).
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c) TGF-p and Haemopoiesis.
TGF-p is constitutively expressed in both the bone marrow and the peripheral blood 
(Cluitmans et al 1995) and is known to be expressed by a number of haematopoietic cell 
types including platelets from which TGF-p1 was first identified (Assoian et al 1983), 
activated macrophages (Assoain et al 1987), B-lymphocytes (Kehrl et al 1986a) and T 
lymphocytes (Kehrl et al 1986b). TGF-p has a strong claim to be an important player in the 
physiologic regulation of early haemopoiesis. It has also been shown to have a central role as 
an immunological mediator. In fact TGF-p has been shown to be not only a potent neutrophil 
chemoattractant (Reibman et al 1990), but also a powerful anti-inflammatory cytokine. In vitro 
it is able to prevent macrophages carrying out the respiratory burst (Tsunawaki et al 1988), 
inhibit B-cell and T-cell proliferation, inhibit T-cell and natural killer cell immune function, 
inhibit B-cell immunoglobulin (IgG and IgM) synthesis, control the generation of a number of 
cytokines as well as regulate the expression of a number of cytokine receptors (Keller et al 
1990; Ranges et al 1987; Rook et al 1986).
In vivo evidence for the role of TGF-p as an anti-inflammatory molecule was derived from 
transgenic mice that had both the alleles for the TGF-p1 gene knocked out (Shull et al 1992; 
Kulkarni et al 1993). These mice have no obvious phenotype at birth but develop a wasting 
syndrome in the first few weeks of life secondary to a widespread and severe multifocal 
autoimmune reaction. This can be interpreted to indicate that there is considerable 
redundancy in the expression of the various forms of TGF-p and that TGF-pi is not essential 
for normal development, only becoming crucial later on in life. However this is not the case 
since further studies have shown that the absence of a phenotype is actually related to the 
transfer across the placenta to the foetus of maternal TGF-p1 (Letterio et al 1994). In fact 
these mice develop a number of histological abnormalities after the first week of life as their 
levels of maternal TGF-pi fall. Furthermore TGF-pi null mice bred from a TGF-pi null 
female have severe cardiac defects and die perinatally, implicating TGF-pi in cardiac 
development. The TGF-pi null mice born to heterozygous females on the other hand 
develop normally to term. These results have confirmed that TGF-p1 is a main player in the 
regulation of the immune response. These knockout mice experience a severe, multifocal, 
mixed inflammatory cell infiltration associated with tissue necrosis in most organs including
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the lungs, heart, liver, and gastrointestinal tract. This leads to organ failure and death. These 
mice appear to have a severe autoimmune disorder and may be a useful model for the study 
of auto-immune disease. However not all TGF-p null mice develop this syndrome, and it 
appears that this phenotype is mouse-strain specific.
TGF-p is also well recognised as a regulator of the proliferation of a number of cell types. 
Since TGF-p has also been shown to induce apoptosis (Jacobsen et al 1995), as with TNF-a 
and the interferons it may be difficult to distinguish between inhibition of proliferation and 
apoptosis when interpreting TGF-p inhibition data. However it is generally thought that TGF- 
p is a potent inhibitor of the proliferation of primitive multipotent haemopoietic progenitors. In 
fact the in vivo administration of TGF-p1 or TGF-p2 can protect mice from otherwise lethal 
doses of myelotoxic chemotherapy (Grzegorzewski et al 1994). In vitro TGF-p has also been 
shown to directly and reversibly inhibit the growth factor driven proliferation of most primitive 
haematopoietic progenitors (Keller et al 1990; Sitnicka et al 1996). Sing et al (1988) showed 
that TGF-pi and TGF-p2 were both able to inhibit colony formation, in the presence of either 
GM-CSF or IL-3, by erythroid (BFU-E), multipotential (CFU-GEMM) and granulocyte- 
macrophage (CFU-GM) by 90-100% at concentrations of 400pM. TGF-p has also been 
detected in long-term bone marrow cultures, where it can inhibit the cycling of primitive 
progenitors (Cashman et al 1990). Interestingly it has also been shown that the addition of 
anti-TGF-p antibody or LAP to long-term bone marrow cultures results in the activation from 
quiescence into cycle and an increased proliferation rate of the primitive haemopoietic cells in 
this system suggesting that TGF-p must be involved in the regulation of proliferation of these 
cells in this culture system and also indicates that TGF-p is an important physiological 
haemopoietic negative regulator (Eaves et al 1991).
Paradoxically TGF-p has also been shown to be able to stimulate the proliferation of more 
mature lineage restricted progenitors (Keller et al 1991) This bidirectional activity has been 
seen with a number of the negative regulators including the inhibitory pentapeptide, TNF-a, 
interferon-y and MIP-1a (see below).
TGF-p has also been implicated in the regulation of differentiation of a variety of 
haematopoietic cells with a similar bi-modal activity. TGF-p has been shown to directly inhibit 
the IL-3 induced expression of the differentiation marker Thy-1 in Thy-1 negative cells,
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suggesting that this molecule may inhibit the differentiation of primitive haematopoietic cells 
(Keller et al 1990). Paradoxically again, TGF-p has been shown to induce the erythroid 
differentiation of burst-forming units-erythroid (BFU-E) cells (Krystal et al 1994). TGF-p has 
also been observed to promote IL-3 dependent basophil differentiation (Sillaber et al 1992), 
while inhibiting eosinophil differentiation in vitro. However the in vivo significance of these 
findings are not clear, since the conditions brought about by in vitro culture are far removed 
from the bone marrow micro-environment. Such results must therefore be interpreted 
cautiously. Furthermore under these in vitro conditions the processes of proliferation and 
differentiation overlap making the interpretation of this type of data difficult.
As has already been noted TGF-p has also been observed to induce apoptosis in a number 
of different cell types, including primitive murine haemopoietic progenitors (Jacobsen et al
1995). TGF-p has been shown to be able to counteract the haemopoietic growth factor 
induced survival of single cell cultures of primitive murine haemopoietic (Lin- Sca+) 
progenitors by inducing apoptosis. These primitive haemopoietic progenitors show an 
absolute requirement for cytokines (such as IL-3 or SCF) to survive in vitro since no 
colonies are derived when the addition of cytokines is delayed for 40 hours. In the presence 
of the relevant cytokine and TGF-p these cells apoptose. Furthermore antibodies to TGF-p 
enhance the survival of these Lin- Sca+ progenitors by neutralising endogenous TGF-p, both 
in the presence and in the absence of haemopoietic growth factors (Jacobsen et al 1995). 
Other studies have shown that TGF-p can also induce apoptosis in more differentiated 
haemopoietic cells including eosinophils (Alam et al 1994) and B-cells (Chaouchi et al 1995) 
as well as in primary hepatocytes (Sanchez et al 1996), and in a number of different cell 
lines. These results suggest that at least part of the inhibitory effects seen by this molecule in 
the past may have been related to programmed cell death. However a number of studies 
have convincingly demonstrated reversible inhibition with TGF-p in primitive haemopoietic 
progenitors (Sitnicka et al 1996). Overall therefore these results suggest that the reversibility 
of TGF-p inhibition may partly depend upon the presence or absence of other signals and 
the cell phenotype.
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1.2.3.6. MIP-1 a and the chemokines.
MIP-1 a is a 69 amino- acid, 8kDa heparin-binding protein that was initially purified and 
characterised from the supernatant of a lipopolysaccharide stimulated macrophage cell line 
RAW 264.7 (Wolpe et al 1987). This protein is now well characterised as a reversible 
inhibitor of primitive haemopoietic cell proliferation (Graham et al 1990), and has been shown 
to be a member of a large and rapidly expanding family of chemotact\c cytokines known as 
the chemokines to which the next section is dedicated.
1.3 The Chemokines.
The MIP-la family of proteins which is also known as the chemokines now has more than 30 
distinct members (Reviewed by Baggiolini et al 1997). Most of these molecules appear to be 
multifunctional, at least in vitro, with very diverse functions described. The first chemokine to 
be purified was platelet factor 4 (PF-4) (Handen and Cohen 1976), and novel molecules are 
still regularly being identified and characterised. Most of these molecules have been identified 
either through the investigation of a biological activity, or through molecular biological 
screening procedures designed to find cDNAs that are highly inducible (Zipfel et al 1989) or 
that encode secreted proteins (Tashiro et al 1993). The members of this family are both 
structurally and to some extent functionally related, possessing limited sequence homology 
and usually four positionally conserved cysteine residues arranged in either of two 
characteristic motifs (Reviewed by Miller and Krangel 1992). The presence or absence of an 
intervening amino-acid between the first two cysteines in these peptides divides the 
chemokine family into two main groups, the CXC and CC groups. Two other chemokine 
groups have also been described including the single-cysteine -C-/lymphotactin class 
(Kelner et al 1994; Dorner et al 1997), and the fractalkine CX3C class, which have 3 amino- 
acids separating the first two cysteines (Bazan et al 1997).
The CXC subfamily chemokines are generally described as neutrophil chemoattractants, 
while the CC subfamily members are generally thought to be monocyte chemoattractants. 
However this is at best a generalisation, since some of these molecules have overlapping 
activities. The genes for the CXC or a chemokines have been mainly mapped to a locus on 
human chromosome 4 (q12-21), while the genes for the C-C or p chemokine family are 
largely located on human chromosome 17 (q11-32). The chemotactic cytokine lymphotactin
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only has three cysteines and has been classified separately into the C* subgroup of 
chemokines of which it is at present the only member (Kelner et al 1994; Dorner et al 1997). 
This molecule chemoattracts lymphocyte subsets but not neutrophils nor monocytes. 
Fractalkine is a CX3C chemokine and is unlike all the other chemokine types. It can exist in 
two forms: either a membrane-anchored or a secreted 95KDa glycoprotein. The soluble 
CX3C chemokine has potent chemoattractant activity for T cells and monocytes. The cell- 
surface-bound protein, which is induced on activated primary endothelial cells, promotes 
strong adhesion of those leukocytes. The structure, biochemical features, tissue distribution 
and chromosomal localization of this CX3C chemokine all indicate that it represents a unique 
class of chemokine that may constitute part of the molecular control of leukocyte traffic at the 
endothelium (Bazan et al 1997).
1.3.1 The CXC chemokines (a-chemokines).
1.3.1.1 Platelet factor 4 (PF-4).
PF4 was the first chemokine to be characterised. It was first recognised as a platelet protein 
with anti-heparin activity (Deutsch et al 1955). The eventual purification of this activity from 
platelet a-granules led to the sequencing of a 7.8kDa 70 amino acid protein (Deuel et al 
1977). Further work revealed that this cytokine is a weak chemoattractant for neutrophils and 
monocytes (Deuel et al 1981) as well as a more potent fibroblast chemoattractant (Senior et 
al 1983). In addition PF4 has been reported to promote the proliferation of fibroblasts as well 
as the synthesis of glycosaminoglycans by chondrocytes (Senior et al 1983). These findings 
suggested not only a possible link between the initiation of thrombosis and the induction of 
inflammation, but also a possible role for this molecule in wound healing. More recent 
investigation has shown that this chemokine is an inhibitor of angiogenesis. It has been 
shown to inhibit angiogenesis in chicken chorioallantoic membranes and to inhibit the 
proliferation of human umbilical endothelial cells (Maione et al 1990). Further work has 
shown that this chemokine can inhibit the proliferation of endothelial cells derived from a 
number of different sources by inhibiting the transition from G1/G0 to S phase, as well as 
inhibiting DNA synthesis of cells already in S phase (Gupta and Singh 1994). These 
experiments however required unusually high concentrations of PF4 for endothelial cell 
growth inhibition (micromolar range as compared to nanomolar concentrations for other
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chemokine activities). However when a potent inhibitor of endothelial cell proliferation was 
purified from media conditioned by activated human peripheral blood leukocytes, the 
inhibitory activity was found to be due to an amino-terminally truncated form of PF-4, 
generated by peptide-bond cleavage between Thr-16 and Ser-17 (Gupta et al 1995). This 
processed form of PF4 inhibits at nanomolar concentrations suggesting that endogenous 
amino-terminal processing of this and perhaps other chemokines plays an important role in 
determining the biological activity and receptor binding of these cytokines.
1.3.1.2 Platelet Basic Protein (PBP).
In the purification of the antiheparin activity from platelet a-granules that led to the 
identification of platelet factor 4, another platelet secretory protein, initially termed p- 
thromboglobulin (p-TG) was recognised. When the complete primary structure of this protein 
was determined (Begg et al 1978), it was found that this molecule showed about 50% 
homology with that of platelet factor 4 as well as sharing the motif of cysteine residues. 
Additional studies identified two other platelet proteins known as Connective Tissue 
Activating Peptide-Ill (CTAP-III) and Low Affinity Platelet Factor 4 (LA-PF4), which on amino- 
terminal sequencing were found to be amino-terminally extended forms of p-thromboglobulin 
(Castor et al 1979; Rucinski et al 1979). Further work confirmed that proteolytic cleavage of 
LA-PF4 can generate p-TG. The precursor of all of these proteins was eventually 
characterised from thrombin-stimulated fresh human platelets (Holt et al 1986) and termed 
Platelet Basic protein (PBP). PBP can generate p-thromboglobulin by proteolytic cleavage 
with trypsin or plasmin. More recently another distinct PBP cleavage product has been 
characterised from LPS stimulated human mononuclear cells. This variant has been termed 
Neutrophil Activating Peptide-2 (NAP-2) since it has a nearly identical amino-terminus and 
similar bioactivity to the previously characterised protein NAP-1 which is now known as 
interleukin-8 (Walz et al 1989). Furthermore monocye conditioned medium has been shown 
to cleave purified CTAP-III into NAP-2 through monocyte derived proteases (Walz and 
Baggiolini 1990). Interestingly NAP-2 can also be generated from platelet derived CTAP-III by 
the proteases chymotrypsin and cathepsin G (Car et al 1991), suggesting that these 
proteases or other similar activities result in the formation of NAP-2 in vivo.
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Platelet Basic Protein(PBP): SSTKGQTKRNLAKGKEESLDSDLYAELRCMCIK..
LA-PF4: RNLAKGKEESLDSDLYAELRCMCIK..
CTAP-III: NLAKGKEESLDSDLYAELRCMCIK...
p-thromboglobulin(p-TG): GKEESLDSDLYAELRCMCIK...
NAP-2: AELRCMCCIK.
Interestingly the main PBP variant found in platelets is CTAP-III, with the parent molecule 
PBP making up approximately 10-30% of the total PBP antigen, p-TG has not been detected 
in unstimulated platelets. It is thought that additional proteolyis may occur following platelet 
activation, perhaps during degranulation. However it is not clear whether this proteolysis of 
PBP is regulated or stochastic. There is however evidence to suggest that the biological 
functions or potencies, or both, of these molecules can be regulated in this manner since 
although the precursor of all these molecules PBP, appears to be totally devoid of activity, its 
cleavage products have been described to have a number of biological functions. NAP-2 is a 
potent chemoattractant and activating factor for neutrophils (Walz et al 1989), while p-TG is a 
fibroblast chemoattractant (Senior et al 1983). Finally both CTAP-III and NAP-2 have been 
shown to be heparin/heparan sulphate degrading enzymes (Hoogewerf et al 1995), and a 
recent report indicates that NAP-2 can also inhibit the formation of growth factor induced 
megakaryocyte colony formation (Gewirtz et al 1995).
1.3.1.3 ylP-10
ylP-10 was the next CXC chemokine identified, as a gene induced by y-interferon (IFN-y) in 
monocytes, fibroblasts and endothelial cells (Luster et al 1985). It was found to display a 
significant homology to PF-4 and p-thromboglobulin, contain the same cysteine motif, and to 
map to human chromosome 4 (q21) near the PF-4 gene (Luster et al 1987). This chemokine 
has been shown to be expressed in IFN-y stimulated keratinocytes, macrophages, fibroblasts 
and endothelial cells (Gattass et al 1994). High levels of ylP-10 are also constitutively 
expressed in lymphoid tissues, including the spleen, thymus and lymph nodes although 
normal unstimulated lymphocytes do not express this chemokine. However ylP-10 is 
expressed constitutively by thymic and splenic stromal cells, as well as activated T cells and 
thymocytes. ylP-10 has been shown to be a chemoattractant for monocytes and T-
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lymphocytes, and to promote T cell adhesion to endothelial cells (Taub et al 1993). It has 
also been shown to have a potent in vivo anti-tumour effect that is T cell dependent (Luster et 
al 1993). Finally it has been reported that this chemokine, like PF-4 and probably by an 
identical mechanism, inhibits endothelial cell proliferation by a specific but non-calcium 
fluxing, cell-surface heparan sulphate binding site (Luster et al 1995).
1.3.1.4 lnterleukin-8 (IL-8).
Interleukin 8 (IL-8), also known as Neutrophil Activating Peptide-1 (NAP-1), was initially 
described as a cDNA clone expressed in activated human lymphocytes that encoded a 
protein with a high level of homology to PF-4 and PBP (Schmid and Weissmann 1987). At 
the same time a monocyte-derived neutrophil activating peptide was purified and found to be 
identical to the protein encoded by this cDNA by a number of independent groups (Schroder 
et al 1987; Walz et al 1987 Yoshimura et al 1987). The cDNA was found to encode a 
polypeptide of 99 amino-acids, including a putative amino-terminal signal sequence. 
Furthermore sequence analysis of mature IL-8 revealed that this chemokine exists in multiple 
forms that differ in truncation at the amino-terminus. Interestingly it has been shown that the 
composition of IL-8 preparations depends on the cell source used to produce it (Van Damme 
1989; Schroder 1990). The most common forms of IL-8 are 72- and 77-amino-acids long 
(Lindley et al 1988; Gimbrone et al 1989), although 79, 71, 70 and 69 amino-acid forms of 
the chemokine have also been described.
Interestingly it has been shown that while endothelial cells secrete primarily the 77 amino- 
acid form, T-cells and monocytes secrete primarily the 72 amino-acid form (Hebert et al 
1990). These investigators also reported that thrombin can convert the 77 amino-acid form 
into the 72 amino-acid form. Furthermore a number of groups have shown that the 72 amino- 
acid protein is at least 10-fold more potent in vitro than the longer form (Hebert et al 1990; 
Nourshargh et al 1992; Clark-Lewis et al 1991), although when tested in vivo however both 
forms are equipotent suggesting that the longer form may be cleaved in vivo by amino- 
peptidases to yield the more active form (Nourshargh et al 1992). It is also interesting to note 
that LPS stimulated monocytes have also been shown to secrete the 70 and 69 amino-acid 
variants of IL-8 (Lindley et al 1988) which have been shown to be about 5-fold more potent 
than the 72 amino-acid form in a number of functional assays (Clark-Lewis et al 1991).
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IL-8 (79aa): EGAVLPRSAKELRCQCIKTYS..........
Natural variants: AVLPRSAKELRCQCIKTYS..........
SAKELRCQCIKTYS..........
AKELRCQCI KTYS..........
KELRCQCIKTYS...........
ELRCQCIKTYS...........
A number of other cell-types have been shown to produce IL-8. Apart from the already 
mentioned monocytes, T-lymphocytes and endothelial cells, other sources of IL-8 include 
fibroblasts (Van Damme et al 1989; Schroder et al 1990), keratinocytes (Larsen et al 1989), 
hepatocytes (Thornton et al 1990), synovial chondrocytes (Brennan et al 1990), articular 
chondrocytes (Lotz et al 1992) and mesothelial cells (Goodman et al 1992). In general it 
would appear that the cells that produce IL-8 are involved in the complex physiological 
responses of inflammation, immunity and wound-healing. Furthermore the signals that induce 
IL-8 secretion are usually pro-inflammatory, and include cytokines like IL-1a, IL-ip and TNF- 
a and bacterial products such as endotoxin. This suggests that IL-8 is a pro-inflammatory 
cytokine involved in the inflammatory cytokine cascade. Indeed IL-8 has been shown to act 
primarily on neutrophils, being a potent neutrophil chemoattractant (Yoshimura et al 1987; 
Lindley et al 1988) as well as a powerful neutrophil activator (Walz et al 1987). IL-8 has been 
shown to induce neutrophil degranulation and the neutrophil respiratory burst, induce a 
transient rise in neutrophil cytosolic free calcium, as well as upregulate neutrophil adhesion 
molecules. It has been reported that this upregulation can trigger adhesion of neutrophils to 
endothelial cells, thereby regulating neutrophil transmigration across blood vessel walls 
(Huber et al 1991). Interestingly in IL-8 transgenic mice (which have raised serum levels of 
IL-8 and increased numbers of neutrophils in the circulation, lungs, liver and spleen) there is 
no evidence of neutrophil extravasation or tissue damage, and neutrophil migration in 
response to IL-8 is severely impaired suggesting that an IL-8 gradient is necessary for its 
chemotactic activity (Simonet et al 1994).
Other research has shown that IL-8, in contrast to PF-4, is a potent angiogenic factor when 
implanted into rat corneas and is capable of stimulating chemotaxis and proliferation of 
human umbilical vein endothelial cells (Koch et al 1992). IL-8 has also been shown to be
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chemotactic for T-lymphocytes (Larsen et al 1989) and fibroblasts (Dunlevy and Couchman
1995) and a recent report has also shown that IL-8 can inhibit the formation of 
megakaryocyte colonies in vitro (Gewirtz et al 1995). Furthermore IL-8 has been shown to 
stimulate keratinocyte proliferation (Sticherling et al 1989), and its presence in psoriatic 
plaques has resulted in this chemokine being implicated in the pathogenesis of psoriasis 
(Gillitzer et al 1991).
The cDNAs for two human IL-8 receptors have been cloned so far: IL-8RA and IL-8RB 
(Holmes et al 1991; Murphy et al 1991). These two molecules are 78% homologous, however 
despite this they have different chemokine binding patterns. This will be discussed further in 
the following sections. However it is interesting to note at this point the knockout mouse 
phenotype obtained when both alleles of the mouse IL-8RA gene were knocked out 
(Cacalano et al 1994). Firstly as one would expect the neutrophils from these mice migrate 
poorly in chemotaxis assays in vitro in response to the IL-8RB chemokine agonists. 
Furthermore these mice show a severely suppressed neutrophil migration response to the 
peritoneal injection of a chemical irritant suggesting that the murine ligand for this putative IL- 
8 receptor is a major physiological determinant of neutrophil-mediated inflammation (Lee et 
al 1995). Surprisingly these knockout mice had a massive expansion of neutrophil and B-cell 
numbers in bone marrow, lymphoid tissue and peripheral blood. It has subsequently been 
shown that when these mice are raised in a germ-free environment, the blood neutrophil 
counts are not raised. This suggests that the defect in neutrophil chemotaxis results in an 
inability to eliminate infection which may result in the release of cytokines that stimulate 
neutrophil generation (Moore et al 1995). Interestingly however these mice do not appear to 
be more susceptible to spontaneous infection.
1.3.1.5 GRO a,p,Y.
There have been three different human gro genes identified, gro-a, gro-p and gro-y. The 
CXC chemokine gro-a was first identified through a subtractive hybridisation approach, as an 
mRNA expressed by a tumorigenic Chinese hamster embryo fibroblast cell line (CHEF) but 
not in a similar non-tumorigenic cell line (Anisowicz et al 1987). The human homolog was 
also characterised and the genes found to encode CXC chemokine proteins. Furthermore 
independent workers purified an autocrine growth factor, which they called Melanoma Growth
29
Stimulatory Activity (MGSA), from the conditioned media of a human melanoma cell line and 
found this to be identical to gro-a (Richmond et al 1988) and to map to the CXC chemokine 
locus on chromosome 4. Further work has shown that gro-a is secreted by endotoxin-treated 
human monocytes and is a neutrophil chemotactic and activating protein (Schroder et al 
1990). Subsequently other cDNAs have been cloned that are highly homologous to gro-a 
and there are now at least three different gro-genes (Tekamp-Olsen et al 1990; lida et al 
1990; Haskill et al 1990). Gro-p is 90% homologous to gro-a and gro-y is 86% homologous. 
These molecules have been shown to be expressed in a number of different cell types 
including fibroblasts, endothelial cells and keratinocytes. MGSA has in fact, like IL-8, been 
purified from the conditioned medium of cultured psoriatic epidermal keratinocytes as a 
neutrophil-activating activity (Schroder et al 1992). MGSA has also been shown to be 
expressed in the epidermis in the differentiated (suprabasal) and non-proliferating 
keratinocyte layers, although the in-vivo significance of this is uncertain (Nanney et al 1995). 
Like the other chemokines however it is clear that these molecules have a number of very 
divergent activities. Apart from being potent inflammatory mediators, they have also been 
shown to be regulators of cell proliferation and more recently regulators of collagen secretion 
by fibroblasts (Unemori et al 1993).
1.3.1.6 The Stromal Derived Factors-1 a and p.
The chemokine SDF-1 was initially cloned as a gene constitutively expressed in bone marrow 
stromal cells (Tashiro et al 1993). Unlike the other CXC chemokines the SDF-1 gene maps 
to a locus on human chromosome 10. Furthermore sequence homologies have shown that 
SDF-1 is related almost equally to both the CC and CXC families. SDF-1 a and SDF-1 p arise 
by differential splicing from a single gene, and differ in four carboxyl-terminal amino-acids 
that are present in SDF-1 p but not in SDF-1 a. SDF-1 has been shown to be a T- lymphocyte 
chemoattractant and is also active on monocytes but not neutrophils. It also stimulates pre-B 
cell proliferation (Nagasawa et al 1994), and knockout mice lacking this chemokine have 
been found to have a severe depletion of B-cell lymphopoiesis as well as a reduction in bone 
marrow myelopoiesis (Nagasawa et al 1996). This suggests that this molecule is critical for 
normal lymphopoiesis and myelopoiesis. SDF-1 has also been shown to be the ligand for the 
chemokine receptor Lestr/fusin which has now been designated CXCR4 (Oberlin et al 1996).
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This receptor has been shown to function as a co-factor for the entry of T-Tropic HIV-1 virus 
into T cell lines. Moreover SDF-1 inhibits HIV-1 entry into these T-cell lines (Bleul et al
1996). SDF-1 has also been recently shown to be a chemotactic factor for CD34+ 
haemopoietic progenitor cells (Aiuti et al 1997).
1.3.1.7 Other CXC chemokines.
A number of other CXC chemokines have been identified from a variety of cell sources. 
These include Granulocyte chemotactic peptide-2 (GCP-2) (Proost et al 1993), MIG which 
was identified as a cDNA induced in monocytes by ylFN (Farber 1990) and ENA-78 (Walz et 
al 1991) which is a 78 amino-acid long, neutrophil activating protein secreted by epithelial 
cells As these molecules are characterised it is becoming increasingly clear that the CXC 
chemokine sub-family comprises a large number of multifunctional proteins, often with 
overlapping functions which suggests a degree of functional redundancy.
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1.3.2 The C-C chemokines (p-chemokines).
The C-C subfamily comprises more than 20 members with different degrees of amino-acid 
sequence homology ranging from 25-70% (Baggiolini et al 1997). This group of chemokines 
maps to human chromosome 17 and includes the monocyte chemoattractant proteins MCP- 
1, MCP-2, MCP-3, MCP-4 as well as the macrophage inflammatory proteins MIP-1 a and 
MIP-1 p, Rantes (Regulated on Activation, Normal T-cell expressed, and secreted), Eotaxin, 
I-309 which is the human homolog of murine TCA-3; HCC-1, HC-14, C10 and the gene fic. 
These chemokines share the typical primary structure of a cleaved signal peptide of between 
20-24 amino-acids and a mature secreted protein which is usually about 70-80 amino-acids 
long, as well as the four positionally conserved cysteines with no intervening amino-acid 
between the first two. Proteins of the C-C subfamily in general do not bind CXC receptors, 
and conversely the CXC chemokines do not bind CC receptors (Reviewed by Miller and 
Krangel 1993).
1.3.2.1 The Macrophage Inflammatory Proteins: MIP-1 a and MIP-1 p.
These chemokines were the first c-c chemokines identified and will be discussed in detail in 
the section 1.3.3.
1.3.2.2 The Monocyte Chemotactic Proteins: MCP-1, MCP-2, MCP-3, MCP-4.
MCP-1 is probably the best characterised CC chemokine. It was first cloned as a Platelet 
Derived Growth Factor (PDGF) induced gene in murine 3T3 fibroblasts and designated JE 
(Rollins et al 1988). Its amino-acid sequence was found to contain the characteristic CC 
family cysteine motif. Further independent work led to the characterisation of two very similar 
proteins with molecular weights of 13 and 15kDa from PHA stimulated human monocytes 
(Yoshimura et al 1989a) and apparently identical proteins from the conditioned media of a 
human glioma cell line (Yoshimura et al 1989b). These proteins were potent monocyte 
chemoattractants and had blocked amino-termini. When these two proteins were sequenced 
they were found to have identical amino-acid primary sequences (Robinson et al 1989) but 
different degrees of O-linked glycosylation; (Jiang et al 1990,1991). Since this protein was a 
potent chemoattractant for monocytes, it was termed Monocyte Chemotactic Protein-1 (MCP- 
1). Natural post-translationally modified variants of MCP-1 have been identified from
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mononuclear cell supernatants, and this protein has been shown to be secreted as not only 
the wildtype molecule but also as amino-terminally truncated and carboxy-terminally 
processed variants with altered bioactivity (Proost et al 1998). MCP-1 has also been shown 
to be expressed in activated fibroblasts (Strieter et al 1989; Yoshimura et al 1990) and 
lymphocytes (Kaczmarek et al 1985), monocytes (Rollins et al 1989), keratinocytes (Barker et 
al 1990), stimulated endothelial cells (Strieter et al 1989) and stimulated vascular smooth 
muscle cells (Valente et al 1988). A wide variety of malignancies and tumour cell lines have 
also been observed to express MCP-1 (Reviewed by Miller and Krangel 1992), but the 
biological relevance of this is as yet undefined.
MCP-1 has been shown to have a wide variety of different immunological functions. Although 
MCP-1 is inactive on neutrophils, it is a potent monocyte chemoattractant. MCP-1 also 
chemoattracts CD4+ and CD8+ T-cells (Carr et al 1994; Loetsher et al 1994; Taub et al 
1995a), basophils (Bischoff et al 1.992), and Natural Killer cells (Maghazachi et al 1994). 
Furthermore MCP-1 is a potent monocyte activator inducing the respiratory burst, an 
increase in cytosolic free calcium and the increased expression of p2 integrins (Reviewed by 
Baggiolini and Dahinden 1994). It is also a potent activator of histamine release in basophils. 
However eosinophils do not respond to MCP-1.
MCP-1 is active at subnanomolar concentrations. Its activities often follow a bimodal dose- 
response with decreasing activity at higher concentrations beyond peak activity. Interestingly 
transgenic mice which constitutively overexpress high levels of MCP-1 protein have been 
shown to have no evidence of monocytic infiltrates or any other inflammatory response 
(Rutledge et al 1995). However these mice are more susceptible to infection by intracellular 
pathogens such as Listeria monocytogenes and Mycobacterium tuberculosis. This suggests 
that high levels of MCP-1 do not result in an inflammatory resonse, perhaps because of 
receptor desensitisation or a loss of the chemoattractant gradient. MCP-1 has however been 
implicated in a number of disease processes as diverse as rheumatoid arthritis, 
atherosclerosis, pulmonary inflammatory diseases, psoriasis and multiple sclerosis (Koch et 
al 1992; Porreca et al 1996; Zhang et al 1994; Gillitzer et al 1993; Ransohoff et al 1993 ).
More recently a number of other C-C chemokines have been cloned that are highly 
homologous to MCP-1 both in sequence (>60% homology) and in activity (Proost et al
1996). These molecules have been designated MCP-2, MCP-3 and MCP-4 (Van Damme et
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al 1992; Uguccioni et al 1996). As these proteins are characterised it is becoming clear that 
there are some differences in cellular specificities between these molecules. All the MCPs 
chemoattract monocytes and lymphocytes, however while MCP-1 is a potent basophil 
activator that does not attract eosinophils, MCP-2 is able to stimulate both basophils and 
eosinophils. Furthermore MCP-3 appears to have the broadest range of activities, acting on 
dendritic cells, natural killer cells, eosinophils and basophils as well as neutrophils (Proost et 
al 1996). MCP-4 appears to share the activites of MCP-3 and Eotaxin, with both of which it 
shares over 60% sequence homology.
1.3.2.3 Eotaxin.
Eotaxin is a C-C chemokine that appears to act primarily on eosinophils. It was initially 
characterised from an established guinea pig model of allergic inflammation as a potent 
eosinophil chemoattractant activity and found to be highly homologous to human MCP-1 
(Jose et al 1994; Kitaura et al 1996). Murine and human homologs have been subsequently 
cloned (Ponath et al 1996a). It has been been shown to be constitutively expressed in a 
number of organs including the lungs, and is rapidly induced on allergen exposure 
(Rothenberg et al 1995a) in these same organs. Eotaxin is rapidly expressed by IFNy 
activated endothelial cells (Rothenburg et al 1995b) and is also expressed by epihelial cells 
(Aguirre et al 1995). It has been shown to rapidly recruit eosinophils to its site of injection in 
vitro (Collins et al 1995). Eotaxin appears to be a highly specific eosinophil chemoattractant 
(Garciazepedia et al 1996) with no activity on monocytes or neutrophils. The eotaxin receptor 
CCR3 cloned from human eosinophils appears to primarily bind Eotaxin and MCP-4, binding 
MCP-3 and Rantes with much weaker affinity (Uguccioni et al 1996; Daugherty et al 1996; 
Ponath et al 1996). Eotaxin appears to be a highly specific chemoattractant for eosinophils 
and may play an important role in a number of eosinophil mediated inflammatory disorders 
such as asthma. The in vivo administation of Eotaxin has been shown to induce pulmonary 
eosinophilia, suggesting that this molecule may in fact be involved in the pathogenesis of 
inflammatory respiratory disorders (Rothenberg et al 1996). More recent work has shown that 
Eotaxin knockout mice that have both alleles of the gene knocked out, have defective early 
eosinophil recruitment after antigen challenge (Rothenberg et al 1997). The late recruitment
34
of eosinophils remains unaltered, however these knockout mice do appear to have altered 
constitutive eosinophil levels.
1.3.2.4 Rantes.
Rantes (regulated on activation normal T-cell expressed and secreted) was originally 
identified as an activated T-cell expressed gene that directs the synthesis of an 8kDa protein 
(Schall et al 1988). Further studies have confirmed Rantes to be a member of the 
chemokine family with considerable sequence homology to MIP-1a. Mapping studies have 
also shown that like the other C-C chemokines the human Rantes gene lies on chromosome 
17q (Donlon et al 1990). Further work has confirmed that like MCP-1, Rantes is a potent 
chemoattractant for monocytes and specific T-lymphocyte subsets, but not neutrophils 
(Schall et al 1990). Rantes is also a potent eosinophil and basophil chemoattractant and 
activator (Kameyoshi et al 1992; Rot et al 1992; Bischoff et al 1993). Furthermore Rantes has 
been shown to be expressed in human eosinophils, which are able to store and release the 
bioactive protein (Ying et al 1996), suggesting that this chemokine may function in an 
autocrine fashion. This C-C chemokine has also been shown to be expressed by a number of 
other cell types including fibroblasts, endothelial cells, astrocytes and renal tubular epithelium 
(Kiene et al 1993; Heeger et al 1992; Sticherling et al 1994; Noe et al 1996) as well as 
platelets (Kameyoshi et al 1992). Rantes is also expressed by activated epidermal and oral 
keratinocytes (Li et al 1996). Moreover dermal fibroblasts have recently been shown to 
release an amino-terminally truncated form of Rantes (Noso et al 1996).
In vivo the intradermal injection of Rantes has been shown to induce eosinophilic and 
monocytic intradermal infiltration, with histological evidence of eosinophilic activation (Meurer 
et al 1993). Rantes also promotes T cell trafficking to the site of chemokine injection 
(Murphy et al 1994) as well as promoting T cell homing to the thymus of SCID mice (Murphy 
et al 1994). These in vivo results suggest that Rantes may be involved in the pathogenesis of 
inflammatory disorders involving these cell types, and this is currently under intensive 
investigation by a number of groups. In fact Rantes has been implicated in diseases such as 
rheumatoid arthritis (Whyte and Binns 1994). Interestingly more recent studies suggest that 
Rantes, as well as MIP-1a and MIP-ip are endogenous HIV suppressive factors (Cocchi et 
al 1995). Furthermore since receptors that bind these C-C chemokines, including the
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receptor CCR-5 have been shown to be involved in the entry of HIV into CD4+ cells, these 
chemokines may be able to prevent HIV entry into these cells by blocking the binding of the 
retrovirus to the receptor (Dragic et al 1996; Cairns and D'Souza 1998).
1.3.2.5. Myeloid Progenitor inhibitory Factors 1 and 2 (MPIF-1, MPIF-2).
Two novel human p-chemokines have been recently characterised as inhibitors of 
haemopoietic primitive cell proliferation (Patel et al 1997). The two polypeptides were 
identified in a cDNA sequencing project and isolated from aortic endothelium and activated 
monocyte libraries respectively. MPIF-1 is a 99 amino-acid polypeptide and is 51% 
homologous to MIP-1a. MPIF-1 appears to be a potent inhibitor of bone marrow low- 
proliferative potential colony forming cells, a committed progenitor that gives rise to 
granulocyte and monocyte lineages. MPIF-1 also appears to be chemotactic for T 
lymphocytes. MPIF-2 is a 93 amino-acid protein showing 42% identity to MIP-1a. It is also 
chemotactic for T lymphocytes and has been described as a potent inhibitor of high 
proliferative potential colony-forming haemopoietic stem cells (HPP-CFC). It is therefore now 
becoming clear that MIP-1a shares its haemopoietic proliferation inhibitory properties with 
other members of the chemokine family.
1.3.2.6. Other CC chemokines.
A number of other C-C chemokines have been described (Baggiolini et al 1997). These have 
not been as well characterised as the cytokines already described and include the 
chemokines TCA-3, MIP-1y, HCC-1, and the genes C10 and fic. The TCA-3 (T-cell activation 
gene-3) gene was first identified by a subtractive hybridisation protocol as a gene that is 
transcriptionally upregulated following T-cell activation (Burd et al 1987). TCA-3 is secreted 
as a 14kDa glycoprotein (Wilson et al 1990). TCA-3 is a monocyte chemoattractant like most 
of the C-C chemokines and the TCA-3 gene is located at the C-C chemokine locus (Wilson 
et al 1990). Interestingly TCA-3 also appears to be chemotactic for neutrophils both in vitro 
and in vivo, a property which is more a feature of C-X-C chemokines (Luo et al 1994). TCA-3 
has also been shown to induce a respiratory burst, granule release, the calcium flux and 
increased adhesiveness to extracellular matrix proteins (Devi et al 1995). Interestingly this 
chemokine also appears to have non-inflammatory activities since it has been shown to
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induce adhesion to fibronectin, chemotaxis and proliferation in primary cultures of mouse 
renal mesangial cells (Luo and Dorf 1996).
MlP-ly was recently cloned from a macrophage cell line Raw 264.7 (Poltorak et al 1995) as a 
cDNA that exhibits significant homology to other C-C chemokines. MIP-1y has also been 
shown to be expressed by a murine Langerhans cell cell line XS 52 and by bone marrow 
dendritic cells (Mohamazadeh et al 1996a and b). Interestingly MIP-1y, which has an 
expected size of 11.3kDa appears to be secreted by XS52 cells as a major 10.5kDa isoform 
and a minor 9kDa variant. This presumably reflects the potential heterogeneity of MIP-1y 
proteins resulting from differential processing as has been observed with other chemokines. 
MIP-1y appears to function through a G-protein coupled receptor and has been shown to 
induce a calcium flux. Furthermore it is chemotactic for T lymphocytes. Although this 
chemokine is not as yet well characterised it is interesting to note that this protein has been 
found to be constitutively expressed in a wide variety of tissues, and circulates in the blood of 
healthy mice at concentrations of approximately 90nM.
HCC-1, like MlP-ly, has only been identified very recently and again although it is not as yet 
fully characterised it too is found in the peripheral blood at high concentrations (1-80nM) 
(Schulz-Knappe et al 1996). It was in fact identified from the haemofiltrate of patients 
undergoing dialysis for chronic renal failure and consists of 74 amino-acids with the 
characteristic four cysteine residues. It is structurally related to MIP-1a with which it is 
approximately 46% homologous. Unlike MIP-1a it has only weak activities on human 
monocytes in that it can induce an intracellular calcium flux and granule release at 100- 
1000nM. However it is not chemotactic for monocytes, and is totally inactive on T 
lymphocytes, neutrophils and eosinophils. Interestingly however HCC-1 has been shown to 
enhance the proliferation of myeloid progenitors with a similar efficacy to MIP-1a but a lower 
potency.
The gene C10 also encodes a C-C chemokine that was identified by the differential screening 
of GM-CSF treated and untreated bone marrow cells (Orlofsky et al 1991). This gene has 
also been mapped to the C-C chemokine locus, however it has a different genomic structure 
from the other C-C chemokines since this gene contains a novel second exon which encodes 
a highly charged 16 amino-acid sequence that is inserted into the amino-terminus of the 
molecule (Berger et al 1996). This cytokine is not yet well characterised.
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In summary it is therefore clear that most if not all of the chemokines play an important role in 
inflammation and the regulation of the immune response. Many of these molecules appear to 
have similar or identical activites which implies a degree of functional redundancy. 
Furthermore like many other cytokines these molecules often have diverse activities. For 
example MIP-1a, which I will now discuss in greater detail, has been shown to not only be 
chemotactic for a variety of inflammatory cells, but to also regulate the proliferation of 
haemopoietic progenitors and clonogenic keratinocytes.
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1.3.3.The Macrophage Inflammatory proteins: MIP-1 a  and MIP-1 p.
The first C-C chemokine to be identified was the human macrophage inflammatory protein 
(MIP). This gene was initially called LD78 (Obaru et al 1986) and was cloned from human 
tonsillar lymphocytes. Shortly after this an 8kDa, acidic heparin-binding protein was purified 
from the conditioned media of a lipopolysaccharide stimulated murine macrophage cell line 
(Wolpe et al 1988). This protein was called Macrophage Inflammatory Protein-1 (MIP-1) 
since it was found to be a potent inflammatory mediator. Further biochemical analysis 
revealed that MIP-1 comprised two proteins, MIP-1a and MIP-1 p. Partial amino-terminal 
sequencing confirmed that MIP-1 a was the murine homolog of LD78.
1.3.3.1 The MIP-1 a gene and its expression.
When the muMIP-1a cDNA was first cloned, after the purification of the murine protein, it was 
found to be 763 base pairs long comprising a short 5’ non-coding region, an open reading 
frame of 276 nucleotides and a long 3’ untranslated region which contains a polyadenylation 
signal and three repeats of an AT rich motif that may be involved in mRNA stability (Caput et 
al 1986; Davatelis et al 1988). Further investigation has shown that the MIP-1 a and MIP-1 p 
genes map to the C-C chemokine locus on human chromosome 17 in the region of q11 to 
q21 (mouse chromosome 11). Moreover MIP-1 a and MIP-1 p have highly homologous 5’ 
flanking regions (over 2 kilobases upstream of the transcription start site). This suggests that 
the expression of these two proteins is co-regulated. In view of this only MIP-1 a expression is 
discussed.
Human MIP-1 a or LD78 has 75% sequence similarity to murine MIP-1 a. There are at least 
two different LD78-like genes in the human genome (Nakao et al 1990). These have been 
termed LD78a and LD78p. They are both transcribed in a number of cell-lines (Nakao et al 
1990). The coding regions of the LD78a and LD78p genes show up to 96% homology. 
However there are two amino-acid changes in the signal peptide sequence as well as three 
amino-acid substitutions in the mature protein. Two of the amino-acid changes in the mature 
protein are conservative serine to glycine changes. However there is a serine to proline 
change in position 2 at the amino-terminal end of the protein that may be of some functional 
significance.
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LD78a
MQVSTAALAVLLCTMALCNQF^SAgLAADTPTACCFSYTSRQIPQNFIADYFETSSQCSKPgVIFLTKRSRQVCADPSEEWVQKYVSDLELSA
LD78P
MQVSTAALAVLLCTMALCNQVLSAPLAADTPTACCFSYTSRQIPQNFIADYFETSSQCSKP£VIFLTKRGRQVCADPSEEWVQKYVSDLELSA
Interestingly Nakao et al (1990) suggested that according to Von Heijne's rule these amino- 
acid changes should both result in similar signal peptide cleavage sites. However Heijne's 
method for predicting signal sequence cleavage sites in fact indicates that while LD78p 
should be cleaved at the expected serine (position 23) to result in the amino-terminus 
APLAADTPT..., the LD78a gene will result in a different signal peptide cleavage site (the 
alanine at position 26), resulting in a -4 amino-terminally truncated protein with the amino- 
terminal sequence of ADTPTA... Interestingly Cocchi et al (1995) have recently purified a -4 
amino-terminally truncated variant of LD78 from the supernatant of CD8+ T lymphocytes. 
They suggest that this is a true LD78 amino-terminus. This therefore indicates that human 
LD78a is probably secreted as a -4 amino-terminally truncated form, while human LD78p is 
secreted in a full-length form (GJ Graham: personal communication). Therefore while murine 
MIP-1 a appears to only be secreted as a full-length 69 amino-acid protein, human MIP-1 a 
(LD78) is probably secreted as both a 69 amino-acid protein (LD78p) and as a 65 amino-acid 
protein (LD78a).
These MIP-1 a genes are single copy genes containing two introns and three exons (Grove 
et al 1990; Oppenheim et al 1991), a gene structure which is generally conserved throughout 
the chemokine family. Furthermore most haemopoietic mature cell types appear to be able to 
express MIP-1 a. Macrophages (Davatelis et al 1988, Wolpe et al 1988), T cells as well as B 
cells (Yamamura et al 1989, Obaru et al 1986, Lipes et al 1988), mast cells (Burd et al 1989), 
eosinophils (Costa et al 1993), neutrophils (Kasama et al 1993) and epidermal Langerhans 
cells (Heufler et al 1992, Matsue et al 1992a, Xu et al 1995) have been shown to express 
MIP-1 a mRNA. Non-haemopoietic cells have also been shown to express MIP-1 a. Primary 
cultures of human fibroblasts (Nakao et al 1990), spermatogonia (Hakovirta et al 1994), 
astrocytes (Kim et al 1995) and a human glioma cell line U105MG (Nakao et al 1990) have 
been shown to express MIP-1 a.
However in most of these cell types cellular stimulation is necessary to induce MIP-1 a mRNA 
expression. Stimuli such as lipopolysaccharide (LPS), intercellular adhesion molecule-1
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(ICAM-1), CD-40, TNF-a and Interferon-y have all been shown to rapidly upregulate MIP-1 a 
expression. On the other hand anti-inflammatory regulators such as TGF-p (Maltman et al
1993), IL-4 (Standiford et al 1993) and IL-10 (Kasama et al 1994) have been shown to 
downregulate the production of MIP-1 a transcripts. MIP-1 a expression appears to be closely 
controlled and although these regulatory mechanisms are not fully understood they are 
probably complex.
1.3.3.2 The MIP-1 Proteins: Structure and Function.
The products of the MIP-1 genes are both secreted heparin-binding proteins. These genes 
encode primary translation products of 92 amino acids, including typical amino-terminal 
signal sequences. In both murine MIP-1 a and MIP-1 p the signal peptide is cleaved after a 
serine residue to generate mature proteins 68-69 amino-acids long. The mature secreted 
forms of both murine and human MIP-1 a and MIP-1 p are approximately 70% homologous 
and run as 8kDa bands on an SDS-PAGE gel. The proteins have the characteristic four 
cysteines that form two disulphide bonds that are critical to the protein’s structure and 
function. Disulphide bridges link the first cysteine to the third and the second cysteine to the 
fourth (Reviewed by Schall 1991).
The CC and CXC chemokines have similar secondary structures (Schall 1991). In fact 
structural analysis of both MIP-1 a and MIP-1 p has shown that these proteins have similar 
secondary and tertiary structure to the CXC chemokines IL-8 and PF-4 (Lodi et al 1994; 
Clements et al 1992) with which they share limited sequence homology. The three 
dimensional structure of MIP-1 p has been resolved by multidimensional nuclear magnetic 
resonance (Lodi et al 1994). Since this protein, like a number of other members of the 
chemokine family has a tendency to form large multimeric aggregates (discussed below) at 
higher concentrations, the studies were performed at a low pH where MIP-1 p is a dimer. 
These studies have shown that with the exception of the amino-terminus which appears to be 
flexible and partially disordered, the MIP-1 p structure is well defined. The main secondary 
structure is a triple- stranded antiparallel p-sheet arranged in a greek key conformation on 
which lies an a-helix. The amino-terminus comprises an irregular strand and a series of turns 
that form a long loop extending from residues 12-20. This is followed by a four residue 
helical turn which leads into strand p1. This structure is very similar to that defined for
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another C-C chemokine Rantes (Skelton et al 1995). Furthermore at the monomer level there 
are many similarities in the tertiary structures of MIP-1 p and the CXC chemokine IL-8 (Clore 
et al 1990; Baldwin et al 1991). There are however a number of differences that may result in 
the different receptor specificities of the two major chemokine families. These include 
differences in the direction of the amino-terminal residues preceding the first cysteine as well 
as differences in the conformation of the first disulphide bridge which is caused by the extra 
amino-acid between the two cysteines in IL-8. Furthermore the a-helix in IL-8 extends 5 
amino-acids longer than in MIP-1 p at the carboxy terminus and the turn between strands pi 
and p2 also differ in conformation at residues 46 and 47.
Although the tertiary structures of MIP-1 p and IL-8 are similar, the quaternary structures that 
result from protein aggregation are quite different. Since CXC chemokines do not generally 
bind CC chemokine receptors, and vice-versa CC chemokines do not bind CXC receptors 
(despite considerable promiscuity in receptor binding in the individual families), these major 
differences in the dimeric CXC and CC chemokine structures have been postulated to 
explain the distinct receptor binding profile of these two subfamilies (Lodi et al 1994). 
Furthermore it has been suggested that the large concave surface of the MIP-1 p dimer is 
involved in the receptor binding of the C-C chemokines. This hypothesis may not however be 
correct since there is now evidence to suggest that these chemokines function as monomers.
1.3.3.3. Aggregation.
Most, if not all, of the chemokines identified so far have a tendency for spontaneous 
aggregation to form homodimers and larger multimeric aggregates. In fact platelet factor 4 
and interleukin 8, whose crystal structures are well characterised (St Charles et al 1989; 
Baldwin et al 1991) have been shown to exist as dimers, with platelet factor 4 also forming 
tetrameric aggregates. Interestingly some of these molecules including MIP-1 a and MIP-1 p 
can form large multimeric aggregates of very high and variable molecular weights at higher 
concentrations in vitro. The physiological relevance of this aggregation is uncertain, and 
although it has been suggested that this phenomenon may help concentrate the chemokine 
at its site of action it is probably more likely that this multimerisation is an artefact related to 
the high concentrations of the protein used in vitro. To investigate this non-aggregating 
chemokine molecules have been generated by different investigators. A chemically
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synthesised non-aggregating monomeric form of IL-8, N-methyl-Leu-25 IL-8 has been shown 
to be fully functional in a number of different assays (Rajarathnam et al 1994). Furthermore a 
number of non-aggregating mutants of MIP-1 a have also been generated (Graham et al 
1994). These mutants termed PM1, PM2 and PM3 were generated by systematically and 
conservatively neutralising carboxy-terminal acidic amino-acid residues using PCR based 
site-directed mutagenesis. These mutants PM1, PM2 and PM3 were found to display 
molecular weights corresponding to the tetramer, dimer and monomer of MIP-1 a 
respectively. Interestingly all three mutants are equipotent with the wildtype molecule in both 
the haemopoietic CFU-A assay and monocyte shape change assays. These mutagenesis 
studies suggest that aggregation is not necessary for activity and indicate that aggregation is 
a dynamic and reversible phenomenon resulting from electrostatic interaction (Graham et al 
1994). Conversely however there is some evidence to suggest that the C-C chemokine MCP- 
1 interacts with its receptor as a homodimer (Zhang and Rollins 1995).
1.3.3.4 Structure-Function Studies.
The above studies suggest that MIP-1 a is active in a monomeric form. Therefore the 
differences in quaternary structure between the CXC and CC chemokines are unlikely to 
explain the disparate receptor binding profiles of these two subfamilies. Since the tertiary 
and secondary structures of these molecules are similar, it is therefore likely that receptor 
selectivity is due to the primary amino-acid sequence of the peptides, with the amino- 
terminus being particularly important (Reviewed by Wells et al 1996; Baggiolini et al 1997). It 
is interesting to note therefore that an analysis of the hydrophobic residues in the CC and 
CXC chemokines has shown that although the core hydrophobic residues of the two families 
are at equivalent positions, which is in keeping with their similar tertiary structures, the 
surface hydrophobic clusters are located in very different regions in the two sub-families. This 
is not only in keeping with the observed differences in quaternary structure, but may help 
partially explain the general lack of receptor cross-binding and reactivity between the two 
sub-families (Covell et al 1994).
To further delineate the residues which define these differences, a number of other studies 
have utilised sequence comparisons of the CXC and CC families, as well as the observed 
three dimensional structures of the chemokines, to guide site-directed mutagenesis studies.
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The mutants generated by these studies have helped to delineate the amino-acids in the 
chemokine molecule which contribute to the molecule’s activity.
C X C  F A M IL Y
IL -8  SAKELRCO C IK TYSK PFH PKFIKELRVIESG PHC AN TEIIVK LSD. G R ELC LD P K E N W V Q R W EK FLK R A EN S  
NAP-2 A E LR C M C IK TTSG  ..IH PK N IQ SLEVIG K G TH C N Q VEVIA TLK D . G RK ICLDPDAPRIKKIVQ KKLAG DESAD  
GROa ASVATELRCO CLO TLQ G .IHPKNIQ SVNVKSPG PHCAO TEVIATLKN. G RK AC LNPASPIVKKIIEKM LNSDKSN  
IP-10  VPLSRTVRCTCISISNQPVNPRSLEKLEIIPASQF CPRV E l IATM KKKGEKRCLNPESKAIKNLLKAVSKEM SKRSP  
PF-4  EAEEDG DLQ CLCVKTTSQ . VRPRHITSLEVTKAGPHCPTAQLIATLKN. G RKICLDLQAPLYKKUKKT ,LES 
C -C  F A M IL Y
M IP-1 a  ASLAADTPTAC.CFSYTSROI PQNFIA D Y F  ETSSQ C SKPG VIFLTKR S. R Q V CADPSEEW VQ K YVSD LELSA* 
M IP-18 APM G SD PPTA C C FSYTA R K LPR N FW D YYETSSL C S Q P A W FQ TK R S .K Q V  CA D PSESW VQ EYVYD LELN  *  
RANTES SPYSSDT. TPCC FA Y IAR PLPRAH IK  E YFY TS G K  CSNPA W FVTR K N .R Q VC A NPEK K W VR EYTN SLEM S  
MCP-1 QPDAINAPVT CC YNFTNRKISVQRLAS YRRITSSK. CPKEAVIFKTTVA. KEI CADPKQKWVQDSMDHLDKQTQTPKT
* Human proteins
IL-8 was one of the first chemokines to be analysed in structure-function studies. Initial work 
focused on determining the importance of the amino- and carboxy- termini in neutrophil 
chemotaxis and exocytosis (Clark-Lewis et al 1991). Analogs of IL-8 were chemically 
synthesised and their activity compared with that of the full-length molecule. These 
investigations showed that the amino-terminal residues 4, 5 and 6 of IL-8 are critically 
important for IL-8 receptor binding and therefore chemokine activity. Moreover, studies with 
amino-terminally truncated forms of IL-8 show that IL-8 analogs with deletions or mutations of 
the ELR motif can function as antagonists of the wildtype molecule (Moser et al 1993).
L-8 (1-72) SALELRCGC
L-8 (4-72) ELRCGC
L-8 (5-72) LRCGC
L-8 (6-72) RCGC
L-8 (7-72) CGC
L-8 AAR (7-72) AARCGC
Wildtype
2-5 fold higher potency than 1 -72.
Binds receptor weakly, partial agonist.
Binds receptor weakly. Receptor antagonist. 
Does not bind IL-8 receptor.
Binds receptor. Antagonist.
It is therefore clear that for IL-8 the ELR motif in the amino-terminus is crucial for the 
biological activities of this CXC chemokine. This tripeptide ELR motif (underlined in the
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sequences above) is not however the only determinant of IL-8 activity since an amino- 
terminal decapeptide lacks both IL-8 activity and receptor binding. On the other hand 
although synthetic analogs shortened at the carboxy-terminus are generally less potent than 
the full-length molecule, a mutant (1-51) lacking the terminal 21 amino-acids, is still active 
suggesting that the carboxyl terminus of IL-8 is not crucial for receptor binding. Interestingly 
however, while the 1-51 analog is approximately 50-fold less potent than the wild-type 
molecule, addition to this mutant of a peptide corresponding to the carboxy-terminal 22 
amino-acids results in a two-fold increase in 1-51 activity suggesting that this portion of IL-8 
may be important in stabilising the three-dimensional structure of IL-8. These studies also 
showed that one of the carboxy-terminal mutants, which was shorter than the wild-type by 
three amino-acids, 1-69 was in fact two-fold more potent than the full-length molecule, 
although further truncation by another three amino-acids, which generates the mutant 1-66, 
results in an analog that is equipotent to IL-8. Independent studies with the CXC chemokine 
NAP-2, which is generated by proteolytic processing from PBP and p-thromboglobulin, have 
also shown that limited carboxy-terminal truncation of NAP-2 can generate variants with 
modestly enhanced activity (Brandt et al 1993; Ehlert et al 1995). What is however 
particularly interesting about these studies is that a carboxy-terminal truncated form of NAP- 
2 was identified in the culture medium of activated peripheral blood mononuclear cells 
(PBMC). This variant NAP-2(1-66) which is four amino-acids shorter than the full-length 
molecule is 3-4 fold more potent than NAP-2, leading the investigators to suggest that limited 
truncation at the carboxy-terminus may be a physiological mechanism for fine-tuning 
chemokine activity. It is interesting to note here that further truncation beyond the 1-66 
resulted in decreased NAP-2 activity. These investigations overall indicate that the carboxy- 
terminus of these molecules is not essential for their activities, although limited carboxy- 
terminal truncation may result in in a modest but significant increase in chemokine activity. 
Furthermore the amino-terminus of these molecules appears to be critical, although not 
sufficient, for biological activity.
Overall these results indicate that there must therefore be additional critical binding sites in 
the IL-8 molecule between the cysteine at position 8 and the cysteine at position 50. 
Experiments utilising rabbit IL-8, which shares 82% sequence identity with human IL-8, but 
has a 200-fold lower affinity for the IL-8A receptor, shed further light on this. It was found that
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simply replacing two amino acids (histidine 13 and threonine 15) in rabbit IL-8 with the 
corresponding amino-acids of the human protein (tyrosine 13 and lysine 15) converts the low- 
affinity binding of rabbit IL-8 to the high affinity binding of the human protein. Therefore this 
region of the IL-8 molecule also appears to be critically important in IL-8 receptor binding, 
either through directly interacting with the IL-8A receptor or indirectly by determining the 
conformation of this chemokine (Schraufstatter et al 1995).
A different approach designed to study the importance of other residues in the IL-8 and IL-8 
receptor interaction involves incorporating the ELR motif into chemokines that do not 
possess IL-8 activity (Clark-Lewis et al 1994). It is clear from a number of studies that 
some of the members of the CXC chemokine sub-family lack the activity of IL-8 on 
neutrophils. Moreover these molecules, which include IP-10, mig and PF-4 (see table above), 
lack the ELR motif and have quite different activity profiles to IL-8. A series of experiments 
have shown that the insertion of the ELR tripeptide motif into PF-4 converts this variant of 
PF-4 into a molecule with IL-8 like activity. However insertion of the ELR motif is not 
sufficient to introduce IL-8 activity into IP-10, which indicates again that the ELR is necessary 
but not sufficient for IL-8 receptor binding. Further studies involving a series of mutants in 
which hybrids were derived by substituting regions of IL-8 into IP-10, have shown that other 
regions of the IL-8 molecule are important for its biological activities. These include the 
residues at positions 30-35, particularly the glycine-proline motif, which defines an atypical 0- 
turn, as well as the region 10-22, which although less critically important includes a number 
of residues that were seen to be important in IL-8 receptor binding (Tyrosine 13, 
Phenylalanines at positions 17 and 21). It is likely that the glycine-proline motif is important to 
provide a structural scaffold for the receptor binding amino-terminal region which includes 
the ELR motif and secondary binding and conformational determinants between residues 10 
to 22 (Clark-Lewis et al 1994).
The amino-terminus of the C-C chemokines is also critical to the receptor binding of these 
molecules. The C-C chemokine Rantes is a potent chemotactic and activating agent for a 
number of leukocytes including T-cells. When overlapping 10 amino-acid peptides scanning 
the whole length of the protein were synthesised and bioassayed, it was found that the 
Rantes decapeptides (1-10), (3-12) and (5-14) were all chemotactic for T-cells suggesting 
that this region of the molecule is sufficient for this Rantes T-lymphocyte chemotaxis.
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Peptides from other regions of the Rantes molecule were inactive (Wells et al 1995). None of 
the peptides were able to give a calcium flux in THP-1 cells, unlike the parent molecule, 
suggesting that the amino-terminal region of Rantes is not sufficient for this activity. 
Independent results have also shown that extension of the Rantes molecule by the retention 
of an amino-terminal initiating methionine produces a Rantes analog, Met-Rantes that is not 
only inactive but is also a potent antagonist of the wildtype molecule in calcium mobilisation 
studies and chemotaxis assays performed on the promonocytic cell line THP-1 (Proudfoot et 
al 1996). This indicates that the integrity of the amino-terminus of Rantes is critical to its 
receptor binding.
Separate studies on another C-C chemokine MCP-1, have also shown that the amino- 
terminus of MCP-1 is crucial for this protein’s activities. A number of chemically synthesised 
amino-terminally truncated mutants of MCP-1 were generated and bioassayed on peripheral 
blood monocytes and THP-1 cells. The results obtained (see overleaf) were somewhat 
surprising but again confirm that the amino-terminus of MCP-1 is a critical determinant of 
MCP-1 receptor binding and activity (Gong and Clark-Lewis 1995). Although these 
observations have parallels with IL-8, the situation with MCP-1 is obviously more complex. 
Firstly, while the nature of the amino-terminal residue is critical, the nature of the amino- 
terminal sidechain can be varied since asparagine and other non-polar residues of various 
types can substitute for the pyroglutamate found in the wildtype molecule. Moreover other 
studies have shown that the deletion of the amino-terminal residue of MCP-1 dramatically 
changes the activities observed for this molecule. Therefore while the wildtype molecule is a 
potent basophil activator with no effect on eosinophils, the 2-76 molecule is a potent 
eosinophil chemoattractant with little effect on basophils (Weber et al 1996). These results 
indicate that the amino-terminus amino-acid is critical in determining the function of this 
molecule. Furthermore deletion of the first two amino-acids results in total loss of activity, 
which is in keeping with this. However further deletion results in the regaining of activity, with 
a molecule that is only fourfold less active than the full-length chemokine in monocyte 
studies.
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MCP-1 *QPDAINAPVTCC Wildtype activity (*  = pyroglutamate).
MCP-1 (Ac) AcQPDAINAPVTCC 300fold less active( Ac = Acetylation).
MCP-1 (Ala1) AQPDAINAPVTCC 300fold less active.
MCP-1 (Asn1) NPDAINAPVTCC ......  Fully active.
MCP-1 (AcAsn1) AcNPDAINAPVTCC Considerably reduced activity.
MCP-1 (Asp1) DPDAINAPVTCC Inactive.
MCP-1 (Ala-1) APDAINAPVTCC Fully active.
MCP-1 (2-76) PDAINAPVTCC 300 fold less potent than MCP-1.
MCP-1 (3-76) DAINAPVTCC Inactive.
MCP-1 (4-76) AINAPVTCC Inactive.
MCP-1 (5-76) INAPVTCC Active but 4fold less potent than MCP-1
MCP-1 (6-76) NAPVTCC Virtually inactive but still binds receptor.
MCP-1 (7-76) APVTCC .. Inactive. Binds and desensitises receptor.
MCP-1 (8-76) PVTCC .. Inactive. Antagonist of MCP-1 (IC50=60nM)
MCP-1 (9-76) VTCC ... Inactive. Antagonist of MCP-1 (IC50=20nM)
MCP-1 (10-76) TCC .. Inactive. Weak antagonist (IC50=600nM)
MCP-1 (11-76) CC..... .. Inactive. Weak antagonist (IC5o=1m-M)
These studies suggest that the amino-terminal residues are not essential for signalling, but 
may be necessary for optimal binding Unlike the ELR in IL-8, the functionally critical amino- 
terminal region of MCP-1 appears to extend over all of the first 10 amino acids of this CC 
chemokine. These studies also suggest that like IL-8, MCP-1 must have other receptor 
binding sites outside the amino-terminus. Independent studies have in fact shown that the 
tyrosine residue at position 28 is very important in receptor binding of MCP-1 (Zhang et al
1994). Interestingly this residue is conserved throughout the C-C family, and the 
corresponding residue in the CXC (Leucine 25) is also highly conserved suggesting that the 
residue at this position may help define the receptor specificities of the two sub-families. This 
has been analysed by mutating leucine in the CXC chemokine IL-8 to the tyrosine typical of 
the CC family. This mutation imparts to IL-8 a novel monocyte chemoattractant activity and 
decreases the molecule’s potency in neutrophil chemoattractant assays, confirming the 
importance of this region in not only IL-8 receptor binding but also in conferring specificity
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between CXC and CC chemokines (Lusti-Narasimhan et al 1995 and 1996;* Reviewed by 
Wells et al 1996). Other investigations indicate that a number of other sites may be involved 
in C-C chemokine receptor binding. The arginine at position 24 in MCP-1 has been seen to 
play a part in MCP-1 activity since its mutation to phenylalanine results in a molecule with 
only 5% of wildtype activity, while deletions of the carboxy terminal a-helix resulted in a 
molecule that possessed -10% of MCP-1 function suggesting that as for IL-8, the carboxy- 
terminus of MCP-1 is not essential, but may be required for optimal activity (Zhang et al
1994).
Finally recent studies on MIP-1 a have shown that a non-heparin binding mutant of MIP-1 a 
called HepMut, which was generated by the neutralisation of two basic amino-acids in the 
region between the two carboxy-terminal cysteines, does not bind the MIP-1 a receptor CCR1 
(Graham et al 1996). This does not appear to be related to the loss of heparin-binding activity 
since the wild-type molecule is still able to bind CCR1 in glycosaminoglycan deficient CHO 
cell lines. This suggests that this region of the CC chemokine MIP-1 a is also critical to CCR- 
1 receptor binding.
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1.3.3.5 MIP-1 a and its Mode of Action: Receptors.
The means by which MIP-1 a exerts its manifold activities on its different target cells are still 
as yet poorly characterised. However several receptors that bind this and other chemokines 
have been cloned by molecular techniques and studies on these receptors are now beginning 
to shed light on the mechanisms of action of these molecules (Reviewed by Baggiolini et al 
1997). These receptors have seven-transmembrane domains and form a distinct group of 
structurally related proteins within the large family of G-protein coupled receptors. They have 
conserved transmembrane region structural motifs as well as two conserved cysteine 
residues, one in the amino-terminal domain and the other in the third extracellular loop. 
These cysteines form a disulphide bond that is crucial for the conformation of the ligand- 
binding site.
The CXC and CC chemokine receptors form two different subgroups with significant 
sequence conservation (CXC receptors: 36-77%; CC receptors: 46-89%), specific 
chromosomal localisation (CXCR genes located on chromosome 2q; CCR genes located on 
chromosome 3p) and sub-group specific binding profiles. The first chemokine receptors to 
be identified were the neutrophil receptors for the CXC chemokine IL-8, IL-8RA and IL-8RB 
(Holmes et al 1991; Murphy et al 1991), now known as CXCR1 and CXCR2 respectively. The 
first C-C chemokine receptor to be cloned was CCR1 (Neote et al 1993), which was isolated 
from HL60 cells treated with PMA. This receptor has been shown to bind MIP-1 a and Rantes, 
as well as MCP-2, MCP-3 and MCP-4 (Uguccioni et al 1996; Franci et al 1995; Ben-Baruch 
et al 1995; Combadiere et al 1995). A receptor for MCP-1 designated CCR2 occurs in two 
RNA-spliced variants CCR2a and CCR2b with different carboxy-terminal regions which alter 
signal transduction but not ligand binding (Charo et al 1994; Myers et al 1995). CCR3, the 
eotaxin receptor, is expressed primarily by eosinophils and binds Eotaxin as well as Rantes 
and MCP-3 but not MIP-1 a or MIP-1 p (Daugherty et al 1996). CCR4 binds the recently 
described chemokines TARC and MDC (Imai et al 1997, 1998). CCR5 also binds MIP-1 a, as 
well as MIP-1 p and RANTES (Samson et al 1996). Studies on the HIV inhibitory activities of 
MIP-1 a, RANTES and MIP-1 p have shown that CCR5 functions as a required co-receptor for 
the entry of M-tropic HIV-1 into CD4+ cells (Dragic et al 1996). Further work has shown that 
a number of other chemokine receptors serve as co-receptors that are necessary for the 
entry of HIV and related lentiviruses into the cell (Cairns and D'Souza 1998). These include
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CCR2 (Doranz et al 1996; Choe et al 1996), CCR3 (Doranz et al 1996; Choe et al 1996), 
CCR8 (Tiffany et al 1997; Horuk et al 1998) as well as CXCR4 (Feng et al 1996) and the 
fractalkine receptor CX3CR (Reeves et al 1997). The discovery of this relationship between 
chemokine receptors and HIV has generated considerable interest in the potential use of 
chemokines or chemokine variants in the treatment and prevention of HIV infection (Cairns 
and D'Souza 1998). A number of other chemokine receptors have been identified including 
the promiscuous CC chemokine receptor D6 which, although specific for the p-chemokine 
family, binds the majority of CC chemokines (Nibbs et al 1997 a and b).
Most of the chemokine receptors identified so far are G-protein coupled receptors.They can 
be sub-classified into four general main categories (Schall and Bacon 1994): specific 
receptors, shared receptors, promiscuous receptors and virally encoded receptors. Specific 
receptors bind only one chemokine and are specific to that molecule. IL-8RA is thought to be 
specific for IL-8 (Lee et al 1992). Shared receptors, which include CCR-1, are able to bind 
more than one chemokine. Most of the chemokine receptors identified so far are shared 
receptors. CCR-1 can in fact bind MIP-1 a, Rantes, MIP-1 p and MCP-1. The Duffy blood 
group erythrocyte antigen has been shown to be a promiscuous chemokine receptor because 
it is able to bind both CXC and CC chemokines (Neote et al 1994). It has also been shown to 
be involved in the binding of the malaria pathogen Plasmodium vivax to red blood cells 
(Horuk et al 1993). Interestingly the Duffy receptor does not seem to be able to signal 
through G protein-coupled mechanisms (Neote et al 1994) and its significance remains 
uncertain. Since there are a large number of Duffy receptors on an erythrocyte, it has been 
suggested that the Duffy antigen may function as a ‘sink’ and mop up excess chemokine 
from the peripheral circulation. Finally the fourth class of chemokine receptors is known as 
the virally encoded chemokine receptors. These include a gene product from 
cytomegalovirus known as US28 which encodes a functional C-C chemokine receptor. US28 
is approximately 30% homologous to the known chemokine receptors and is able to bind 
MIP-1 a, Rantes, and MCP-1 as well as transduce a signal via a calcium mobilisation pathway 
(Gao et al 1994). A gene product from Herpesvirus samiri has also been shown to bind CXC 
chemokines and share over 30% homology with the IL-8 receptors (Ahuja et al 1993). The 
biological role of these viral proteins is not known, but it is likely that these receptors are 
involved in the pathogenesis of infection with these viral pathogens.
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1.3.3.6. MIP-1 a and its Mode of Action: Signal Transduction.
The signalling mechanisms by which MIP-1 a exerts its activities are not well understood. 
However it is clear that the effects of MIP-1 a on a number of cell types can be abrogated by 
the pretreatment of the cells with Bordatella pertussis toxin, which inhibits signal transduction 
through a G protein termed Gai (McColl et al 1993). This indicates that at least a proportion of 
MIP-1 a’s activities are mediated through G-protein coupled receptors. MIP-1 a has also been 
shown to induce a calcium flux in a number of target cells. This rapid and transient rise in 
intracellular calcium levels is sensitive to inhibition by pertussis toxin and is probably a result 
of the increased inositol triphosphate release by the G-protein activated enzyme 
phospholipase C. A considerable variety of downstream cascades have been reported to be 
activated by these operative G-proteins. These include phospholipase C (PLC), adenyl 
cyclase which generates cAMP, as well as phospholipase A2. MIP-1 a has also been shown 
to activate phospholipase A2 in monocytes (Locati et al 1994), which in turn induces a rapid 
release of arachidonic acid that is thought to be important in chemotaxis. Moreover 
investigations on the myeloid leukaemia derived cell line M07e indicates that MIP-1 a 
treatment does indeed result in an increase in phosphatidylcholine levels and cAMP 
implicating phospholipase C and adenyl cyclase in the inhibition of M07e cell proliferation 
(Mantel et al 1995). Phospholipase C generates diacylglycerol (DAG) and inositol 
triphosphate (IP3). DAG can then activate protein kinase C, while IP3 releases the 
intracellular calcium stores, which results in the calcium flux. Moreover since the generation 
of cAMP by adenyl cyclase may be an inhibitory stimulus to haemopoietic cell proliferation, it 
has been suggested that this is the mechanism by which MIP-1 a regulates haemopoietic 
progenitor proliferation (Mantel et al 1995). The mechanisms by which cAMP functions to 
generate these inhibitory activities remain unclear. However cAMP has been shown to inhibit 
the interaction of the two proto-oncogene products ras and raf (Cook et al 1993), which 
results in the uncoupling of one of the major mitogenic signalling pathways, the mitogen 
activated kinase (MAPK) pathway (Wu et al 1993). Other studies suggest that MIP-1 a, by 
increasing intracellular cAMP levels, can block the activation of Raf-1 kinase, a component of 
the MAPK signalling pathway, induced by growth factors (Aronica et al 1995). Since growth 
factors such as GM-CSF (Miyazawa et al 1991) and EGF (Wu et al 1993) have been shown
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to function through this pathway, this suggests that MIP-1 a may inhibit cellular proliferation 
induced by such cytokines through this mechanism.
1.3.3.7 Biological Activities of MIP-1 a: MIP-1 a and the Immune Response.
MIP-1 a has been characterised primarily as an inflammatory cytokine. It is a potent 
chemoattractant and activator for a number of different inflammatory cell types in vitro. 
MIP-1 a is a potent monocyte chemoattractant (Schall et al 1990) as well as a modulator of 
macrophage function (Fahey et al 1992). MIP-1 a has also been shown to chemoattract 
distinct populations of lymphocytes (Taub et al 1993; Schall et al 1993). These studies have 
shown that MIP-1 a can attract both CD4+ and CD8+ T lymphocytes, and B cells as well as 
regulate lymphocyte activation (Taub et al 1996). MIP-1 a has also been shown to be able to 
induce the migration and activation of eosinopils (Rot et al 1992), and of basophils and mast 
cells (Alam et al 1992; Bischoff et al 1993). The activities displayed by this chemokine in vitro 
suggest that MIP-1 a may be involved in the pathogenesis of a number of inflammatory and 
allergic disorders (Baggiolini and Dahinden 1994). MIP-1 a has in fact been implicated in the 
pathogenesis of a number of inflammatory lung diseases including pulmonary fibrosis 
(Standiford et al 1993). MIP-1 a has also been shown to be involved in the pathogenesis of 
experimental autoimmune encephalomyelitis (EAE), which is a murine model for the 
demyelinating disease multiple sclerosis (Karpus et al 1995). These studies have shown that 
specific antibody to MIP-1 a can significantly ameliorate the severity of both EAE and 
bleomycin induced lung injury suggesting that this molecule may be involved in the 
autoimmune process that results in the tissue injury of these disease processes. Interestingly 
data obtained from MIP-1 a knockout mice indicates that MIP-1 a is necessary for the 
development of the autoimmune myocarditis induced by coxsackie viral infection (Cook et al
1995). These results together indicate that MIP-1 a is a major player in the pathogenesis of 
inflammatory processes in vivo, with perhaps a specific role in the initiation of autoimmune 
reactions. Moreover MIP-1 a knockout mice have also been shown to have an altered 
response to Influenza viral infection resulting in a delayed clearance of this pathogen, 
suggesting that this chemokine may be involoved in the immune response to this viral 
infection. On the other hand however MIP-1 a knockout mice have apparently normal
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haemopoiesis. No obvious differences in peripheral blood or bone marrow differentiated and 
primitive blood cells are observed in these mice, with apparently normal spleen and lymph 
node lymphocyte numbers.
1.3.3.8 Biological Activities of MIP-1 a: The Regulation of Cell Proliferation,
a) Haemopoiesis.
MIP-1 a is now well characterised as an inhibitor of primitive haemopoietic cell proliferation. 
Prior to the identification of this chemokine, a number of studies had shown that an extract of 
bone marrow contains an inhibitor of both in vitro and in vivo haemopoietic stem cell assays 
(Lord et al 1976). Furthermore studies showed that the bone marrow macrophage is a likely 
source of this inhibitor, and that the macrophage cell line J774.2 produces a similar inhibitory 
activity. This activity was purified and when characterised by amino-terminal sequencing and 
DNA cloning, was found to be due to the chemotactic cytokine MIP-1 a (Graham et al 1990). 
MIP-1 a is able to inhibit growth factor mediated colony formation by CFU-A haemopoietic 
progenitors at picomolar to low nanomolar concentrations. It also inhibits haemopoietic 
progenitors from undergoing DNA synthesis. Furthermore MIP-1 a also inhibits day 12 CFU- 
S haemopoietic progenitors in vivo. MIP-1 a does not however have any inhibitory effects on 
the proliferation of the more committed GM-CFC progenitors (Graham et al 1990).
This inhibitory activity has been confirmed by a number of other groups and studies have 
shown that recombinant murine MIP-1 a can inhibit the in vitro colony formation of a number 
of different primitive haemopoietic progenitors, including CFU-GM, BFU-E and CFU-GEMM 
(Broxmeyer et al 1990; Eaves et al 1991). Furthermore the increase in CFU-S induced by in 
vitro culture in the presence of IL-6 or IL-3 is reduced in the presence of MIP-1 a. The growth- 
factor stimulated proliferation of the multipotential haemopoietic FDCP-mix A4 cell line has 
also been shown to be inhibited by MIP-1 a (Lord et al 1992). Furthermore in long-term bone 
marrow cultures MIP-1 a has been shown to be able to inhibit the ability of fresh medium to 
stimulate entry into S-phase of primitive high proliferative potential clonogenic cells in this 
system (Eaves et al 1993). On the other hand more differentiated progenitors with low 
proliferative potential are not inhibited and there is in fact conversely some evidence to 
suggest that the proliferation of more mature progenitors is enhanced by MIP-1 a (Broxmeyer
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et al 1990). This bimodal form of activity has also been observed with a number of other 
negative regulators including TGF-p (see above).
Overall these studies show that MIP-1 a can inhibit the proliferation of a variety of primitive 
haemopoietic cell types. Other studies however suggest that MIP-1 a, unlike TGF-(3, is not an 
inhibitor of the most primitive stem cell, although it does undoubtedly inhibit the proliferation 
of early haemopoietic progenitors. These investigations which include complex competitive 
repopulation studies indicate that MIP-1 a does not inhibit the haemopoietic long-term 
repopulating cell (Quiesnaux et al 1993; Soma et al 1996). Moreover MIP-1 a, unlike TGF-p, 
does not inhibit proliferation in the HPP-CFC-1 assay, which is thought to detect primitive 
stem cells. Furthermore separate studies have also shown that in stroma non-contact long­
term bone marrow cultures, MIP-1 a does not inhibit the proliferation of the most primitive 
cells in this system, the long-term bone marrow culture initiating cells (LTBMC-IC). 
Surprisingly however MIP-1 a has been shown to be able to prolong the maintenance of the 
LTBMC-IC in long-term bone marrow cultures (Verfaillie et al 1994). The mechanism of this 
activity may be the result of a direct interaction of MIP-1 a with the LTBMC-IC, but appears to 
be dependent on an uncharacterised effect of the stroma on the function of MIP-1 a. It has 
been suggested that the stromal cell may activate the MIP-1 a by producing an accessory 
factor. However structural activation of the MIP-1 a molecule by the stromal cell has not been 
excluded. The effects of MIP-1 a on the most primitive haemopoietic cell population is 
therefore not as yet fully defined.
However it is clear that MIP-1 a does inhibit the proliferation of early haemopoietic progenitors 
including the CFU-S (Cooper et al 1994). Furthermore MIP-1 a can also protect this 
population of cells from the cytotoxicity of anti-cancer chemotherapy in vivo (Dunlop et al 
1992; Lord et al 1992; Lord et al 1995). Dunlop et al (1992) have demonstrated protection of 
the CFU-S/CFU-A compartment from the double injections of the cell-cycle-specific drug 
cytosine arabinoside, while Clements et al (1992) have shown that the in vivo injection of 
MIP-1 a into mice protects the CFU-S from subsequent killing by tritiated thymidine. Lord et al 
(1992) have also demonstrated that MIP-1 a can protect the CFU-S from the toxicity of 
another cell-cycle specific drug hydroxyurea. Further studies have shown that MIP-1 a also
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speeds up the recovery of thse primitive haemopoietic progenitors after cytotoxic therapy 
(Lord et al 1995).
However most anti-cancer chemotherapy regimes usually involve combinations of a number 
of different cytotoxics with different mechanisms of action. These drug combinations usually 
include non-cycle specific drugs. There is however in vivo evidence to suggest that MIP-1 a 
can ameliorate the myelotoxicity of the non-cycle specific drug cyclophosphamide in mice 
(Parker et al 1995). If this is confirmed then MIP-1 a may have a potential role in the 
amelioration of the myelotoxicity induced by cytotoxic chemotherapy since this is the main 
dose limiting factor in most cytotoxic regimens. MIP-1 a has also been shown to be unable to 
inhibit the proliferation of chronic myeloid leukaemic progenitors (Eaves et al 1993), therefore 
this molecule may also be potentially useful in the purging of tumour cells ex vivo from stem 
cell harvests.
If MIP-1 a is to be a useful therapeutic agent it must be non-toxic. MIP-1 a is a potent 
inflammatory mediator and this activity has the potential to cause considerable side-effect. 
The use of the non-heparin binding mutant HepMut may however resolve this concern since 
this mutant has been shown to retain the stem cell inhibitory functions of MIP-1 a, while 
apparently having no activity on monocytes in vitro (Graham et al 1996). Moreover if MIP-1 a 
is to be useful as a myeloprotective agent, it must not at the same time inhibit the proliferation 
of neoplastic cells since this would hinder the treatment of the malignancy. The activity of 
MIP-1 a on a wide variety of cell lines has therefore been evaluated and the results indicate 
that MIP-1 a does not have any significant inhibitory activity on these clonogenic cancer cells 
(Korfel et al 1994; Parkinson E.K.- personal communication).
A MIP-1 a variant BB10010 has been investigated in clinical phase I and II trials. These trials 
indicate that although MIP-1 a is safe, and is able inhibit primitive haemopoietic progenitors in 
cancer patients (Broxmeyer et al 1998), it is however unable to reduce the toxicity of cytotoxic 
chemotherapy (Bernstein et al 1997).
b) MIP-1 a and Spermatogenesis.
MIP-1 a has also been shown to inhibit the proliferation of a number of non-haemopoietic 
clonogenic cell types. MIP-1 a is constitutively expressed in the seminiferous epithelium and
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has been recognised to be an inhibitor of the proliferation of DNA synthesis in primitive 
spermatogonia in vitro (Hakovirta et al 1994). Paradoxically MIP-1 a increases the DNA 
synthesis of more mature and differentiated spermatogonia. These observations suggest that 
MIP-1 a may be a physiological regulator of spermatogenesis. It is however interesting to note 
that MIP-1 a knockout mice appear to have normal fertility. This suggests that MIP-1 a is not 
essential for normal spermatogenesis.
c) MIP-1 a and Clonogenic Epidermal Keratinocyte Proliferation.
MIP-1 a has also been shown to be expressed in the epidermis. Studies investigating 
epidermal cytokine mRNA expression by reverse-transcriptase polymerase chain reaction 
(RT-PCR) technology, has revealed that MIP-1 a is expressed in the epidermis and that the 
only detectable source of this cytokine in the epidermis is the Langerhans cell (Heufler et al 
1992; Matsue et al 1992a,b and c). This is perhaps not surprising since MIP-1 a has been 
shown to be expressed by a wide variety of haemopoietic cell types, and epidermal 
Langerhans cells are immunologically immature dendritic cells derived from the haemopoietic 
stem cell (Frelinger et al 1979). However while most haemopoietic cell types require some 
form of stimulation to express this cytokine, in the epidermis MIP-1 a is expressed 
constitutively by the Langerhans cell, as seen by both RT-PCR and Northern blotting (Heufler 
et al 1992; Matsue et al 1992; Parkinson et al 1993). Keratinocytes on the other hand do not 
express MIP-1 a constitutively. Furthermore inflammatory stimuli do not appear to induce 
MIP-1 a expression in keratinocytes, although the expression of Rantes and IL-8 is induced 
by treatment with TNF-a or IFN-y (Li et al 1996).
Interestingly Langerhans cells appear to downregulate MIP-1 a expression rapidly on in vitro 
culture and maturation. This is somewhat surprising since the other main cytokine expressed 
by these cells, IL-1p, is gradually and massively upregulated during the in vitro culture and 
maturation of these cells into potent immunostimulatory dendritic cells (Heufler et al 1992). 
This is very different from what has been observed in macrophages where MIP-1 a and IL-1p 
are both greatly upregulated on activation.
Langerhans cells are known to be immunologically naive dendritic cells which undergo major 
changes in morphology, phenotype and function when they mature into potent
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immunostimulatory cells. The stimulus for this alteration is either in vivo activation which 
results in their migration out of the epidermis or in vitro culture (Reviewed by Schuler in 
‘Epidermal Langerhans Cells’: CRC Press 1991). Therefore the Langerhans cell expresses 
MIP-1 a primarily when it is immunologically immature and paradoxically downregulates the 
expression of this protein when it is immunologically active. The role of this chemokine in the 
epidermis is unclear but these results suggest that the constitutive expression of this protein 
is only required when the epidermal Langerhans cell is immunologically naive.
Interestingly the Langerhans cell has been previously postulated to play more than just an 
immunological role in the epidermis. Langerhans cells have in fact been implicated in the 
regulation of epidermal keratinocyte proliferation (Potten and Allen 1976). Could therefore 
Langerhans cell derived MIP-1 a serve to function as a paracrine regulator of epidermal 
keratinocyte proliferation? Initial studies performed with the only available preparation of 
MIP-1 a in our laboratory at the time, a partially purified protein derived from the transient 
transfection of COS 7 cells, have shown that this preparation of MIP-1 a does reversibly 
inhibit the proliferation of clonogenic human epidermal keratinocytes (Parkinson et al 1993). 
Furthermore this activity is fully reversible with a specific polyclonal anti-MIP-1a antibody 
confirming that indeed this cytokine does not only inhibit the proliferation of primitive 
haematopoietic cells, but can also inhibit keratinocyte proliferation. These results appear to 
suggest that Langerhans cell derived MIP-1 a may function as a physiological paracrine 
negative regulator of keratinocyte proliferation in the epidermis.
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1.4 The Epidermis.
The epidermis is a stratified squamous epithelium. Structural and functional studies indicate 
that epithelial stem cells have many of the properties of haemopoietic stem cells. Epithelia, 
like the haemopoietic system, are constantly regenerating tissues. However epithelia, unlike 
haemopoiesis, have a high degree of visible structural order. Although many epithelial 
tissues differ in structure and function they mainly share a unifying theme in that they all 
undergo continual lifelong cell turnover which is characterised by specific patterns of 
proliferation within morphologically defined units (Potten and Morris 1988). The long life of 
these units, their patterns of proliferation and their response to irradiation or cytotoxic 
chemotherapy (clonal regeneration) all indicate that these units contain stem cells.
Epithelia are a diverse group of tissues which line most of the body’s surfaces, cavities and 
tubes. Epithelial interfaces are involved in a wide range of activities such as protection, 
secretion and absorption. Supported by a basement membrane which separates the 
epithelium from the underlying connective tissue, epithelia consist of one or more layers of 
cells closely bound to one another by a variety of specialisations of the cell membrane. 
Epithelia are classified into two main categories depending on the number of cell layers. 
Simple epithelia comprise a single layer of cells while stratified epithelia are composed of 
more than one layer. Stratified squamous epithelia consist of a variable number of cell layers 
which undergo both morphological and functional transition from the cuboidal basal layer to 
the flattened surface layers. The basal cells undergo regular mitotic division giving rise to a 
succession of cells which are progressively pushed towards the free surface. During this 
migration to the surface these cells undergo differentiation. At the epithelial surface cells are 
being continually sloughed off and replaced from the deeper layers. There are basically two 
main types of stratified squamous epithelia: non-keratinising and keratinising. The epidermis 
is a stratified squamous keratinising epithelium. The differentiated epithelial cells of this 
tissue contain keratin, which is formed in those epithelia that cover exposed surfaces. Keratin 
is a tough fibrillar protein that gives the epidermis many of its special features. Fortunately 
the structural organisation of these two main types of stratified squamous epithelia are 
essentially similar. Unfortunately however the epidermis varies greatly in structure from site to 
site which considerably complicates epidermal cell-kinetic studies.
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The epidermis is comprised mainly of keratinocytes which play a major role in providing the 
protective barrier of the skin. There are also a number of other cells in the epidermis which 
have their own specific function, such as the Langerhans cell, the melanocyte and the Merkel 
cell. These cell types will be discussed in turn.
1.4.1 The Keratinocyte.
Keratinocytes originate from the superficial ectoderm of the embryo. From a very early stage 
of development keratinocytes demonstrates a high degree of spatial and organisational 
specificity within the epidermis. These cells assemble into layers and in the post-natal skin 
vertically into columns. Interestingly the non-keratinocytes assume a non-random distribution 
among the keratinocytes. The epidermis can therefore be histologically subdivided into 
several layers or zones:
1) The basal layer or stratum basale
2) The prickle or spinous layer or stratum spinosum
3) The granular layer or stratum granulosum
4) The cornified keratin layer or stratum corneum.
1.4.1.1 The Basal Layer.
The basal layer cells are usually regarded as forming the proliferating compartment of the 
epidermis. Basal cells are distinguished by an intracellular cytoskeleton composed of a 
relatively dispersed, but extensive network of keratin filaments. These filaments are made up 
of a 1:1 ratio of two distinct keratin proteins K5 and K14 (Nelson and Sun 1983). Additional 
features of basal cells which are also found in the suprabasal spinous cells, are 
desmosomes, which interconnect the cells in a three dimensional lattice. Desmosomes 
contain desmogleins and desmocollins which are members of the cadherin family and 
connect to keratin filaments intracellularly (Reviewed by Fuchs 1993). Basal cells rest on the 
basement membrane and are in apposition superiorly with the spinous cells, border each 
other laterally, and have a definite polarity which can still be recognised in vitro (Stanley et al 
1980). Their relationship with the underlying basement membrane, with which they interact by 
hemidesmosomes, is thought to be important not only in maintaining epithelial integrity but 
also in the regulation of epithelial cell differentiation (Watt F.M. et al 1988).
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Although the basal layer was originally described as consisting of a “homogeneous 
population of cells by Pinkus in 1927, it is now clear that this layer is made up of a 
heterogeneous population of cells structurally, functionally and also biochemically (Lavker et 
al 1982). Hibbs and Clark in 1959 were the first to note that basal cells appeared to be 
morphologically different in different parts of the epidermis. They observed that in human 
abdominal epidermis basal cells in the rete ridges were cuboidal in shape while as the basal 
cell approached the apices of the dermal papillae they became columnar in shape. They also 
noted that the basal cells at the apex of the rete ridges had less pronouced finger like 
projections into the dermis than basal cells at the apex of the dermal papilla. However their 
observations were ignored until cell kinetic studies strongly indicated that the basal layer was 
heterogeneous.
a) Basal keratinocyte heterogeneity. Where are the stem cells?
It is now thought that the basal layer comprises a mixture of cells with very different 
proliferative potentials. A large proportion of these basal cell have little or no proliferative 
potential and are poised to leave the basal layer and undergo the program of terminal 
differentiation. A large number of the remaining basal cells have some proliferative potential 
and although the precise position of the ‘ultimate’ epidermal stem cell remains uncertain 
there is no doubt that the basal layer contains clonogenic keratinocytes which are 
continuously proliferating (probably best described as transit amplifying or progenitor cells) 
and which are continuously replacing the cell loss in the layers above them. However Potten 
and Hendry (1973) have shown that when epidermis is severely damaged by irradiation only 
about 10% of the basal keratinocytes have sufficient proliferative potential to regenerate the 
epidermis by forming recognisable foci of new epidermis. Potten and Morris (1988) suggest 
that this 10% may be the stem cell population, although a further 50% of basal cells are also 
capable of cell division, the rest presumably being keratinocytes committed to terminal 
differentiation. However further studies suggest that these basal cells may not be the 
keratinocyte stem cell with the highest proliferative potential. For many years it has been 
observed that epidermal wounds in follicular epidermis can reepithelialize from the hair 
follicle, and studies by Al-Bawari and Potten (1976) demonstrated that after doses of 
irradiation that completely destroyed the interfollicular areas of epidermis, surviving cells
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migrated from the follicle openings. Therefore in cases of extreme epidermal damage 
interfollicular epidermis can be regenerated by follicle derived cells. More recently studies 
have shown that the bulge region (or the upper intermediate part) of the follicle in both rats 
(Kobayashi et al 1993) and human scalp (Rochat et al 1994) contains a large number of 
epidermal cells with a very high proliferative potential (up to 130 doublings) suggesting that 
the ultimate epidermal stem cell may reside here. However the position of the epidermal 
stem cell in non-follicular epidermis and normal unwounded epidermis has not as yet been 
clearly defined.
Further evidence for the heterogeneity in basal keratinocyte proliferative potential comes 
from the in-vitro culture of keratinocytes. It has been demonstrated that when sheets of 
cultured epidermal keratinocytes are grafted onto a suitable recipient, they form epidermis 
that persists for considerable periods of time (Gallico et al 1984), suggesting that in vitro 
culture does not result in the loss of the stem cell compartment. However it has also been 
shown that only a small fraction of the basal keratinocytes cultured in vitro have a high 
proliferative potential. The in vitro assays of these cells reveal keratinocytes with very 
different proliferative potentials (Barrandon and Green 1987b). There are cells with a high 
proliferative potential which are known as holoclones. These colonies were made up of small 
very regular cells and can give rise to more holoclones or to paraclones which on the other 
hand have little proliferative potential and are at the end of their reproductive lifespan. The 
holoclone is thought to resemble the stem cell, with the paraclone being a mature progenitor. 
A mixed population of cells termed meroclones which appear to be transit amplifying or 
progenitor cells of varying maturity have also been described.
This in vitro data would be in keeping with the model proposed by Lavker et al in 1983 of a 
mixed population of basal keratinocytes functioning as follows:
Stem cells->Transit amplifying cells-*Postmitotic cells
However it is not as yet clear how far this \n-vitro data can be extended to the in-vivo 
situation. Also the successful transplantation studies of in vitro expanded keratinocytes do 
not necessarily indicate that the epidermal stem cell is still present in in-vitro culture, since 
there is some evidence to suggest that cells with only a relatively limited in vitro life
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expectancy can be transplanted, forming healthy epidermis that can persist for several years 
(Gallico 1984). Moreover epidermal keratinocytes can only be passaged in vitro a limited 
number of times. Since stem cells are thought to last at least the lifespan of the individual, 
the holoclone which undergoes senescence after a limited number of passages may in some 
way be different from the stem cell. On the other hand in vitro culture may result in the loss of 
a cell’s ‘sternness’ as a result of the stem cell being removed from its ‘niche’. This niche, that 
is the stem cell’s microenvironment, is thought to play a crucial role in preventing the cell 
from proliferation and/or differentiation (Potten 1981; Schofield 1983; Lajtha 1979), hence 
maintaining its “sternness”. According to this niche theory once the stem cell is out of this in- 
vivo microenvironment and placed in tissue culture, where it encounters a very different 
milieu of growth factors and other stimuli that it does not usually encounter in vivo, the stem 
cell will exit the stem cell compartment and undergo active proliferation. Therefore the most 
primitive stem cells may not be maintained in vitro.
The slow cycling nature of the stem cell has also been used to demonstrate this 
heterogeneity of the epidermal basal layer. Bickenbach et al (1981) have shown that when 
newborn mice are labelled with a series of injections of tritiated thymidine, nearly all the basal 
keratinocytes are labelled initially. If the basal keratinocytes are a homogeneous population a 
50% reduction in labelling at every round of division should occur. This would rapidly result in 
a low background level of labelling. However if the animals are examined several months 
after labelling a small proportion of heavily labelled cells can still be found. Although labelled 
basal non-keratinocytes have to be excluded (eg Langerhans cells which have a slow 
turnover in the epidermis and would also retain labelling), a population of label retaining basal 
keratinocytes is identified. Interestingly Morris (1986) has shown that when murine epidermis 
is treated with a labelled carcinogen, and the epidermis also exposed to tritiated thymidine, 
the basal layer label retaining cells are also found to be carcinogen retaining. It has been 
suggested that these label-retaining basal cells are the epidermal stem cells. On the other 
hand however it has also been shown that the bulge area of the hair follicle also contains 
large numbers of label retaining cells (Cotsarelis et al 1990). The significance of these label 
retaining cells with regards to interfollicular epidermis remains a matter for debate, although 
it appears clear that the hair follicle is the main repository of clonogenic keratinocytes 
(Rochat et al 1994). It has been proposed that under normal conditions the follicular stem
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cells do not participate in the renewal of interfollicular epidermis. However each hair follicle 
constitutes a unique reserve of of clonogenic cells that can be recruited when the epidermis 
is damaged. Therefore under normal conditions clonogenic basal cells, the label-retaining 
cells, function as interfollicular epidermal stem cells (Rochat et al 1994). There is as yet little 
evidence to suggest that the formation of both hair and the epidermis is the property of a 
single follicular keratinocyte stem cell.
1b) The Basal Layer and Epidermal Structural Organisation: The EPU.
The basal layer which is clearly comprised of a heterogeneous population of keratinocytes 
has a definite pattern of organisation which appears to vary in complexity depending on the 
epidermal site. In certain sites such as the thin epidermis of the mouse ear or back, the 
epidermis is highly organised into vertical ordered columns of suprabasal keratinocytes and 
flattened terminally differentiated squames (Mckenzie 1969) which probably extends into the 
basal layer. This structural organisation has led to the proposal of the ‘epidermal proliferative 
unit’ (EPU) hypothesis by Potten (1974).
Since fixing, dehydration and embedding produce much distortion and limit the optical 
resolution, the ordered structure of epidermis was not appreciated until 1969 when 
specialised histological methods for analysing epidermis became available. The stratum 
corneum appears to consist of several flat and featureless layers when observed under 
normal H&E section. However when it is chemically swollen in 0.1M NaOH it reveals a 
remarkable degree of structural organisation (MacKenzie 1969; Christophers 1971.). The 
flattened keratinised cells are seen to be precisely stacked one above the other in ordered 
columns of cells. When viewed from above the squames appear as flat, hexagonal plates 
and are easily appreciated by scanning electron micrography, or by staining the cells using 
silver impregnation methods (Mackenzie and Linder 1973). These layers in thin mouse 
epidermis are particularly evident from the surface appearance of the epidermis after silver 
staining of sheets of epidermis or in scanning electron micrographs. These squames which 
appeared perfectly aligned into columns, can in the thin mouse back or ear epidermis, be 
projected back through the ten or so cell layers to the basal layer. These findings suggested 
that the epidermal columns could each be separate proliferative units (Potten et al 1974; 
1976) termed 'Epidermal Proliferative Units' or EPUs. The EPU in mouse ear epidermis
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contains approximately 20 cells, half of which are differentiating or differentiated, while the 
other half (-10) form a lower proliferating layer. Interestingly there is very little variation in the 
number of cells in this bottom layer per column/EPU. Of these 10 cells 3 or 4 appear to be 
arranged in a subunit consisting of a single Langerhans’ cell and 2 or 3 basal cells in contact 
with it (Allen and Potten 1974). This subunit is surrounded by a ring of approximately 6 cells, 
where under steady state conditions most of the keratinocyte proliferation occurs. It is 
thought that each unit contains a single clonogenic cell (Potten and Hendry 1973). Studies 
using tritiated thymidine have shown that the central subunit in the EPU contains the slowly 
cycling label retaining cell while the peripheral ring of cells appear to be cycling faster than 
the central cells. These peripheral cells appear to be more mature cells (Christophers 1971) 
since upwards migration tends to occur at the EPU edges. The central label retaining cell in 
the EPU is unlikely to be the most primitive epidermal stem cell, since then approximately 
10% of the basal layer cells, 5% of the total mouse ear epidermal cells, would be stem cells. 
In view of the probable heterogeneity of the stem cell and progenitor cell compartments it is 
likely that the central basal EPU cell may be a more mature stem cell, or like the day 12 CFU- 
S, an early transient amplifying cell.
The role of the immature dendritic Langerhans’ cell in the central subunit of the EPU remains 
unclear. It has been postulated to be the EPU stem cell although this is now clearly incorrect 
(Morris 1985). The Langerhans’ cell may however be involved in the regulation of the 
proliferation of the EPU clonogenic cell ( Potten and Allen 1976).
Although our understanding of the proliferative organisation of the epidermis owes a lot to the 
EPU concept, unfortunately the epidermis is very variable in its organisational structure from 
site to site, between species and with age (Wright and Allison 1984). For example although 
primate epidermis shows a columnar pattern, there is a considerable degree of variation in 
the extent to which these columns interdigitate with each other. Also in some sites such as 
palmar and plantar epidermis which have a high turnover rate (including mouse footpad), 
there is no discernable EPU. In fact an EPU could not be demonstrated in oral mucosa, lip, 
nipple or vagina (Mackenzie 1973). On the other hand a number of investigators (Menton and 
Eisen 1971, Mackenzie 1981) have shown that there is a columnar pattern of organisation in 
human stratum corneum from the abdomen, scalp, chest and arm. However this could not be 
traced beneath the stratum granulosum. Also the overlap zone between contiguous squames
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was more marked in human epidermis, although the stratum granulosum cells can exhibit a 
highly organised pattern (Hume and Potten 1983). Therefore in body sites where the 
epidermis is thicker, there is little structural evidence to support the existence of the EPU. 
Furthermore in experiments using chimeric animals, cells with markers that had originated 
from different embryos appeared to cross the EPU boundaries (Schmidt et al 1987) in mouse 
back epidermis. On the other hand however studies of the patterns of intercellular junction 
communication in both mouse (Kam et al 1986) and human epidermis (Salomon et al 1988) 
suggest that in vivo the epidermis is subdivided into many small communication 
compartments which are very similar both in size and organisation to the EPUs. Furthermore 
studies of retrovirally labelled keratinocytes, transduced in vitro and retransplanted back to in 
vivo sites, have demonstrated that these cells redevelop an ordered columnar structure with 
restriction of transduced, p-gal staining, cells to individual columnar units (Mackenzie et al 
1997; Kolodka et al 1998). Therefore, although the concept of the EPU has been 
controversial, there is considerable evidence for its existence as an intrinsic feature of the 
epidermis.
Epidermal heterogeneity clearly complicates the study of epidermal stem cells. It is likely that 
such regional differences are intrinsic to the genetic program of the epidermal cells of the 
particular site. In palmar and sole epidermis, which are much thicker than most other body 
regions, the epidermis is thick at birth and contains large quantities of a specific keratin K9 
which is only present in minute quantities at other epidermal sites (Knapp 1986). Also the 
transplantation of sole epidermis to the chest of a guinea-pig results in a graft that maintains 
the histologic features of its donor site (Billingham 1963). This suggests that this regional 
variability is intrinsic to the gene expression pattern of the cells (Miller et al 1993).
These regional differences in the epidermal cells' genetic program may explain the very 
different spatial order noted in monkey palm epithelium, which is highly organised into regular 
and alternating deep and shallow rete ridges (Lavker and Sun 1982 and 1983). They 
recognised two morphologically distinct populations of cells in the epidermal basal layer 
depending on the presence or absence of well-developed cellular projections extending deep 
into the papillary dermis, resulting in a highly convoluted epidermal-dermal junction. They 
described these cells as serrated and non-serrated cell respectively. The non-serrated cells 
were present in the basal layer of the deep rete ridges and appeared to be morphologically
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primitive and slow cycling. They were heavily melanised and occupied a highly-protected site 
in the epidermis. These cells were thought to represent the palm epidermal stem cell 
population. They appeared to give rise to a population of rapidly proliferating cells located 
immediately above them in the suprabasal layers. The serrated cells were located in the 
basal layer of the shallow rete ridges and appeared to be transient amplifying epidermal cells 
that had ascended along the shoulder of the deep rete ridge.
Interestingly a separate group have also shown that receptors for epidermal growth factor 
(EGF) are primarily present on the basal cells in the deep rete ridges (Misumi 1991). 
Moreover p! integrin, which has been suggested to be a useful marker for the most primitive 
keratinocytes in vitro (Jones and Watt 1993), has also been shown to be expressed primarily 
in these same cells positioned in the deep rete ridges of human palm epidermis (Jones et al
1995) suggesting that this may be the site of epidermal stem cells in the non-follicular human 
palm skin.
c) The Integrins and Basal Cell Heterogeneity. A Keratinocyte Stem Cell Marker?
The integrins are a large family of widely expressed cell surface adhesion receptors (Hynes 
1992). All integrins discovered to date are heterodimers of a and p subunits which are 
products of separate genes and are mutually interdependent for correct processing and 
surface expression. Integrins possess a generally conserved structure with a large 
extracellular domain, a transmembrane segment and usually a short intracellular C-terminal 
cytoplasmic domain. Integrins perform their functions primarily by interacting with 
components of the insoluble extracellular matrix or surface proteins on other cells. They 
serve as membrane-spanning molecular bridges between extracellular ligands - such as 
fibronectin, vitronectin, collagen, laminin - and intracellular cytoskeletal proteins. They are 
also important signalling molecules with the signal transmission occuring in two directions: 
extracellular cues are transmitted into the cell following integrin-ligand binding leading to 
events such as tyrosine phosphorylation, intracellular calcium fluxes, changes in the 
cytoskeleton, cell activation and differentiation. On the other hand cells can regulate the 
function of their surface integrins (Reviewed by Faull and Ginsberg 1995).
Studies have shown that as keratinocytes leave the basal layer they downregulate integrin 
function and expression (Adams and Watt 1990). This downregulation may be central to the
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upward movement of basal cells committed to terminal differentiation. In vitro data suggests 
that during terminal differentiation, human epidermal keratinocytes lose their adhesiveness to 
fibronectin, laminin and collagen (types I and IV) because of the down regulation firstly of 
integrin function and then of cell surface integrin expression. This keratinocyte differentiation 
programme suggests that the more primitive epidermal basal cells have a special relationship 
with the underlying basement membrane. Interestingly in an in vitro differentiation model 
where human epidermal keratinocytes are induced to differentiate in a suspension of 
methylcellulose, the integrin ligand fibronectin is able to inhibit keratinocyte terminal 
differentiation by binding to the integrin a5|31 receptor (Adams and Watt 1989). This 
suggests that the in vivo relationship of the undifferentiated keratinocyte with its ‘niche’ may 
be involved in the regulation of its differentiation.
Interestingly Jones and Watt (1993) have also shown that the proliferative potential of human 
epidermal keratinocytes in vitro bears a log linear relationship with the expression of p1 
integrin. They have shown that cells with the highest colony forming efficiency are able to 
adhere most rapidly to type IV collagen, fibronectin or keratinocyte extracellular matrix and 
also have the highest expression of a2, a3, a5 and p1 integrin, suggesting that these 
integrins may be markers for keratinocyte ‘sternness’ and may prove useful in determining 
the site of the most primitive epidermal cells. On the other hand keratinocytes with a limited 
capacity for cell division (between 1 -5 rounds) adhered more slowly and expressed lower 
levels of the same integrins.
To examine the distribution of integrin expression immunohistochemical analyses of human 
skin from different sites have been performed (Jones, Harper and Watt 1995). The integrin- 
bright cells in human foreskin epidermis were found adjacent to the tip of the dermal 
papillae, while in the human palm the integrin-bright regions were in the tips of the deep rete 
ridges. Also in the scalp a cuff of integrin-bright cells was seen where the hair follicles 
opened onto the skin. These results indicate that the most primitive epidermal keratinocytes 
occupy these integrin-bright sites. However although this distribution in integrin expression 
in the basal layer is in keeping with the observation that the basal layer consists of a 
heterogeneous population of keratinocytes, nearly 40% of the basal cells were integrin bright, 
which suggests that not all integrin-bright basal cells are ‘true’ stem cells since it is thought 
that the proportion of basal cells that are stem cells is much lower than this. It is likely that the
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integrin-bright population comprises not only the small stem cell pool but also a pool of transit 
amplifying cells. Therefore although pi integrin is a surface marker of epidermal stem cells, it 
is not sufficient to define the stem cell pool exclusively. As for haemopoietic stem cells, a 
number of markers will probably be needed to separate out the epidermal stem cell pool. 
Finally Jones et al (1995) have also shown that when primary foreskin keratinocytes are 
cultured on plastic dishes as sheets of cells that can be detached from the culture dishes 
with dispase, the keratinocytes form patches of integrin-bright cells. This suggests that 
integrin expression is an intrinsic feature of the clonogenic cell program and not dependent 
on the stem cell ‘niche.’ Interestingly, when the normal program of integrin expression in the 
epidermis is disturbed by the suprabasal overexpression of p i, a2pi, or a5pi integrins in 
transgenic mice under the control of the involucrin promoter, epidermal homeostasis is upset 
with perturbed keratinocyte differentiation and epidermal hyperproliferation (Carroll, Romero 
and Watt 1995). The mechanism that results in this phenotype remains unclear. It has been 
postulated that the abnormal pattern of suprabasal integrin expression alters basal 
keratinocyte proliferation and differentiation.
1.4.1.2 The Stratum Spinosum.
As the basal keratinocytes move up into the suprabasal layers, they start flattening out and in 
histologic section appear to be joined to each other by ‘spines’ that protrude from the cell 
membrane. These spines correspond to bundles of keratin filaments which insert into the 
desmosomes of the adjacent cells. Spinous cells contain large and dense bundles of these 
differentiation-specific keratin filaments which form concentric rings around the nucleus. 
These cells devote much of their protein synthesising machinery to manufacturing these new 
keratins (keratin 1 and keratin 10) forming cytoskeletal filaments that aggregate into thin 
(tonofilaments) bundles (Eichner 1986). In addition spinous cells make glutamine and lysine 
rich envelope proteins which are deposited on the inner surface of the plasma membrane of 
each cell.
The stratum spinosum varies considerably in thickness, but in human skin it usually forms 
between four to eight layers, with the spinous cells in the upper layer being much more 
flattened than the suprabasal layer cells. In these uppermost cells new organelles, called 
lamellar granules can be identified, which are membrane-bound structures containing a
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series of disk-like lipid bilayers which apart from providing the epidermis with its protective 
properties (Landmann et al 1988; Menon et al 1992), also promote the shedding of dead 
corneocytes (Williams et al 1991). These lamellar granules are clustered at the cell margins 
and contain the cell membrane coating lipids that will be released in the uppermost layer of 
the stratum granulosum.
1.4.1.3 The Stratum Granulosum.
The next epidermal layer has a characteristic appearance which gives it its name. The 
keratinocytes at this stage of their differentiation program contain irregularly shaped electron 
dense keratohyalin granules. In human epidermis this layer is usually two to three cell layers 
thick although it is thicker in the epidermis of the palm and the sole. The keratohyalin 
granules become progressively larger as the keratinocyte moves into the outermost granular 
layer and contain, in normal thin epithelium, the protein profilaggrin. Profilaggrin is a major 
component of keratohyalin and contains between ten and twelve tandemly repeated filaggrin 
units. Profilaggrin is processed into the intermediate filament-associated protein filaggrin by 
specific dephosphorylation and proteolysis. Filaggrin is a histidine rich basic protein which is 
involved in the bundling of tonofilaments into large macrofibrillar cables. This process of 
increased fibrillar packing is thought to enable the keratin filaments to survive the major cell 
destructive phase that will soon occur (Reviewed by Fuchs 1990). The keratinocytes in the 
granular layer also make the protein loricrin and a number of other structural proteins that will 
form major components of the cornified cell envelope. Cells in this layer have on the other 
hand stopped generating keratins and envelope proteins. As the granular cell reaches the 
stratum corneum it sheds the lipid filled lamellar granules. These coalesce outside the cell 
where they release their contents which seal the spaces between the granular and stratum 
corneum cells in lamellar sheets which are responsible for the barrier properties of the 
epidermis.
The granular layer is the last viable cell layer in the epidermis since the terminally 
differentiated stratum corneum is non-viable. The cells in the uppermost granular layer are in 
a state of preparation for the terminal differentiation program that results in keratinocyte 
programmed cell death or apoptosis. This complicated process, which is inadequately
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understood, occurs rapidly over about 5-6 hours and results in the formation of the cornified 
layer.
1.4.1.4 Stratum Corneum.
The number of cell layers in the cornified layer depends on the skin site and is very variable. 
In the sole of the foot or the palms of the hands the stratum corneum is much thicker than in 
other body sites and may even be over a hundred layers thick. In regions where the skin is 
thin the number of cell layers is also variable (Leigh, Lane and Watt 1994). Cell size in the 
stratum corneum is also variable depending on the region, age and sex of the subject. 
Individual corneocytes also differ significantly in structure depending on their position in the 
stratum corneum relative to the skin surface and stratum granulosum.
The geometrical pattern of stacking of keratinocytes as they leave the suprabasal layers to 
enter the stratum corneum varies between skin site, species and age (Allen and Potten 1974; 
MacKenzie 1981) and has already been discussed (cf section on EPU). As these 
differentiating cells reach the stratum corneum they become permeable which allows the 
entry of extracellular calcium into the cell (Rice and Green 1979). This activates epidermal 
transglutaminase, which then catalyses the formation of peptide bonds that cross-link the 
keratinocyte envelope proteins into a rigid cage containing keratin macrofibrils. All vestiges of 
metabolic activity cease and the end result is flattened cellular skeletons which are fused 
together and suspended in a matrix of extracellular lipid. This barrier of dead terminally 
differentiated keratinocytes sealed together by lipid in a regularly arranged pattern forms an 
impermeable, insoluble protective barrier.
1.4.2 Non-Keratinocyte Epidermal Cells.
There are a number of other cell types in the epidermis apart from keratinocytes. Langerhans 
cells, melanocytes, Merkel cells and a number of other cells can also be found. These cells 
will now be discussed in turn.
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1.4.2.1 The Melanocyte.
Melanocytes, unlike keratinocytes which are derived from the superficial ectoderm, are 
derived from the neural crest (Wright and Alison 1984). From this region undifferentiated 
melanoblasts migrate into the epidermis early in foetal development and take up a non- 
random distribution in the epidermis among the keratinocytes as a fixed cell population 
(Rawles 1947). Melanocytes are secretory dendritic cells and are predominantly found in the 
basal layer. They are easily recognised from the epidermal keratinocyte under the light 
microscope since they have a pale cytoplasm, lack keratin filaments and contain brown-black 
melanin pigment. Their unique characteristic is the presence of this pigment in 
melanosomes, which are small membrane bound structures in the cytoplasm that represent 
different stages in melanin granule formation. The number of melanosomes in a melanocyte 
is very variable and depends on the location of the melanocyte. Melanosomes are able to 
transfer the pigment in these melanin granules from their dendritic processes to 
keratinocytes, resulting in basal cell pigmentation. There is generally a fairly constant ratio of 
one melanocyte to thirty-six keratinocytes in the epidermis, and although this ratio may vary 
somewhat from site to site, there is little doubt that there is an intimate relationship between 
keratinocytes and melanocytes. The structural and functional significance of this distribution 
has been described in the epidermal-melanin unit (EMU) model.
1.4.2.2 The Merkel cell.
Merkel cells are neuroendocrine cells found in the epidermis, hair follicle and mucosal 
epithelium. Unlike both the melanocyte and the Langerhans’ cell the Merkel cell probably 
originates in the epidermal ectoderm (Moll et al 1990) and in fact keratins have been 
identified in these cells. Like the melanocyte the Merkel cell is typically located in the basal 
layer. There are fewer Merkel cells than melanocytes or Langerhans’ cells in the epidermis. 
In certain sites, such as the finger-pads, palms, feet, face and lips the Merkel cells are more 
prevalent. This is in keeping with the mechanosensory role of these cells. These cells are 
thought to be able to release neurotransmitters (Tachibana et al 1995) and are associated 
with intraepidermal unmyelinated nerve endings with which they appear to synapse. Merkel 
cells are thought to store these neurotransmitters in small intracellular membrane bound 
granules. These cells may also have a number of other functions and may have both
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chemoattractive and trophic activities on peripheral nerve endings (Tachibana-et al 1995). It 
has also been suggested that these cells may be involved in the regulation and maintenance 
of the keratinocyte population, perhaps by secreting paracrine factors that can modulate 
keratinocyte proliferation and differentiation (Hartshuhe 1989).
1.4.2.3 The Y&T-cell.
T-cells have been known to be present in epithelia for some time, however their function has 
been largely unknown. Although both a|3 and y b  T-cells have been detected in human 
epidermis (Bos et al 1990), a number of studies have suggested that the majority of 
epidermal T-cells are y b  T-cells (Reviewed by Tigelaar and Lewis 1995). These cells form a 
dendritic network amongst basal layer keratinocytes and display striking T-cell receptor 
homogeneity. Nearly all epidermal y b  T-cells in normal adult mice, regardless of strain, 
express identical yb  T-cell receptors all using the same y  and y  gene coding segments and 
lack the diversity seen in other ap and y b  T-cells (Asarnow et al 1988). Therefore unlike other 
T-cells, whose T-cell receptor heterogeneity permits the recognition of a broad array of 
antigens, yb  dendritic epidermal T-cell antigen recognition is very restricted and may be 
limited to one ligand. Interestingly such cells are found not only in the epidermis, but also in 
the epithelium of the tongue, intestinal tract, vagina and uterus (Itohara et al 1990).
The role of these cells is not fully understood (Reviewed by Boismenu and Havran 1998). It 
has been suggested that these cells may have an immune surveillance role, recognising a 
common self-antigen expressed by transformed, damaged or otherwise altered cells in the 
epidermal microenvironment (Asarnow et al 1988). The antigen in question has not as yet 
been characterised, although studies have shown that epidermal y b  T-cells are able to 
recognise physically/chemically stressed keratinocytes in vitro (Havran et al 1991). A number 
of studies have shown that dendritic epidermal T-cells are able to secrete a number of 
cytokines (Reviewed by Takashima and Bergstresser 1996) including IL-2, IL-3, IL-4 and 
IFN-y. Furthermore these cells can be stimulated to secrete the keratinocyte growth factor 
KGF suggesting that y b  epidermal T-cells may be involved in the control of keratinocyte 
proliferation on epithelial wounding (Boismenu et al 1994). Interestingly T-cell receptor 
mutant mice lacking y b  T-cells have reduced intestinal epithelial cell turnover suggesting that 
these cells are involved in the regulation of the proliferation of intestinal epithelial cells
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(Komano et al 1995). In vitro studies using an epidermal yb T-cell cell line also suggest that 
these cells can be stimulated to secrete MIP-1 a, MIP-1 p, RANTES and lymphotactin 
(Boismenu et al 1996). The role of these molecules is not clear, although they too may be 
able to modulate the functions of nearby keratinocytes and Langerhans cells. However 
MIP-1 a has not been detected in epidermal yb T-cells in vivo, the only detectable source 
being Langerhans cells (see below). However epidermal keratinocytes do appear to secrete 
IL-7, which is both a mitogen and a survival factor for epidermal yb T-cells. These and other 
studies suggest that a complex network of interactions exists between keratinocytes, yb  
dendritic epidermal T-cells and Langerhans cells (Takashima and Bergstresser 1996).
1.4.2.4 The Langerhans Cell.
This cell was named after the German medical student Paul Langerhans who in 1868 
described a population of intraepidermal dendritic cells in skin impregnated with gold 
chloride. This phenotype led him to postulate that these cells were nerve cells. It is now clear 
however that these dendritic cells are derived from the haemopoietic stem cell (Katz et al 
1979; Frelinger et al 1979) and that there are a number of different Langerhans cell 
phenotypes (Nestle et al 1993). Dendritic cell progenitors are thought to originate in the bone 
marrow, enter the blood and seed non-lymphoid tissues such as the epidermis, where they 
develop into a stage of dendritic cell (sometimes referred to as immature dendritic cells) with 
optimal capabilities for antigen uptake, presentation and processing. Langerhans cell 
progenitors have been found both in bone marrow and circulating in peripheral blood (Inaba 
1992a, 1992b) and large numbers of dendritic cells with a phenotype very similar to 
Langerhans cells can be cultured in vitro from both bone marrow and peripheral blood in the 
presence of cytokines such as GM-CSF and IL-4 (Romani et al 1994).
Under the light microscope the Langerhans cell is not easily identified in the epidermis. Their 
presence is sometimes suggested by their clear cytoplasm and their suprabasal position. The 
use of histochemical or immunohistochemical techniques (using anti-CD1a antibody) have 
made their identification easier. Langerhans cells do however have a characteristic 
ultrastructural appearance (Birbeck et al 1961). Under the electron microscope these cells 
possess a lobulated or indented nucleus, a clear cytoplasm and characteristically contain 
distinctive intracytoplasmic granules. The presence of these granules, now known as Birbeck
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granules, has become established as one of the hallmarks of the Langerhans cell since 
these granules are not found in any other cell type. The function of Birbeck granules remains 
a matter for debate. Most of the granules in the Langerhans cell are found in the cell 
cytoplasm but some are found near or attached to the plasma membrane. This has led to two 
main lines of thought, one proposing that the Langerhans cell granule has a secretory role, 
the other suggesting an endocytic role (Reviewed by Schuler 1991). Despite some discord, it 
is clear that Langerhans cell granules can participate in the trafficking of molecules that enter 
the cell by receptor-specific endocytosis. The study of Langerhans cell protein secretion has 
been difficult since obtaining enough purified fresh Langerhans cells for these experiments 
involved the sacrifice of several hundred mice. However now that Langerhans cells can be 
cultured in vitro from bone marrow in large numbers these issues may be more easily 
addressed. Furthermore ‘Langerhans cell like’ cell lines have recently been isolated from the 
epidermis of newborn mice (Xu et al 1995a). These cell lines may be useful in these studies. 
However in view of the known functional and phenotypic heterogeneity of epidermal 
Langerhans cells and of these cell lines (Shibaki et al 1995; Xu et al 1995b), results from 
these studies may be only of limited value. The in vitro expansion of Langerhans cells from 
CD34 positive cells in the presence of the appropriate growth factors may also prove useful 
for these studies, although similar problems are likely to be encountered. Furthermore it has 
been observed that when Langerhans cells, freshly isolated and purified from the epidermis 
by immuno-magnetic panning, are cultured in vitro they alter their protein expression pattern 
which indicates that in vitro culture can alter the phenotype of these cells (Heufler et al 1992). 
Interestingly these studies have shown that freshly isolated Langerhans cells express IL-1p 
and MIP-1 a mRNA. However on in vitro culture MIP-1 a expression is downregulated while 
IL-1 p is strongly upregulated. In vitro expansion and cell-line work must therefore be 
interpreted cautiously since the Langerhans cell’s phenotype and activation state must be 
taken into account.
Epidermal development and the Langerhans cell.
Langerhans cells are thought to migrate into the epidermis early on in development and are 
distributed non-randomly in this tissue. Studies have shown that LC can be identified in 
human embryonic epidermis as early as 7-9 weeks estimated gestational age (Fujita et al
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1991). These dendritic cells appear to be smaller and less dendritic than adult Langerhans 
cells, and phenotypically heterogeneous. Birbeck granules can easily be delineated by a 
specific anti-Birbeck Granule antibody by 10 weeks estimated gestational age. By the second 
trimester these cells resemble adult Langerhans cells both morphologically and 
phenotypically. Furthermore biopsies from different body sites in the second trimester 
indicate that the development of these epidermal dendritic cells undergoes regional 
differences during this time. Langerhans cell numbers in the palms and soles, which increase 
up to 12 weeks estimated gestational age, are seen to subsequently decrease and are rarely 
detected after 18 weeks. In other regions however, the Langerhans cell numbers are greater 
after 16 weeks estimated gestational age. Interestingly during this second trimester regional 
variations in epidermal development also become evident with the epidermis of the palms 
and soles showing earlier keratinisation with a thicker stratum corneum than elsewhere in the 
body (Holbrook et al 1980) but there is as yet no evidence to suggest that the two are related. 
In fact the mechanism that regulates foetal epidermal Langerhans cell numbers remains 
undefined.
Langerhans cell distribution.
In the adult these regional variations in Langerhans cell density persist. The number of 
Langerhans cells per mm2 of skin surface varies from 460-1000/mm2, the average adult 
human having approximately 2X109 Langerhans cells in the skin (Reviewed by Schuler 
1991). There are now several reported studies in the literature analysing Langerhans cell 
distribution. These studies also reveal that there is considerable inter-subject variability in 
Langerhans cell density at any given site.
The Langerhans Cell and the immune response.
There is no doubt that the Langerhans cell has immune functions during the inductive phase 
of immune reponses that originate in the epidermis. Langerhans cells function as potent 
accessory cells for the induction of primary T-cell dependent immune responses originating 
in the skin. It is also thought that Langerhans cells are immature precursors of lymphoid 
dendritic cells. Evidence for this comes from the in-vitro culture of freshly isolated epidermal 
Langerhans cells (Steinman et al 1995). In culture these cells increase in cell size and T-cell
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immunostimulatory activity and there is extensive remodelling of the cell surface. Major 
histocompatiblity antigens class I and II products are upregulated as are ICAM-1 and LFA-3. 
This apparent phenotypic change is accompanied by a functional maturation as these cells 
become efficient at capturing and presenting foreign antigen to T-cells. After this these 
immunologically mature dendritic cells downregulate their antigen processing function and 
express their MHC-peptide complexes for several days. Interestingly cytokines such as GM- 
CSF and TNF-a are able to induce this dendritic cell maturation. The epidermal Langerhans 
cell therefore appears to be a phenotypically immature immune cell that can be induced to 
take up an immunologically mature phenotype on exposure to certain stimuli. Following 
antigen uptake these cells migrate from the skin through the dermis, where mature dendritic 
cells with some of the features of Langerhans cells have been observed, to the draining 
lymph nodes where they can initiate an immune response. Little is known about what 
happens to these dendritic cells after they have carried out their antigen presenting function 
in the lymph node. It has been suggested that after encountering antigen, mature dendritic 
cells can become targets for natural killer cell-mediated destruction (Shah et al 1986). It has 
also been proposed that these cells may undergo spontaneous apoptosis (Ludewig et al
1995).
There appears to be a considerable flux of dendritic cells in cutaneous afferent lymphatics 
This seems to argue against an origin from the less-abundant pool of epidermal Langerhans 
cells (Steinman et al 1995) particularly since a number of studies have shown that the 
turnover of the resident epidermal dendritic cells is slow in the steady state. In fact in the 
experiments that defined the haematopoietic origin of Langerhans cells (Katz et al 1979) it 
took 30-60 days for the donor bone marrow derived Langerhans cells to start replacing the 
original recipient cells. Similar findings have been observed by Krueger et al (1983) who 
found that the turnover of these epidermal dendritic cells took several months. Chen et al 
(1986) also observed prolonged survival of some dendritic cells in transplanted skin, finding 
donor skin derved Langerhans cells as late as six months after skin transplantation. Although 
proliferating Langerhans cells have been observed in the epidermis this is unlikely to explain 
the numerical discrepancy. The well recognised heterogeneity of this cell population may 
however in part account for these observations. There may be different pools of dendritic 
cells in the skin, some of which are long lived and others short lived (Steinman et al 1995).
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Langerhans cells are therefore found not only in the epidermis, but also in the dermis, 
draining lymphatics and lymph nodes. They are also found in non-keratinised, stratified 
squamous epithelia like the conjunctiva, the corneal limbus, oral mucosa, tonsillar and 
oesophageal epithelium, vagina and uterine cervix. These cells are normally absent from 
other epithelia, but may settle there if squamous metaplasia has taken place (Reviewed by 
Schuler 1991). They are also found in the thymus. Considering the immune surveillance 
function of these cells as outposts of the immune system it is perhaps surprising that these 
cells are not more widely distributed. Dendritic cells have been observed in the lungs but 
these appear to be phenotypically distinct from epidermal Langerhans cells in that they lack 
the hallmark Birbeck granule. There are also CD1a positive cells in the stroma of the 
placenta and in the submucosa of the bladder, but their precise lineage remains to be 
characterised. It has been suggested that there may in fact be cells with many of the features 
of Langerhans cells present throughout the body, however this remains controversial.
The Langerhans cell and the regulation of keratinocyte proliferation.
It has also been suggested that the Langerhans cell is also involved in regulating the 
proliferation of keratinocytes in the epidermis. However although the hypothesis proposed is 
plausible, the evidence for the role of the Langerhans cell in keratinocyte proliferation has 
been circumstantial and must be interpreted with some caution. A number of questions 
remain. However it is thought that these cells must have other roles apart from immune 
surveillance (Schuler 1991). Moreover the epidermal Langerhans cell has been shown to 
constitutively express MIP-1 a when it appears to be immunological quiescent (Heufler et al 
1992; Matsue et al 1992; Parkinson et al 1993). The geographical location of the Langerhans 
cell in the EPU and the inhibitory profile of MIP-1 a suggest that this multifunctional cytokine 
may not be functioning primarily as an inflammatory mediator in the epidermis. This 
chemokine may play a part in the network of regulatory cytokines that control the proliferation 
of primitive keratinocytes in the EPU (Parkinson et al 1993).
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1.5. Regulators of Epidermal Keratinocyte Proliferation.
The decision of a clonogenic keratinocyte to enter the cell-cycle from quiescence is controlled 
by a number of positive and negative regulatory growth factors. A number of keratinocyte 
mitogens have been identified. These include members of the Epidermal Growth Factor 
(EGF) family such as Transforming Growth Factor-a (TGF-a), amphiregulin and EGF itself 
as well as the Fibroblast Growth Factor homologue Keratinocyte Growth Factor (KGF) and 
Interkeukin 6 (IL-6). A number of negative regulators have also been characterised and these 
include TGF-p, TNF-a, and the Epidermal Pentapeptide (EPP). These growth factors and 
their role in epidermal keratinocyte proliferation will now be discussed in turn.
1.5.1 Positive Regulators.
1.5.1.1 The Epidermal Growth Factor (EGF) Family.
The EGF family of growth factors is characterised by a conserved amino-acid sequence 
including six essential cysteine residues that form three conserved disulphide bonds 
(Reviewed by Todaro et al 1990). This structurally conserved domain is characteristically 
cleaved from a larger membrane-bound precursor polypeptide and is then released into the 
surrounding medium. The soluble growth factor can then function to regulate cell proliferation 
in an autocrine or paracrine manner. A number of EGF-like molecules have been descibed, 
however only EGF, TGF-a and amphiregulin will be discussed here.
a) Transforming Growth Factor-a (TGF-a).
TGF-a was initially discovered as a factor produced by cells transformed by sarcoma viruses 
and by various human tumour cells. This factor binds to the EGF receptor and is able to 
convey a transient transformed phenotype to normal cells in culture (DeLarco et al 1979; 
Todaro et al 1980). A 50 amino-acid polypeptide, human TGF-a is highly homologous to 
human EGF, and like EGF the primary translation product of the TGF-a gene exists as a 
transmembrane glycoprotein. The mature TGF-a molecule is proteolytically derived from this 
transmembrane precursor (Teixido et al 1987; Gentry et al 1987). TGF-a is expressed in a 
wide variety of tissues including the epidermis. Further study has shown that TGF-a is 
expressed by epidermal keratinocytes and functions as a keratinocyte autocrine regulator
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(Coffey et al 1987). TGF-a also promotes keratinocyte migration in vitro and it has been 
suggested that this migration is essential for the maintenance of keratinocyte colony growth 
(Barrandon and Green 1987). This cytokine functions in the epidermis by activating 
epidermal growth factor receptors (EGFRs) on the surface of basal keratinocytes and is more 
potent than EGF.
Elevated levels of TGF-a have been associated with a variety of hyperproliferative skin 
diseases, such as psoriasis and cancer (Gottlieb et al 1988; Elder et al 1989; Derynck et al 
1987). The expression of TGF-a in tumours is often accompanied by enhanced synthesis of 
the EGF/TGF-a receptor (Gottlieb et al 1988). In squamous cell carcinomas elevated levels 
of both TGF-a and EGF receptors have been identified (Ozanne et al 1986). Further 
evidence for a direct role for TGF-a and the EGF receptor in the pathogenesis of 
hyperproliferative epidermal disorders comes from transgenic mice overexpressing TGF-a in 
the basal layer of the epidermis under the control of the keratin 14 promoter (Vassar and 
Fuchs 1991). These mice have a wrinkled and flaky skin, with a markedly thickened 
epidermis and bromodeoxyuridine labelling indicates that there is approximately a two-fold 
increase in the number of DNA synthesising cells in the mitotically active basal layer. These 
mice also have a pronounced granular layer in the epidermis. Interestingly these mice do not 
appear to be at an increased risk of squamous cell carcinoma although skin papillomas are 
common at sites of injury or mechanical abrasion, as well as on TPA treatment. These 
results suggest that although TGF-a is a very potent keratinocyte mitogen, TGF-a 
dysregulation alone is not sufficient to induce carcinogenesis.
However TGF-a does appear to be crucial to the determination of normal skin architecture 
since TGF-a knockout mice have a deranged epidermal structure (Mann et al 1993; Luetteke 
et al 1993). Although mice homozygous for a disrupted TGF-a gene are healthy and fertile, 
with a normal thickness epidermis and apparently normal keratinocyte maturation, their coat 
is abnormally wavy with pronounced waviness of the whiskers and hair and there is 
considerable disarray, disorientation and misalignment of the hair follicles. These mice also 
have corneal abnormalities with corneal scarring and superficial opacity as well as reduced 
eyeball size and open eyelids at birth. These results therefore indicate that TGF-a plays a 
central role in determining the architecture of the epidermis and the corneal epithelium. Since 
surprisingly loss of TGF-a does not appear to influence epidermal keratinocyte proliferation
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or differentiation it is likely that the loss of this cytokine can be compensated for by 
recruitment of a related molecule encoded by a different gene. This is likely since a number 
of different ligands are known to be able to compete with TGF-a for binding to the EGF 
receptor. Confirmation of this hypothesis comes from EGF-receptor (EGF-R) knockout mice 
which have impaired epithelial development in a number of organs including the epidermis 
(Miettinen et al 1995). These mice die soon after birth and have abnormally thin skin which is 
often almost transparent. This skin is very fragile and contains a significantly decreased 
number of hair follicles which are disorientated and which did not often penetrate the 
epidermis. These mice have a much more severe phenotype than TGF-a knockouts which 
indicates that a number of EGF-R ligands are involved in binding to the EGF-R in the 
epidermis.
b) Epidermal Growth Factor (EGF).
EGF was first isolated from the submammary gland of the male mouse as a protein that 
accelerated incisor tooth eruption and eyelid opening in the new-born animal (Cohen 1962). It 
was then shown to be a a potent mitogen for epidermal keratinocytes (Cohen 1975). Further 
studies have shown that EGF is mitogenic for a number of other cell types in culture 
(Reviewed by Prigent and Lemoine 1992). A 53 amino-acid peptide, it is derived from a 1217 
amino-acid precursor that is initially expressed as a transmembrane molecule. Proteolytic 
cleavage of this precursor generates the mature EGF protein. EGF is not detected at all in 
foetal life (Popliker et al 1987). In the adult apart from the curiously high concentrations found 
in the submaxillary gland, in urine and in milk, EGF only appears to be expressed at easily 
measurable levels in the adult kidney and by the Brunner’s glands of the small intestine (Rail 
et al 1985). In vivo, in the epidermis, EGF is therefore likely to play a secondary role to TGF- 
a. Like TGF-a, EGF also functions by activating the 170kDa tyrosine kinase EGF receptor 
which is expressed by almost all cell types but most abundantly by epithelial cells (Green et al 
1984). Like TGF-a, EGF is a potent mitogen for epidermal keratinocytes. EGF also 
stimulates the migration of these cells from the centre of keratinocyte colonies in vitro, and is 
used in the routine culture of these cells in vitro (Rheinwald and Green 1977).
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c) Amphiregulin.
Amphiregulin is a heparin-binding member of the EGF receptor ligand family and was initially 
discovered as a secreted product of a human breast adenocarcinoma cell line MCF-7 treated 
with TPA (Schoyab et al 1988). The truncated form consists of 78 amino-acids and the 
carboxyl terminal half of this cytokine is highly homologous to EGF. Amphiregulin is a 
bifunctional growth regulator, stimulating the proliferation of normal epithelial cells but 
inhibiting the growth of a variety of human tumour cells. Amphiregulin competes with EGF in 
binding to the EGF receptor, and can substitute for EGF and/or TGF-a in stimulating the 
proliferation of both human and murine keratinocytes (Shoyab et al 1989). Recent studies 
suggest that like TGF-a, amphiregulin may be involved in the pathogenesis of a number of 
hyperproliferative disorders (Piepkorn et al 1996).
d) Heparin-binding EGF-like Growth Factor (HB-EGF).
HB-EGF is a new member of the EGF family and was initially purified from the conditioned 
media of the U-937 macrophage-like cell line (Higashiyama et al 1991). Like TGF-a it is 
expressed by human keratinocytes and functions as an autocrine factor for these cells 
(Hashimoto et al 1994). It is therefore clear that there are a number of EGF-R ligands that 
can function as mitogens, implying a degree of functional redundancy already seen in the 
haemopoietic system. This helps explain why knockout mice deficient in only one of these 
keratinocyte mitogens do not have as severe a phenotype as the EGF-R knockouts.
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Non-EGF family mitogens.
1.5.1.2 Keratinocyte Growth Factor (KGF): A FGF-like Keratinocyte Mitogen.
Keratinocyte Growth Factor (KGF) is a member of the fibroblast growth factor (FGF) family. 
Also known as fibroblast growth factor 7 (FGF 7), it is made by dermal fibroblasts and is a 
paracrine growth factor for epidermal keratinocytes (Rubin et al 1989; Finch et al 1989). In 
culture KGF is a more potent growth factor than the autocrine growth factor TGF-a. In vivo 
KGF mRNA transcripts can be detected in the dermis of normal and wounded skin (Finch et 
al 1989). Furthermore a high affinity tyrosine kinase receptor for KGF (KGFR) has been 
identified on cultured keratinocytes (Miki et al 1991, 1992), although KGFR is not present on 
dermal fibroblasts. KGFR has been shown to be a splice variant of the FGF receptor-2 
(FGFR2), and can bind both KGF and acidic FGF (aFGF) which is also a keratinocyte 
mitogen. Since KGF is the most potent keratinocyte mitogen known, and since the level of 
KGF expression has been shown to increase by as much as 160 fold (Werner et al 1992) 
upon skin injury, it is likely that this paracrine factor secreted by dermal fibroblasts plays an 
important role in vivo. Direct evidence for this in vivo role comes from transgenic mouse 
studies. Transgenic mice were generated in which KGF expression was driven by the keratin 
14 promoter to elicit autocrine production of the factor to the basal layer of the epidermis 
(Guo et al 1993). These mice exhibited a gross increase in epidermal thickness 
accompanied by alterations in epidermal growth and differentiation, with marked suppression 
of hair follicle morphogenesis and suppression of adipogenesis. The few follicles that did 
develop however developed normally. As with the TGF-a transgenic animals, KGF transgenic 
mice developed no skin papillomas.
These results suggest that KGF can function as a potent mitogen in vivo. To further 
investigate the function of KGF in vivo KGF knockout mice have been generated (Guo et al
1996). The fur of these mice develops a rough, greasy and matted appearance with time 
indicating that the maintenance of a smooth and healthy hair coat is dependent on KGF. 
However further study on these mice has surprisingly shown that these mice develop no 
abnormalities in epidermal growth or wound healing. Furthermore TGF-a and KGF double 
knockout mice also have no evidence of any abnormality in epidermal proliferation or wound 
healing (Guo et al 1996). This is perhaps not surprising since both EGF and aFGF can 
activate EGFR and KGFR respectively, and therefore still be able to control keratinocyte
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proliferation in the absence of KGF. Therefore the KGF knockout mice have shed little light 
on the in vivo role of KGF in the regulation of epidermal proliferation and in wound healing.
To try to elucidate this a dominant negative KGF receptor transgene has been constructed 
and overexpressed in the basal cells of mouse epidermis under the control of the Keratin 14 
promoter (Werner et al 1994). It has been previously shown that mutated FGF receptors that 
lack kinase activity block FGF receptor signalling by forming non-functioning hetero-dimers 
with wild-type receptors on ligand binding (Ueno et al 1991). One would therefore expect the 
epidermal basal cells of these transgenic mice to be unable to signal through the KGFR. 
Interestingly the skin of these mice appears to be macroscopically normal. However 
histological analysis has revealed that these mice develop epidermal atrophy, with flattened 
epidermal basal cells which have pyknotic nuclei after six weeks of life, being normal at birth. 
BRDU analysis has confirmed that there is a reduced steady state proliferation rate in the 
epidermis, suggesting that loss of KGFR signalling perturbs the homeostatic mechanisms 
involved in maintaining keratinocyte proliferation. In addition these mice exhibit abnormal hair 
follicle morphology as well as reduced hair follicle numbers. Furthermore the dermis of these 
mice appears to be altered as well, with thickening of the dermis characterised by 
replacement of the normal dermal adipose tissue by connective tissue. This may be an 
indirect result of the loss of epidermal keratinocyte KGF reponsiveness, since the transgene 
does not appear to be expressed in the dermis. Furthermore wound-healing and re- 
epithelialisation are impaired in these trasgenic mice indicating that signalling through the 
KGFR may be important for normal keratinocyte migration and proliferation in wound-healing. 
However although the results of the K14 driven, dominant negative KGFR transgenics 
appear quite conclusive it has to be pointed out that this dominant negative receptor can 
complex with all FGFRs. Furthermore this transgene product may have downstream effects 
that go beyond its direct effect on the FGFR pathway. Therefore from this data alone, it is 
difficult to understand the precise role of KGF in the epidermis. However it certainly appears 
likely that the FGFR tyrosine kinase pathway is involved in the regulation of epidermal 
proliferation and wound-healing.
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1.5.1.3 Other Positive Regulators.
A number of other cytokines have been shown to enhance the growth of keratinocytes in 
vitro. These include IL-6 (Grossman et al 1989), and the chemokine IL-8 (Sticherling 1989). 
Both of these cytokines have been identified in psoriatic plaques and have therefore been 
implicated in the pathogenesis of this hyperproliferative skin disorder. IL-6 is also interesting 
in that the overexpression of IL-6 in the basal cells of stratified squamous epithelia of 
transgenic mice under the control of the keratin 14 promoter results surprisingly in mice that 
have a thickened stratum corneum. The mechanisms by which increased IL-6 
overexpression in the basal layer of the epidermis causes a thicker stratum corneum are not 
fully understood. However these mice are also smaller than normal and have retarded hair 
growth (Turksen et al 1992). The in vivo role of the CXC chemokine IL-8 in the epidermis 
remains undefined. It is however interesting to note that epidermal keratinocytes can express 
IL-8, suggesting a possible autocrine role for this chemokine.
It is therefore clear that there are a number of positive regulators of keratinocyte proliferation. 
On the other hand fewer negative regulators have been identified, perhaps because these 
molecules are generally more difficult to characterise in in vitro assays.
1.5.2 Negative Regulators of Keratinocyte Proliferation.
A number of negative regulators of keratinocyte proliferation have been described. These 
factors induce the withdrawal of the epidermal keratinocyte from the cell-cycle into a 
quiescent or Go state. This withdrawal from the cell-cycle may be important not only to 
regulate keratinocyte stem cell/progenitor cell numbers, but also for the irreversible 
commitment of a keratinocyte to terminally differentiate (Fuchs et al 1993). The most 
extensively studied negative regulators of epidermal cell proliferation are the TGF-ps.
1.5.2.1 TGF-p.
Although the prototype of the TGF-|3 family, TGF-p1, was originally defined as a factor which 
stimulated the proliferation of normal rat kidney fibroblasts in soft agar (Roberts et al 1981), 
further work has demonstrated that this family of cytokines has a wide number of different 
biological activities. In fact studies have shown that TGF-p is a negative regulator of 
haemopoietic stem cell proliferation (see section 1.2.3.5) as well as a potent negative
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regulator of keratinocyte proliferation in vitro and in vivo (Shipley et al 1986). TGF-pi has 
been shown to cause a marked reduction in pH] thymidine labelling in cultured human 
keratinocyte progenitors as well as inducing growth arrest in keratinocyte precursors in serum 
free medium. The majority of the keratinocyte progenitors cultured in the presence of TGF-p 
arrest in the Gi phase of the cell-cycle (Shipley et al 1986; Coffey et al 1988a). Since this 
growth inhibition is reversible this effect is not due to cytotoxicity. Furthermore TGF-p has 
been shown to induce terminal differentiation in normal human epithelial cells (Masui et al 
1986), although this is not a general mechanism of action for this cytokine since this does not 
occur in either cultured human foreskin keratinocytes nor in mouse keratinocyte cell lines 
(Shipley et al 1986; Coffey et al 1988b). Interestingly keratinocyte progenitors have been 
shown to secrete bioactive TGF-p, as well as having specific TGF-p surface receptors, 
suggesting that TGF-p functions in an autocrine fashion in primitive keratinocytes. In fact 
both anti-TGF-p antibody and the TGF-p latency associated peptide (LAP) are able to 
increase the proliferation rate of epidermal keratinocyte progenitors (Bottinger et al 1996). It 
is therefore clear that TGF-p is involved in the autocrine regulation of keratinocyte 
proliferation regulation in vitro. TGF-p is also a potent regulator of keratinocyte proliferation 
in vivo. Transgenic mice overexpressing TGF-pi in the epidermal suprabasal layer under 
the control of the keratin K1 promoter results in animals that have a taut shiny skin (Sellheyer 
et al 1993). Epidermal hyperproliferation has also been observed in TGF-pi knockout mice, 
although the skin in these mice is of normal thickness suggesting that other members of the 
TGF-p family may take over the role of TGF-p1 in its absence (Glick et al 1993). Furthermore 
the keratinocytes of these mice have a much higher rate of malignant progression both in 
vivo and in vitro (Glick et al 1994a and 1994b). Moreover the expression of a dominant 
negative type II TGF-p receptor in the epidermis of transgenic mice blocks TGF-p mediated 
growth inhibition and results in markedly hyperplastic and hyperkeratotic epidermis (Wang et 
al 1997). These results demonstrate that TGF-p is a physiological negative regulator of 
epidermal keratinocyte progenitors in vivo.
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1.5.2.2 TNF-a.
TNF -a has been shown to inhibit the proliferation of epidermal keratinocytes (Pillai et al 1989; 
Vieira et al 1996). Moreover keratinocytes and keratinocyte cell lines can secrete TNF-a, 
although unstimulated keratinocytes express only low levels of TNF-a mRNA and bioactive 
protein (Kock et al 1990). Since TNF-a has been reported to induce programmed cell death 
(Reinartz et al 1996), the inhibitory activity of TNF-a on keratinocytes may be related to an 
induction of apoptosis in these cells. However this keratoinhibitory activity may be 
reversible. This suggests that TNF-a is a negative regulator of keratinocyte proliferation, 
although it can also stimulate keratinocyte differentiation (Pillai et al 1989).
Further work has shown that keratinocytes express receptors for TNF-a and that the signal 
transduction cascades activated by this receptor regulate the expression of the cell-cycle 
regulatory proteins Cyclin A, Cyclin B and cdc2 as well as the phosphorylation state of the 
retinoblastoma protein Rb (Vieira et al 1996). These downstream events probably result in 
the growth arrest observed in these cells and indicate that TNF-a is a negative regulator of 
keratinocyte proliferation in vitro. However TNFa may play any one of a number of different 
potential roles in the epidermis since it has been shown to be bioactive in vitro not only on 
keratinocytes, but also on melanocytes and Langerhans cells (Reviewed by Wakefield et al 
1991).
1.5.2.3 Epidermal pentapeptide (EPP).
The pentapeptide (pyroGlu-Glu-Asp-Ser-Gly) was initially purified from mouse epidermis as 
an inhibitor of epidermal keratinocyte proliferation (Elgjo et al 1986). Further work has 
demonstrated that synthetically synthesised EPP also inhibits epidermal keratinocyte 
proliferation both in vivo and in vitro. This molecule is therefore a potential physiological 
regulator of keratinocyte regulation. Furthermore interestingly EPP has also been shown to 
inhibit murine hair growth in vivo as well as inhibit the incorporation of 3H thymidine into 
murine anagen hair follicles in vitro (Paus et al 1991). Therefore this pentapeptide may be 
involved in the control of not only epidermal keratinocyte proliferation but also hair follicle 
growth. There is however as yet little evidence to suggest a physiological role for this 
molecule.
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1.5.2.4 MIP-1a
Recent studies have shown that the chemokine MIP-1a is constitutively expressed in the 
epidermis by the epidermal Langerhans cell (Matsue et al 1992; Heufler et al 1992; 
Parkinson et al 1993). It has also been shown that an impure preparation of COS 7 cell 
derived MIP-1a is a potent and reversible inhibitor of clonogenic keratinocyte proliferation in 
vitro (Parkinson et al 1993). However further investigation has shown that the bacterial 
recombinant form of MIP-1a does not inhibit keratinocyte proliferation although it does inhibit 
the CFU-A and CFU-S haemopoietic assays. On the other hand the activity of the COS 7 cell 
derived kerato-inhibitory form is reversible by a specific polyclonal antibody to bacterial 
recombinant MIP-1a (R&D systems). This has strongly suggested that MIP-1a does inhibit 
clonogenic epidermal keratinocyte proliferation, although the discrepancy in the activity of 
these two forms of MIP-1a has not been explained.
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Aims of Thesis.
A number of studies have shown that the chemokine MIP-1a is a multi-functional cytokine, 
with a variety of different activities. This is not surprising since it is now clear that many 
cytokines are multi-functional. TGF-p for example has potent anti-inflammatory properties, 
while also being a powerful inhibitor of the proliferation of a wide variety of cell types, such as 
primitive haemopoietic and keratinocyte progenitors. MIP-1a has been shown to have a 
number of inflammatory properties. However it can also inhibit the proliferation of primitive 
haemopoietic cells as well as protect these multipotent cells from the toxicity of cytoreductive 
chemotherapy.
MIP-1a has also been shown to be expressed by a number of different cell types. Most of 
these cell types require some form of stimulation or activation to express this cytokine. 
However this chemokine is constitutively expressed in the epidermis by the epidermal 
Langerhans cell. The role of this molecule in the epidermis is unclear. However a number of 
observations suggest that this cytokine may not be behaving simply as an inflammatory 
mediator in normal epidermis. Since MIP-1a is known to be a negative regulator of 
haemopoietic progenitor cell proliferation, it is possible that MIP-1a may function in a similar 
manner on keratinocytes. Preliminary results have shown that when derived from the 
transient transfection of COS 7 cells, MIP-1a reversibly inhibits keratinocyte proliferation. 
However the pure bacterial recombinant molecule is inactive on keratinocytes, although it is 
active on the haemopoietic assay. The aim of this project was therefore to investigate the 
reason for this discrepancy, and to try and elucidate the potential role of MIP-1a in the 
epidermis.
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Materials
2.1. Tissue Culture Supplies
Beatson Institute Central Services
Amicon (USA)
Becton Dickinson UK Ltd
Clonetics (USA)
Sterile PBS
Sterile glassware and pipettes 
Sterile PE
Sterile double distilled water 
Penicillin(7.5mg/ml)
Streptomycin (1 Omg/ml)
Centriprep 10 spin columns
Tissue culture plates (35,60,90 mm) 
Falcon tubes (15ml and 50ml)
Bovine pituitary extract 
Epidermal growth Factor 
Insulin
Hydrocortisone
Amphotericin
Gentamycin
Keratinocyte growth medium
Costar
DIFCO Laboratories (Michigan, USA) 
Gibco Life Technologies (Paisley, UK)
Nunc (Roskilde, Denmark)
Gelman Sciences (UK)
Genetics Institute, Mass. (USA)
6 well plates 
Cell scrapers
Bactoagar
Special Liquid Medium 
Keratinocyte SFM
Dulbecco's modified Eagles medium
Foetal calf serum
MEM alpha medium
200mM glutamine
Sodium bicarbonate
Trypsin
Tissue culture flasks 
Nunc cryotubes
Sterile acrodiscs syringe filters 
(0.2mm and 0.45mm)
Human MIP-1a
R&D Systems (UK) Bacterial recombinant Murine and human MIP-1a
Polyclonal neutralising antibody to muMIP-1a,TNF-a 
Recombinant Latency Associated Peptide 
(Neutralizes TGF-131,2 and 3)
Non-aggregating MIP-1a mutants
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SIGMA Chemical Co. (Poole, UK)
Worthington Biochemical (UK)
2.2. Bacterial hosts and media
Beatson Institute Central Services
Beta Labs (UK)
Bibby-Sterillin Ltd (UK)
Difco labs (Detroit, USA)
Gibco (Paisley, Scotland)
2.3. Molecular Biology
Beatson Institute Oligo Service
Bethesda Research Laboratories 
Gibco(UK)
Pharmacia 
Qiagen Inc.
Ampicillin
Agarose bound chymotrypsin
Plasmin
Thrombin
Cathepsin G
Donor herd horse serum
Bovine serum albumin (fraction V)
Heparin sulphate
Heparan sulphate
Chondroitin sulphate
DEAE dextran
Chloroquine
Trypsin
L-broth
Sterile glassware 
Yeast extract
Sterilin 9cm bacteriological plates 
Agar
Bactotryptone
Bactoagar
E.Coli host strain DH5a 
Ampicillin
Oligonucleotides
DNA molecular weight markers 
DNA mass ladder
Agarose and low melting point agarose 
Restriction endonucleases with buffer concentrates 
Taq DNA polymerase, 10X PCR buffer, MgCL.
T4 DNA ligase and ligase buffer 
Calf Intestinal Alkaline Phosphatase
dNTPs (100mM set)
Qiagen plasmid preparation kits 
Qiaquick DNA purification kits
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2.4. Protein Biochemistry
Amersham International (UK)
BDH Chemicals Ltd. (Poole, UK)
Boehringer-Mannheim UK (Lewes, UK)
Dow Chemical Company (UK)
Du Pont NEN
Eastman Kodak Co.
(Rochester, USA)
Millipore
Pharmacia
Pierce & Warriner (UK)
R&D Systems (Abingdon, UK)
Schleicher & Schuell 
(Dassel, Germany)
Severn Biotech Ltd. 
(Kidderminster, UK)
Sigma Immunochemicals (UK)
Technical Photo Systems 
(Cumbernauld, UK)
Whatmann International Ltd. 
(Maidstone, UK)
ECL Western blotting detection reagents 
Rainbow molecular weight markers
Acrylamide
bis-acrylamide
All chemicals other than those listed below.
Saranwrap 
Iodine 125*
X-OMATAR X-ray film 
DUP-1 duplicating film 
X-ray cassettes
Immobilon P
FPLC LCC-500 system 
Heparin Sepharose CL-6B 
Blue Sepharose 
Sephadex G-25
Resource 1 ml reverse phase column 
Hi-Trap desalting columns
GF5 excellulose desalting columns 
lodogen reagent
Quantikine transforming growth 
factor p-1 immunoassay
Nitrocellulose membranes
Design-a-Gel 40% (w/v) acrylamide,
2% (w/v) bis-acrylamide solution.
Anti-goat IgG 
Anti-rabbit IgG
( Both horseradish peroxidase conjugate)
Sodium orthovanadate
PMSF
Aprotonin
Trifluoro-acetic acid (TFA)
Tricine 
Silver Nitrate
Fuji Medical RX X-ray film
3MM filter paper
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2.5. Chemicals
SIGMA chemical Co. (Poole, UK)
James Burroughs Ltd. (Witham, UK)
GIBCO BRL (Paisley, UK)
Fisons Scientific Equipment 
(Loughborough, UK)
Fluka Chemika-Biochemica AG 
(Switzerland)
Taab Laboratories and Equipment Ltd
2.6. Solutions
2.6.1 Tissue Culture
MEM Alpha Stock (Gibco)
MEM Alpha x 2 (for 100ml)
RPMI 1640 
L-broth (L-Amp broth)
Bromophenol blue 
Dithiothreitol (DTT) 
MOPS 
TEMED 
T riton-X 100 
FURA-2 AM
Ethanol
TRIzol reagent
Formaldehyde (38% w/v)
Propan-2-ol
Glycerol
HPLC grade acetonitrile 
Anhydrous sodium carbonate 
Magnesium chloride 
Sodium chloride
Formamide
Glutaraldehyde
Dissolve 5 litre pack in water, add 
50ml MEMx100 vitamins (Gibco) 
and 100mg gentamycin sulphate. 
Make up to 1500ml with water 
and filter sterilise.
MEM alpha stock 
L-Glutamine (200mM)
Sodium Bicarbonate (7.5%)
Donor Horse Serum
(For MEM Alpha x 1, add equal 
of distilled water or agar)
RPMI 10x stock 
Distilled water 
L-Glutamine (200mM)
Sodium Bicarbonate (7.5%)
Yeast extract 
Bactotryptone 
NaCI
Ampicillin (50mg/ml)
21ml
1ml
3ml
25ml
volume
100ml
860ml
10ml
1.5ml
5g
10g
10g
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2.6.2 Agarose Gel Electrophoresis, Northern Blotting and Hybridisation
10 x TE (for 1 litre) Tris/HCI pH8 12.1g
EDTA 3.7g
Water to 1 litre
2.6.3 SDS-PAGE Polyacrylamide Gel Electrophoresis
Resolving Gels
17.5% Polyacrylamide gel Water 3 ml
Acrylamide mix (30%) 11.6ml
1.5M Tris (pH 8.8) 5.0 ml
10% SDS 0.2ml
10% ammonium persulphate 0.2ml 
TEMED 0.01ml
15% Polyacrylamide gel Water 4.6ml
Acrylamide mix (30%) 10 ml
1.5MTris (pH 8.8) 5 ml
10% SDS 0.2ml
10% ammonium persulphate 0.2ml 
TEMED 0.01ml
5% Stacking gel Water 6.8ml
Acrylamide mix (30%) 1.7ml
I.OMTris (pH 6.8) 1.25ml
10% SDS 0.1ml
10% ammonium persulphate 0.1ml 
TEMED 0.01ml
10 x SDS/DTT 20% SDS 0.1 ml
1MDTT 0.1ml
1M Tris (pH 6.8) 30^ 1
Complete to 1 ml with water
1x SDS/PAGE buffer Glycine 28.8g
Tris.HCI 6.05g
SDS 2.0g
up to 21 with dH20
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Methods
2.7. Cell Culture
2.7.1 Derivation and culture of human epidermal keratinocytes.
Normal human epidermal keratinocytes were obtained from human foreskins, obtained after 
paediatric therapeutic circumcisions, from Yorkhill children's hospital, Glasgow. The tissue 
was washed in PBS, cut into thin strips and trypsinised overnight at 4°C using 0.125% (w/v) 
trypsin, 0.01% EDTA in PBS. Epidermal cells were then separated from the underlying 
dermis by scraping a scalpel along the epidermal layer. Cells were centrifuged at 1000rpm 
for 5 minutes and resuspended in a single cell suspension in growth medium.
Human epidermal keratinocytes (HEKS) were grown in serum free keratinocyte medium 
(KGM) supplemented with bovine pituitary extract (50|i,g/ml), recombinant epidermal growth 
factor (5ng/ml), recombinant insulin (5ng/ml) and hydrocortisone (0.5 (ig/ml). Penicillin (37.5n 
g/ml) and streptomycin (10 jxg/ml) were also added to inhibit bacterial infection. All cells were 
incubated in a moist atmosphere at 37°C and gassed with air containing 5% (v/v) carbon 
dioxide. The medium was changed every 2-3 days.
Cells were passaged at subconfluence by firstly rinsing with PBS and then removal from 
flasks or plates with trypsin (trypsin 0.1%(w/v), EDTA 0.01 % (w/v) in PBS) for approximately 
5-10 minutes at room temperature. Trypsin was inactivated by adding ten volumes of serum- 
containing medium and removed by centrifugation at 1000rpm for 10 minutes at 4°C.The 
supernatant was then removed and the cells resuspended in fresh growth medium and 
replated if required.
The cells were harvested after approximately 20 population doublings. Stocks of HEKs were 
kept frozen in liquid nitrogen as follows. The cells were resuspended at a concentration of 
106/ml in ice-cold special liquid medium (SLM; Gibco) containing 10% serum (as above) plus 
10% (v/v) dimethylsulphoxide (DMSO). The cells were then aliquoted into cryotubes and the 
ampoules wrapped in cotton wool and placed in a plastic box. The ampoules were initially 
placed at -70°C for 24 hours and then stored in liquid nitrogen. The cotton wool insulation 
ensures gradual cooling of the cells and enhances cell viability on thawing.
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Cells were thawed by transferring the ampoule directly from liquid nitrogen to water at 37°C. 
Once thawed the cells were added to ten volumes of prewarmed growth medium, 
centrifuged, resuspended in fresh growth medium and plated as required.
2.7.2 HEK clonogenic assays (KGM assays).
HEKs were seeded at 104 cells per 35mm culture well in six well plates in the appropriate 
keratinocyte growth medium with or without the protein preparation being assayed. The 
medium was removed after 72 hours and the adherent cells refed with the same 
KG M/preparation under assay. After 5 days the colonies were rinsed with PBS, and then 
fixed in 10% (v/v) formaldehyde in PBS. The cells were stained with 10% Giemsa/PBS for 
10 minutes. The stain was then washed off with water and the plates left to dry before being 
scored under a low power microscope.
2.7.3 Cell lines.
All cell lines were obtained from the frozen stocks of the Beatson Institute and were 
maintained at 37°C in a dry atmosphere of 5% C02 in air. The COS 7 cell line, which is an 
SV40 transformed African Green Monkey kidney cell line (Gluzman et al 1981) and the 
Chinese Hamster Ovary epithelial cell line (CHO) originated by Puck (1955) were maintained 
in special liquid medium (SLM) containing 10% (v/v) foetal calf serum (FCS) and 4mM 
glutamine.
2.7.3.1 CHO and COS 7 cell lines.
These cell lines were seeded at 105/ ml of medium and allowed to reach near-confluence. 
The growth medium was then removed, the cells rinsed with warm PBS, and then 
trypsinised by incubating with 0.25% trypsin in PBS for five minutes at room temperature. 
The cells were then resuspended in fresh medium containing serum and quantitated using a 
haemocytometer. They were then centrifuged at 1000rpm for 5 minutes. The cells were 
resuspended in fresh medium at a concentration of 105/ ml.
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2.8. Mice
All mice were housed within the animal facility of the Beatson Institute. Female mice, aged 
between 8-12 weeks were used for all the experiments. For the in-vitro CFU-A assay bone 
marrow from the femurs of the mouse strain B6D2F1 was used, whereas for the derivation of 
bone marrow macrophages, femoral bone marrow from strain CD1 mice or MIP-1a 
knockout mice (strain C57B1, which were a generous gift of Dr Don Cook (Dept, of 
Pathology, University of North Carolina at Chapelhill, NC.) were used.
2.9. Harvesting of bone marrow
Bone marrow was obtained from femora of mice. Mice were killed either by C02 asphyxiation 
or cervical dislocation. The femurs were then carefully removed using surgical scissors, and 
stripped of excess muscle using a tissue soaked in ethanol. Both ends of the femur were 
removed with scissors and the bone marrow plug expelled by flushing with 2mls of SLM 
through a 21 gauge needle. The cells were re-suspended thoroughly by vigorous pipetting 
using an automatic pipette aid. The cells were then washed in PBS and nucleated cells 
quantitated using a haemocytometer. Approximately 1.5x107 cells were routinely obtained 
from each femur. Cells were then resuspended at the appropriate concentration and in the 
appropriate medium for their application (see below).
2.10. The In Vitro CFU-A Assay.
Bone marrow cells were obtained as described above. For the detection of primitive 
progenitor cells, CFU-A assays were carried out. 2x104 total bone marrow cells in 4mls of 
supplemented a-modified MEM containing 20% DHS and 0.3% Bacto agar (Difco, USA) 
were seeded on top of an underlayer of the same medium containing 0.6% Bacto agar /10% 
L929 CM / 10% AF1-19T CM in 45mm Petri dishes (Sterilin). Cultures were incubated at
37°C in a fully humidified atmosphere of 10% C02, 5% 0 2 and 85% N2 for 11 days. This 
semi solid agar culture gave rise to the formation of macroscopic colonies, which have been 
previously shown to consist of mature haemopoietic lineages (Pragnell et al 1988; Lorrimore 
et al 1990). Although colonies smaller than 2mm in size do appear in the CFU-A assay, only 
colonies greater than 2mm were scored since it has been previously demonstrated that these 
larger colonies are derived from primitive haemopoietic cells. For all experimental
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procedures involving this assay, a "direct addition" protocol was adopted whereby putative 
inhibitory cytokines are assessed for their potential effects on CFU-A colony formation by 
directly adding various concentrations to the bottom layer of agar (Graham et al 1992).
2.11. Recombinant DNA techniques.
2.11.1 Host cells.
Library efficient competent E.coli, strain DH5a (Gibco) was used. DH5as and their 
derivatives were grown at 37°C shaking at 150 rpm in a new Brunswick G25 shaker in 
Terrific broth or L-broth liquid medium, or on inverted 1.5% (w/v) agar L-broth plates also at 
37°C, in both cases supplemented with the appropriate antibiotics. Ampicillin was used at a 
final concentration of 50jig/ml.
2.11.2. Transformation of bacterial hosts.
Competent cells were thawed slowly at 4°C, and 100[xl aliquots put into precooled 15ml 2059 
falcon tubes. An appropriate amount of plasmid DNA or ligation mix (<10ng) was pipetted 
onto the cells and then mixed by gently tapping the tube, and incubated on ice for 30 
minutes. The cells were then heat-shocked at 42°C for 45 seconds, cooled on ice for two 
minutes and then 0.9mls of L-broth added. This was incubated for 1 hour at 37° C shaking at 
225rpm in a New Brunswick G25 shaker, to allow time for the expression of the ampicillin 
resistance gene. 100-200^ils of this infected broth was then spread onto 1.5% (w/v) agar/ 
L-broth plates supplemented with the appropriate antibiotic. The plates were allowed to dry 
for five minutes, then inverted and incubated overnight to allow colony formation. To identify 
colonies containing recombinant plasmid in which the lac Z gene of the vector had been 
disrupted, blue/white selection on X-gal was often employed. Prior to spreading the cells, 
40pils of a 20ng/ml solution of X-gal, mixed with 160mls of L-broth, was spread onto the plate 
and left for one hour to permit full absorption into the agar. White colonies will contain a non 
functional lacZ gene.
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2.11.3 Bacterial glycerol stocks.
Host strains and their derivatives containing the plasmids of interest, were stored as glycerol 
stocks for future retrieval. Stationary cultures in liquid medium were mixed with an equal 
volume of a 30 % (v/v) glycerol/ L-broth solution, cooled on ice, then frozen at -70°C. Cells 
were retrieved using a sterilised tungsten loop.
2.11.4. Preparation, Manipulation and purification of plasmid DNA.
a) Preparation of plasmid DNA.
Plasmids were prepared using the commercially available Qiagen plasmid kit (Qiagen Inc. 
USA) as follows. Bacterial pellets were resuspended in the recommended volume 
(depending on the scale of the plasmid preparation) of resuspension buffer (100mg/ml 
RNase A, 50 mM Tris/HCI, 10mM EDTA, pH 8.0). The suspension was transferred to non­
glass Oakridge centrifuge tubes ( Nalgene) and the appropriate volume of lysis buffer 
(200mM NaOH, 1% SDS) was added. The solutions were then mixed by gentle inversion and 
incubated at room temperature for 5 minutes. The required volume of neutralisation buffer 
(3M KAc, pH 5.5) was added, mixed and incubated on ice for 15 minutes. Tubes were then
spun at 4°C for 30 minutes at 10000 rpm in a Sorvall RC-5B superspeed centrifuge 
containing SS-34 rotors. The supernatant was then poured through a double layered gauze 
swab to remove particulate material. To purify the DNA, a QIAGEN-tip column (size 100, 
500, or 2500) was equilibrated with equilibration buffer (750mM NaCI, 50mM MOPS, 15% 
ethanol, 0.15% Triton X-100, pH 7). The filtered supernatant was then applied to the column, 
and the column washed with wash buffer (1M NaCI, 50mM MOPS, 15% ethanol, pH 7). DNA 
was then eluted using the recommended volume of elution buffer (1.25M NaCI, 50mM 
Tris/HCI, 15% ethanol, pH 8.5) for that particular column. DNA was precipitated with 0.7
volumes of isopropanol and centrifuged at 10000 rpm at 4°C for 30 minutes as described 
above. The DNA pellet was washed with 5ml of ice-cold 70% ethanol and following 
recentrifugation with 70% ethanol at room temperature. The pellet was then air dried for 5 
minutes, redissolved in a suitable volume of sterile distilled water and stored at -20°C.
99
b) Measurement of nucleic acid concentration by spectrophotometry.
The absorbance (A) at 260 nm and 280 nm of DNA and RNA solutions was measured in a 
500^1 quartz cuvette, using TE, distilled water or TE/0.1% (w/v)SDS as a blank where 
appropriate. An A260 of 1 unit is equivalent to 50ng/ml of plasmid or genomic DNA, and 40 
jxg/ml of RNA or single-stranded DNA. The OD26o/OD28o ratio gives an estimate of the purity 
of the nucleic acid. Pure preparations of DNA and RNA have an OD260/OD 280 ratio of 1.8 
and 2.0 respectively. If theOD260/OD 280 ratio was significantly lower than the above, this was 
due to contaminants, which were removed by phenol, chloroform/isoamyl alcohol extraction 
and ethanol precipitation before remeasurement of the OD260/OD 280 ratio. When the 
concentration of the nucleic acid in the sample was too high (A260>1), the sample was diluted 
in distilled water and the OD260/OD 280 ratio remeasured.
c) Restriction digests.
Restriction digests were carried out in small volumes buffered using concentrated solutions 
available with the restriction enzymes from the supplier (GIBCO). Small quantities of plasmid 
DNA (2ngs) were digested in a total volume of 20fils using 5-10 units of enzyme per pig of 
DNA, depending on the enzyme used and the number of sites present. Larger preparative 
digests were carried out in larger volumes. For double digests, suppliers' information was 
consulted and the appropriate buffer used.
d) Agarose gel electrophoresis.
DNA fragments were resolved on non-denaturing agarose gels and visualised by ethidium 
bromide staining. In general 1% (w/v) agarose gels were used, but smaller fragments (100- 
500bp) were separated on 2% agarose gels. Gel mixes containing the appropriate amount of 
agarose in 1X TAE buffer (50X TAE buffer is 2M Tris, 50mM EDTA, 57.1 ml/L glacial acetic 
acid) were heated in a microwave to dissolve the agarose and then cooled to approximately 
60°C. Ethidium bromide was then added to make up a final concentration of 5[ig/ml, and the 
gel mix was then poured into the appropriate gel caster. Gels were allowed to set at room 
temperature and then installed into the electrophoresis tank in 1X TAE buffer. Samples 
containing one-tenth volume of gel-loading buffer were loaded and separated at a constant
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voltage -100V. Molecular weight standards used include the bacteriophage X (Hind Ill- 
digested) and the 1 kb ladder (Gibco). After the DNA had migrated the required distance, the 
DNA was visualized by UV fluorescence of the ethidium bromide on a UV transilluminator. A 
Polaroid photograph of the illuminated DNA was usually taken.
e) Purification of DNA fragments from agarose gels.
DNA fragments were purified from regular TAE agarose gels using the QIAGEN QIAquick gel 
extraction kit. The DNA fragment was excised with a sterile scalpel from the agarose gel on 
the UV transilluminator. The DNA fragment was then weighed in an eppendorf tube and 
three volumes/ weight equivalent of the supplied buffer QX1 was added to one volume of gel. 
The reaction was incubated at 50°C for 10 minutes. To help dissolve the gel the reaction was 
mixed by inverting the eppendorf tube several times during the reaction. 10|als of 3M 
sodium acetate pH 5.0 was then added and the sample loaded onto the QIAquick column 
which was placed in a 2ml collection tube. The reaction was centrifuged in a microfuge at 
13000rpm for 60 seconds and the flow-through fraction discarded from the collection tube. 
The QIAquick column was returned to the same collection tube. The DNA was then washed 
with 0.75mls of the supplied buffer PE and centrifuged again for 60 seconds. The wash flow­
through was discarded and the column recentrifuged for an additional minute. This extra spin 
removes residual wash buffer. The QIAquick column was then placed in a clean 1.5 mis 
eppendorf tube and the DNA eluted by adding 50pils 10mM Tris-HCI pH 8.5 to the middle of 
the column membrane and cenrifuging again at 13000 rpm for one minute. The DNA was 
then stored at -20°C.
f) Ligation of DNA fragments into plasmids.
Both plasmid and potential DNA insert were digested and purified as described above. The 
plasmid was dephosphorylated at its termini to prevent religation, by including two units of 
calf intestinal alkaline phosphatase in the restriction enzyme digest reaction. Approximately 
20 ng of dephosphorylated plasmid DNA was then added to the following reaction mix in a 
final volume of 20nls with water: 4-fold molar excess of the potential DNA insert, 4ptls of 5X 
ligation reaction buffer (0.25 M Tris HCI (pH7.6), 50mM MgCI2, 5mM dATP, 5mM
dithiothreitol, 25% (w/v) polyethylene glycol-8000), and 1^ 1 of T4 DNA ligase (1U/nl). The
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reaction was incubated at 16 °C in the water-bath in the cold-room for 16-24 hours. 1-3[xls of 
the ligation reaction mix was then diluted 5 fold in TE pH7.5 (10mM Tris-HCI and Na2 EDTA) 
and used to transform competent cells as described.
2.11.5. Engineering DNA fragments by the polymerase chain reaction using plasmid 
DNA as template: Site directed mutagenesis by overlap extension,
a) Design and synthesis of oligonucleotides.
For each mutant two single-stranded oligonucleotide (oligo) primers were synthesised and 
purified as descibed below. The oligos were 20-40 bases in length and were designed such 
that they were complimentary to opposite strands and opposite ends of the DNA sequence of 
interest. The oligos contained the required restriction enzyme sequence 5' to the sequence 
complimentary to the template. This allowed subcloning of the required PCR-generated DNA 
fragment into the appropriate restriction sites of the chosen plasmid vector. The 3' ends of 
the designed oligos was either a G or a C base if possible in order to enhance priming from 
the oligo.
Oligonucleotides were synthesised at the Beatson Institute on an Applied Biosystems model 
381A DNA synthesiser according to the manufacturers' instructions. The DNA was 
immobilised on a column and eluted from the column in 29% ammonia (v/v), by passing the 
ammonia continuously through the column for three five minute periods separated by 20 
minute intervals. The resulting DNA-ammonia solution was sealed in a glass vial and 
incubated overnight at 55°C. The DNA was then precipitated in 2.5 volumes of ethanol at 
20°C by adding ammonium acetate to a final concentration of 0.1MNH4Ac. and then
centrifuged at 13000 rpm in a microfuge. The oligos were resuspended in 100nls water and 
precipitated by the addition of 2.5 volumes of ethanol and then sodium acetate pH 5.2 to a 
final concentration of 0.1 M Na Ac. This was mixed by vortexing and cooled to -70°C for one 
hour, and the nucleic acid pelleted by centrifugation for 30 minutes at 13000 rpm at 4°C in a 
microfuge. The DNA was then washed in 70% (v/v) ethanol,freeze-dried and dissolved in 
distilled water. After quantitation by spectrophotometry the oligos were diluted to a 10^M 10X 
stock and stored at -20°C until required.
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b) Polymerase chain reactions (PCRs).
PCRs were carried out using Taq polymerase as specified by the manufacturer (Perkin 
Elmer). The PCR reactions were performed in a total volume of 50jxls and the template used 
was circular plasmid DNA containing the sequence of interest, diluted to a final concentration 
of 10-7 to 10'9g/ jxl. The primers were used at a concentration of 10nM. The reaction 
contained 5jaIs of 10X Taq polymerase buffer (provided with the enzyme by the 
manufacturers); 2[xls from 5mM stock solutions of each of dATP, dTTP, dGTP, and dCTP; 3 
fxls of 25mM MgCI2; the primers and template and finally distilled water to 50|xls. The reaction
was overlayed with 50jxls of paraffin. The Taq was added just prior to starting the PCR 
reaction. The reaction mixture was subjected to 25 to 30 cycles of denaturation (1
minute, 94°C), annealing (90 seconds, 50°C) and extension (5 minutes, 72°C) using a Perkin 
-Elmer-Cetus DNA thermal cycler 480. Reactions were incubated for 10 minutes at 72°C 
after the final cycle, then gradually cooled to 4°C. The PCR reaction products were analysed 
by agarose gel electrophoresis and the required DNA band purified from the agarose gel by 
the QIAquick method already described.
c) PCR mediated site-directed mutagenesis of plasmid DNA sequences: gene splicing 
by overlap extension.
The polymerase chain reaction was used to generate specific mutations in the murine 
MIP-1a cDNA. To generate each mutant four specific primers were used (Primers P1, P2, 
P3, P4.). Primers P1 and P4 were complimentary to approximately 30 bases of opposite DNA 
strands, at the opposite termini of the murine MIP-1a cDNA. Primers P2 and P3 contained 
sequences complimentary to opposite strands of the DNA site to be mutated and primed in 
opposite directions. These two primers, P2 and P3, contained the point mutation in the 
overlapping region. Primers P2 and P3 were both designed to have essentially three sections 
with the central section having the deletion mutation of interest. The flanking ends (around 
this mutation) of the primers P2 and P3 were complimentary such that these primers 
contained 30-36 complimentary bases.
To generate each mutant required three separate PCR reactions. The first two PCR 
reactions involved primers P1 and P2, and primers P3 and P4 respectively in separate 
reactions with the wildtype cDNA as template and the PCR reaction conditions already
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described. These two reactions generated overlapping double-stranded DNA fragments 
containing the required point-mutation in the overlapping region. These two double stranded 
DNA fragments were then purified by gel extraction and used as a template for a final PCR 
reaction with the end primers P1 and P4. This resulted in the full-length mutated cDNA of 
interest (see diagram below). Approximately 100ng of each DNA fragment was used as 
template.
PCR reaction 1
P2 
<-------
wt MIP-1a cDNA.
 ►
P1
This PCR reaction generates the N-terminal end of the mutant cDNA (X).
PCR reaction 2
P4
A  wt MIP-1a cDNA.
----------------------------  W----------------------------------------------
P3
PCR reaction 2 generates the C-terminal end of the mutant cDNA (Y). Since the designed 
primers P2 and P3 both span the mutated site, the generated cDNAs X and Y overlap. These 
two cDNAs were therefore purified and used together as a template to yield the cDNA of the 
MIP-1a mutant by a third PCR reaction.
PCR reaction 3
P4
PI  *  X
The full-length mutated cDNAs were gel purified and ligated into the plasmid pMTx and 
cloned as already described. Miniplasmid preparations of the clones obtained were then 
performed and their cDNA inserts sequenced by the dideoxy-mediated chain termination 
method described below to eliminate PCR-generated artifact and identify the required cDNA
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clones. The required clones were then utilised to generate the required mutant MIP-1a 
cDNA plasmids. These plasmids were then used to generate the required protein mutants by 
the transient transfection of COS 7 cells using DEAE dextran.
Wildtvpe MIP-1 a cDNA sequence.
-23 -20 -10
Met Lys Val Ser Thr Thr Ala Leu Ala Val Leu Leu Cys Thr Met Thr Leu 
ATG AAG GTC TCC ACC ACT GCC CTT GCT GTT CTT CTC TGT ACC ATG ACA CTC
Cys Asn Gin Val Phe Ser Ala Pro Tyr Gly Ala Asp Thr Pro Thr Ala Cys 
TGC AAC CAA GTC TTC TCA GCG CCA TAT GGA GCT GAC ACC CCG ACT GCC TGC
+20
Cys Phe Ser Tyr Ser Arg Lys lieu Pro Arg Gly Phe lieu Val Asp Tyr Phe 
TGC TTC TCC TAC AGC CGG AAG ATT CCA CGC CAA TTC ATC GTT GAC TAT TTT
+30 +40
Glu Thr Ser Ser Leu Cys Ser Gin Pro Gly Val lie Phe Leu Thr Lys Arg 
GAA ACC AGC AGC CTT TGC TCC CAG CCA GGT GTC ATT TTC CTG ACT AAG AGA
Asn Arg Gin lie Cys Ala Asp Ser Lys Glu Thr Trp Val Gin Glu Tyr lie 
AAC CGG CAG ATC TGC GCT GAC TCC AAA GAG ACC TGG GTC CAA GAA TAC ATC
+1 +10
+50 +60
+69
Thr Asp Leu Glu Leu Asn Ala End
ACT GAC CTG GAA CTG AAT GCC TGA
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Primers used:
P1 CCG CGC CTC GAG ATG AAG GTC TCC ACC ACT GCC
P4 CCG CGG AAT TCA GGC ATT CAG TTC CAG GTC AGT
-1 AAC CAA GTC TTC TCA CCA TAT GGA GCT GAC
GTC AGC TCC ATA TGG TGA GAA GAC TTG GTT 
- 2 AAC CAA GTC TTC TCA TAT GGA GCT GAC ACC
GGT GTC AGC TCC ATA TGA GAA GAC TTG GTT 
-3 AAC CAA GTC TTC TCA GGA GCT GAC ACC CCG
CGG GGT GTC AGC TCC TGA GAA GAC TTG GTT 
-4 AAC CAA GTC TTC TCA GCT GAC ACC CCG ACT
AGT CGG GGT GTC AGC TGA GAA GAC TTG GTT 
-5 AAC CAA GTC TTC TCA GAC ACC CCG ACT GCC
GGC AGT CGG GGT GTC TGA GAA GAC TTG GTT 
-6 AAC CAA GTC TTC TCA ACC CCG ACT GCC TGC
GCA GGC AGT CGG GGT TGA GAA GAC TTG GTT 
-7 AAC CAA GTC TTC TCA CCG ACT GCC TGC TGC 
GCA GCA GGC AGT CGG TGA GAA GAC TTG GTT 
-8 AAC CAA GTC TTC TCA ACT GCC TGC TGC TTC 
GAA GCA GCA GGC AGT TGA GAA GAC TTG GTT 
-9 AAC CAA GTC TTC TCA GCC TGC TGC TTC TCC 
GGA GAA GCA GCA GGC TGA GAA GAC TTG GTT
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Amino-terminally truncated MIP-1a mutants.
APYGADTPTACC  wildtype
PYGADTPTACC  -1
YGADTPTACC  -2
GADTPTACC  -3
ADTPTACC  -4
DTPTACC  -5
TPTACC  -6
PTACC  -7
TACC  -8
ACC  -9
Mutants -1 and -7 were not secreted by COS 7 cells, while mutant -9 appeared to be poorly 
secreted. A number of studies have previously shown that the amino-acid proline (P) at 
position +1 does not allow signal peptidase cleavage (Von Heijne 1986; Nothwehr and 
Gordon 1990). Therefore primers were synthesised to generate -1 and -7 mutant cDNAs with 
proline to alanine substitutions.
AYGADTPTACC... -1 P-^A
ATACC... -7 P-»A
Primers used:
-1 P-»A AAC CAA GTC TTC TCA GCA TAT GGA GCT GAC
GTC AGC TCC ATA TGC TGA GAA GAC TTG GTT 
-7P->A AAC CAA GTC TTC TCA GCG ACT GCC TGC TGC
GCA GCA GGC AGT CGC TGA GAA GAC TTG GTT
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Again these cDNAs were ligated into the plasmid pMTx, and the mutant protein was 
expressed by the transient dextran transfection of COS 7 cells. The -1 P-*A mutant and the 
-7 P->A mutant were both secreted as detailed in the Western blot below.
2.11.6. Sequencing of plasmid DNA.
Sequencing was carried out on the Applied Biosystems ABI373 DNA sequencing system by 
Robert Mcfarlane. The recommended Applied Biosystems Taq Terminator sequencing 
protocol for this system was used (PRISM Ready Reaction Dyedeoxy Terminator Cycle Kit). 
This kit produces terminated fragments from unlabelled primers extended by AmpliTaq DNA 
polymerase. Each dideoxynucleotide is labelled with a different fluorescent dye so that one 
can carry out the four base reactions simultaneously in one tube and electrophorese them 
together in one gel lane. Approximately 1 ng of double-stranded plasmid DNA was mixed 
with 3.2 pmoles of the sequencing primer and the volume was made up to 10.5nls with high 
grade deionised water. 9.5jils of the Applied Biosystems premix was then mixed with the 
above and the reaction performed in a Perkin Elmer thermal cycler 9600. The thermal cycler 
was initially heated to 96°C and the reaction hot-started. The thermal cycler program used 
involved a 15 second period at 96°C, followed by 1 second at 50°C and then 4 minutes at 
60°C. 25 cycles were performed and at the end of this the mix was soaked at 4°C.
To remove the unincorporated dye terminators two phenol/chloroform extractions were 
performed. To do this 80jxls of high grade deionised water were first added to the reaction 
mix, followed by lOO i^ls of phenol/chloroform/water (68:18:14). The mixture was vortexed for 
60 seconds and then microfuged at 13000rpm. The aqueous (upper) phase was separated 
from the lower (organic) phase. The organic phase was discarded and the aqueous phase 
retained. The extraction was repeated with another 100fxls of phenol/chloroform/water. 15jxls 
of 2M sodium acetate pH 4.5 was then added to the final aqueous phase and the dye labelled 
DNA precipitated using 2.5 volumes of ethanol. The reaction was mixed and left to stand on 
dry ice for 15 minutes. The DNA was then spun down in a microfuge (13000rpm for 15 
minutes) and the supernatant carefully removed. The DNA pellet was washed with 500jxls 
70% ethanol and reprecipitated by another spin (13000rpm for 15 minutes). The supernatant 
was carefully removed and the pellet dried under vacuum for 5 minutes. An appropriate 
volume of loading buffer was added to the pellet and this was then heated at 92°C for two
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minutes and then put on ice. The sample was then loaded onto a 6% acrylamide/urea gel, 
and the dideoxyterminated DNA run. The Applied Biosystems ABI 373 hardware and 
software is then able to generate sequence data by simultaneous multicolour dye detection. 
The sequences generated were then checked manually and corrected if necessary.
2.12. Introduction of recombinant vectors into mammalian ceils.
2.12.1 Transfection mediated by DEAE-Dextran.
COS 7 cells were transfected using DEAE dextran as a facilitator to introduce plasmid DNA 
into the cells. The method used was that described in “Molecular Cloning - A laboratory 
Manual” (Sambrook, Fritsch and Maniatis 1990). Twenty-four hours before transfection, 
exponentially growing COS 7 cells were harvested by trypsinisation and seeded onto 10 cm 
dishes at 5X105 cells/dish. The cells were incubated for 24 hours at 37°C in a 5% C02 
incubator. The plates were then aspirated and the cells rinsed twice with serum and 
glutamine free SLM (Gibco). 4 mis of DEAE dextan DNA media was then added to each 
plate and the cells were incubated for 12-14 hours with shaking at 37°C in 5% C02.
DEAE dextran DNA media was made up by adding 5mls of DEAE dextran (2.5mg/ml), 5mls 
of 1M Tris pH7.3, 0.5mls of glutamine (200mM), 0.5 mis of streptomycin (10,000U/ml) and 
0.67 mis of penicillin (750ng/ml) and 38.3 mis of SLM (GIBCO). This solution was filter 
sterilised using a 0.2pi filter (Gelman Sciences) and the plasmid DNA of interest was then 
added to a concentration of 0.1 to 1 ng/ml.
The cells were then rinsed with prewarmed (37°C) serum and glutamine free SLM and then 
incubated for 5 hours in 5mls of SLM containing 10% heat inactivated foetal calf serum 
containing 0.1 mM chloroquine (the foetal calf serum was heat inactivated by treatment at 
55°C for 30 minutes). After the chloroquine treatment, which is thought to enhance 
transfection efficiency, each dish was rinsed once with serum-free SLM and then incubated 
in 10 mis of SLM containing heat inactivated foetal calf serum for 24 hours. The COS 7cells 
were then rinsed once with serum free SLM and incubated for 72hours in 4 mis of serum- 
free SLM. The medium was harvested after these 72 hours and the required protein purified, 
analysed and bioassayed as required. In order to obtain valid controls when assaying the 
above proteins, mock COS 7 cell transient transfections were also performed either without a 
plasmid or with the parent pMTx vector.
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2.12.2. Stable transformations.
Stably transformed CHO cell lines expressing human MIP-1a were obtained from Genetics 
Institute, Cambridge, Mass., USA, These methotrexate resistant cells were cultured in the 
presence of methotrexate unless the collection of MIP-1a containing supernatant was 
required, when the cells were grown in serum-free medium in the absence of methotrexate.
2.13. MIP-1a protein purification and preparation for bioassays .
The cell supernatants were collected, and then centifuged at 2000 rpm to remove any cellular 
debris. The supernatants were then filtered through 0.2[xm filters and stored at -20°C until 
required for the purification of MIP-1a. The purification of MIP-1a from cell supernatants has 
been previously described (Graham et al 1992).
The purification procedure used in these analyses involved a combination of heparin- 
sepharose and blue-sepharose affinity chromatography. The supernatant was initially loaded 
on to a heparin sepharose affinity column (Pharmacia Ltd) to which the MIP-1a protein 
bound. The column was then washed with 0.1 M NaCI/0.02M Tris pH7.6 to elute the heparin 
non-binding proteins (fraction H1), and then the MIP-1a and other heparin-binding proteins 
were eluted with 0.5M NaCI/0.02MTris pH7.6 (faction H2). This H2 fraction contained partially 
purified MIP-1a. This eluted material in the H2 fraction, when further purification was 
required, was loaded directly onto a blue-sepharose affinity column (Pharmacia Ltd) to which 
the MIP-1a bound avidly. The column was then washed with 2M NaCI/ 0.02M Tris pH 7.6 to 
remove non-binding proteins (fraction B1) and the material was eluted using 4.5M MgCI2 
(fraction B2). This B2 fraction comprised MIP-1a purified to a single band on a silver stained 
SDS-PAGE gel. Where H2 or B2 were to be used in keratinocyte or CFU-A bioassays they 
were first desalted using a sephadex G25 column into phosphate buffered saline. When the 
material was to be used for electospray mass spectroscopy B2 was desalted into HPLC 
grade water. All the purification and desalting procedures were performed on the Pharmacia 
LCC-500 FPLC system.
The H2 fraction was also purified further using reverse phase chromatography on the FPLC 
system. A 1 ml Resource (Pharmacia) reverse phase column was used. The system was run 
at 1 ml/min and the proteins were eluted off the column using a gradient of 0 to 100% 
acetonitrile and a gradient volume of at least 15 column volumes (15mls). The solvent
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system used was 0.1% TFA in degassed double distilled water (Solvent A) and 0.1% TFA in 
degassed acetonitrile (Solvent B). After loading the sample onto the column, the column was 
first washed with 5 column volumes (5mls) of solvent A and then the 0-100% gradient of 
acetonitrile/ 0.1%TFA applied. All the eluted fractions were collected and stored at -20°C. 
The fractions were then analysed by Western blotting and silver staining. If the fractions were 
to be bioassayed, the samples were dried down under vacuum, redissolved in PBS and then 
applied to the cells of interest.
2.14. Protein characterisation.
2.14.1. SDS Polyacrylamide gel electrophoresis.
Polyacrylamide gels were prepared using a commercially available acrylamide/ bisacrylamide 
stock solution: 30% w/v acrylamide / 0.8% w/v bisacrylamide (Severn Biotech Ltd.) as 
described in "Molecular Cloning: A Laboratory Manual" (Sambrook, Fritsch and Maniatis). 15- 
17.5% SDS-PAGE gels were usually used. The appropriate volumes of 
acrylamide/bisacrylamide mix, water, 1.5M Tris pH 8.8, 10% SDS, 10% ammonium 
persulphate and TEMED (Sigma) were mixed and poured between two minigel glass plates. 
Approximately 1 ml of water saturated iso-butanol was layered on top of the solution to enable 
a smooth interface between stacking and resolving gels to be formed, and the gel was left to 
set at room temperature. A 5% stacking gel was prepared essentially as above but with 
differing amounts of additives and using a 1M Tris buffer pH 6.8 (again as described in 
Maniatis). The water saturated butanol was poured off, and the top of the gel thoroughly 
washed using distilled water. Approximately 3-4mls of stacking gel solution was then poured 
between the glass plates overlaying the solid gel and an appropriate comb was inserted to 
construct wells. This was then left to set for at least one hour. When the wells had set the 
comb was carefully removed. Samples were prepared for electrophoresis by adding 20[il of 
each sample to 5jxl SDS/DTT and 5nl of gel loading buffer (50% bromophenol blue solution/
50% glycerol) in 1.5ml Eppendorf tubes and heated at 100°C for 3 minutes to denature and 
reduce the proteins. Samples were loaded onto the gel along with molecular weight rainbow 
markers (Amersham) to enable sizing of discrete bands and to check transfer had occurred 
during Western blotting.
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Glycine SDS-PAGE gel electrophoresis was carried out at room temperature in SDS-PAGE 
electrophoresis buffer (28.8g glycine, 6.05g tris.HCI, 2g of SDS and made up to 2 litres with 
distilled H20) at 100-150V until the blue dye front almost reached the bottom of the gel. 
Tricine SDS-PAGE gels were performed when higher resolution in the range 5 to 20kDa was 
required (Schagger and Von Jagow 1987). In these tricine gels a spacer gel section was set 
in between the separating and stacking gels. The composition of the separating, spacer and 
stacking gels are outlined below.
Stacking Gel Spacer gel 
4%T, 3%C 10%T 3%C
49.5% T, 1 ml 6.1ml
3% C solution 
49.5% T, 6% C -
solution
Gel buffer 3.1ml 10ml
Glycerol
Urea
Add water to a 12.5ml 30ml
final volume of
|........................... Separating Gels..........................|
10%t 3%C 16%T 3%C 16.5%T 6%C 16.5%T,6%C
with 6M urea
6.1ml 10ml
10ml
4g
30ml
10ml
4g
30ml
10ml
10ml
4g
30ml
10ml
10ml
10.8g 
30ml
These tricine discontinous SDS PAGE gels were made up as outlined for the glycine SDS- 
Page gels above. The buffers used in this system are outlined below.
Buffer Tris (M) Tricine (M) pH SDS(%)
Anode buffer 0.2 - 8.9
Cathode buffer 0.1 0.1 8.25 0.1
Gel buffer 3.0 - 8.45 0.3
The gel was run at 100V continously until the dye-front had reached the bottom of the gel. 
The gel was then removed from the gel-tank and either silver stained or blotted onto 
nitrocellulose paper for Western blotting.
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2.14.2. Silver staining.
The protein bands were fixed by placing the polyacrylamide gel in a solution containing 50% 
methanol and 10% acetic acid for ten minutes. This solution was then discarded and the gel 
placed in 10% ethanol/10% acetic acid for another 10 minutes. Again this solution was 
discarded and the gel was placed in 10% gluteraldehyde for 10 minutes. Following this the 
gel was washed at least six times in distilled water over approximately ten minutes.
The gel was then placed in a solution of 40piM DTT for ten minutes (A 1M DTT stock solution 
was stored at -20°C). The solution was again discarded and the gel incubated in 0.1% silver 
nitrate for a further ten minutes. The gel was then rinsed several times with distilled water 
and then placed in a small amount of developer solution until this became discoloured. (The 
developing solution was made up by dissolving 15g anhydrous sodium carbonate in 500mls 
of water, and then adding 500jxls of formaldehyde.) The developer solution was replaced 
with fresh solution and the gel developed until the protein bands appeared. The gel was then 
washed in water to prevent further developing. Silver stained gels were used to assess the 
purity and the protein content of all conditioned media.
2.14.3. Western blotting.
The protein (usually MIP-1a) content of cell conditioned media was also analysed by Western 
blotting. The contents of the gel were transferred to nitrocellulose membranes (Schleicher & 
Schuell) by semi-dry blotting using minigel electroblotting equipment (Biotech Instruments
Ltd.) at a constant current of 8mA/cm2 gel area for 30 minutes as follows. Briefly, many 
pieces of Whatman 3MM blotting paper were cut to match the dimensions of the 
polyacrylamide gel (usually 6cm x 9cm), as was a piece of nitrocellulose. Six pieces of 
blotting paper were soaked in electroblotting buffer and layered on top of each other. Any air 
bubbles were removed by rolling using a plastic pipette. The nitrocellulose membrane was 
then placed on the filter paper followed by the polyacrylamide gel, again removing any air 
bubbles. Six pieces of blotting paper soaked in the same electroblotting solution were placed 
on top of the gel and the apparatus assembled. The electroblotter was then turned on and 
run at the above mentioned conditions. After blotting, the membrane was incubated in 
BLOTTO solution (5% Marvel dried milk in PBS, 0.1% NP40) for 30 minutes to block non­
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specific binding sites. The membrane was then exposed to the primary polyclonal goat anti- 
MIP-1a antibody at the appropriate dilution (usually 1:1000) in 10mls of BLOTTO for 1 hour. 
This was discarded and then membrane washed in several changes of BLOTTO for 45 
minutes. The membrane was then incubated with the secondary anti-goat IgG antibody 
conjugated to horse radish peroxidase in 10mls of BLOTTO for 1 hour after which this was 
discarded and the membrane washed in several changes of PBS/ 0.1% Tween for 30 
minutes. Antibody binding was then visualised using an enhanced chemiluminescence 
(ECL) kit (Amersham), which involved agitating the membrane in ECL solutions for 60 
seconds. The membrane was then wrapped in Saranwrap and exposed to X-OMAT AR X- 
ray film for the appropriate time to enable visualisation of protein bands.
2.14.4. TGF-p1 protein quantitation using ELISA
TGF-|31 protein content of partially purified MIP-1a derived from the transient transfection of 
COS 7 cells using DEAE-Dextran was determined using a commercially available "sandwich 
technique" ELISA kit (R&D systems, UK). This kit adopts an alternative protocol to 
traditional ELISA based methodology in that initial TGF-p binding to the plate is accomplished 
via TGF-p type II receptor adherent to the well (rather than an antibody) which recognises all 
TGF-p isoforms. The kit then specifically detects TGF-pi via a polyclonal secondary 
antibody conjugated to horse radish peroxidase. As only active TGF-p is capable of binding 
to the type II receptor, this method necessitates acid activation of TGF-p present in 
conditioned media samples. 1ml of transfection supernatant was acid treated by adding 
200(nl of 1N HCI for 10 minutes and then neutralised by adding 200^1 of 1.2N NaOH/0.5M 
HEPES. As a control, a standard curve of pure TGF-|31 was prepared by diluting 500^1 of a 
2000pg/ml stock into 500^1 of RD5I diluent (see manufacturers instructions). Serial dilutions 
from 1000pg/ml to 31.25pg/ml were then carried out. Although human TGF-p1 was used as 
a control, the assay kit detects murine or primate TGF-p1 with equivalent accuracy. 200|mI of 
standards and samples were then loaded in duplicate into a 96 well plate, covered with a 
plastic film and incubated at room temperature for 3 hours. Plate contents were discarded 
and each well washed x 3 with 400^1 of wash buffer. 200^1 of anti-TGFpi conjugate was 
then added to each well and incubated at room temperature for a further 90 minutes. Each
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well was then washed x 3 with 400^ x1 of wash buffer after which 200^1 of substrate solution 
was added to each well. The plate was incubated at room temperature for 20 minutes to 
allow colour development and 50[xl of stop solution was then added to each well. The optical 
density of each well was then determined using a Beckman DU 650 spectrophotometer set to 
450nm. Readings at 570nm were also taken and subtracted from the 450nm readings to 
correct for optical imperfections in the polystyrene microtiter plate.
2.15. 125l labelling of MIP-1a protein
MIP-1a protein preparations were labelled using lodo-gen (Pierce, U.S.A.), a commercially 
available iodination reagent which resembles a four-fold chloramine T molecule. 10^g of 
MIP-1a in PBS was incubated with 10jxg of immobilised iodogen and 1mCi Na125l (New 
England Nuclear) in Eppendorf tubes for 15 minutes on ice. All work involving 125l was 
carried out behind a protective lead impregnated screen. Unincorporated iodine was then 
separated from labelled protein by applying the reaction mixture to a disposable desalt 
column (GF5 excellulose columns; Pierce) and eluting with PBS. 500^1 fractions were 
collected and counts per minute assessed in a gamma counter to detect the peak of protein 
associated radioactivity. The three most active fractions were then pooled yielding a solution 
of MIP-1 a protein labelled to high specific activity (2.5x107 cpm/mg). The integrity of the 
labelled protein was then checked by SDS-PAGE. Iodination does not affect the biological 
potency of the protein in the CFU-A assay (Graham et al 1993). The radiolabelled 
preparations were used to analyse the purity of the partially purified MIP-1 a (Results section).
2.16. Electrospray Mass spectroscopy.
Electrospray mass spectroscopy was used to analyse the molecular weight of both bacterial 
and COS 7 cell derived MIP-1 a . Electrospray mass spectroscopy was carried out with the 
help of Tino Krell at the Department of Biochemistry, University of Glasgow. Mass 
spectroscopy was performed on a VG platform quadrupole mass spectrometer (2-3000 amu 
range) fitted with a pneumatically assisted electrospray (ionspray source) and controlled via 
the MG mass-Lynx software (VG Biotech Ltd, Altrincham, Cheshire, UK). Carrier solvent (1:1 
(v/v) acetonitrile/water) infusion was controlled at 10 ml/min using a Harvard syringe pump
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(Harvard apparatus, Ma.,USA.). Protein samples were dissolved in carrier solvent containing 
2% formic acid, 0.1% acetic acid (to minimize MIP-1 a aggregation) and at a concentration of 
20 pmol/nJ, centrifuged at 5000x g for 2 minutes and then 10-20 i^l samples injected into the 
carrier stream. Capillary voltages were between 2.8 and 3.2kV, extraction cone voltages 20- 
30V, and the focusing cone voltage offset by +10V. The source temperature was set at 
65°C, the nebulising gas flow at 101/h, and the drying gas flow at 2501/hr. Lens stack voltages 
were adjusted to give the maximum ion currents. The m/z range 700-1500, which contained 
>95% of the signal intensity for protein samples, was scanned at least 10 times with a sweep 
time of 5 seconds. The instrument was calibrated over this Mr range immediately before use 
with horse heart myoglobin.
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Results.
3.1. Introduction.
MIP-1 a is known to inhibit the proliferation of specific populations of haemopoietic stem cells. 
A partially purified form of MIP-1 a, derived from the transient transfection of COS 7 cells, is 
also able to reversibly inhibit the proliferation of clonogenic cultured epidermal keratinocytes 
(Parkinson et al 1993). This partially purified preparation of MIP-1 a (90-95% pure) which will 
be called Gl MIP-1 a was generated by colleagues at the Genetics Institute (Cambridge, 
Mass.,USA) and partially purified by Dr GJ Graham. It was used because when these 
experiments were first performed a bacterial recombinant form of MIP-1 a was not available. 
When a bacterial recombinant form of MIP-1 a (bMIP-1a) became commercially available 
this was found to be unable to inhibit the proliferation of keratinocytes in the KGM assay 
although in common with Gl MIP-1 a it did inhibit the proliferation of cells in the haemopoietic 
CFU-A and CFU-S assays. Surprisingly however a specific polyclonal antibody to this 
bacterial recombinant chemokine was shown to be able to fully reverse the keratinocyte 
inhibitory activity of Gl MIP-1 a implicating this chemokine in the inhibition of keratinocyte 
proliferation. However the inactivity of bMIP-1a on the KGM assay suggested that this 
chemokine requires some form of activation to inhibit keratinocyte proliferation.
Since I only had access to a very limited supply of Gl MIP-1 a, the first step in investigating 
the keratinocyte inhibitory activity of this chemokine involved the generation of this protein by 
the transient transfection of COS 7 cells in our laboratory (Lab MIP-1 a).
3.1.1. The Preparation of Lab MIP-1 a.
COS 7 cells were transfected with the plasmid pMTx.MIP-1a (murine MIP-1 a cDNA) as 
described in Section 2.14.1. The supernatant obtained from this DEAE dextran transient 
transfection was then partially purified by heparin sepharose affinity chromatography 
(Graham et al 1992). The murine MIP-1 a containing fraction (H2) was then desalted into PBS 
and analysed by SDS-PAGE, silver staining and Western blotting (figure 1a).
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H1 represents the non-heparin binding protein fraction and H2 fractions 9 and 10 the heparin 
binding fractions. These two H2 fractions were pooled, and termed Lab MIP-1 a. Lab MIP-1 a 
was slightly less pure than Gl MIP-1 a as can be seen in figure 1b. However this Lab MIP-1 a 
preparation is still relatively pure as many of the higher molecular weight bands seen in the 
silver stained gel in figure 1b are gel artefacts since they are also present in the pure 
bacterial MIP-1 a preparation. Lab MIP-1 a was analysed by Western blotting and the 
approximate concentration of MIP-1 a in these partially purified preparations was determined. 
Furthermore the biological activity of Lab MIP-1 a was tested in the haemopoietic CFU-A 
assay in order to further quantitate the preparation.
3.1.2. The activity of Lab MIP-1 a on CFU-A colony formation.
Lab MIP-1 a and bacterial MIP-1 a were analysed in the haemopoietic CFU-A assay. The 
results which are presented in figure 1 c show that the the bacterial recombinant protein was 
able to inhibit the CFU-A assay with an ED 50 of approximately 10ng/ml. Lab MIP-1 a was 
also able to inhibit colony formation in the CFU-A assay with an ED50 of 10-20jaIs of Lab 
MIP-1 a (figure 1c ). These results are in agreement with previous results (Graham et al 
1990).
3.1.3. Effects of Lab MIP-1 a on keratinocyte colony formation.
Lab MIP-1 a was then tested in the KGM assay to confirm the kerato-inhibitory activity of this 
protein. The assay was performed using a range of concentrations of both Lab and Gl 
MIP-1 a . The results are shown in figure 2  and show that both MIP-1 a preparations are able 
to inhibit keratinocyte colony formation with similar potencies. Half maximal inhibition was 
obtained with a MIP-1 a concentration of approximately 30ng/ml. Figure 3 demonstrates the 
keratinocyte colonies in the KGM assay: both control colonies and inhibited keratinocytes are 
displayed. bMIP-1a (R&D systems) was also analysed in these assays (figure 2 ) . This 
preparation of murine MIP-1 a is inactive in the KGM assay. bMIP-1a was unable to inhibit 
keratinocyte proliferation even at concentrations as high as lO^g/ml.
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3.1.4. The inhibitory activity of LAB MIP-1 a is reversed by a specific polyclonal 
antibody to bacterial murine MIP-1 a.
The activity of Gl MIP-1 a on keratinocyte proliferation can be reversed by a specific 
polyclonal antibody to bacterial murine MIP-1 a (Parkinson et al 1993). The kerato-inhibitory 
activity of LAB MIP-1 a can also be reversed by this specific polyclonal anti-murine MIP-1 a 
antibody (obtained from R&D systems) as shown in figure 4. Although this reversal is not 
complete it is statistically significant (p< 0.01). It is therefore clear that as seen with Gl MIP- 
1a, the inhibitory activity of Lab MIP-1 a is primarily due to the MIP-1 a protein.
3.1.5. Summary.
These experiments were carried out to ensure that MIP-1 a derived by the dextran transient 
transfection of COS 7 cells in our laboratory (Lab MIP-1 a) was able to inhibit clonogenic 
keratinocyte proliferation in the KGM assay, since only a limited amount of Gl MIP-1 a 
material was available. A keratinocyte inhibitory form of MIP-1 a, Lab MIP-1 a, functionally 
identical to Gl MIP-1 a was now readily available in the laboratory. Therefore Gl MIP-1 a and 
Lab MIP-1 a were used interchangeably in the experiments now described (these two 
preparations will from now on be termed COS MIP-1 a), which attempt to elucidate why 
bacterial MIP-1 a is inactive in the KGM assay, while COS MIP-1 a is a potent inhibitor of 
clonogenic keratinocyte proliferation.
Although the reason for this discrepancy was not clear, since the COS MIP-1 a preparations 
were impure, it was possible that MIP-1 a required an accessory factor to inhibit keratinocyte 
proliferation. On the other hand it was possible that the mammalian cell expression system 
was able to activate MIP-1 a through some form of structural modification which the bacterial 
expression system was unable to effect. Furthermore these results also suggested that the 
keratinocyte and the haemopoietic stem cell (CFU-A) have different MIP-1 a receptors.
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3.2. Putative accessory factors.
3.2.1. Proteoglycans.
A number of studies have shown that MIP-1 a, like all the other members of the chemokine 
family (Witt and Lander 1994), is able to bind a number of proteoglycans, including heparan- 
sulphate as well as heparin. Furthermore it has been previously suggested that 
proteoglycans may be able to modulate the function of a number of cytokines (Ruoslahti and 
Yamaguchi 1991). Since previous studies with the CXC chemokine IL-8 have shown that 
heparan sulphate is able to modulate the activity of this chemotactic cytokine (Webb et al 
1993), we postulated that the interaction between this proteoglycan and the chemokine may 
activate the COS preparation’s keratoinhibitory activity. To investigate this hypothesis, bMIP- 
1a was assayed (100ng/ml) in the presence of different concentrations of heparin, heparan 
sulphate and chondroitin sulphate A and B. Only the results obtained with the highest 
proteoglycan dose used are presented (1 jxg/ml), however similar results were obtained at all 
the concentrations tested (10ng/ml, 100ng/ml, 1 jig/ml). These results, presented in figure 5, 
show that these proteoglycans do not function as accessory factors for bacterial MIP-1 a in 
the KGM assay at the concentrations tested . These results do however suggest that these 
proteoglycans alone can alter the colony forming efficiency of this assay. In fact heparin 
sulphate significantly increased keratinocyte colony formation (p=0.006). None of the other 
proteoglycans tested altered keratinocyte proliferation significantly). The mechanism of the 
increased colony-forming efficiency seen in the described experiments was not clear. 
Interestingly however previous studies have suggested that in the absence of EGF, heparin 
sulphate can inhibit the cells in the KGM assay (IC50= 500ng/ml) although this inhibition is 
completely overridden by EGF(Cook et al 1991). However other experiments have also 
shown that the mitogenic activity of EGF is not modulated by heparin (Aviezer et al 1994). It 
is possible however that heparan sulphate is either able to modify the activity of other 
mitogenic and/or inhibitory factors in the KGM assay or that it is able to decrease cell loss by 
functioning as a cell survival factor. Overall however it is clear that the bioactivity of bacterial 
MIP-1 a in this assay is unaltered by the proteoglycans tested.
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3.2.2. Do COS 7 cells secrete a co-factor for the HEK inhibitory activity of MIP-1 a?
If MIP-1 a does require an accessory factor to inhibit keratinocyte proliferation, the above 
results suggest that COS 7 cells secrete this putative co-factor. In order to investigate this 
further the proteins secreted by untransfected COS 7 cells were analysed to determine 
whether they could function as co-factors for bMIP-1a in the KGM assay.
a) Constitutively expressed heparin-binding accessory factor?
Since the transient transfection of COS 7 cells by DEAE Dextran involves the collection of 
expressed MIP-1 a in serum-free medium over a 72 hour period, 10 mis of COS 7 cell 
serum-free conditioned medium was collected after 72 hours of culture. This medium was 
then partially purified by heparin sepharose affinity chromatography and both the heparin 
binding (COS H2) and the heparin non-binding protein (COS H1) fractions were desalted into 
phosphate buffered saline. Titrated quantities of these protein preparations COS H1 and 
COS H2 (1%, 3%, 5%) were then assayed in the presence or absence of bMIP-1a (assayed 
concentration 100ng/ml). The controls for this experiment included keratinocytes cultured in 
the presence of either bacterial recombinant MIP-1 a alone (100ng/ml), or keratinocytes 
cultured with the COS H1 and H2 fractions alone (1%, 3%, 5%). The results of these 
experiments are presented below in figure 6. They suggest that COS 7 cells do not 
constitutively secrete a co-factor for this chemokine at the concentrations tested.
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b) Does MIP-1 a stimulate COS 7 cells to secrete a MIP-1 a co-factor?
Although COS 7 cells do not appear to constitutively secrete a co-factor, it is possible that 
these cells will only produce this putative molecule in the presence of MIP-1 a. To investigate 
this a range of concentrations of bacterial recombinant murine MIP-1 a (100ng/ml, l^g/ml, 
10|ag/ml) were incubated for 72 hours in the presence of sub-confluent COS 7 cells cultured 
in 10 mis of serum-free medium. This supernatant containing MIP-1 a ( ‘COS+’ ) was then 
collected, partially purified by heparin affinity chromatography, desalted and bioassayed on 
the keratinocyte assay at three different dilutions (1%, 3%, 5%). An identical flask of sub­
confluent COS cells was at the same time cultured in the absence of bacterial recombinant 
MIP-1 a in 10 mis of serum free medium and this ‘COS- ' supernatant was also partially 
heparin purified, desalted and bioassayed as a control to the ‘COS+’ preparation at identical 
dilutions. Only the results obtained at the highest concentrations assayed (5%) are presented 
in figure 7 since at the three concentrations tested, the incubation of bMIP-1a with COS 7 
cells did not appear to activate the chemokine. These results suggested that in serum-free 
medium COS 7 cells do not secrete a co-factor for MIP-1 a. Furthermore if MIP-1 a is being 
activated by some form of structural activation, these results suggest that the incubation of 
bMIP-1a with COS 7 cells in serum-free medium does not result in this functional activation.
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c) Do COS 7 cells only secrete a co-factor for MIP-1 a during transient transfection?
The above results suggest that COS 7 cells do not secrete an accessory factor for MIP-1 a. 
The dextran transient transfection may however stimulate COS 7 cells to secrete this putative 
co-factor. To investigate this a mock dextran transient transfection was performed using the 
parental plasmid vector (pMTx). The control dextran transfection proteins in the culture 
media obtained were partially purified by heparin affinity chromatography and desalted into 
PBS. These proteins were assayed in the presence or absence of bacterial recombinant MIP- 
1a in the KGM assay. The results are presented in figure 8 and show that at the 
concentrations tested the control dextran transient transfection partially purified proteins have 
no detectable effect on the activity of bMIP-1a in the inhibition of clonogenic keratinocyte 
proliferation. Therefore it appears that that COS 7 cells do not secrete an accessory factor for 
MIP-1 a during the mock dextran transient transfection.
d) Does the inactive bacterial MIP-1 a alter the bioactivity of COS 7 cell MIP-1 a?
The above results all appear to suggest that COS 7 cells do not secrete a MIP-1 a co-factor. 
To test this co-factor hypothesis further, it was decided to investigate the effect of the inactive 
bacterial protein on the active COS 7 cell MIP-1 a preparation. If an accessory factor is 
present in functional excess of the MIP-1 a protein in this active preparation, a sub-inhibitory 
dose of the COS 7 MIP-1 a preparation may be made more potent by the addition of the 
recombinant bacterial MIP-1 a. Sub-inhibitory concentrations of COS 7 cell MIP-1 a were 
therefore bioassayed in the presence or absence of a titration of inactive bacterial murine 
recombinant MIP-1 a (10fxg/ml; 1%, 3% and 5% dilutions). The controls used were the 
identical sub-inhibitory concentration of COS 7 cell MIP-1 a alone, or bacterial MIP-1 a alone, 
while the positive control used was the COS 7 cell derived bioactive MIP-1 a at a ten-fold 
higher concentration. The results of these experiments are presented in figure 9 below.
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Although these results suggested that the addition of bMIP-1a to sub-inhibitory doses of the 
bioactive COS 7 MIP-1 a may antagonise the bioactivity of the active preparation at a 100:1 
molar excess (5%b), these results did not reach statistical significance.
3.2.3. Summary.
Overall these results indicate that the chemokine MIP-1 a does not require an accessory 
factor for its inhibitory activity on keratinocyte proliferation. The selected glycosaminoglycans 
were unable to activate bacterial recombinant MIP-1 a, while COS 7 cells do not appear to 
produce an accessory factor constitutively or in the presence of bacterial recombinant MIP- 
1a. Furthermore the dextran transfection process does not appear to stimulate COS 7 cells 
to synthesise the putative co-factor. Finally although the inactive bacterial protein protein did 
appear to anatagonise the bioactivity of COS MIP-1 a at concentrations reaching 
approximately a 100:1 molar excess, this result did not achieve statistical significance. Since 
bMIP-1a is known to bind CCR1, CCR3, CCR5 and CCR9 at the concentrations tested, 
these results appear to suggest that none of these chemokine receptors are the keratinocyte 
MIP-1 a receptor. The results of the incubation of bMIP-1a with COS MIP-1 a however did 
indicate that if an accessory factor for MIP-1 a is present in the latter, it is certainly not present 
at concentrations in excess of the chemokine concentration.
Moreover overall these results suggest that the COS preparation does not contain an 
accessory factor for MIP-1 a. In order to investigate this further, additional purification of COS 
MIP-1 a was performed.
3.3. Purification.
In order to attempt to understand why Gl MIP-1 a is active it was decided to attempt to further 
purify the MIP-1 a from the active COS preparation. If a co-factor is present in the active 
preparation it should be possible to inactivate the MIP-1 a by purifying the chemokine to 
homogeneity. On the other hand if despite this purification of the protein to homogeneity, the 
chemokine remains bioactive in the KGM assay, this would suggest that COS MIP-1 a does 
not require an accessory factor to inhibit keratinocyte proliferation.
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3.3.1. Further purification of Gl MIP-1 a.
MIP-1 a has been previously shown to bind avidly to blue sepharose affinity columns, and this 
binding affinity has been used to purify MIP-1 a (Graham et al 1992). COS MIP-1 a was 
therefore further purified by blue sepharose affinity chromatography. This involved eluting the 
less strongly binding proteins with 2M NaCI / 0.02M Tris pH 7.6 (fraction B1), and then the 
most avidly binding proteins with 4.5M MgCI2 (fraction B2). The MIP-1 a containing fraction 
(fraction B2) was then analysed by SDS-PAGE and silver-staining and found to comprise a 
single band. The silver stain SDS-PAGE gel shown below in figure 10, suggests that the B2 
fraction is a pure preparation of the chemokine. In order to increase the sensitivity of 
detection of any contaminating background proteins, the B2 and bacterial MIP-1 a 
preparations were also analysed by autoradiography. Both protein preparations were 
radiolabelled with 125l and examined on a 15%SDS-PAGE gel by autoradiography. The 
autoradiographs were exposed for sufficiently long periods of time to ensure a very high 
sensitivity. The autoradiograph presented in figure 11 shows that the B2 preparation is as 
pure as the commercially available bacterial protein. Even on prolonged exposure no other 
bands were detected confirming the high level of purity of B2 MIP-1 a.
This B2 fraction which is essentially pure MIP-1 a in MgCI2 was then desalted into PBS and 
bioassayed in the KGM assay at a 5% dilution. The controls used for this assay included 
desalted 4.5M MgCI2, as well as the inactive bacterial MIP-1 a. The Gl MIP-1 a preparation 
was also used as a control. The results of these assays are presented in figure 12. They 
suggest that B2 is still able to inhibit clonogenic keratinocyte proliferation albeit at a reduced 
potency. This therefore indicated that a pure form of MIP-1 a as determined by both silver 
staining and autoradiography is still able to inhibit clonogenic keratinocyte proliferation in the 
KGM assay.
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3.3.2.The activity of B2 is reversed by specific anti-MIP-1a polyclonal antibody.
The above results suggest that the pure MIP-1 a in the B2 preparation is still able to inhibit 
keratinocyte proliferation in vitro. To further demonstrate that the activity in this purified 
preparation is due to MIP-1 a, specific polyclonal antibody to MIP-1 a was added to the B2 
preparation for one hour at 37°C. The results of this experiment are presented in figure 13 
and show that the antibody is able to reverse the activity of B2 (This antibody reversal is 
statistically significant: p = 0.013; paired t-test).
3.3.3. Why is the B2 MIP-1 a preparation not as potent as COS MIP-1 a ?
It is clear from the above that when COS MIP-1 a is purified by the combination of heparin 
and blue sepharose affinity chromatography, this pure form of the protein (B2) is still active in 
inhibiting the KGM assay, although it is not as potent as the partially pure heparin purifed 
protein. To elucidate the role of MgCI2 in the inactivation of COS MIP-1 a 1 ml of 4.5M MgCl2 
was added to 1 ml of COS MIP-1 a and the mixture was allowed to stand at room temperature 
for 1 hr. A similarly diluted preparation of COS MIP-1 a, diluted in phosphate buffered saline, 
was used as a control. Both preparations were then desalted and assayed in the KGM assay. 
The pure MIP-1 a B2 preparation was also assayed at a similar concentration. The results of 
these experiment are presented below in figure 14 . These results suggest that MgCl2 is able 
to reduce the ability of COS MIP-1 a to inhibit clonogenic epidermal keratinocyte proliferation. 
The reason for this is not entirely clear. However Mg2+ is well recognised as being very 
effective at altering the stability of specific protein conformations. Magnesium is in fact the 
most potent cation - according to the Hofmeister series - in this ion-protein interaction (T.E. 
Creighton 1991). This may explain why B2 is less potent than Gl MIP-1 a. Furthermore Mg2+ 
is also one of the most potent precipitants of proteins and it is also possible that the high salt 
concentrations used in the protein purification resulted in the "salting out" of the chemokine. 
It is however clear from these results that Mg2+ does reduce the potency of Gl MIP-1 a on 
the KGM assay.
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3.3.4. Does B2 contain low levels of other keratinocyte inhibitors?
The above results strongly suggest that B2 is a pure preparation of MIP-1 a. Furthermore they 
indicate that the keratoinhibitory activity in B2 is due to MIP-1 a. It does however remain 
possible that a very potent synergistic inhibitory factor is present at 'vanishingly1 low 
concentrations in B2. Since MIP-1 a has been previously shown to upregulate the 
expression of the keratinocyte inhibitor TGF-pi in macrophages (Maltman et al 1993), and 
since this molecule can inhibit keratinocyte proliferation at low concentrations, the B2 
preparation was analysed for the presence of this cytokine. Enzyme-linked immunosorbent 
assay (ELISA) showed that the total TGF-pi concentration (both the active and the inactive 
species) in B2 was less than 5pg/ml (minimum detectable dose). Therefore when B2 is 
assayed in the KGM assay at a 5% dilution the TGF-pl concentration in the assay must be 
less than 250 femtograms/ml or 10 femtomolar. Furthermore other studies have shown that 
most cell types secrete TGF-p primarily (>90%) as a biologically inactive molecule - in the 
presence of the latency associated peptide LAP (Miyazono et al 1991). Therefore it is likely 
that the amount of active TGF-pi in the B2 preparation is less than 1 femtomolar. These 
concentrations of TGF-pi have been previously shown to be unable to inhibit keratinocyte 
proliferation in this assay, with half-maximal growth inhibition observed at 1 ng/ml (Cook et al 
1991). Therefore overall these results suggest that TGF-pi is not contributing to the 
inhibitory activity in B2. However the above ELISA does not exclude TGF-p2 and TGF-p3. In 
view of this further experiments were performed to test whether the latency associated 
peptide (LAP), which reverses the activity of TGF-p 1, 2 and 3, would influence the activity of 
Gl MIP-1 a. Unfortunately LAP substantially increases keratinocyte proliferation in the 
controls by inhibiting autocrine TGF-p making these assays very difficult to interpret since 
there are now at least three variables in these assays (LAP, endogenous TGF-p and MIP- 
la), two of which interact with each other (figure 15). What is clear from this data however is 
that keratinocyte proliferation in the KGM assay is endogenously regulated by TGF-p. 
Furthermore since previous experiments have shown that anti-MIP-1a antibody does not 
result in a similar increase in keratinocyte proliferation in the anti-MIP-1a antibody control 
assays, the activity in COS MIP-1 a is unlikely to be due either wholly or in part to TGF-p.
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These results therefore overall suggest that TGF-p is not involved in the inhibitory activity in 
COS MIP-1 a. Furthermore TNF-a was not detected by Western blotting in COS MIP-1 a (data 
not shown). Finally the other known potent keratinocyte inhibitor Epidermal Pentapeptide is 
unlikely to be present in COS MIP-1 a since this preparation has been desalted.
3.3.5. Summary.
These results suggested that a pure form of COSMIP-1a is still able to inhibit keratinocyte 
proliferation. Moreover this activity was still reversed by anti-MIP-1a antibody. These results 
suggested that the activity in the COSMIP-1a preparation was wholly due to the chemokine. 
Nevertheless further studies were performed to ensure that other established potent 
keratinocyte inhibitors were not present in 'vanishingly' small concentrations in the apparently 
pure B2 preparation. ELISA analyses suggested that TGF-pi was not detectable in B2. 
However KGM assays using the TGF-p Latency Associated Peptide (LAP) were unhelpful 
since these experiments introduced a separate variable into these assays: keratinocyte 
derived autocrine TGF-p. Finally TNF-a was not detectable in B2. Also Epidermal 
Pentapeptide was unlikely to be present in B2 since this material had been prepared for the 
KGM assay by desalting, which would have removed this small molecule from this 
preparation.
Coupled with the results presented in the previous section, these findings indicated that 
COSMIP-1 a did not contain an accessory factor, and that the kerato-inhibitory activity of this 
preparation was pobably due to a activated form of the chemokine. Since there was little 
objective difference between the inactive bacterial form of MIP-1 a and COSMIP-1 a on 
SDS-PAGE gel analyses, it was clear that this activation process had to be the result of some 
form of subtle structural alteration of the chemokine molecule.
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3.4. The activity of human MIP-1 a derived from a stably transfected CHO cell line .
The above results demonstrate that while MIP-1 a is secreted in an active form by the 
mammalian COS 7 cell expression system, the prokaryotic bacterial expression system 
secretes a protein that is inactive on keratinocytes. Since bacteria lack some of the post- 
translational regulatory mechanisms present in mammalian cells, we postulated that the COS 
7 cell expression system may be able to secrete a functionally active MIP-1 a protein as a 
result of some form of structural alteration. To investigate this further we tested the activity of 
MIP-1 a generated from a different mammalian cell, a stably transfected Chinese hamster 
ovary (CHO) cell line. If CHO cell derived MIP-1 a was active in the KGM assay, this cell line 
would prove to be a very useful source of MIP-1 a for further analyses of the activation 
process.
This CHO cell line which was stably transfected to express human MIP-1 a (LD78p) was a gift 
from Genetics Institute (Mass., USA). This cell-line is cultured in the presence of 
methotrexate to select for the stably transfected cells as already described in the methods 
section. When supernatant containing MIP-1 a was required, the CHO cells were washed 
twice with serum-free Special Liquid Medium (Gibco) and the cells were cultured for 72 
hours. The supernatant was then collected and analysed by Western blotting for the 
presence of MIP-1 a. The supernatant was then partially purified by heparin affinity 
chromatography, desalted and analysed for the presence of MIP-1 a by SDS-PAGE gel 
electrophoresis followed by Western-blotting or silver-staining. This CHO cell derived protein 
was then bioassayed in the clonogenic keratinocyte assay at 1%, 3% and 5% dilutions of a 
10ng/ml preparation. The results of these assays are presented in figure 16 and are 
representative of three separate assays. The CHO cell MIP-1 a did not significantly inhibit 
keratinocyte proliferation. Furthermore this human CHO cell derived MIP-1 a has been 
previously shown in our laboratory to be active on the murine haemopoietic CFU-A assay, 
confirming the biological activity of this chemokine preparation. These results appear to 
suggest that not all eukaryotic cells are able to secrete a form of MIP-1 a that is able to inhibit 
keratinocyte proliferation in the KGM assay. The alternative explanation is that huMIP-1a, 
unlike muMIP-1a, does not inhibit keratinocyte proliferation.
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3.5. Does some form of structural alteration activate MIP-1 a ?
The above results have shown that murine COS MIP-1 a is able to inhibit clonogenic 
keratinocyte proliferation in a very pure form as defined by the presence of a single band on 
both a silver stained SDS-PAGE gel and an autoradiograph of 125l labelled protein. This and 
the previous results have suggested that MIP-1 a is activated by some form of subtle 
structural alteration. There is a precedent in the chemokine family for activation by structural 
alteration. For example the neutrophil activating CXC chemokine NAP-2 is derived from the 
cleavage of the full-length peptide Platelet Basic Protein (PBP), which has little activity on 
neutrophils (Walz and Baggiolini 1989). Another CXC chemokine PF-4 has recently been 
shown to be secreted by activated human peripheral blood leukocytes in an amino-terminal 
truncated form which is fifty times more potent than the full-length protein in inhibiting the 
proliferation of endothelial cells (Gupta et al 1995). It was therefore postulated that in order to 
inhibit keratinocyte proliferation, MIP-1 a may need to be activated through some form of 
structural alteration.
3.5.1. Protein Sequencing.
Since the purified form of COS MIP-1 a (B2) was still able to inhibit human epidermal 
clonogenic keratinocyte proliferation, it was decided to analyse the MIP-1 a protein present in 
this preparation by Edman degradation protein sequencing. The bacterial recombinant 
murine MIP-1 a protein obtained from R&D systems was known to have the wildtype amino- 
terminal sequence (/\PYGADTPT... ). The COS 7 cell derived protein preparation was 
also shown to primarily comprise the wildtype full-length protein like the bacterial recombinant 
cytokine. However the sequencing reaction also suggested the presence very low 
concentrations of a -4 amino-acid truncated variant of MIP-1 a (ADT ...).
Full-length murine MIP-1 a: APYGADTPTACC........
- 4 murine MIP-1 a variant: ADTPTACC.........
Interestingly when one of the human variants of MIP-1 a, LD78, was initially sequenced 
(Obaru et al 1986) the signal peptidase cleavage site was initially thought to be at position -4 
and the wildtype protein was thought to be what is now thought to be a -4 mutant. The
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presence of the detected -4 mutant in the COS 7 supernatant may therefore be related to the 
presence of an alternative signal peptidase cleavage site. Interestingly further study of the 
MIP-1 a sequence revealed that in fact this -4 position may potentially function as a signal 
peptidase cleavage site (Von Heijne 1986; Von Heijne personal communication). This -4 
variant may therefore be an alternative product of signal peptidase cleavage.
Human MIP-1a /LD78 (Obaru et al 1986):  ADTPTACC....
(Full-length equivalent of murine protein: APLAADTPTACC..... )
There is some evidence in the literature that MIP-1 a can be secreted as a -4 truncated 
mutant. Studies investigating human immunodeficiency virus (HIV) suppressive factors have 
suggested that an immortalised human CD8+ T lymphocyte cell line secretes a -4 truncated 
variant of human MIP-1 a (Cocchi et al 1995). Furthermore this -4 human MIP-1 a protein
(ADTPTACCFSYTSR ) was the only MIP-1 a variant detected (secreted at 615ng/ml).
The authors therefore suggested that this sequence may in fact correspond to the actual 
human T-lymphocyte MIP-1 a amino-terminus. However this is different to previously 
suggested (but not sequenced) published sequences of LD78 (Nakao et al 1990; Schall et al 
1991).
Nakao et al (1990) APLAADTPTACC... (LD78p)
Nakao et al (1990) ASLAADTPTACC... (LD78a)
Schall et al (1991): _SLAADTPTACC...
Rollins et al (1991): ASLAADTPTACC..
It therefore is clear that there has been some confusion in the literature regarding the amino- 
terminal sequence of the mature human MIP-1 a protein. As has already been described in 
the introduction, Nakao et al (1990) suggested that there are at least two non-allelic human 
MIP-1 a genes: LD78a and LD78p. The amino acid sequences of these two genes vary in 
only 5 amino-acids, with two of these amino-acid changes being conservative, reciprocal 
serine to glycine changes. However the other 3 amino-acid changes are clustered around the 
signal peptidase cleavage site. Nakao et al (1990) suggested that these two homologous
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human MIP-1 a genes probably result in identical signal peptide cleavage sites to create 
nearly identical 69 amino-acid molecules.
Figure 17.
LD78a and LD78B amino-acid sequences including signal peptide.
LD78a
MQVSTAALAVLLCTMALCNQRSASLAADTPTACCFSYTSRQIPQNFIADYFETSSQCSKPGVIFLTKRSRQVCADPSEEWVQKYVSDLELSA
LD78p
MQVSTAALAVLLCTMALCNQVLSAPLAADTPTACCFSYTSRQIPQNFIADYFETSSQCSKPSV1FLTKRGRQVCADPSEEWVQKYVSDLELSA 
The 5 amlno-aclds differences between LD78a and LD78P are underlined.
The mature proteins LD78a and LD78B according to Nakao et al (1990).
LD78a: ASLAADTPTACC...
LD780: APLAADTPTACC...
However on closer inspection of the two different signal peptidase cleavage sites, if Von 
Heijne's rule for the prediction of signal sequence cleavage is followed (Von Heijne 1986), 
these two genes result in different signal peptidase cleavage sites. While LD78a should be 
secreted as a -4 amino-terminally truncated 65 amino-acid protein (Von Heijne's -3, -1 rule 
indicates that the amino-acid glutamine (Q) should not be present at position -3 in the signal 
sequence), LD78(3 should be secreted as a 69 amino acid molecule.
LD78a: ___ ADTPTACC...
LD78P: APLAADTPTACC...
This has not however been previously defined in the literature, probably because it is very 
difficult to separate such homologous proteins of this size on an SDS-PAGE gel or by HPLC. 
However Nakao et al (1990) showed that both LD78a and LD78p mRNAs are transcribed. 
Furthermore the findings of Cocchi et al (1995) suggest that a -4 protein is secreted. 
Interestingly similar findings have previously been observed with other chemokines. In fact 
sequence analysis of IL-8 has shown that not only does it occur in natural mixtures of 
multiple forms that differ in truncation at the amino-terminus, but that the composition of IL-8 
preparations depends on the cell source used to produce it rather than on the purification 
method (Van Damme 1990; reviewed by Van Damme 1991). However the variability in the
150
amino-terminus of these chemokines is probably not all related to different signal peptidase 
cleavage sites.
The above results therefore suggest that MIP-1 a may be secreted in different amino-terminal 
truncated forms. Moreover recent work in this laboratory has shown that these different 
amino-terminal variants of MIP-1 a have very different chemokine receptor-binding affinities 
(R.J. Nibbs and G.J. Graham personal communication). We therefore postulated that murine 
MIP-1 a may be activated by the mammalian COS 7 cells into a keratinocyte inhibitory peptide 
by amino-terminal truncation.
3.5.2. Amino-terminal truncated mutants.
The human form of MIP-1 a, LD78, was initially identified as a mRNA induced in tonsillar 
lymphocytes. As already discussed above, the gene was thought to secrete a protein that is a 
-4 variant of the full-length protein (Obaru et al 1986). This -4 truncated amino-acid sequence 
has previously been used in our laboratory to generate non-aggregating human mutants of 
MIP-1 a. A bacterial recombinant -4 amino-terminally truncated mutant form of LD78 or 
human MIP-1 a was therefore available in our laboratory. This non-aggregating mutant has 
three amino-acid substitutions at the carboxy terminus which neutralise specific acidic 
residues, as discussed in section 1.3.3.3.
Full-length hu MIP-1 a: APLAADTPTA CC FSY C ADPSEEWVQKYVSDLELSA
-4 hu MIP-1a mutant 1 (M1): ADTPTA CC FSY........C AD PS EEWVQQYVSN LQLSA*
*The mutations at the carboxy-terminus were generated to result in a non-aggregating 
mutant.
This non-aggregating truncated mutant M1 forms dimeric aggregates and has been shown to 
inhibit proliferation of haemopoietic stem cells in the CFU-A assay with a potency that is 
indistinguishable from that of the wildtype molecule. This truncated protein was therefore 
analysed in the KGM assay. Bovine serum albumin (BSA from Sigma Ltd) was used as a 
carrier protein in these experiments to minimise chemokine loss (0.5 mg/ml BSA). BSA 
alone, at the concentrations used, had no effect on keratinocyte proliferation. The results of 
these assays are presented in figure 18 and show that the amino-terminally truncated form 
of hu MIP-1 a M1, unlike the full-length protein, is able to inhibit keratinocyte proliferation in 
the KGM assay. Furthermore this activity is reversible by a specific polyclonal antibody to
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human MIP-1 a (figure 19). The full-length human MIP-1 a molecule is inactive when 
analysed in this assay at concentrations up to 10[Ag/ml. Furthermore the murine non­
aggregating mutant proteins, which have a full-length amino-terminus were also found to be 
inactive. This suggests that the activity seen in the truncated human M1 is related to the N- 
terminal truncation and not the non-aggregating state.
However although the kerato-inhibitory activity of this amino-terminally truncated form of MIP- 
1 a was confirmed in several assays, there appeared to be significant variability in the kerato- 
inhibitory activity of various batches of truncated protein. The cause of this variability was not 
clear in these experiments, but may have been related to repeated freeze-thawing. However 
it was clear that some batches of the bacterial amino-terminally truncated preparations were 
more active than others. Further analysis of COS 7 MIP-1 a using electrospray mass 
spectroscopy was therefore performed to attempt to determine the molecular mass of any 
truncated form of kerato-inhibitory MIP-1 a in this preparation.
3.5.3. Electrospray Mass Spectroscopy.
The mass of a protein is a definitive and informative parameter that is now experimentally 
accessible as a result of the recent technological advances in the field of mass 
spectrometry. Electrospray mass spectroscopy (EMS) is able to accurately determine the 
molecular weight of proteins and polypeptides with picomolar sensitivity (Siuzdak 1994). A 
number of studies have used EMS to determine structural modifications in proteins that result 
in minor mass differences that are not detectable by the standard methods of protein 
analysis. In order to determine the mass or molecular weight of the purified COS 7 cell 
derived MIP-1 a (B2 fraction) this active preparation was analysed by EMS with the help of Dr. 
Tino Krell (Department of Biochemistry, Glasgow University). The EMS of MIP-1 a was 
considerably complicated by the aggregating nature of the chemokine. This was partly 
abrogated with the use of 0.1% acetic acid. The results obtained are presented in figure 20. 
They suggested that the B2 preparation is made up of a mixture of different MIP-1 a variants 
which differ at their amino-terminal end. The wildtype protein appeared to be the main 
species. However a number of other amino-terminally truncated species were also detected 
with molecular weights of 7805, 7716, 7559, 7500, 7422, 7217 and 7142. These species are 
likely to correspond to -1 MIP-1a (calculated mass 7813), -2 MIP-1a (calculated mass 7716),
152
-3 MIP-1 a (calculated mass 7553), -4 MIP-1 a (calculated mass 7496), -5 MIP-1 a (calculated 
mass 7425) and -7 MIP-1 a (calculated mass 7209) and probably a variant of the -8 protein 
(calculated mass 7112).
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3.5.4. Activation by proteolytic cleavage.
The above results appeared to indicate that an amino-terminally processed MIP-1 a species 
is the keratinocyte-inhibitory species, however the variability we had observed in the activity 
of the -4 non-aggregating mutant was concerning. In order to study this activation process 
further it was decided to investigate whether bMIP-1a can be activated by proteolytic 
cleavage of the amino-terminus using proteases with recognition sites in this area. It had 
been previously shown that the active truncated CXC chemokine NAP-2 is formed by the 
proteolytic cleavage of CTAP-III by chymotrypsin and cathepsin G (Car et al 1991). The 
inactive full-length bacterial recombinant MIP-1 a (b) was therefore incubated with cathepsin 
G (CG at 0.25|xg/ml), agarose bound chymotrypsin (C at 0.25fxg of protein/ ml), plasmin (P at 
1U/ml ) and thrombin (T at 1 U/ml ) and then analysed for kerato-inhibitory activity. 
Approximately 5^g of murine MIP-1 a was incubated with each of the above proteases. The 
proteases were all incubated for approximately 1 hour at 37°C in phosphate-buffered saline 
pH 7.4 as previously described (Car et al 1991). Parallel control reactions were also set up 
without MIP-1 a. Furthermore after the chymotrypsin incubation the reaction was 
microcentrifuged and then filtered through a 0.2jx filter to remove the agarose bound 
chymotrypsin.
The reactions were then all diluted by addition to 6mls of keratinocyte containing KGM and 
bioassayed. The results, which are presented below in figure 21 show that none of the control 
reactions comprising only protease were able to inhibit keratinocyte proliferation. Plasmin 
has been previously shown to activate TGF-p by cleaving LAP from the inactive parent 
molecule, therefore an increase in keratinocyte colony formation was anticipated. However 
the resulting plasmin concentration in these KGM assays (< 0.1 U/ml) was not high enough to 
be active on TGF-p (1-2U/ml) as shown by Lyons et al (1990).
Furthermore bMIP-1a was not activated by cathepsin G, plasmin or thrombin. However 
chymotrypsin was able to generate a weak keratinocyte inhibitory form of MIP-1 a (statistically 
significant p= 0.014; paired t-test). The chymotrypsin control had no detectable effect on 
keratinocyte proliferation.
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This result suggested that like the CXC chemokine CTAP-III, the inactive bacterial 
recombinant murine MIP-1a can be converted into a weakly active MIP-1a species by 
chymotrypsin proteolytic cleavage. None of the other three proteases used were able to 
activate the chemokine. Since chymotrypsin cleaves peptide bonds at the carboxyl end of 
tyrosine, phenylalanine and tryptophan. It was therefore possible that truncation of MIP-1a at 
the very accessible amino-terminal tyrosine at position 3 was activating the chemokine. 
However other sites of proteolytic activation could not be ruled out.
3.5.5. Summary
These results suggested that amino-terminal processing may convert the MIP-1a molecule 
into an inhibitor of keratinocyte colony formation. However this truncated form of human MIP- 
1a mutant M1 did not appear to be as active in inhibiting cells in the KGM assay as Gl MIP- 
1 a. The reason for this discrepancy may be that one of the other variants detected by EMS is 
considerably more potent than this -4 amino-terminally processed form. It was interesting to 
note at this point that the MIP-1a amino-terminus contains a near-perfect cleavage site for 
the lnterleukin-1 p Converting Enzyme (ICE) family of proteases. The four amino-acid motif 
YGAD at positions -3 to -6 in the MIP-1a amino-terminus is very similar to the W AD motif 
recognised by ICE (Sleath et al 1990; Wilson et al 1994). ICE cleaves at the carboxyl end of 
the aspartate in this motif. Although COS 7 cells do not appear to express ICE (Ceretti et al 
1992), epidermal Langerhans cells express functional ICE (Ariizumi et al 1995). Furthermore 
ICE knockout mice appear to have a defect in the export of a number of cytokines other than 
IL-1p ( Kuida et al 1995). Processing by ICE appeared to be a potential mechanism by which 
MIP-1 a could be converted into an inhibitor of keratinocytes..
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Figure 22.Proteolvtic processing by lnterleukin-1 B Converting enzyme. 
Recognised ICE cleavage sites (....ASP - X....) include:
...YVADJJ-X
...YVHD^A
...YVHD^G
...YVFDJJA
...LSAD^G
*Where X  is any amino-acid (Wilson et al 1994).
**Although AYVHDtyAP... is cleaved, HDAP... is not (Sleath et al 1990). 
When both the human and murine MIP-1a amino-termini are examined 
potential ICE cleavage sites are identified:
Murine MIP-1a:
APYGAD^TPTA...
Murine MIP-1a is likely to be a substrate for ICE (Sleath et al 1990; Wilson et 
al 1994; Ramage et al 1995).
Human MIP-1a (LD78B but not LD78a: see section 1.3.3.1):
LD78a mature amino-terminus: ADTPTA....
LD78a is not likely to be an ICE substrate: (see above: Sleath et al 1990). 
LD78p mature amino-terminus: APLAAD|}TPTA....
LD 78p is likely to be cleaved by ICE (Sleath et al 1990; Wilson et al 1994; 
Ramage et al 1995)
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3.6. Reverse Phase Chromatography.
The above results suggest that Gl MIP-1a contains low concentrations of amino-terminally 
truncated forms of this chemokine. Therefore in order to identify the kerato-inhibitory species 
it was decided to attempt to purify the active form of MIP-1a by reverse phase 
chromatography. Gl MIP-1a was therefore purified by reverse phase chromatography as 
shown in figure 23. The protein preparation was eluted from a reverse phase column by 
increasing concentrations of acetonitrile/ 0.1%TFA. All the fractions eluted were assayed in 
the KGM assay. The results of these assays are presented in figure 24 and indicate that the 
most active fractions were fractions 19, 20 and 21 (figure 24). This was surprising since 
fraction 19 did not appear to have any detectable MIP-1 a although this fraction did appear to 
have an approximately 70kDa band (see figure 25). Further analysis revealed that the most 
potent active fraction was fraction 20 (figure 26). Furthermore the activities of all these active 
fractions (19, 20 and 21) were reversible with specific goat polyclonal antibody to MIP-1 a 
(figure 27). These results show that the MIP-1 a concentration does not define the kerato- 
inhibitory activity of the reverse phase fractions 19, 20 and 21. Furthermore it is clear that in 
fraction 19 there is no detectable MIP-1 a on the silver-stained SDS-PAGE gel, although the 
activity of this fraction is fully reversible by anti-MIP-1 a antibody.
The identity of the 70kDa band in fraction 19 is not known. We decided to investigate whether 
this 70kDa protein is able to potentiate the activity of MIP-1 a. We postulated that since MIP- 
1 a  is present at very low concentrations in fraction 19, if this 70 kDa band potentiates the 
activity of the chemokine, the addition of bacterial recombinant MIP-1 a to this preparation 
should increase the activity of fraction 19. The results of this assay are presented in figure 28 
and show that bacterial recombinant MIP-1 a does not increase the activity of fraction 19. On 
the other hand these results suggest that bMIP-1a may in fact decrease the activity of 
fraction 19. The mechanism by which this occurs is not clear but it may be due to direct 
competition of high levels of bMIP-1a for receptor binding or perhaps indirectly as a result of 
MIP-1 a aggregation leading to the sequestering of the active MIP-1 a mutant. This effect on 
the active MIP-1 a molecule (see figure 9) has only been observed at very high relative 
concentrations of bMIP-1a to the active molecule, suggesting that the full-length molecule is 
a poor antagonist of the active species. What is however clear is that these results indicate
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that the observed 70kDa band is not an accessory factor for MIP-1 a. Moreover since the 
activity of fraction 19 is fully reversible by the specific polyclonal antibody to the chemokine 
these results suggest that the active form of MIP-1 a in this preparation is very potent. 
Since the chemokine is not detected in fraction 19 on a silver-stained SDS-PAGE gel or 
Western blot the active form of the chemokine is probably active at picomolar 
concentrations. Furthermore it is clear that this active form of the chemokine must be present 
in the COS 7 cell preparation at very low concentrations.
The active RPC fractions 19, 20 and 21 were analysed further by Edman degradation protein 
sequencing. However no sequence was detected in fraction 19 and only the full-length MIP- 
1a sequence was detected in fractions 20 and 21. ESM spectroscopy of these samples 
encountered similar difficulties and no molecular weight was detected in fraction 19. These 
results may however be partly a result of chemokine loss and protein dilution during the 
chemokine purification process.
3.6.1. Summary.
Overall these results suggested that COS MIP-1 a comprises mainly the inactive form of MIP- 
1a, the active form comprising only a small proportion of the chemokine concentration. 
These results also suggested that the active form of MIP-1 a is very potent, probably being 
active at picomolar concentrations. These results also appeared to indicate that the kerato- 
inhibitory activity may be due to a structurally altered form of MIP-1 a. It was postulated that 
in light of our electrospray data on the B2 preparation, and the activity of the -4 amino- 
terminally truncated mutant M1, that the chemokine is activated by amino-terminal truncation. 
It was decided that the best way to investigate this further was the generation of amino- 
terminally truncated MIP-1 a mutants in order to assess their activity in the KGM assay.
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3.7. Amino-terminally truncated MIP-1 a mutants.
Amino-terminally truncated MIP-1 a mutant cDNAs were generated by overlap extension PCR 
and inserted into the plasmid pMTx (as described in methods section 2.13.5.). These 
mutants were initially synthesised in COS 7 cells. The obvious disadvantage of pursuing this 
course of action is that the COS 7 cell system appears to generate a heterogeneous mixture 
of MIP-1 a variants. However our studies suggested that the COS 7 cell transfection system 
primarily generates the protein encoded by the transfected cDNA. Therefore if amino- 
terminal truncation does result in a protein that is considerably more potent than the wildtype 
molecule (perhaps 100-1000 fold more active) we postulated that there should be very 
significant differences in the activities of the COS 7 cell derived truncated mutants despite 
the heterogeneity of the secreted chemokine.
Since previous studies have shown that the amino acids next to the conserved cysteines in a 
number of chemokines are crucial to receptor binding it was decided to generate a number 
of amino terminally truncated mutants extending to the alanine at position 10 next to the two 
cysteines.
Amino-terminally truncated MIP-1 a mutants.
AP Y G ADTPTACC  wildtype
PYGADTPTACC  -1
YG ADTPTACC  -2
G ADTPTACC  -3
ADTPTACC  -4
DTPTACC  -5
TPTACC  -6
PTACC  -7
TACC  -8
ACC  -9
As described in the methods section the -1 and -7 mutants were not secreted at detectable 
levels. This was not entirely surprising since the amino-acid proline at position +1 is known to 
inhibit signal peptidase activity, therefore preventing the secretion of these chemokines 
(see section 2.13.5). In view of this, the proline at position +1 in these two mutants was 
replaced by an alanine to generate a -1 P->A and a -7 P->A mutants.
The -1 and -7 proline to alanine (P-*A) mutants.
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APYGADTPTACC... Wildtype.
AYGADTPTACC... -1 P ^A
ATACC... -7 P-»A
These alanine to proline mutants were both secreted by the COS 7 cell expression system. 
However further analysis revealed that most of these mutants were secreted at considerably 
lower concentrations than the wildtype MIP-1 a protein. Indeed the -5 and the -9 mutants 
appeared to be poorly secreted (see figure 29). This made quantitation of the mutants to 
equivalent concentrations for bioassay difficult. Furthermore since these mutants were poorly 
secreted, the purification and attempted concentration of these proteins resulted in an 
increase in the concentration of the background proteins. When the MIP-1 a mutants were 
equilibrated to roughly equivalent concentrations very variable concentrations of these 
background contaminant proteins were obtained. This was a significant concern since the
small quantities of MIP-1 a mutants generated prevented further protein purification. However
limited analyses of these mutants in both the KGM assay and in the CFU-A assay were 
performed. The results, presented in figure 30, appeared to suggest that amino-terminal 
truncation did not generate a potent kerato-inhibitory MIP-1 a species. Amino-terminal 
truncation did however alter the activity of MIP-1 a in the CFU-A assay (figure 31). These 
results suggested that the sequential amino-terminal truncation of the first four amino acids 
does not significantly alter the activity of MIP-1 a on the CFU-A assay. However further 
truncation beyond the -4 amino-acid results in significant loss of activity, with complete loss of 
activity after the -6 truncation.
The results obtained with the COS 7 cell derived proteins seemed to unequivocally show that 
MIP-1 a does not become a potent keratinocyte inhibitory protein when truncated at the 
amino-terminus by between 1 and 9 amino-acids. Electrospray mass spectrometry analyses 
had however suggested that COS cell transfection may generate a complex mixture of 
MIP-1 a variants. It was therefore possible that this had modified the result of the COS 7 
derived mutants assays. The inability to generate larger quantities of purified mutants for 
analysis, by Edman degradation protein sequencing and electrospray mass spectroscopy, 
meant that it had to be assumed that the mutant MIP-1 a cDNA constructs were mainly 
secreting the expected truncated protein variants. Furthermore the low concentrations of
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MIP-1 a mutants generated, and the presence of significant concentrations of contaminating 
proteins in these preparations, may have masked the anticipated activity.
In view of this, human MIP-1 a amino-terminally truncated mutants were generated in 
the Saccharomyces cervisae strain MC2 (Clements et al 1992) in collaboration with British 
Biotechnology (BBT: Oxford, UK). These mutant proteins were made as a fusion to pre-pro 
yeast alpha-factor. The yeast cultures yielded the MIP-1 a mutants in the culture medium, 
following which these proteins were then purified by reverse phase HPLC by BBT. Initial 
studies with these proteins suggested in a number of assays that the -6 amino-terminally 
truncated form was significantly active in the inhibition of keratinocyte proliferation in the KGM 
assay with an ED50 of between 10-30ng/ml (Figures 32,33). Further analyses however 
detected significant variability in the keratinocyte inhibitory activity of this mutant and we have 
been unable to consistently observe this documented inhibition in all our assays. This 
inconsistency had been previously observed with the -4 human non-aggregating MIP-1 a 
mutant and its cause has not as yet been defined. It may however be due to changes in the 
protein's three dimensional structure induced by, for example, repeat freeze-thawing.
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4. Discussion.
A number of studies have shown that chemokines often display diverse functions. It is clear 
that the chemokine MIP-1 a is not only a potent inflammatory mediator but also an inhibitor of 
primitive haemopoietic cell proliferation (section 1.3.3.7.). This inhibitory activity of MIP-1 a 
on primitive haemopoietic cells led us to study the activity of MIP-1 a on the proliferation of 
other cell types. Initial investigations showed that a partially purified form of murine MIP-1 a, 
derived from COS 7 cells, inhibited the proliferation of clonogenic human epidermal 
keratinocytes in vitro in the serum-free KGM assay. Furthermore this activity is reversible by 
specific polyclonal antibodies to bacterial recombinant murine MIP-1 a, suggesting that the 
keratinocyte inhibitory activity of this partially pure preparation is due to the chemokine. The 
pure bacterial recombinant MIP-1 a protein does not however inhibit keratinocyte proliferation 
although in common with COS MIP-1 a it is active in inhibiting haemopoietic stem/progenitor 
cell proliferation in the CFU-A assay (Section 3.1). The experiments described have 
attempted to investigate the mechanism through which MIP-1 a is activated to inhibit 
keratinocyte proliferation.
4.1. The Activity of Heparin Purified COS MIP-1 a.
These experiments have shown that although the active COS MIP-1 a is a very pure 
preparation (90-95% pure) it does contain a small number of contaminants (Section 3.1.1.). 
The initial concern was that the kerato-inhibitory activity could have been due to very low 
concentrations of some other inhibitory molecule such as TGF-p. However TGF-p1 was not 
detectable by ELISA in the active, blue sepharose purified, COS MIP-1 a (section 3.3.1.). 
Furthermore specific polyclonal anti-MIP-1 a antibodies were able to reverse the COS MIP-1 a 
activity. This commercially available antibody preparation to bacterial MIP-1 a was unlikely to 
be able to neutralise the activity of any other inhibitory molecule in COS MIP-1 a (section
3.1.4). However in order to try and exclude the presence of TGF-p2 and TGF-p3 the Latency 
Associated Peptide LAP was assayed in the presence of COS MIP-1 a. These results were 
confounded by the significant increase in keratinocyte proliferation induced by LAP 
presumably through the inhibition of autocrine TGF-p making these KGM assays difficult to
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interpret (section 3.3.4). Nevertheless since the anti-MIP-1a antibody did not alter colony 
formation in the control plates it appears that this antibody was not capable of interfering with 
the activity of TGF-p. These studies therefore suggested that the keratinocyte inhibitory 
activity of COS MIP-1 a is unlikely to be due to TGF-p or any other contaminant, and 
suggested that MIP-1 a is an inhibitor of clonogenic keratinocyte proliferation.
4.2. The Keratoinhibitory Activity of COS MIP-1 a: Co-Factor or Structural Activation?
Since bacterial recombinant MIP-1 a was inactive in the KGM assay, we postulated that the 
activity of COS MIP-1 a was due to either
I) The presence of an activating co-factor, or
II) Some form of structural alteration not detected by SDS-PAGE analyses.
The chemokines are known to bind heparin and a number of other proteoglycans. These 
polysulphated molecules have been previously shown to enhance the neutrophil chemotactic 
activity of the CXC chemokine IL-8 (Webb et al 1993). We therefore postulated that COS 7 
cell derived proteoglycans may be able to activate the kerato-inhibitory activity of MIP-1 a. 
However heparin, heparan sulphate and chondroitin sulphate did not activate MIP-1 a 
(Section 3.2.1). Moreover our studies were unable to detect any evidence to suggest the 
presence of a COS 7 cell derived activating co-factor (Section 3.2.2). COS 7 cells did not 
appear to constitutively secrete a MIP-1 a co-factor. Furthermore COS 7 cells did not secrete 
a co-factor in the presence of the chemokine confirming that MIP-1 a does not induce an 
activating co-factor. Interestingly however our results suggest that the bacterial recombinant 
form of MIP-1 a can weakly antagonise the activity of the COS MIP-1 a preparation (Sections 
3: figure 28). This was seen both when heparin purified COS MIP-1 a (figure 9) and when 
reverse phase purified COS MIP-1 a (figure 28) were incubated with bacterial MIP-1 a. The 
results were however statistically significant only in the latter experiment. This discrepancy is 
probably related to the low level of keratinocyte inhibition seen in figure 9 with 0.05% Gl MIP- 
1a. When more significant inhibition is generated (figure 28), the antagonism becomes 
statistically significant. The results from both sets of experiments overall suggest that
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bacterial MIP-1 a weakly antagonises the activity of COS MIP-1 a. This antagonism could be 
due to either protein aggregation or direct competition for the keratinocyte MIP-1 a receptor. 
As discussed in Section 1.3.3.3, MIP-1 a has a tendency to aggregate at higher 
concentrations. This aggregation may result in the sequestration of the kerato-inhibitory form 
of the chemokine by bacterial MIP-1 a, reducing the binding of the active molecule to the 
receptor. However the non-aggregating murine MIP-1 a mutant M1, which is only able to form 
tetrameric aggregates, was still able to act as a weak antagonist. This suggested that the 
antagonistic effect of bacterial MIP-1 a was a result of direct although weak competition for 
the keratinocyte MIP-1 a receptor. These studies therefore overall suggested that the 
keratinocyte inhibitory activity of MIP-1 a does not require a co-factor and that the bacterial 
protein may still be able to bind the receptor and antagonise the activity of COS MIP-1 a.
4.3. Purified COS MIP-1 a is still active.
We were therefore unable to demonstrate the presence of an activating MIP-1 a accessory 
factor in COS MIP-1 a (Section 3.2.). Further evidence against this hypothesis came from the 
analysis of the activity of Blue Sepharose purified COS MIP-1 a (Section 3.3.). Previous work 
in this laboratory had shown that MIP-1 a binds very avidly to Blue Sepharose and can only be 
eluted from a Blue Sepharose column with high concentrations of MgCI2. Blue Sepharose 
affinity chromatography was therefore used to further purify COS MIP-1 a. This resulted in a 
very pure preparation of the chemokine (figure 10). In fact careful analyses of radiolabelled 
B2 revealed a single 8kDa MIP-1 a band with no evidence of any contaminating proteins 
despite prolonged exposures to enhance the detection of background proteins (figure 11).
B2 was still active in the KGM assay and this activity was reversible by anti-MIP-1a 
antibodies (Section 3.3.2). This implied that the keratinocyte inhibitory activity of COS 
MIP-1 a was unlikely to be dependent on the presence of a co-factor, but that some form of 
structural alteration brought about by COS 7 cells was activating the chemokine. This 
inhibitory activity of COS MIP-1 a also appeared to be quite sensitive to inactivation by the 
high concentrations of the cation Mg++ used in these purification experiments (Section
3.3.3.). Mg++ is recognised to be the most effective cation in the Hofmeister ion-protein
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interaction series and may be inactivating COS MIP-1 a by altering the protein's three- 
dimensional structure.
4.4. The Structural Activation of MIP-1 a.
Our results strongly suggested that MIP-1 a is activated by some form of structural alteration 
to become an inhibitor of keratinocyte proliferation. However analyses by glycine SDS-PAGE 
gel electrophoresis revealed no obvious differences between bacterial MIP-1 a and COS 
MIP-1 a. The activating process therefore probably results in either a very subtle alteration in 
the COS MIP-1 a molecule's structure or a radical alteration in a small fraction of the COS 7 
MIP-1 a. A conformational change in the three-dimensional structure of the molecule brought 
about by the mammalian cell expression system but not by the bacterial expression system 
may explain these findings. On the other hand since MIP-1 a is a relatively small protein, 
minor changes in the chemokine's primary structure by amino-terminal or carboxy-terminal 
truncation may not be easily detected by SDS-PAGE gel electrophoresis. However careful 
analyses utilising Tricine SDS-PAGE gel electrophoresis, which is very sensitive to minor 
changes in protein mass/charge, did not demonstrate any detectable differences between 
bacterial MIP-1 a and COS MIP-1 a. In order to investigate this further, the pure form of COS 
MIP-1 a, B2, was analysed further by protein sequencing (Section 3. 5.1). Initial results with a 
number of different COS MIP-1 a samples revealed only the full-length wildtype murine MIP-
1a sequence (APYGADT ), identical to the bacterial recombinant protein sequence.
However the sequence ADT... was also detected at very low concentrations. The 
significance of this result was not clear, however it suggested the presence of a -4 amino- 
terminally truncated MIP-1 a molecule. Since no other sequences were detected, and since 
there is a precedent for activation by amino-terminal truncation in the chemokine family, we 
postulated that this -4 amino-terminally truncated molecule may be the active species in COS 
MIP-1 a (Section 3.5.1.)
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4.5. The Amino-Terminus in the Chemokine Family of Proteins.
Sequence analysis of chemokines has previously revealed that a number of these proteins 
can occur in multiple forms that differ through truncation at the amino-terminus (Section
1.3.3.4). IL-8, the prototypic CXC chemokine, has been previously shown to exist in at least 6 
different amino-terminally processed forms (Van Damme 1991). Different amino-terminally 
truncated forms of natural IL-8 have been observed in a number of laboratories (Section
1.3.1.4.). Furthermore it appears that the composition of IL-8 depends on the cell source, 
rather than on the purification method (Van Damme 1989; Schroder 1990b). Since the 
amino-terminus of this molecule has been shown to be important for receptor binding, it is 
clear that this amino-terminal processing is important for the biological activity of the 
molecule. Similarly the CXC chemokine Platelet Basic Protein (PBP) has also been shown to 
be processed to generate several amino-terminal truncated forms with quite different 
bioactivities. The parent molecule PBP is in fact converted by exposure to various proteases 
to a number of different molecules with different activities: CTAP-III, p-Thromboglobulin, 
NAP-2 (Walz et al 1989; Walz and Baggiolini 1990). Platelet factor 4 (PF-4) is another CXC 
chemokine that has been shown to naturally exist in an amino-terminally truncated state. A 
70 amino-acid protein, the parent full-length molecule has been shown to be able to inhibit 
endothelial cell proliferation by blocking cell-cycle progression through S-phase at unusually 
high concentrations (micromolar range). Other studies have shown that when isolated from 
activated human leukocyte culture supernatants, PF-4 is a significantly more potent inhibitor 
of endothelial cell prolieration (>50 fold more potent). This enhanced activity is due to an 
amino-terminally processed form of PF-4 generated by peptide bond cleavage between Thr- 
16 and Ser-17, a site which is surprisingly located downstream from the highly conserved and 
structurally important CXC motif (Gupta et al 1994 and 1995). This N-terminal processing of 
PF-4 appears to represent an important mechanism for regulating the activity of PF-4 
(Section 1.3.1.1.).
The amino-terminus of the C-C sub-family of chemokines has also been shown to be 
critically important in receptor binding (see chapter 1.3.3.4). Studies on the C-C chemokine 
MCP-1 have shown that minor alterations in the amino-terminus of the parental molecule 
can result in significant changes in the bioactivity of this protein. Removal of one amino-acid 
from MCP-1 to generate a 2-76 form significantly alters the activity of this molecule. While the
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wildtype molecule is a potent basophil activator with no effect on eosinophils, the 2-76 
molecule is a potent eosinophil chemoattractant with little effect on basophils (Weber et al 
1996). Extension of RANTES by one amino-acid (a methionine) at the amino-terminus results 
in a RANTES analog that is not only inactive, but also functions as a potent antagonist of the 
wildtype molecule (Proudfoot et al 1996). Furthermore a derivative that was created by 
chemical modification of the RANTES amino-terminus, aminooxypentane (AOP)-RANTES, is 
a subnanomolar antagonist of CCR5 (Simmons et al 1997; Mack et al 1998). It is therefore 
clear that the amino-terminus helps define the biological activity of the chemokines.
It has also been suggested that proteolytic modification of the chemokines by amino-terminal 
truncation may be an important physiological mechanism for modulating and determining the 
biological activity and receptor binding of chemokines. This has been confirmed by recent 
studies which have shown that a truncated form of the parental RANTES molecule, -2 
RANTES (3-68) is secreted by dermal fibroblasts (Noso et al 1996). RANTES has also been 
shown to be a substrate for the leukocyte activation marker CD26 (Oravecz et al 1997). 
CD26 possesses dipeptidyl peptidase IV activity and converts the full-length Rantes molecule 
to the -2 amino-terminally truncated Rantes (3-68). This truncation significantly alters the 
function of the Rantes molecule. There are therefore precedents for functional modulation of 
the chemokines by amino-terminal truncation. Activation of MIP-1 a through this mechanism 
would therefore appear to be an attractive means for generating the keratinocyte inhibitory 
activity in COS MIP-1 a.
4.6. MIP-1 a, Signal Peptidase and Amino-terminal truncation.
Most of our experiments in the laboratory involved using the murine COS MIP-1 a protein on 
human epidermal keratinocytes. Human MIP-1 a, also known as LD78 is about 75% 
homologous to murine MIP-1 a. It was first cloned from tonsillar lymphocytes by Obaru et al in 
1986. This sequence suggested that the LD 78 signal peptidase cleavage site resulted in a -4 
form of MIP-1 a. However more recent studies have suggested a different cleavage site. 
Signal peptidase cleaves the transient secretory signal sequence, found on most secretory 
proteins, from the mature protein. This sequence serves to initiate protein export across the 
membrane of the endoplasmic reticulum. A number of studies have shown that the cleavage 
site for this enzyme is defined by the signal sequence which comprises three distinct regions:
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a basic N-terminal region, a central hydrophobic region and a more polar C-terminal region 
(Von Heijne 1986). The cleavage site is usually 4-6 amino-acids downstream from the end of 
the hydrophobic region with residues occupying positions -1 and -3 relative to the cleavage 
site being the most important ones in defining the precise position of cleavage. This 
observation has been formally incorporated into the "-1, -3 rule" by Von Heijne (1986). This 
rule has been used very successfully to predict the most likely site of signal peptidase 
cleavage. We have been advised that murine MIP-1a does in fact have two potential signal 
peptide cleavage sites separated by 4 amino acids (personal communication Von Heijne 
1995). Therefore signal peptidase cleavage may result in a -4 amino-terminally truncated 
murine MIP-1a which may be the kerato-inhibitory species. Previous studies have however 
predominantly identified the full-length protein suggesting that, if this is the mechanism of 
activation, this is the preferred cleavage site. Interestingly however other studies have also 
identified a -4 human MIP-1a variant. Cocchi et al (1995) characterised a CD8+ T cell-line 
derived HIV suppressive factor as -4 amino-terminally truncated human MIP-1a. The 
mechanism which generates these two different amino-termini has not been identified. A 
number of different possibilities exist:
I. Different genes (ie LD78a and LD78P) expressing proteins with different amino-termini.
II. Alternative mRNA splicing sites.
III. Alternative signal peptidase cleavage sites.
IV. Post-translational modification intracellularly or extracellularly.
I. Different genes (LD78a and LD78B).
There are three different although highly homologous human MIP-1a genes (Nakao et al 
1990), termed LD78a, LD78p and LD78y. LD78y is a pseudo-gene and is not expressed. 
However LD78a and LD78p both appear to be expressed in a number of cell lines (Nakao et 
al 1990). These two proteins are almost identical but recent studies in our laboratory suggest 
that they may be structurally and functionally distinct (Nibbs and Graham: personal 
communication). They differ only in five amino-acids: two of these changes are conservative 
serine to glycine substitutions at the carboxy-terminus, while the other three changes are 
non-conservative and are clustered around the signal peptide cleavage site. Nakao et al
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(1990) suggested that the signal peptide cleavage sites of these two human MIP-1a proteins 
are at the same position. It is likely however that due to the substrate specificity of eukaryotic 
signal peptidase, according to Von Heijne's method (Von Heijne 1986) for predicting signal 
sequence cleavage sites, that these two highly homologous genes result in proteins with 
different amino-terminal lengths. The mature LD78(3 secreted protein should therefore be 
secreted as a full-length protein similar in length to the murine protein (see figure overleaf), 
while the mature LD78a may be secreted as a -4 truncated molecule (when compared with 
the murine protein).
The MIP-1a (LD78) Signal Sequences and Putative Signal Peptidase Cleavage Sites. 
Murine M IP -la
MK V SIT ALA VLLCTMTLCN Q VFS |  AP Y GADTPTACC.........
Human LD78a
MQVSTAALAVLLCTMALCNOF* S ASLAj ADTPTACC........
Human LD78P
MQVSTAALAVLLCTMALCNQVLSJAPLAADTPTACC.........
The putative cleavage sites o f signal sequences are indicated by arrows. An asterisk is inserted to 
maximise the homology. The amino-acid differences between L D 78a  andLD 78$ are underlined.
II. Alternative mRNA Splicing Sites.
A novel p-chemokine CKp8 (also known as Myeloid Progenitor Inhibitory Factor-1: MPIF-1), 
which exhibits 51% identity and 67% similarity to human MIP-1a has recently been 
characterised (Patel et al 1997). More recent studies have in fact identified two expressed 
splice variants of this p-chemokine termed CKp8 and CKps-1 (Youn et al 1998). CKp8 
mRNA was found to be 51 nucleotides (17 amino-acids) shorter than CKp8-1. Both these 
molecules were found to be agonists of CCR1. This was the first example of alternative 
splicing producing two active p-chemokines from a single gene. This mechanism could be 
employed by other p-chemokine genes, however an alternatively spliced form of MIP-1a
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mRNA has never been cloned despite extensive PCR based studies. This makes alternative 
MIP-1 a mRNA splicing very unlikely.
III. Alternative Signal Peptidase Cleavage Sites.
This has already been discussed and could potentially explain the presence of the full-length 
and the -4 truncated protein in COS 7 MIP-1 a. However we are not aware of a precedent for 
this since signal peptidase only appears to cleave at a single site in any one protein.
IV. Post-Translational Modification Intracellularlv or Extracellularlv.
Several examples of post-translational modification of both a -  and p- chemokines have been 
recorded. The amino-terminus and function of the p-chemokine Rantes has been shown to 
be altered in vivo by the dipeptidyl-peptidase IV activity of CD26 which generates -2 (3-68) 
Rantes from the full-length molecule (Oravecz et al 1997). CD26 is expressed on the cell 
surface of macrophages and T lymphocytes where it presumably functions. It specifically 
recognises the N-terminal motif NH2-X-Pro (where X is any amino-acid). Since several 
chemokines, including muMIP-1a have this amino-terminal motif it is likely that CD26 may 
regulate the function of a number of chemokines. Other studies have recently shown that 
another p-chemokine, the 76 amino-acid MCP-1, is secreted by mononuclear cells as a 
combination of at least three different processed forms: MCP-1 (5-76), MCP-1 (6-76) and a 
carboxy-terminally processed form MCP-1 (1-69) as well as the wildtype glycosylated and 
non-glycosylated forms (Proost et al 1998). MCP-2 was also found to be secreted as a 
mixture of amino- and carboxy-terminally processed forms: MCP-2(6-76), MCP-2(1-74). 
Interestingly these molecules displayed significantly different activities. It is therefore clear 
that post-translational processing of the chemokines adds another level of complexity to what 
is already an intricate system comprising many molecules with overlapping functions. 
However it would appear that post-translational modification at the amino- and carboxy- 
termini is used to modulate the activities of these molecules.
Our findings had suggested that COS 7 cells secrete both the full-length and a truncated 
form of MIP-1 a. We therefore postulated that MIP-1 a is activated to become an inhibitor of 
keratinocyte proliferation in the KGM assay by the amino-terminal truncation of 4 amino-
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acids. However the mechanism of activation both in vitro, in the COS 7 cell transfection, and 
in vivo, possibly in the epidermal Langerhans cell, could be due to any one of the above.
4.7. Amino-terminally truncated MIP-1 a and keratinocyte proliferation .
As alluded to above there has been some confusion in the literature regarding the mature 
amino-terminus of huMIP-1a (Section 3.5.1). In a series of reviews on the chemokine family 
a number of different mature amino-terminal human MIP-1 a sequences have been listed.
Schall (1991) suggested that the amino-terminus of human MIP-1 a was SLAADTPACC....
while Stoeckle et al (1990) suggested that the amino-terminus was ADTPTACC  as
indicated by Obaru et al (1986) who first identified the gene. Miller and Krangel indicate that 
although the signal peptide cleavage site for murine MIP-1 a was known, the signal peptidase 
cleavage site for human MIP-1 a had not been defined. Other studies have suggested that 
signal peptidase cleavage results in a molecule with an amino-terminus that is similar to the 
murine amino-terminus: ASLAADTPTACC...(Nakao et al 1990). It appears however that 
none of these investigators have sequenced the amino-terminus of human MIP-1 a.
Previous experiments carried in this laboratory investigating the aggregation of MIP-1 a had 
involved the generation of non-aggregating bacterial murine and human recombinant MIP-1 a 
peptides in collaboration with R&D systems (Minneapolis). The murine non-aggregating 
MIP-1 a mutants were generated as full-length molecules (Graham et al 1994). The -4 
amino-terminally truncated sequence for human MIP-1 a described by Obaru et al (1986) was 
however used to generate the human non-aggregating MIP-1 a mutants. A -4 truncated non­
aggregating form of human MIP-1 a, with wildtype activity in the CFU-A assay, was therefore 
available in our laboratory. This MIP-1 a variant huM1 did however have three carboxy- 
terminal mutated amino-acids to prevent the non-covalent protein aggregation:
 QKYVSDLELSA (Wildtype COOH terminus) was mutated to
 QQYVSNLQLSA (-4 non-aggregating human mutant COOH terminus).
The neutralisation of these charged amino-acids partly abrogates protein aggregation (Parker 
et al submitted: 1998). This -4 non-aggregating mutant was found to be able to inhibit
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keratinocyte proliferation in the KGM assay (section 3.5.2/ figure 18). This activity was 
reversible with anti-human MIP-1 a antibodies (figure 19). Our studies also showed that the 
full-length wildtype and non-aggregating murine mutant MIP-1 a proteins were not active in 
the KGM assay, although they inhibited cell proliferation in the CFU-A assay. This indicated 
that the activity of the human non-aggregating mutant was not related to the loss of 
aggregation. This result suggested that the loss of 4 amino-terminal amino-acids resulted in 
the generation of a kerato-inhibitory huMIP-1a.
Significant variability in the keratinocyte inhibitory activity of different batches of human 
MIP-1 a mutant was however noted. The reason for this variability was not clear although 
similar problems have been previously encountered by other investigators (Broxmeyer et al
1994). Broxmeyer indicates that significant variability in bioactivity has been observed with 
MIP-1 a obtained from different sources.This has also been seen with different MIP-1 a 
batches obtained from the same source. It has been suggested that this may be largely due 
to protein aggregation. However our findings suggest that differences in the amino-terminus 
of these MIP-1 a preparations may also be important.
The use of 0.1 - 0.5% bovine serum albumin as a carrier protein in our experiments did 
decrease this variability, but it did not abrogate it. This suggested that this variability in activity 
may have been partly due to protein loss, however this should have been controlled for in all 
these experiments. There may be other reasons for this variability, perhaps relating to protein 
modification by repeat freeze thawing. Also the incomplete removal of trifluoroacetic acid 
(TFA) from the protein preparation by freeze-drying, prior to the dissolving of MIP-1 a in PBS, 
may also perhaps explain some of this variability since recent studies have shown that minor 
variations in pH and sodium chloride concentration over a range of physiological and near 
physiologic conditions can have dramatic effects on chemokine to receptor binding (Dairaghi 
et al 1997). Although the experiments described analysing the activity of different MIP-1 a 
preparations were carefully controlled for, the pH and sodium chloride concentrations in 
these assays were not routinely tested. Minor fluctuations in pH or salt concentrations in 
these assays could therefore be partly responsible for some of the variability seen.
These results did nonetheless suggest however that a bacterial recombinant -4 truncated 
mutant of human MIP-1 a could inhibit keratinocyte proliferation in the KGM assay. It was also 
clear that this molecule was not as potent as the presumed active species in COS MIP-1 a.
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Our estimates suggested that the active species in COS MIP-1 a was probably between 100- 
1000 times more potent. Therefore even if the -4 variant was active, it was unlikely to be the 
only active species in COS MIP-1 a. In order to elucidate this further COS MIP-1 a was 
analysed by electrospray mass spectroscopy. Electrospray mass spectrometry is an accurate 
means of obtaining molecular mass information on a wide variety of molecules with 
picomolar to femtomolar sensitivity. It is considerably more sensitive at detecting proteins 
than SDS-PAGE gel electrophoresis and has been widely used in biochemical research to 
analyse a number of different types of modifications in protein structure (Siuzdak et al 1994). 
MIP-1 a aggregation made analysis by electrospray difficult, but the addition of acetic acid 
and acetonitrile prior to the injection of the preparation into the mass spectrometer appeared 
to resolve this problem (Graham et al 1992). Electrospray mass spectrometry of this acidified 
preparation of COS 7 MIP-1 a suggested that this preparation comprises a number of 
different truncated MIP-1 a variants (Section 3.5.3/ figure 20). These studies suggested that 
COS 7 MIP-1 a may contain small quantities of different truncated forms of MIP-1 a, ranging 
from -1 to -7. Altogether these analyses appeared to suggest that the inhibition of 
keratinocyte proliferation by COS 7 cell MIP-1 a may be due to the presence of a structurally 
altered, amino-terminally truncated form of MIP-1 a. Since the -4 MIP-1 a molecule was not 
as potent as the COS MIP-1 a preparation, we therefore postulated the presence of an 
alternative, more potent, amino-terminally truncated MIP-1 a species in COS MIP-1 a. In order 
to investigate this further we systematically generated a series of amino-terminally truncated 
MIP-1 a mutants. Since we had no laboratory data to suggest truncation beyond the 
structurally conserved -CC- cysteine residues, we generated nine sequentially truncated 
mutants ranging from -1 to -9 MIP-1 a.
4.8. Systematic amino-terminal truncation of the MIP-1 a molecule.
A series of amino-terminally truncated MIP-1 a molecules were generated both in COS 7 cells 
and in S. Cervisae and bioassayed in the KGM assay. Considerable difficulty was 
experienced in generating adequate amounts of COS 7 murine MIP-1 a mutants because 
many of these mutants were poorly expressed compared with the wildtype molecule (Section
3.7.). The studies performed with these mutants suggested that amino-terminal truncation did
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not potentiate the ability of wildtype COS MIP-1 a to inhibit keratinocyte proliferation (figure 
30). It is possible however that some of these mutants are not generated as the intended 
truncation mutant. These studies were also hindered by the inability to analyse the COS 7 
mutants by either sequencing or electrospray mass spectrometry. Further studies using 
purified S.cervisiae derived mutants generated in collaboration with British Biotechnology 
were therefore performed. These assays initially suggested that truncation at the amino- 
terminus altered the keratinocyte inhibitory property of human MIP-1 a, with the -6 mutants 
being the most active truncated species, with an ED50 of ~30ng/ml (figure 32). However 
these results could not be consistently repeated. The cause of this variability in activity was 
again unclear, although inactivation by repeat freeze-thawing could cause this loss of activity. 
It is also possible that alteration of the MIP-1 a primary structure by amino-terminal truncation 
alone is not sufficient to generate a kerato-inhibitory molecule. Further modifications in the 
MIP-1 a secondary and/or tertiary structure may be necessary to generate a MIP-1 a molecule 
with keratinocyte inhibitory properties.
The COS 7 amino-terminally truncated MIP-1 a mutants were also analysed in the CFU-A 
assay (figure 31). Amino-terminal truncation up to and including -4 MIP-1 a had little effect on 
the activity of MIP-1 a in the CFU-A assay, but truncation beyond this resulted in the loss of 
CFU-A activity, suggesting that the amino-terminal four amino-acids are critical to the activity 
of MIP-1 a in this assay. Similar results have been obtained with the S. cervisiae mutants 
(G.J. Graham: personal communication).
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4.9. Potential Alternative Activating Mechanisms.
These results have been unable to clearly define the activating mechanism of the 
keratinocyte inhibitory activity in COS 7 MIP-1 a. Although further studies may still define -6 
MIP-1 a as the active species, if none of the amino-terminal mutants investigated thus far are 
the kerato-inhibitory species, a number of other potential mechanisms of activation may need 
to be considered.
a) Amino-terminal truncation beyond the -9 amino-acid.
Amino-terminal truncation beyond the -9 position tested so far should result in a MIP-1 a 
variant that can be differentiated from the full-length molecule by SDS-PAGE analysis. 
However these studies suggest that the active species is present in COS 7 MIP-1 a in very 
low concentrations. On the other hand since our analyses were unable to demonstrate a 
MIP-1 a variant with this degree of amino-terminal truncation, and since the two conserved 
cysteines at positions +10 and +11 are essential to give rise to the disulphide bonds that 
maintain the p-chemokine three dimensional structure, we did not analyse truncations 
beyond the threonine at position 9. There is however a precedent for functional activation 
by amino-terminal truncation beyond these two conserved cysteines. Previous studies 
isolated a PF-4 derivative that is generated by peptide bond cleavage between Thr-16 and 
Ser-17, a site located downstream from the highly conserved and structurally important 
CXC, from activated human leukocyte culture supernatants (Gupta et al 1995). This 
truncated form of PF-4 acts as a potent inhibitor of endothelial cell proliferation and is -50 
fold more potent on endothelial cells than PF-4. Therefore it remains possible that MIP-1 a 
is activated by COS 7 cells by N-terminal truncation beyond the CC motif. However unless 
such a molecule is detected in COS 7 MIP-1 a attempting to construct further N-terminal 
mutants is not envisaged.
b) Carboxy-terminal truncation.
The carboxy-terminus is considered to be less important for chemokine receptor binding 
than the amino-terminus. This may however be a reflection of the difficulty inherent in 
carboxy-terminal sequencing. Previous studies have shown that a number of both a- and 
p-chemokines are secreted as a mixture of amino- and carboxy- terminal truncated
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variants. The a-chemokine NAP-2 has been shown to naturally exist as a -4 carboxy- 
terminal truncated variant while the p-chemokines MCP-1 and MCP-2 both have been 
shown to occur naturally in carboxy-terminally truncated forms (Proost et al 1998). The 
functional significance of these truncations is not fully understood. Furthermore the 
purification and characterisation of these variants from the wildtype molecule has been 
found to be very difficult by a number of investigators. Our studies have been unable to 
exclude the presence of a carboxy-terminal truncation activation. It is important to note 
that the masses for at least the first two (-1 and -2) MIP-1 a mutants detected by 
electrospray mass spectroscopy could indicate the presence of -1 and -2 carboxy-terminal 
mutants (amino terminal sequence APYG....; carboxy-terminal sequence ....ELNA). 
Therefore carboxy-terminal processing could explain the activity of COS MIP-1 a. In order 
to investigate this, carboxy-terminal sequencing of highly purified and concentrated active 
COS MIP-1 a fractions needs to be carried out. At present carboxy-terminal sequencing is 
not easily accessible. However recent developments in this area and in the field of mass- 
spectrometry using tandem HPLC and electrospray mass spectrometry may in the near 
future make automated sequencing of picomolar quantities of protein feasible (Wilm et al 
1996). Further analysis of COS MIP-1 a using these technologies may become available in 
the near future.
c) Alterations in the Three-Dimensional Structure of MIP-1 a.
The studies described have suggested that modification of the primary structure of MIP- 
1a may be required for keratinocyte inhibition. This form of modification may result in 
changes in the secondary and perhaps also the tertiary structure of this protein. This may 
in turn result in the unveiling of specific residues that are critical for binding to the 
keratinocyte receptor. Alternatively it is possible that there are differences in the three- 
dimensional structures of COS 7 and bacterial recombinant MIP-1 a that cannot be 
detectable by SDS-PAGE electrophoresis. Such differences could be responsible for the 
functional alteration observed. COS 7 cells may be more able to bring about this type of 
modification than either E.coli or S.cervisiae. Further studies comparing the structures of 
bacterial MIP-1 a and COS 7 MIP-1 a may become necessary, however these studies may 
be difficult to perform in view of not only the heterogeneity of COS 7 MIP-1 a, but also the
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difficulties encountered in generating sufficient amounts of COS 7 MIP-1 a for these 
studies.
4.10. Future Studies. 
a) Identification of a Different Source of Keratinocyte Inhibitory MIP-1 a.
These studies have confirmed that COS 7 MIP-1 a is able to potently and reversibly inhibit 
clonogenic keratinocyte proliferation in vitro. The precise nature of the activating 
mechanism has not been fully characterised but is likely to be due to some form of 
structural modification. Future studies should attempt to identify other sources of kerato- 
inhibitory MIP-1 a. A potential source is the Langerhans cell cell-line XS52 (Xu et al 1995). 
This cell-lines have been derived from the epidermis of newborn mice and resemble 
resident epidermal Langerhans cells. We have now acquired this growth-factor dependent 
and slow-growing cell line which has been shown to express MIP-1 a mRNA and protein 
(A. Takashima: Personal communication). Further studies with this cell-line as a potential 
source of kerato-inhibitory MIP-1 a may shed some light on the mechanism of MIP-1 a 
activation.
b) Identification of a Keratinocyte Cell-Line Responsive to COS MIP-1 a.
The use of primary clonogenic human epidermal keratinocytes in these experiments has 
both advantages and disadvantages. These cells are as close as one can get in vitro to 
the epidermal basal and suprabasal keratinocyte stem/progenitor cell (Kolodka et al 
1998). The cells in this assay are heterogeneous with respect to proliferation potential. 
Further heterogeneity can be introduced to these assays by the use of cells at different 
stages of passage, although this can be controlled for. The identification of a keratinocyte 
cell-line that is responsive to COS 7 MIP-1 a would significantly facilitate further in vitro 
studies. Studies on a number of keratinocyte cell-lines including Balb-Mk, TFKs and in 
house transformed cell-lines have suggested that the Balb-Mk cell line may be able to 
respond to COS MIP-1 a (R. Nibbs: personal communication). The use of this cell-line may 
prove valuable in the future, particularly for both receptor and signalling studies.
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c) Characterisation of the The MIP-1 a Keratinocyte Receptor.
The results described have confirmed the findings of Parkinson et al (1993) who showed 
that COS 7 cell derived MIP-1 a inhibits the proliferation of epidermal keratinocytes in vitro. 
Clonogenic epidermal keratinocytes therefore appear to possess at least one receptor for 
this chemokine. Members of the chemokine family have been shown to interact with their 
target cells using members of the G-protein-coupled heptahelical receptor family. A 
number of a- and p- chemokine receptors have been cloned. These receptors are 
mainly specific for their respective subfamilies, although they often have significant 
overlap in their ligand binding profiles. At least nine p-chemokine receptors have been 
described so far. These receptors show significant sequence homology at a number of 
sites. This has been successfully applied in this laboratory by Dr R.J. Nibbs to clone a 
number of chemokine receptors including CCR1, CCR3, CCR5 and the novel chemokine 
receptor D6 using a PCR based approach (Nibbs et al 1997a and b). No keratinocyte 
MIP-1 a receptor has however been cloned to date using this approach. Reverse 
transcriptase PCR using clonogenic human epidermal keratinocyte mRNA and 
oligonucleotide primers derived from regions that show conservation of amino acid 
sequence has also been attempted. This resulted in the cloning of a murine IL-8 receptor 
but no p-chemokine receptor was cloned. This may indicate that there is significant 
heterogeneity between the oligonucleotide sequences used in this degenerate PCR 
cloning strategy and the corresponding sites on the putative clonogenic keratinocyte 
receptor. Future studies will be directed at attempting to clone these growth inhibitory 
receptors. Receptor binding studies using the keratinocyte inhibitory form of MIP-1 a may 
help in the identification of these receptors. These studies have not been possible to date 
because of the lack of adequate amounts of purified COS 7 cell MIP-1 a protein.
d) Characterisation of the MIP-1 a Signalling Pathways.
The identification of the active MIP-1 a keratinocyte inhibitory species would allow the 
investigation of the MIP-1 a signalling pathways. It would be particularly interesting to 
compare the mode of action of TGF-p and MIP-1 a. Studies on the activity of MIP-1 a on 
the cyclins, cyclin dependent kinases and their inhibitors as well as pRb and p53 may
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explain the growth-inhibitory activity of MIP-1 a. Further work involving techniques such as 
differential display or subtractive hybridisation may also be worthwhile pursuing and 
potentially could result in the cloning of as yet uncharacterised target genes.
e) In vivo studies.
Studies on the expression of MIP-1 a in both normal, hyperproliferative and wounded 
epidermis are planned using both immunocytochemistry and in situ hybridisation. It would 
be interesting to find out whether MIP-1 a expression co-localises with Langerhans cell 
markers such as CD1a, and whether other bone-marrow derived epidermal cells such as 
y b T-cells, which can be induced to express MIP-1 a in vitro (Boismenu et al 1996), 
express MIP-1 a in the epidermis. It would also be interesting to investigate whether MIP- 
1a expression is altered in hyperproliferative disorders such as psoriasis. Previous studies 
have however suggested that MIP-1 a protein expression is very difficult to detect using 
immunocytochemistry. Recent investigations also suggest that MIP-1 a may be involved in 
murine skin wound repair (Di Pietro et al 1998). The study of MIP-1 a expression and 
function in this model is particularly relevant since MIP-1 a appears to have the ability to 
act both as an inflammatory mediator and an inhibitor of keratinocyte proliferation.
f) MIP-1 a and the Langerhans cell.
Previous studies have shown that the primary source of MIP-1 a expression in the 
epidermis is the Langerhans cell. We have (in collaboration with D. Klatzmann and S 
Holmes) examined the epidermis of transgenic mice whose epidermal dendritic cell 
population has been partially ablated through the targetted expression of Herpes simplex 
thymidine kinase and the use of gancyclovir. The epidermis of these mice had a reduced 
epidermal dendritic cell population (Salomon et al 1994), but no overt epidermal 
hyperplasia. There was however evidence of significant keratinocyte apoptosis in the 
epidermis of these mice suggesting a significant bystander effect. This made evaluation of 
the Langerhans celll loss difficult (S. Holmes: personal communication).
More recent studies have suggested that TGF-|31 knockout mice appear to have a defect 
in normal murine Langerhans cell development (Borkowski et al 1996, 97), the epidermis
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of these mice being depleted of Langerhans cells. However studies have also shown that 
the epidermis in these mice contains hyperproliferative keratinocytes due to TGF-J3 loss 
(Glick et al 1993,1994) making it impossible to comment on the effect of Langerhans cell 
MIP-1 a loss on epidermal keratinocyte proliferation. The study of keratinocyte proliferation 
in MIP-1 a knockout mice is therefore currently underway.
g) Transgenic Mice
The ability to study the in vivo function of specific molecules using transgenic mouse 
technology has become a valuable tool for the investigation of the intricate biological 
processes involved in the regulation of the complex cellular processes that ultimately lead 
to cellular differentiation, proliferation or apoptosis. Targetted gene expression to a 
specific tissue, or inactivation of the gene of interest by homologous recombination, are 
now routinely used in the study of important cellular proteins.
MIP-1 a Knockout Mice.
The biological role of MIP-1 a in vivo has been examined in mice in which the gene 
encoding MIP-1 a has been disrupted (Cook et al 1995). Although homozygous MIP-1 a 
mutant (-/-) mice have no overt haematopoietic abnormalities, these mice have 
significantly altered responses to viral pathogens suggesting that MIP-1 a is an important 
mediator of virus-induced inflammation in vivo. Studies are currently underway in this 
laboratory to investigate the in vivo role of MIP-1 a in murine epidermis by examining the 
skin of MIP-1 a knockout (-/-) mice. Preliminary results have shown that a proportion of 
these MIP-1 a knockout mice have hyperplastic epidermis (Holmes and Mackie: personal 
communication). This phenotype may depend on the genetic background of the mouse as 
has been previously observed with TGF-p knockout mice (Schull et al 1992; Dickson et al
1995).
If these studies do in fact show that MIP-1 a knockout mice have hyperplastic epidermis, 
further studies will be carried out involving the transplantation of normal bone marrow to 
these mice. Previous studies have shown that Langerhans cells are derived from bone 
marrow stem cells, and reside in the epidermis for long periods (Section 1.4.2.3).
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Treatment of the epidermis with radiotherapy does however result in epidermal 
Langerhans cell ablation, as well as bone marrow aplasia. The transplantation of normal 
bone marrow, after radiotherapy, to these mice will result in the repopulation of the 
epidermis with MIP-1 a expressing Langerhans cells. This may be able to reverse the 
epidermal and would conclusively demonstrate the paracrine role of MIP-1 a.
Further studies on the effect of the loss of MIP-1 a on tumour initiation, promotion and 
progression are also currently being carried out on these MIP-1 a knockout mice. This 
studies will investigate the effect of this mutation on epidermal carcinogenesis.
Targetted MIP-1 a Overexpression to the Epidermis.
Targetted overexpression of the active MIP-1 a species to the basal /suprabasal layers of 
the epidermis using specific keratin promoters is also planned. A keratin 14 construct 
previously used for the targetted over-expression of IL-6 and KGF in murine epidermis 
has been acquired from the laboratory of Dr E. Fuchs (Turksen et al 1992). However a 
better understanding of the activating mechanism needs to be acquired before these 
studies can be performed.
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4.11. Potential Clinical Relevance of MIP-1 a.
a) Stem cell inhibition.
Since in vivo animal studies had suggested that MIP-1 a may be able to protect the 
haemopoietic stem cell compartment from the cytotoxicity of chemotherapy (Dunlop et 
al 1992; Lord et al 1992), this chemokine has been investigated in Phase I and II 
clinical studies. Phase I studies have shown that a non-aggregating form of MIP-1 a, 
BB10010, is safe and is able to reduce the cycling status of marrow myeloid 
progenitors (Broxmeyer et al 1998). This effect was reversible. However a randomised 
Phase II study has suggested that this MIP-1 a variant does not appear to alter the rate 
of bone marrow recovery following high dose chemotherapy (Bernstein et al 1997). 
MIP-1 a also appeared to have no effect on the incidence and severity of mucositis. 
This study therefore appears to suggest that MIP-1 a does not protect either 
haemopoietic or epithelial stem cells from the toxicity of high dose chemotherapy. 
However since full-length MIP-1 a does not inhibit epithelial stem cell proliferation it is 
perhaps not surprising that this study has not shown any evidence of epithelial stem 
cell protection. Further in vivo studies need to be performed using the kerato-inhibitory 
form of MIP-1 a to determine whether this molecule can protect epithelial stem cells 
from the toxicity of cancer chemotherapy.
b) MIP-1 a and inflammatory disease.
A number of studies have shown that chemokines are potent pro-inflammatory 
molecules, and that the the primary receptor-binding domain of these proteins is the 
amino-terminus (Reviewed by Baggiolini et al 1997). Several studies have also shown 
that the chemokines are naturally modified by amino-terminal truncation, and that this 
structural modification results in major functional modulation. Amino-terminal 
truncation often results in the generation of potent chemokine antagonists which may 
be able to function as anti-inflammatory molecules. These may be therapeutically 
useful in the clinic in the treatment of inflammatory diseases such as arthritis (Gong et 
al 1997). It would therefore be interesting to study the in vitro inflammatory profiles of 
the amino-terminally truncated MIP-1 a mutants generated in these studies. If these
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proteins exhibit any anti-inflammatory activity, then further analyses using in vivo 
models should be performed to evaluate the therapeutic potential of these molecules.
c) MIP-1 a and Carcinogenesis.
The studies presented in this thesis suggest that a structurally altered form of MIP-1 a 
is able to inhibit keratinocyte proliferation. Other studies in this laboratory have shown 
that this COS 7 MIP-1 a is not able to inhibit the proliferation of a number of human 
squamous cell carcinoma cell-lines (K. Parkinson: personal communication), although 
interestingly TGF-pl was still able to inhibit some of these cell-lines. These studies 
appear to suggest that the transformation of normal keratinocytes involves loss of 
responsiveness to the inhibitory activity of MIP-1 a. They also suggest a role for MIP- 
1a in carcinogenesis similar to the role previously suggested in the development of 
chronic myeloid leukaemia (Eaves et al 1993). Further studies into the signal 
transduction pathways of COS MIP-1 a in keratinocytes and their derangement in 
squamous cell carcinomas may reveal as yet unrecognised alterations in the cellular 
machinery. These may then be manipulated with either specific signal transduction 
regulators or perhaps through targetted gene therapy.
198
Bibliography
Abkowitz J.L., Linenberger M.L., Newton M.A., Shelton G.H., Ott R.L., and Guttorp P. (1990). 
Evidence for the maintenance of haematopoiesis in a large animal by the sequential activation of stem 
cell clones. Proceedings of the National Academy of Science USA 87, 9062-9066.
Abramson S., Miller R.G., and Phillips R.A. (1977). The identification in adult bone marrow of 
pluripotent and restricted stem cells of the myeloid and lymphoid systems. Journal of Experimental 
Medicine 145, 1567-1578.
Adams, J.C. and Watt, F.M. (1989). Fibronectin inhibits the terminal differentiation of human 
keratinocytes. Nature 340, 307-309.
Adams, J.C. and Watt, F.M. (1990). Changes in keratinocyte adhesion during terminal differentiation - 
reduction in fibronectin binding precedes a5(31-integrin loss from the cell-surface. Cell 63, 425-435.
Aguirre, V., Gonzalo, J.A., and GutierrezRamos, J.C. (1995). Expression of murine eotaxin by 
alveolar epithelial-cells during induced pulmonary eosinophilia parallels kinetics of eosinophil 
infiltration. Blood 86, 2012
Ahuja, S.K. and Murphy, P.M. (1993). Molecular piracy of mammalian interleukin-8 receptor type-b 
by herpesvirus saimiri. Journal of Biological Chemistry 268, 20691-20694.
Aiuti, A., Webb, I.J., Bleul, C., Springer, T., and GutierrezRamos, J.C. (1997). The chemokine SDF-1 
is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism 
to explain the mobilization of CD34+ progenitors to peripheral blood. Journal of Experimental 
Medicine 185, 111-120.
Al-Barwari, S.E. and Potten, C.S. (1976). Regeneration and dose-response characteristics of irradiated 
mouse dorsal epidermal cells. International Journal of Radiation Biology 30, 201-216.
Alam, R., Forsythe, P.A., Stafford, S., Lettbrown, M.A., and Grant, J.A. (1992). Macrophage 
inflammatory protein-la activates basophils and mast- cells. Journal of Experimental Medicine 176, 
781-786.
Alam, R., Forsythe, P., Stafford, S., and Fukuda, Y. (1994). Transforming growth factor-^ abrogates 
the effects of hematopoietins on eosinophils and induces their apoptosis. Journal of Experimental 
Medicine 1 7 9 ,1041-1045.
Allen T.D. and Potten C.S. (1974). Fine structural identification and organisation of the epidemal 
proliferative unit. Journal of Cell Science 15, 291-319.
Amatruda, T.T., Steele, D.A., Slepak, V.Z., and Simon, M.I. (1991). G al6 , a g-protein a -
subunit specifically expressed in hematopoietic-cells. Proceedings Of The National Academy Of 
Sciences Of The United States Of America 88, 5587-5591.
Amaya, E., Musci, T.J., and Kirschner, M.W. (1991). Expression of a dominant negative mutant of the 
FGF receptor disrupts mesoderm formation in xenopus embryos. Cell 66, 251-210.
Anisowicz, A., Bardwell, L., and Sager, R. (1987). Constitutive overexpression of a growth-regulated 
gene in transformed chinese-hamster and human-cells. Proceedings Of The National Academy Of 
Sciences Of The United States Of America 84, 7188-7192.
Arai, H. and Charo, I.F. (1996). Differential regulation of g-protein-mediated signaling by chemokine 
receptors. Journal of Biological Chemistry 271, 21814-21819.
199
Arenzana-Seisdedos F, Virelizier JL, Rousset D, Clark-Lewis I, Loetscher P, Moser B,
Baggiolini M (1996). HIV blocked by chemokine antagonist. Nature 383:400
Argyris T.S. (1980). Epidermal growth following a single application of 12-O-tetradecanoylphorbol- 
13-acetate in mice. American Journal of Pathology 98, 639-648.
Ariizumi K, Kitajima T, Bergstresser OR, Takashima A. (1995). Interleukin-1(3 converting enzyme in 
murine Langerhans cells and epidermal-derived dendritic cell lines. European Journal of Immunology 
25(8):2137-2141.
Aronica, S.M., Mantel, C., Gonin, R., Marshall, M.S., Sarris, A., Cooper, S., Hague, N., Zhang, X.F., 
and Broxmeyer, H.E. (1995). Interferon-inducible protein-10 and macrophage inflammatory protein- 
l a  inhibit growth factor stimulation of raf-1 kinase activity and protein synthesis in a human growth 
factor dependent haemopoietic cell line. Journal of Biological Chemistry 270, 21998-22007.
Asamow DM, Kuziel WA, Bonyhadi M, Tigelaar RE, Tucker PW, Allison JP (1988). Limited 
diversity of gamma delta antigen receptor genes of Thy-1+ dendritic epidermal cells. Cell 55(5):837- 
847
Assoian, R.K., Komoriya, A., Meyers, C.A., Miller, D.M., and Sporn, M.B. (1983). Transforming 
growth factor-(3 in human-platelets -identification of a major storage site, purification, and 
characterization. Journal of Biological Chemistry 258, 7155-7160.
Assoian, R.K., Fleurdelys, B.E., Stevenson, H.C., Miller, P.J., Madtes, D.K., Raines, E.W., Ross, R., 
and Sporn, M.B. (1987). Expression and secretion of type-(3 transforming growth-factor by activated 
human macrophages. Proceedings Of The National Academy Of Sciences Of The United States Of 
America 84, 6020-6024.
Atchison, R.E., Gosling, J., Monteclaro, F.S., Franci, C., Digilio, L., Charo, I.F., and Goldsmith, M.A.
(1996). Multiple extracellular elements of CCR5 and HIV-1 entry -dissociation from response to 
chemokines. Science 274, 1924-1926.
Aviezer D, Yayon A. (1994). Heparin-dependent binding and autophosphorylation of epidermal 
growth factor (EGF) receptor by heparin-binding EGF-like growth factor but not by EGF. Proceedings 
of the National Academy of Science of the U S A 91(25):12173-12177.
Baggiolini, M. and Dahinden, C.A. (1994). CC-chemokines in allergic inflammation. Immunology 
Today 15, 127-133.
Baggiolini M., Dewald B., Moser B. (1997). Human Chemokines: an update. Annual Reviews in 
Immunology 15: 675-705
Baines, P. and Visser, J.W.M. (1983). Analysis and Separation of Murine Bone Marrow Stem Cells by 
H33342 Fluorescence activated Cell Sorting. Experimental Haematology 11, 701-708.
Baldwin, E.T., Weber, I.T., Stcharles, R., Xuan, J.C., Appella, E., Yamada, M., Matsushima, K., 
Edwards, B.F.P., Clore, G.M., Gronenbom, A.M., and Wlodawer, A. (1991). Crystal-structure of 
interleukin-8 - symbiosis of NMR and crystallography. Proceedings Of The National Academy Of 
Sciences Of The United States Of America 88, 502-506.
Barker, J.N.W.N., Jones, M.L., Swenson, C., Mitra, R.S., Elder, J.T., Fantone, J.C., Ward, P.A., Dixit, 
V.M., and Nickoloff, B.J. (1990). Keratinocyte (kc) production of a biologically-active monocyte 
chemoattractant. Journal of Investigative Dermatology 94, 505
Barrandon, Y. and Green, H. (1985). Cell-size as a determinant of the clone-forming ability of human 
keratinocytes. Proceedings Of The National Academy Of Sciences Of The United States Of America 
82, 5390-5394.
Barrandon, Y. and Green, H. (1987a). Cell-migration is essential for sustained growth of keratinocyte 
colonies - the roles of transforming growth factor-a and epidermal growth-factor. Cell 5 0 ,1131-1137.
200
Barrandon, Y. and Green, H. (1987b). 3 clonal types of keratinocyte with different capacities for 
multiplication. Proceedings Of The National Academy Of Sciences Of The United States Of America 
84, 2302-2306.
Bartelmez, S.H., Bradley, T.R., Bertoncello, I., Mochizuki, D.Y., Tushinski, R.J., Stanley, E.R., 
Hapel, A.J., Young, I.G., Kriegler, A.B., and Hodgson, G.S. (1989). Interleukin-1 plus interleukin-3 
plus colony-stimulating factor-1 are essential for clonal proliferation of primitive myeloid bone- 
marrow cells. Experimental Hematology 1 7, 240-245.
Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, Greaves DR, Zlotnik A, Schall TJ
(1997). A new class of membrane-bound chemokine with a CX3C motif. Nature 385(6617):640-644.
Becker A.J., McCulloch E.A., Siminovitch L., and Till J.E. (1965). The effect of differing demands 
for blood cell production or DNA synthesis by haemopoietic colony forming cells of mice. Blood 26, 
296-308.
Begg G.S., Pepper D.S., Chesterman C.S., and Morgan F.J. (1978). Complete covalent structure of |3- 
thromboglobulin. Biochemistry 17, 1739
Ben-Baruch A, Xu L, Young PR, Bengali K, Oppenheim JJ, Wang JM. (1995). Monocyte chemotactic 
protein-3 (MCP3) interacts with multiple leukocyte receptors. C-C CKR1, a receptor for macrophage 
inflammatory protein-1 alpha/Rantes, is also a functional receptor for MCP3. Journal of Biological 
Chemistry 270(38):22123-22128.
Berger, M.S., Taub, D.D., Orlofsky, A., Kleyman, T.R., Coupayegerard, B., Eisner, D., and Cohen, 
S.A. (1996). The chemokine CIO - immunological and functional analysis of the sequence encoded by 
the novel second exon. Cytokine 8, 439-447.
Bergstresser, P.R., Edelbaum, D., Kitajima, T., Xu, S., Ariizumi, K., and Takashima, A. (1995). CSF-
I secreted by fibroblasts promotes the growth of dendritic cells. Journal Of Cellular Biochemistry 9
Bernstein SH, Eaves CJ, Herzig R, Fay J, Lynch J, Phillips GL, Christiansen N, Reece D, Ericson S, 
Stephan M, Kovalsky M, Hawkins K, Rasmussen H, Devos A, Herzig GP. (1997) A randomized phase
II study of BB-10010: a variant of human M IP-la for patients receiving high-dose etoposide and 
cyclophosphamide for malignant lymphoma and breast cancer. Br J Haematol 99 (4):888-895
Bickenbach, J.R. (1981). Identification and behavior of label-retaining cells in oral-mucosa and skin. 
Journal Of Dental Research 6 0 ,1611-1620.
Birbeck, M.S., Breathnach, A.S., and Everall, J.D. (1961). An electron microscope study of basal 
melanocytes and high-level clear cells (Langerhans cells) in vitiligo. Journal of Investigative 
Dermatology. 37, 51-64.
Bischoff, S.C., Krieger, M., Brunner, T., and Dahinden, C.A. (1992). Monocyte chemotactic protein-1 
is a potent activator of human basophils. Journal of Experimental Medicine 175, 1271-1275.
Bischoff, S.C., Krieger, M., Brunner, T., Rot, A., Vontschamer, V., Baggiolini, M., and Dahinden,
C.A. (1993). Rantes and related chemokines activate human basophil granulocytes through different 
G-protein-coupled receptors. European Journal Of Immunology 23, 761-767.
Bleul, C.C., Farzan, M., Choe, H., Parolin, C., Clarklewis, I., Sodroski, J., and Springer, T.A. (1996a). 
The lymphocyte chemoattractant SDF-1 is a ligand for lestr/fusin and blocks HIV-1 entry. Nature 382, 
829-833.
Bleul, C.C., Fuhlbrigge, R.C., Casasnovas, J.M., Aiuti, A., and Springer, T.A. (1996b). A highly 
efficacious lymphocyte chemoattractant, stromal cell-derived factor-1 (SDF-1). Journal of 
experimental medicine 1 8 4 ,1101-1109.
201
Bogden AE., Moreau JP., Gamba-Vitalo C., Deschamps de Pailette E., Tubiana M., Frindel E. and 
Carde P.(1998). AcSDKP, a negative growth regulator, protects the stem cell compartment during 
chemotherapy, enhancing the myelopoietic response to GM-CSF. International Journal of Cancer. 76 
(1): 38-46.
Boismenu R., and Havran WL. (1994). Modulation of epithelial cell growth by intraepithelial yS T- 
cells. Science 266: 1253-1255.
Boismenu R., Feng L., Xia YY., Chang JC., Havran WL. (1996). Chemokine expression by 
intraepithelial yb T-cells. Implications for the recruitment of inflammatory cells to damaged epithelia. 
Journal of Immunology 157 (3): 985-992.
Boismenu R, Havran WL (1998). Gammadelta T cells in host defense and epithelial cell 
biology. Clinical Immunology and Immunopathology 86(2): 121-133.
Boring, L., Gosling, J., Monteclaro, F.S., Lusis, A.J., Tsou, C.L., and Charo, I.F. (1996). Molecular- 
cloning and functional expression of murine JE (monocyte chemoattractant protein-1) and murine 
macrophage inflammatory protein-la receptors - evidence for 2 closely linked CC chemokine 
receptors on chromosome 9. Journal of Biological Chemistry 271, 7551-7558.
Borkowski, T.A., J.J. Letterio, A.G. Farr, and M.C. Udey (1996). A role for endogenous TGF-(3 1 in 
Langerhans cell biology. The skin of TGF-pi null mice is devoid of epidermal Langerhans cells. J. 
Exp. Med. 184: 2417-2422
Borkowski T.A., John J. Letterio, Crystal L. Mackall, Atsushi Saitoh, Xiao-Jing Wang, Dennis R. 
Roop, Ronald E. Gress, and Mark C. Udey (1997). A Role for TGF|3-1 in Langerhans Cell Biology: 
Further Characterization of the Epidermal Langerhans Cell Defect in TGF|3-1 Null Mice. Journal of 
Clinical Investigation 100 (3): 575-581.
Bos JD, Teunissen MB, Cairo I, Krieg SR, Kapsenberg ML, Das PK, Borst J. (1990). T-cell receptor 
gamma delta bearing cells in normal human skin. Journal of Investigative Dermatology 94(l):37-42
Bottinger, E.P., Factor, V.M., Tsang, M.L.S., Weatherbee, J.A., Kopp, J.B., Qian, S.W., Wakefield, 
L.M., Roberts, A.B., Thorgeirsson, S.S., and Sporn, M.B. (1996). The recombinant proregion of 
transforming growth-factor-pi (latency-associated peptide) inhibits active transforming growth factor. 
Proceedings Of The National Academy Of Sciences Of The United States Of America 93, 5877-5882.
Bradley TR and Hodgson GS. (1979). Detection of primitive macrophage progenitor cells in mouse 
bone marrow. Blood 54:1446-1450.
Brandt, E., Petersen, F., and Flad, H.D. (1993). A novel molecular variant of the neutrophil-activating 
peptide NAP-2 with enhanced biological-activity is truncated at the C-terminus - identification by 
antibodies with defined epitope specificity. Molecular Immunology 30, 979-991.
Brennan, F.M., Zachariae, C.O.C., Chantry, D., Larsen, C.G., Turner, M., Maini, R.N., Matsushima, 
K., and Feldmann, M. (1990). Detection of interleukin-8 biological activity in synovial fluids from 
patients with rheumatoid arthritis and production of interleukin-8 mRNA by isolated synovial cells. 
European Journal Of Immunology 20, 2141-2144.
Broxmeyer, H.E., Lu, L., Platzer, E., Feit, C., Juliano, L., and Rubin, B.Y. (1983). Comparative- 
analysis of the influences of human y, a  and p interferons on human multipotential (CFU-GEMM), 
erythroid (BFU-E) and granulocyte-macrophage (CFU-GM) progenitor cells. Journal of Immunology 
1 3 1 ,1300-1305.
Broxmeyer, H.E., Sherry, B., Lu, L., Cooper, S., Oh, K.O., Tekampolson, P., Kwon, B.S., and Cerami,
A. (1990). Enhancing and suppressing effects of recombinant murine macrophage inflammatory 
proteins on colony formation in vitro by bone-marrow myeloid progenitor cells. Blood 76, 1110-1116.
202
Broxmeyer HE. (1994). Advances in understanding of biological effects of interleukin-11, leukemia 
inhibitory factor, and macrophage inflammatory protein 1 alpha. Current Opinion in Hematology 
1(3): 197-202.
Broxmeyer HE., Orazi A., Hague NL., Sledge GW., Rasmussen H., Gordon MS. (1998) Myeloid 
progenitor cell proliferation and mobilisation effects of BB10010, a genetically engineered variant of 
human M IP-la in a phase I clinical trial in patients with relapsed /refractory breast cancer. Blood 
Cells Molecules and Disease 24 (1): 14-30.
Burd, P.R., Freeman, G.J., Wilson, S.D., Berman, M., Dekruyff, R., Billings, P.R., and Dorf, M.E.
(1987). Cloning and characterization of a novel T-cell activation gene. Journal of Immunology 139, 
3126-3131.
Burd, P.R., Rogers, H.W., Gordon, J.R., Martin, C.A., Jayaraman, S., Wilson, S.D., Dvorak, A.M., 
Galli, S.J., and Dorf, M.E. (1989). Interleukin-3 dependent and interleukin-3 independent mast-cells 
stimulated with IGE and antigen express multiple cytokines. Journal of Experimental Medicine 170, 
245-257.
Burgess A. and Nicola N. (1983). Growth Factors and stem cells. In Growth factors and stem cells. 
Academic Press New York.
Cacalano, G., Lee, J., Kikly, K., Ryan, A.M., Pittsmeek, S., Hultgren, B., Wood, W.I., and Moore, 
M.W. (1994). Neutrophil and B-cell expansion in mice that lack the murine IL-8 receptor homolog. 
Science 265, 682-684.
Cairns JS. and D'Souza MP. (1998). Chemokines and HIV-1 second receptors: The therapeutic 
connection. Nature Medicine 4 (5): 563-568.
Capel B., Hawley R.G., and Mintz B. (1990). Long and short lived murine haematopoietic stem cell 
clones individually identified with retroviral integration markers. Blood 75, 2267-2270.
Caput, D., Beutler, B., Hartog, K., Thayer, R., Brownshimer, S., and Cerami, A. (1986). Identification 
of a common nucleotide-sequence in the 3' untranslated region of mRNA molecules specifying 
inflammatory mediators. Proceedings Of The National Academy Of Sciences Of The United States Of 
America 83, 1670-1674.
Car B.D., Baggiolini M., and Walz A. (1991). Formation of neutrophil activating peptide 2 from 
platelet derived connective tissue activating peptide-III by different tissue proteinases. Biochemical 
Journal 275, 581-584.
Carde, P., Masse, A., Ramirez, L., Grillon, C., Bindoula, G., Radassi, K., Ardouin, P., and Sainteny, F. 
(1995). The tetrapeptide acSDKP (goralatide) protects mice from doxorubicin lethal toxicities 
(survival and hematopoietic recovery), and enhances the effect of G-CSF. Blood 86, 2742.
Carlostella, C., Cazzola, M., Ganser, A., Bergamaschi, G., Pedrazzoli, P., Hoelzer, D., and Ascari, E.
(1988). Synergistic antiproliferative effect of recombinant interferon-y with recombinant interferon-a 
on chronic myelogenous leukemia hematopoietic progenitor cells (CFU-GEMM, CFU-MK, BFU-E, 
and CFU-GM). Blood 72, 1293-1299.
Carr, M.W., Roth, S.J., Luther, E., Rose, S.S., and Springer, T.A. (1994). Monocyte chemoattractant 
protein-1 acts as a T-lymphocyte chemoattractant. Proceedings Of The National Academy Of Sciences 
Of The United Of America 91, 3652-3656.
Carroll, J.M., Romero, M.R., and Watt, F.M. (1995). Suprabasal integrin expression in the epidermis 
of transgenic mice results in developmental defects and a phenotype resembling psoriasis. Cell 83, 
957-968.
203
Cashman, J.D., Eaves, A.C., Raines, E.W., Ross, R., and Eaves, C.J. (1990). Mechanisms that regulate 
the cell-cycle status of very primitive hematopoietic cells in long-term human marrow cultures. 1. 
Stimulatory role of a variety of mesenchymal cell activators and inhibitory role of TGF-p. Blood 75, 
96-101.
Cashman, J.D., Eaves, A.C., and Eaves, C.J. (1994). The tetrapeptide acSDKP specifically blocks the 
cycling of primitive normal but not leukemic progenitors in long-term culture - evidence for an 
indirect mechanism. Blood 8 4 ,1534-1542.
Castor C.W., Ritchie J.C., Williams C.H., Scott M.E., Whitney S.L., Myers S.L., Sloan T.B., and 
Anderson B.E. (1979). Connective Tissue activation XIV. Comparison and actions of a human platelet 
autocoid mediator. Arthritis and Rheumatism 260.
Castor C.W., Miller J.W., and Walz D.A. (1983). Structural and biological characterisation of 
connective tissue activating peptide (CTAP-III) a major human platelet derived growth factor. 
Proceedings of the national academy of science USA 80, 765
Caux, C., Saeland, S., Favre, C., Duvert, V., Mannoni, P., and Banchereau, J. (1990). Tumor necrosis 
factor-a strongly potentiates interleukin-3 and granulocyte macrophage colony-stimulating factor 
induced proliferation of human CD34+ hematopoietic progenitor cells. Blood 75, 2292-2298.
Caux, C., Favre, C., Saeland, S., Duvert, V., Durand, I., Mannoni, P., and Banchereau, J. (1991). 
Potentiation of early hematopoiesis by tumor necrosis factor-a is followed by inhibition of 
granulopoietic differentiation and proliferation. Blood 78, 635-644.
Caux, C., Moreau, I., Saeland, S., and Banchereau, J. (1992). Interferon-y enhances factor-dependent 
myeloid proliferation of human CD34+ hematopoietic progenitor cells. Blood 79, 2628-2635.
Cerretti DP, Kozlosky CJ, Mosley B, Nelson N, Van Ness K, Greenstreet TA, March CJ, Kronheim 
SR, Druck T, Cannizzaro LA. (1992). Molecular cloning of the interleukin-1 beta converting enzyme. 
Science 256(5053):97-100.
Chaouchi, N., Arvanitakis, L., Auffredou, M.T., Blanchard, D.A., Vazquez, A., and Sharma, S.
(1995). Characterization of TGF-pi induced apoptosis in normal human B-cells and lymphoma B-cell 
lines. Oncogene 11, 1615-1622.
Charo, I.F., Myers, S.J., Herman, A., Franci, C., Connolly, A.J., and Coughlin, S.R. (1994). 
Molecular-cloning and functional expression of 2 monocyte chemoattractant protein-1 receptors 
reveals alternative splicing of the carboxyl-terminal tails. Proceedings Of The National Academy Of 
Sciences Of The United States Of America 91, 2752-2756.
Cheifetz, S., Weatherbee, J.A., Tsang, M.L.S., Anderson, J.K., Mole, J.E., Lucas, R., and Massague, J. 
(1987). The transforming growth fact or-(3 system, a complex pattern of cross-reactive ligands and 
receptors. Cell 48, 409-415.
Chen, C. and Okayama, H. (1987). High-efficiency transformation of mammalian cells by plasmid 
DNA. Molecular and Cellular Biology 7, 2745-2752.
Chen, H.D., Ma, C.L., Yuan, J.T., Wang, Y.K., and Silvers, W.K. (1986). Occurrence of donor 
langerhans cells in mouse and rat chimeras and their replacement in skin-grafts. Journal of 
Investigative Dermatology 86, 630-633.
Chertkov J.L., Drize N.J., Gurevitch G.A., and Udalor G.A. (1985). Cells responsible for restoration 
of haemopoiesis in long term bone marrow culture. Leukaemia Research 6, 659-663.
Choe, H., Farzan, M., Sun, Y., Sullivan, N., Rollins, B., Ponath, P.D., Wu, L.J., Mackay, C.R., Larosa,
G., Newman, W., Gerard, N., Gerard, C., and Sodroski, J. (1996). The p-chemokine receptors
CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85, 1135-1148.
204
Christophers E. (1971). Cellular architecture of the stratum comeum. Journal of Investigative 
Dermatology. 56, 165-169.
Clarklewis, I., Schumacher, C., Baggiolini, M., and Moser, B. (1991). Structure activity relationships 
of interleukin-8 determined using chemically synthesized analogs - critical role of NH2-terminal 
residues and evidence for uncoupling of neutrophil chemotaxis, exocytosis, and receptor-binding 
activities. Journal of Biological Chemistry 266, 23128-23134.
Clarklewis, I., Dewald, B., Geiser, T., Moser, B., and Baggiolini, M. (1993). Platelet factor-4 binds to 
interleukin-8 receptors and activates neutrophils when its N-terminus is modified with glu-leu-arg. 
Proceedings Of The National Academy Of Sciences Of The United States Of America 90, 3574-3577.
Clarklewis, I., Dewald, B., Loetscher, M., Moser, B., and Baggiolini, M. (1994). Structural 
requirements for interleukin-8 function identified by design of analogs and CXC chemokine hybrids. 
Journal of Biological Chemistry 2 6 9 ,16075-16081.
Clarklewis, I., Kim, K.S., Rajarathnam, K., Gong, J.H., Dewald, B., Moser, B., Baggiolini, M., and 
Sykes, B.D. (1995). Structure activity relationships of chemokines. Journal Of Leukocyte Biology 57, 
703-711.
Clements, J.M., Craig, S., Gearing, A.J.H., Hunter, M.G., Heyworth, C.M., Dexter, T.M., and Lord, 
B.I. (1992). Biological and structural-properties of M IP-la expressed in yeast. Cytokine 4, 76-82.
Clore, G.M., Appella, E., Yamada, M., Matsushima, K., and Gronenbom, A.M. (1990). 3-
dimensional structure of interleukin-8 in solution. Biochemistry 29, 1689-1696.
Cluitmans, F.H.M., Esendam, B.H.J., Landegent, J.E., Willemze, R., and Falkenburg, J.H.F. (1995). 
Constitutive in vivo cytokine and hematopoietic growth-factor gene expression in the bone marrow and 
peripheral blood of healthy individuals. Blood 85, 2038-2044.
Cocchi, F., Devico, A.L., Garzinodemo, A., Arya, S.K., Gallo, R.C., and Lusso, P. (1995). 
Identification of Rantes, M IP-la, and MIP-1 (3 as the major HIV-suppressive factors produced by 
CD8+ T-cells. Science 270, 1811-1815.
Coffey, R.J., Derynck, R., Wilcox, J.N., Bringman, T.S., Goustin, A.S., Moses, H.L., and Pittelkow, 
M.R. (1987). Production and auto-induction of transforming growth factor-a in human keratinocytes. 
Nature 328, 817-820.
Coffey, R.J., Bascom, C.C., Sipes, N.J., Gravesdeal, R., Weissman, B.E., and Moses, H.L. (1988a). 
Selective inhibition of growth related gene expression in murine keratinocytes by transforming growth 
factor-p. Molecular and Cellular Biology 8, 3088-3093.
Coffey, R.J., Sipes, N.J., Bascom, C.C., Gravesdeal, R., Pennington, C.Y., Weissman, B.E., and 
Moses, H.L. (1988b). Growth modulation of mouse keratinocytes by transforming growth factor-p. 
Cancer Research 4 8 ,1596-1602.
Cohen, S. (1962). Isolation of a mouse submaxillary gland protein accelerating incisor eruption and 
eyelid opening in the newborn animal. Journal of Biological Chemistry 2 3 7 ,1555-1562.
Cohen, S. and Carpenter, G. (1975). Human Epidermal Growth Factor: isolation and chemical and 
biological properties. Proceedings Of The National Academy Of Sciences Of The United Of America 
72, 1317-1321.
Collins, P.D., Marleau, S., Griffithsjohnson, D.A., Jose, P.J., and Williams, T.J. (1995). Cooperation 
between interleukin-5 and the chemokine eotaxin to induce eosinophil accumulation in-vivo. Journal 
of Experimental Medicine 182, 1169-1174.
Combadiere C, Ahuja SK, Van Damme J, Tiffany HL, Gao JL, Murphy PM.(1995). Monocyte 
chemoattractant protein-3 is a functional ligand for CC chemokine receptors 1 and 2B. Journal of 
Biological Chemistry 270(50):29671-29675.
205
Cook, D.N., Beck, M.A., Coffman, T.M., Kirby, S.L., Sheridan, J.F., Pragnell, I.B., and Smithies, O.
(1995). Requirement of M IP-la for an inflammatory response to viral infection. Science 269, 1583- 
1585.
Cook, S.J. and Mccormick, F. (1993). Inhibition by cAMP of ras-dependent activation of raf. Science 
262, 1069-1072.
Cook PW, Pittelkow MR, Shipley GD. (1991). Growth factor-independent proliferation of normal 
human neonatal keratinocytes: production of autocrine- and paracrine-acting mitogenic factors. Journal 
of Cellular Physiology 146(2):277-289.
Cooper, S., Mantel, C., and Broxmeyer, H.E. (1994). Myelosuppressive effects in vivo with very low 
dosages of monomeric recombinant murine macrophage inflammatory protein-la. Experimental 
Hematology 22,186-193.
Costa, J.J., Matossian, K., Resnick, M.B., Beil, W.J., Wong, D.T.W., Gordon, J.R., Dvorak, A.M., 
Weller, P.F., and Galli, S.J. (1993). Human eosinophils can express the cytokines TNF-a and M IP-la. 
Journal Of Clinical Investigation 91, 2673-2684.
Cotsarelis, G., Sun, T.T., and Lavker, R.M. (1990). Label-retaining cells reside in the bulge area of 
pilosebaceous unit - implications for follicular stem cells, hair cycle, and skin carcinogenesis. Cell 61, 
1329-1337.
Coulombel, L., Eaves, A.C., and Eaves, C.J. (1983). Enzymatic treatment of long-term human marrow 
cultures reveals the preferential location of primitive hematopoietic progenitors in the adherent layer. 
Blood 62, 291-297.
Covell, D.G., Smythers, G., Gronenbom, A.M., and Clore, G.M. (1994). Analysis of hydrophobicity in 
the a  and (3 chemokine families and its relevance to dimerization. Protein Science 3, 2064-2072.
Creighton T. E. (1993). Proteins: Structures and Molecular Properties, W. H. Freeman and Company, 
New York.
Cuturi, M.C., Murphy, M., Costagiomi, M.P., Weinmann, R., Perussia, B., and Trinchieri, G. (1987). 
Independent regulation of tumor necrosis factor and lymphotoxin production by human peripheral- 
blood lymphocytes. Journal of Experimental Medicine 165, 1581-1594.
Dalbey, R.E. and Vonheijne, G. (1992). Signal peptidases in prokaryotes and eukaryotes - a new 
protease family. Trends In Biochemical Sciences 17, 474-478.
Dairaghi D.J., Oldham E.R., Bacon K. R., and Schall T.J. Chemokine receptor CCR3 function is 
highly dependent on local pH and Ionic stength. (1997) The Journal of Biological Chemistry 272 (7) 
28206-28209.
Daugherty, B.L., Siciliano, S.J., Demartino, J.A., Malkowitz, L., Sirotina, A., and Springer, M.S.
(1996). Cloning, expression, and characterization of the human eosinophil eotaxin receptor. Journal of 
Experimental Medicine 183, 2349-2354.
Davatelis, G., Tekampolson, P., Wolpe, S.D., Hermsen, K., Luedke, C., Gallegos, C., Coit, D., 
Merryweather, J., and Cerami, A. (1988). Cloning and characterization of a cDNA for murine 
macrophage inflammatory protein (MIP), a novel monokine with inflammatory and chemokinetic 
properties. Journal of Experimental Medicine 167, 1939-1944.
Del Sal G., Ruaro E.M., Philipson L., and Schneider C. (1994). The growth arrest specific gene, gas 1 
is involved in growth suppression. Cell 70, 595-607.
DeLarco, J.E. and Todaro, G.J. (1979). Growth Factors produced by murine sarcoma virus- 
transformed cells. Proceedings Of The National Academy Of Sciences Of The United Of America 75, 
4001-4005.
206
Deng, H.K., Liu, R., Ellmeier, W., Choe, S., Unutmaz, D., Burkhart, M., Dimarzio, P., Marmon, S., 
Sutton, R.E., Hill, C.M., Davis, C.B., Peiper, S.C., Schall, T.J., Littman, D.R., and Landau, N.R.
(1996). Identification of a major coreceptor for primary isolates of HIV-1. Nature 381, 661-666.
Derynck, R., Jarrett, J.A., Chen, E.Y., Eaton, D.H., Bell, J.R., Assoian, R.K., Roberts, A.B., Sporn, 
M.B., and Goeddel, D.V. (1985). Human TGF-(3 cDNA sequence and expression in normal and 
transformed cells. Nature 316, 701-705.
Derynck, R., Goeddel, D.V., Ullrich, A., Gutterman, J.U., Williams, R.D., Bringman, T.S., and 
Berger, W.H. (1987). Synthesis of mRNAs for TGF-a and TGF-{3 and the EGF receptor by human 
tumours. Cancer Research 47, 707-712.
Derynck, R., Balentien, E., Han, J.H., Thomas, H.G., Wen, D.Z., Samantha, A.K., Zachariae, C.O., 
Griffin, P.R., Brachmann, R., Wong, W.L., Matsushima, K., and Richmond, A. (1990). Recombinant 
expression, biochemical characterisation, and biological activity of MGSA/gro protein. Biochemistry 
29, 10225-10233.
Desauvage, F.J., Gurney, A., Carvermoore, K., and Moore, M.W. (1994). Thrombocytopenia in c-mpl 
deficient mice. Blood 84, A 390
Deuel, T.F., Keim, P.S., Farmer, M., and Heinriksen, R.L. (1977). Platelet Factor-4: Complete amino- 
acid sequence. Proceedings Of The National Academy Of Sciences Of The United States Of America 
74, 2256
Deuel, T.F., Senior, R.M., Chang, D., Griffin, G.L., Heinrikson, R.L., and Kaiser, E.T. (1981). Platelet 
factor-4 is chemotactic for neutrophils and monocytes. Proceedings Of The National Academy Of 
Sciences Of The United States Of America-Biological Sciences 78, 4584-4587.
Deutsch, E., Johnson, S.A., and Seegers, W.H. (1955). Differentiation of certain platelet factors 
related to blood coagulation. Circulation Research 3, 110
Devi, S., Laning, J., Luo, Y., and Dorf, M.E. (1995). Biologic activities of the P-chemokine TCA-3 
on neutrophils and macrophages. Journal of Immunology 154, 5376-5383.
Dexter T.M., Allen T.D., and Lajtha L.G. (1976). Conditions controlling the proliferation of
haemopoietic stem cells in vitro.. Journal of cellular physiology 91, 335-344.
Dexter T.M. and Moore M.A.S. (1977). In  vitro duplication and cure of haemopoietic defects in
genetically anaemic mice. Nature 269, 412-414.
Dexter T.M. (1982). Stromal cell associated haemopoiesis. Journal of cellular physiology Suppl. 1: 
87-94.
Dickson MC, Martin JS, Cousins FM, Kulkami AB, Karlsson S, Akhurst RJ. (1995). Defective 
haematopoiesis and vasculogenesis in transforming growth factor-pi knock out mice. Development 
Jun;121(6):1845-1854
DiPietro LA., Burdick M., Low QE., Kunkel SL., and Streiter RM. (1998). M IP-la as a critical 
macrophage chemoattractant in murine wound repair. Journal of Clinical Investigation 101: 1693- 
1698.
Donlon, T.A., Krensky, A.M., Wallace, M.R., Collins, F.S., Lovett, M., and Clayberger, C. (1990). 
Localization of a human T-cell-specific gene, Rantes (dl7sl36e), to chromosome 17qll.2-ql2. 
Genomics 6, 548-553.
Doranz, B.J., Rucker, J., Yi, Y.J., Smyth, R.J., Samson, M., Peiper, S.C., Parmentier, M., Collman, 
R.G., and Dorns, R.W. (1996). A dual-tropic primary HIV-1 isolate that uses fusin and the (3- 
chemokine receptors CCR5, CCR3 and CCR2B as fusin co-factors. Cell 8 5 ,1149-1158.
207
Dorner B, Muller S, Entschladen F, Schroder JM, Franke P, Kraft R, Friedl P, Clark-Lewis I, Kroczek 
RA Purification, structural analysis, and function of natural ATAC, a cytokine secreted by CD8(+) T 
cells. Journal of Biological Chemistry (1997) 272(13):8817-8823
Dragic, T., Litwin, V., Allaway, G.P., Martin, S.R., Huang, Y.X., Nagashima, K.A., Cayanan, C., 
Maddon, P.J., Koup, R.A., Moore, J.P., and Paxton, W.A. (1996). HIV-1 entry into CD4+ cells is 
mediated by the chemokine receptor CCR5. Nature 381, 667-673.
Dube S., Fisher J., and Powell J.S. (1988). Glycosylation at specific sites of erythropoietin is essential 
for biosynthesis, secretion and biological function. Journal of Biological Chemistry 2 6 3 ,17516-17521.
Dubois, C.M., Ruscetti, F.W., Palaszynski, E.W., Falk, L.A., Oppenheim, J.J., and Keller, J.R. (1990). 
TGF-P is a potent inhibitor of interleukin-1 receptor expression: proposed mechanism of inhibition of 
IL-1 action. Journal of Experimental Medicine 172, 737-744.
Dunlevy, J.R. and Couchman, J.R. (1995). Interleukin-8 induces motile behavior and loss of focal 
adhesions in primary fibroblasts. Journal of Cell Science 108, 311-321.
Dunlop, D.J., Wright, E.G., Lorimore, S., Graham, G.J., Holyoake, T., Kerr, D.J., Wolpe, S.D., and 
Pragnell, I.B. (1992). Demonstration of stem-cell inhibition and myeloprotective effects of 
SCI/rhMIP-la in vivo. Blood 79, 2221-2225.
Eaves, C.J., Sutherland, H.J., Cashman, J.D., Otsuka, T., Lansdorp, P.M., Humphries, R.K., Eaves,
A.C., and Hogge, D.E. (1991). Regulation of primitive human hematopoietic-cells in long-term 
marrow culture. Seminars In Hematology 28, 126-131.
Eaves, C.J., Cashman, J.D., Kay, R.J., Dougherty, G.J., Otsuka, T., Gaboury, L.A., Hogge, D.E., 
Lansdorp, P.M., Eaves, A.C., and Humphries, R.K. (1991). Mechanisms that regulate the cell-cycle 
status of very primitive hematopoietic-cells in long-term human marrow cultures .2. Analysis of 
positive and negative regulators produced by stromal cells within the adherent layer. Blood 78, 110- 
117.
Eaves, C.J., Cashman, J.D., Wolpe, S.D., and Eaves, A.C. (1993). Unresponsiveness of primitive 
chronic myeloid-leukemia cells to M IP-la, an inhibitor of primitive normal hematopoietic-cells. 
Proceedings Of The National Academy Of Sciences Of The United States Of America 90, 12015- 
12019.
Ehlert, J.E., Petersen, F., Kubbutat, M.H.G., Gerdes, J., Flad, H.D., and Brandt, E. (1995). Limited 
and defined truncation at the C-terminus enhances receptor binding and degranulation activity of NAP- 
2 - comparison of native and recombinant NAP-2 variants. Journal of Biological Chemistry 270, 6338- 
6344.
Eichner, R., Sun, T.T., and Aebi, U. (1986). The role of keratin subfamilies and keratin pairs in the 
formation of human epidermal intermediate filaments. Journal of Cell Biology 1 0 2 ,1767-1777.
Elbaz, O., Budel, L.M., Hoogerbrugge, H., Touw, I.P., Delwel, R., Mahmoud, L.A., and Lowenberg,
B. (1991). Tumor necrosis factor regulates the expression of G-CSF receptor expression on human 
acute myeloid leukaemia cells and granulocytes. Blood 77, 989-995.
Elder, J.T., Fisher, G.J., Lindquist, P.B., Bennett, G.L., Pittelkow, M.R., Coffey, R.J., Ellingsworth, 
L., Derynck, R., and Voorhees, J.J. (1989). Overexpression of TGF-a in psoriatic epidermis. Science 
243, 811-814.
Elgjo, K., Reichelt, K.L., and Hennings, H. (1986). Purified epidermal pentapeptide inhibits 
proliferation and enhances terminal differentiation in cultured mouse epidermal cells. Journal of 
Investigative Dermatology. 87, 555-558.
208
Endres, M.J., Clapham, P.R., Marsh, M., Ahuja, M., Turner, J.D., Mcknight, A., Thomas, J.F., 
Stoebenauhaggarty, B., Choe, S., Vance, P.J., Wells, T.N.C., Power, C.A., Sutterwala, S.S., Doms, 
R.W., Landau, N.R., and Hoxie, J.A. (1996). Cd4-independent infection by HIV-2 is mediated by 
fusin/CXCR4. Cell 87, 745-756.
Ernst, C.A., Zhang, Y.J., Hancock, P.R., Rutledge, B.J., Corless, C.L., and Rollins, B.J. (1994). 
Biochemical and biologic characterization of murine monocyte chemoattractant protein-1 - 
identification of 2 functional domains. Journal of Immunology 152, 3541-3549.
Fahey, T.J., Tracey, K.J., Tekampolson, P., Cousens, L.S., Jones, W.G., Shires, G.T., Cerami, A., and 
Sherry, B. (1992). Macrophage inflammatory protein-1 modulates macrophage function. Journal of 
Immunology 148, 2764-2769.
Fairbaim, L.J., Cowling, G.J., Reipert, B.M., and Dexter, T.M. (1993). Suppression of apoptosis 
allows differentiation and development of a multipotent hematopoietic-cell line in the absence of 
added growth- factors. Cell 74, 823-832.
Fairbaim, L.J., Cowling, G.J., Dexter, T.M., Rafferty, J.A., Margison, G.P., and Reipert, B. (1994). 
Bcl-2 delay of alkylating agent-induced apoptotic death in a murine hematopoietic stem-cell line. 
Molecular Carcinogenesis 11, 49-55.
Farber, J.M. (1990). A macrophage mRNA selectively induced by y-Interferon encodes a member of 
the platelet factor-4 family of cytokines. Proceedings Of The National Academy Of Sciences Of The 
United States Of America 87, 5238-5242.
Faull, R.J. and Ginsberg, M.H. (1995). Dynamic regulation of integrins. Stem Cells 13, 38-46.
Feng Y, Broder CC, Kennedy PE, Berger EA. (1996) HIV-1 entry cofactor: functional cDNA cloning 
of a seven-transmembrane, G protein-coupled receptor. Science 272(5263):872-877.
Finch, P.W., Rubin, J.S., Miki, T., Ron, D., and Aaronson, S.A. (1989). Human KGF is FGF related 
with properties of a paracrine effector of epithelial cell growth. Science 245, 752-755.
Ford, C.E., Hamerton, J.L., Barnes, D.W.H., and Loutit, J.F. (1956). Cytological Identification of 
Radiation Chimaeras. Nature 177, 452-454.
Franci C, Wong LM, Van Damme J, Proost P, Charo IF. (1995). Monocyte chemoattractant protein-3, 
but not monocyte chemoattractant protein-2, is a functional ligand of the human monocyte 
chemoattractant protein-1 receptor. Journal of Immunology 154(12):6511-6517
Franz, T., Lohler, J., Fusco, A., Pragnell, I., Nobis, P., Padua, R., and Ostertag, W. (1985). 
Transformation of mononuclear phagocytes in vivo and malignant histiocytosis caused by a novel 
murine spleen focus-forming virus. Nature 3 1 5 ,149-151.
Frelinger J.G., Hood L., Hill S., and Frelinger J.A. (1979). Mouse epidermal la molecules have a bone 
marrow origin. Nature 282, 321-323.
Frindel, E. and Guigon, M. (1977). Inhibition of CFU-S entry into cycle by a bone-marrow extract. 
Experimental Haematology 5, 74
Frindel, E. and Monpezat, J.P. (1989). The physiological role of the endogenous colony-forming units- 
spleen(CFU-S) inhibitor acSDKP. Leukemia 3, 753-754.
Fuchs, E. (1990). Epidermal differentiation: The bare essentials. Journal of Cell Biology 111, 2807- 
2814.
Fuchs, E. (1993). Epidermal differentiation and keratin gene expression. Journal of Cell Science 
Supplement 17. 197-208.
209
Fujita, M., Furukawa, F., Horiguchi, Y., Ueda, M., Kashiharasawami, M., and Imamura, S. (1991). 
Regional-development of Langerhans cells and formation of Birbeck granules in human embryonic 
and fetal skin. J. Inv. Derm. 97, 65-72.
Funk, P.E., Kincade, P.W., and Witte, P.L. (1994). Native associations of early hematopoietic stem- 
cells and stromal cells isolated in bone-marrow cell aggregates. Blood 83, 361-369.
Gallico, G.G., Oconnor, N.E., Compton, C.C., Kehinde, O., and Green, H. (1984). Permanent 
coverage of large bum wounds with autologous cultured human epithelium. New England Journal Of 
Medicine 377,448-451.
Ganser, A., Carlostella, C., Greher, J., Volkers, B., and Hoelzer, D. (1987). Effect of recombinant 
interferon-a and interferon-y on human bone marrow derived megakaryocytic progenitor cells. Blood 
70, 1173-1179.
Gao, J.L. and Murphy, P.M. (1994). Human cytomegalovirus open reading frame us28 encodes a 
functional (3-chemokine receptor. Journal of Biological Chemistry 269, 28539-28542.
Garciazepeda, E.A., Rothenberg, M.E., Ownbey, R.T., Celestin, J., Leder, P., and Luster, A.D. (1996). 
Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to 
explain tissue eosinophilia. Nature Medicine 2, 449-456.
Gattass, C.R., King, L.B., Luster, A.D., and Ashwell, J.D. (1994). Constitutive expression of 
interferon y-inducible protein-10 in lymphoid organs and inducible expression in T-cells and 
thymocytes. Journal of Experimental Medicine 779,1373-1378.
Geiser, T., Dewald, B., Ehrengruber, M.U., Clarklewis, I., and Baggiolini, M. (1993). The interleukin- 
8 related chemotactic cytokines gro-a, gro-(3, and gro-y activate human neutrophil and basophil 
leukocytes. Journal of Biological Chemistry 268, 15419-15424.
Gentry, L.E., Twardzik, D.R., Lim, G.J., Ranchalis, J.E., and Lee, D.C. (1987). Expression and 
characterization of TGF-a precursor protein in transfected mammalian-cells. Molecular and Cellular 
Biology 7, 1585-1591.
Gentry, L.E., Lioubin, M.N., Purchio, A.F., and Marquardt, H. (1988). Molecular events in the 
processing of recombinant type-1 pre-pro- TGF-(3 to the mature polypeptide. Molecular and Cellular 
Biology 8, 4162-4168.
Gewirtz, A.M., Zhang, J., Ratajczak, J., Ratajczak, M., Park, K.S., Li, C.Q., Yan, Z.Q., and Poncz, M. 
(1995). Chemokine regulation of human megakaryocytopoiesis. Blood 86, 2559-2567.
Gillitzer R, Berger R, Mielke V, Muller C, Wolff K, Stingl G. (1991). Upper keratinocytes of psoriatic 
skin-lesions express high levels of NAP-1/ IL-8 m-RNA in-situ. Journal of Investigative Dermatology 
97: 73-79.
Gillitzer, R., Wolff, K., Tong, D., Muller, C., Yoshimura, T., Hartmann, A.A., Stingl, G., and Berger, 
R. (1993). MCP-1 mRNA expression in basal keratinocytes of psoriatic lesions. Journal of 
Investigative Dermatology. 1 0 1 ,127-131.
Gimbrone, M.A., Obin, M.S., Brock, A.F., Luis, E.A., Hass, P.E., Hebert, C.A., Yip, Y.K., Leung,
D.W., Lowe, D.G., Kohr, W.J., Darbonne, W.C., Bechtol, K.B., and Baker, J.B. (1989). Endothelial 
interleukin-8 - a novel inhibitor of leukocyte-endothelial interactions. Science 2 4 6 ,1601-1603.
Glick, A.B., Kulkami, A.B., Tennenbaum, T., Hennings, H., Flanders, K.C., Oreilly, M., Spom, M.B., 
Karlsson, S., and Yuspa, S.H. (1993). Loss of expression of TGF-|3 in skin and skin tumors is 
associated with hyperproliferation and a high risk for malignant conversion. Proceedings Of The 
National Academy Of Sciences Of The United States Of America 90, 6076-6080.
210
Glick, A.B., Lee, M.M., Darwiche, N., Kulkami, A.B., Karlsson, S., and Yuspa,. S.H. (1994a). 
Targeted deletion of the TGF-(31 gene causes rapid progression to squamous-cell carcinoma. Genes & 
Development 8, 2429-2440.
Glick, A.B., Lee, M.M., Kulkami, A.B., Karlsson, S., and Yuspa, S.H. (1994b). Rapid malignant 
progression of epidermal tumors derived form TGF-pi null mice keratinocytes. Journal of 
Investigative Dermatology. 102, 525
Gluzman, Y. (1981). Sv40-transformed simian cells support the replication of early SV40 mutants. 
Cell 2 3 ,175-182.
Gomezcambronero, J., Huang, C.K., Gomezcambronero, T.M., Waterman, W.H., Becker, E.L., and 
Shaafi, R.I. (1992). GM-CSF induced protein tyrosine phosphorylation of microtubule-associated 
protein-kinase in human neutrophils. Proceedings Of The National Academy Of Sciences Of The 
United States Of America 89, 7551-7555.
Gong, J.H. and Clarklewis, I (1995). Antagonists of monocyte chemoattractant protein-1 identified by 
modification of functionally critical NH2-terminal residues. Journal of Experimental Medicine 181, 
631-640.
Gong, J.H., Uguccioni, M., Dewald, B., Baggiolini, M., and Clarklewis, I (1996). Rantes and MCP-3 
antagonists bind multiple chemokine receptors. Journal of Biological Chemistry 271, 10521-10527.
Gong JH, Ratkay LG, Waterfield JD, Clark-Lewis I. An antagonist of monocyte chemoattractant 
protein 1 (MCP-1) inhibits arthritis in the MRL-lpr mouse model. Journal of Experimental Medicine 
1997 186(1):131-137
Goodman, R.B., Wood, R.G., Martin, T.R., Hansonpainton, O., and Kinasewitz, G.T. (1992). 
Cytokine-stimulated human mesothelial cells produce chemotactic activity for neutrophils including 
NAP-l/IL-8. Journal of Immunology 148, 457-465.
Gordon, M.Y., Riley, G.P., Watt, S.M., and Greaves, M.F. (1987). Compartmentalization of a 
hematopoietic growth-factor (GM-CSF) by glycosaminoglycans in the bone-marrow 
microenvironment. Nature 326, 403-405.
Gottlieb, A.B., Chang, C.K., Posnett, D.N., Fanelli, B., and Tam, J.P. (1988). Detection of TGF-a in 
normal, malignant, and hyperproliferative human keratinocytes. Journal of Experimental Medicine 
167, 670-675.
Graham G.J., Wright E.G., Hewick R., Wolpe S.D., Wilkie N.M., Donaldson D., Lorimore S., and 
Pragnell I.B. (1990). Identification and characterisation of an inhibitor of haemopoietic stem cell 
proliferation. Nature 344, 442-444.
Graham G.J. and Pragnell I.B. (1991a). Negative regulators of haemopoiesis- current advances. 
Progress in Growth Factor Research 2,181-192.
Graham, G.J. and Pragnell, I.B. (1991b). Treating cancer - the potential role of stem-cell inhibitors. 
European Journal Of Cancer 27, 952-953.
Graham G.J. and Pragnell I.B. (1992a). The haemopoietic stem cell: properties and control 
mechanisms. Seminars in cell biology 3, 423-434.
Graham, G.J. and Pragnell, I.B. (1992b). SCI/MIP-la - a potent stem-cell inhibitor with potential 
roles in development. Developmental Biology 151, 377-381.
Graham, G.J., Zhou, L., Weatherbee, J.A., Tsang, M.L.S., Napolitano, M., Leonard, W.J., and 
Pragnell, I.B. (1993). Characterization of a receptor for M IP-la and related proteins on human and 
murine cells. Cell Growth & Differentiation 4 , 137-146.
211
Graham, G.J., Mackenzie, J., Lowe, S., Tsang, M.L.S., Weatherbee, J.A., Issacson, A., Medicherla, J., 
Fang, F., Wilkinson, P.C., and Pragnell, I.B. (1994). Aggregation of the chemokine M IP-la is a 
dynamic and reversible phenomenon - biochemical and biological analyses. Journal of Biological 
Chemistry 269, 4974-4978.
Graham, G.J., Wilkinson, P.C., Nibbs, R.J.B., Lowe, S., Kolset, S.O., Parker, A., Freshney, M.G., 
Tsang, M.L.S., and Pragnell, I.B. (1996). Uncoupling of stem cell inhibition from monocyte 
chemoattraction in M IP-la by mutagenesis of the proteoglycan binding site. Embo Journal 15, 6506- 
6515.
Graham G.J. and Wright E.G. (1997) Haemopoietic stem cells: their heterogeneity and regulation. 
International Journal of Experimental Pathology 78(4): 197-218
Grainger, D.J., Kemp, P.R., Liu, A.C., Lawn, R.M., and Metcalfe, J.C. (1994). Activation of TGF-|3 is 
inhibited in transgenic apolipoprotein(a) mice. Nature 370, 460-462.
Green, M.R. and Couchman, J.R. (1984). Distribution of EGF receptors in rat-tissues during 
embryonic skin development, hair formation, and the adult hair-growth cycle. Journal of Investigative 
Dermatology. 8 3 ,118-123.
Greenberger J.S. (1991). The Haematopoietic microenvironment. Critical Reviews in Oncology and 
Haematology 11, 65-84.
Grilion, C., Rieger, K., Bakala, J., Schott, D., Morgat, J.L., Hannappel, E., Voelter, W., and Lenfant, 
M. (1990). Involvement of thymosin-beta-4 and endoproteinase ASP-N in the biosynthesis of the 
tetrapeptide acSerAspLysPro a regulator of the hematopoietic system. Febs Letters 274, 30-34.
Grossman, R.M., Krueger, J., Yourish, D., Granellipipemo, A., Murphy, D.P., May, L.T., Kupper, 
T.S., Sehgal, P.B., and Gottlieb, A.B. (1989). Interleukin-6 is expressed in high-levels in psoriatic skin 
and stimulates proliferation of cultured human keratinocytes. Proceedings Of The National Academy 
Of Sciences Of The United States Of America 86, 6367-6371.
Grove, M., Lowe, S., Graham, G., Pragnell, I., and Plumb, M. (1990). Sequence of the murine 
hematopoietic stem-cell inhibitor macrophage inflammatory protein-la gene. Nucleic Acids Research 
18, 5561
Grzegorzewski, K., Ruscetti, F.W., Usui, N., Damia, G., Longo, D.L., Carlino, J.A., Keller, J.R., and 
Wiltrout, R.H. (1994). Recombinant TGF-(31 and TGF-(32 protect mice from acutely lethal doses of 5- 
fluorouracil and doxorubicin. Journal of Experimental Medicine 1 8 0 ,1047-1057.
Guo, L.F., Yu, Q.C., and Fuchs, E. (1993). Targeting expression of keratinocyte growth factor to 
keratinocytes elicits striking changes in epithelial differentiation in transgenic mice. Embo Journal 12, 
973-986.
Guo, L.F., Degenstein, L., and Fuchs, E. (1996). Keratinocyte growth factor is required for hair 
development but not for wound-healing. Genes & Development 1 0 ,165-175.
Gupta, S.K. and Singh, J.P. (1994). Inhibition of endothelial cell proliferation by platelet factor-4 
involves a unique action on S phase progression. Journal of Cell Biology 127, 1121-1127.
Gupta, S.K., Hassel, T., and Singh, J.P. (1995). A potent inhibitor of endothelial-cell proliferation is 
generated by proteolytic cleavage of the chemokine platelet factor-4. Proceedings Of The National 
Academy Of Sciences Of The United States Of America 92, 7799-7803.
Gurney, A.L., Carvermoore, K., Desauvage, F.J., and Moore, M.W. (1994). Thrombocytopenia in c- 
mpl-deficient mice. Science 2 6 5 ,1445-1447.
Hakovirta, H., Vierula, M., Wolpe, S.D., and Parvinen, M. (1994). M IP-la is a regulator of mitotic 
and meiotic DNA synthesis during spermatogenesis. Molecular And Cellular Endocrinology 99, 119- 
124.
212
Hall P.A. and Watt F.M. (1989). Stem Cells: The generation and maintenance of cellular diversity. 
Development 106, 619-633.
Handin, R.I. and Cohen, H.J. (1976). Purification and binding properties of human platelet factor 4. 
Journal of Biological Chemistry 251, 4273
Hannon G.J. and Beach D. (1994). p l5 INK4Bis a potential effector of TGF-(3 induced cell cycle arrest. 
Nature 371, 257-260.
Harrison D.E., Astle C.M., and Lemer C. (1988). Number and continuous proliferative pattern of 
transplanted primitive immunohaemopoietic stem cells. Proceedings of the national academy of 
science USA 85, 822-826.
Harrison D.E. and Lemer C. (1991). Most primitive haemopoietic stem cells are stimulated to cycle 
rapidly after treatment with 5-Fluorouracil. Blood 7 8 ,1237-1240.
Hartschuh, W. and Weihe, E. (1989). Pancreastatin-like immunoreactivity in epidermal merkel cells of 
pig and man. Neuroscience Letters 98, 258-263.
Hashimoto, K., Higashiyama, S., Asada, H., Hashimura, E., Kobayashi, T., Sudo, K., Nakagawa, T., 
Damm, D., Yoshikawa, K., and Taniguchi, N. (1994). Heparin-binding epidermal growth factor-like 
growth-factor is an autocrine growth-factor for human keratinocytes. Journal of Biological Chemistry 
269, 20060-20066.
Haskill, S., Peace, A., Morris, J., Sporn, S.A., Anisowicz, A., Lee, S.W., Smith, T., Martin, G., Ralph, 
P., and Sager, R. (1990). Identification of 3 related human gro genes encoding cytokine functions. 
Proceedings Of The National Academy Of Sciences Of The United States Of America 87, 7732-7736.
Hatzfeld, J., Li, M.L., Brown, E.L., Sookdeo, H., Levesque, J.P., Otoole, T., Gurney, C., Clark, S.C., 
and Hatzfeld, A. (1991). Release of early human hematopoietic progenitors from quiescence by 
antisenseTGF-pl or Rb-oligonucleotides. Journal of experimental medicine 174, 925-929.
Havran WL., Chien YH., Allison JP. (1991). Recognition of self-antigens by skin-derived T-cells with 
invariant yb antigen receptors. Science 252: 1430-1432.
Hebert, C.A., Luscinskas, F.W., Kiely, J.M., Luis, E.A., Darbonne, W.C., Bennett, G.L., Liu, C.C., 
Obin, M.S., Gimbrone, M.A., and Baker, J.B. (1990). Endothelial and leukocyte forms of IL-8 - 
conversion by thrombin and interactions with neutrophils. Journal of Immunology 145, 3033-3040.
Heeger, P., Wolf, G., Meyers, C., Sun, M.J., Ofarrell, S.C., Krensky, A.M., and Neilson, E.G. (1992). 
Isolation and characterization of cDNA from renal tubular epithelium encoding murine Rantes. Kidney 
International 41, 220-225.
Heufler, C., Parkinson, E.K., Graham, G.J., Koch, F., Topar, G., Kampgen, E., Romani, N., Pragnell, 
I.B., and Schuler, G. (1992a). Cytokine gene expression in murine epidermal Langerhans cells -MIP- 
l a  is a major product and inhibits the proliferation of keratinocyte stem-cells. J. Inv. Derm. 98, 515
Heufler, C., Topar, G., Koch, F., Trockenbacher, B., Kampgen, E., Romani, N., and Schuler, G. 
(1992b). Cytokine gene-expression in murine epidermal cell suspensions - IL-1(3 and M IP-la are 
selectively expressed in Langerhans cells but are differentially regulated in culture. Journal of 
Experimental Medicine 1 7 6 ,1221-1226.
Higashiyama, S., Abraham, J.A., Miller, J., Fiddes, J.C., and Klagsbrun, M. (1991). A heparin-binding 
growth-factor secreted by macrophage-like cells that is related to EGF. Science 251, 936-939. 
Hodgson, G.S. and Bradley, T.R. (1979). Properties of Haematopoietic Stem Cells Surviving 5- 
Fluorouracil Treatment: Evidence for a Pre-CFU-S Cell? Nature 281, 381-382.
Hodivala, K.J. and Watt, F.M. (1994). Evidence that cadherins play a role in the down-regulation of 
integrin expression that occurs during keratinocyte terminal differentiation. Journal of Cell Biology 
124, 589-600.
213
Holbrook, J.A. and Odland, G.F. (1980). Regional development of the human epidermis in the first 
trimester embryo and the second trimester fetus (Ages related to the timing of amniocentesis and fetal 
biopsy). Journal of Investigative Dermatology. 7 4 ,161-168.
Holbrook, K.A. (1994). Ultrastructure of the epidermis. In The Keratinocyte Handbook. Leigh, Lane, 
and Watt, eds. (Cambridge: Cambridge University Press),
Holmes, W.E., Lee, J., Kuang, W.J., Rice, G.C., and Wood, W.I. (1991). Structure and functional 
expression of a human interleukin-8 receptor. Science 2 5 3 ,1278-1280.
Holt J.C., Harris M.E., Holt A.M., Lange E., Henschen A., and Niewiarowski S. (1986). 
Characterisation of human platelet basic protein, a precursor form of low affinity platelet factor-4 and 
(3-thromboglobulin. Biochemistry 25, 1988
Hoogewerf, A.J., Leone, J.W., Reardon, I.M., Howe, W.J., Asa, D., Heinrikson, R.L., and Ledbetter, 
S.R. (1995). CXC chemokines connective-tissue activating peptide-III and neutrophil-activating 
peptide-2 are heparin and heparan sulfate-degrading enzymes. Journal of Biological Chemistry 270, 
3268-3277.
Horuk, R., Chitnis, C.E., Darbonne, W.C., Colby, T.J., Rybicki, A., Hadley, T.J., and Miller, L.H. 
(1993). A receptor for the malarial parasite Plasmodium vivax - the erythrocyte chemokine receptor. 
Science 267,1182-1184.
Homk R, Hesselgesser J, Zhou Y, Faulds D, Halks-Miller M, Harvey S, Taub D, Samson M, 
Parmentier M, Rucker J, Doranz BJ, Doms RW. (1998). The CC chemokine 1-309 inhibits CCR8- 
dependent infection by diverse HIV-1 strains. Journal of Biological Chemistry 273(1):386-391.
Huang E, Nocka K, Beier DR, Chu TY, Buck J, Lahm HW, Wellner D, Leder P, Besmer P (1990). 
The hematopoietic growth factor KL is encoded by the SI locus and is the ligand of the c-kit receptor, 
the gene product of the W locus. Cell 63:225-233.
Huber, A.R., Kunkel, S.L., Todd, R.F., and Weiss, S.J. (1991). Regulation of transendothelial 
neutrophil migration by endogenous interleukin-8. Science 254, 99-102.
Hudak, S., Hunte, B., Culpepper, J., Menon, S., Hannum, C., Thompsonsnipes, L.A., and Rennick, D. 
(1995). Flt3/flk2 ligand promotes the growth of murine stem-cells and the expansion of colony- 
forming cells and spleen colony-forming-units. Blood 85, 2747-2755.
Hume, W.J. and Potten, C.S. (1983). Proliferative units in stratified squamous epithelium. Clinical 
And Experimental Dermatology 8, 95-106.
Hunter, M.G., Bawden, L., Brotherton, D., Craig, S., Cribbes, S., Czaplewski, L.G., Dexter, T.M., 
Drummond, A.H., Gearing, A.H., Heyworth, C.M., Lord, B.I., Mccourt, M., Varley, P.G., Wood, 
L.M., Edwards, R.M., and Lewis, P.J. (1995). BB-10010 - an active variant of human macrophage 
inflammatory protein-la with improved pharmaceutical properties. Blood 86, 4400-4408.
Hynes, R.O. (1992). Integrins - versatility, modulation, and signaling in cell-adhesion. Cell 69, 11-25.
Iida, N. and Grotendorst, G.R. (1990). Cloning and sequencing of a new gro transcript from activated 
human monocytes - expression in leukocytes and wound tissue. Molecular and Cellular Biology 10, 
5596-5599.
Ikebuchi, K., Wong, G.G., Clark, S.C., Ihle, J.N., Hirai, Y., and Ogawa, M. (1987). Interleukin-6 
enhancement of interleukin-3-dependent proliferation of multipotential hematopoietic progenitors. 
Proceedings Of The National Academy Of Sciences Of The United States Of America 84, 9035-9039.
Ikebuchi, K., Clark, S.C., Ihle, J.N., Souza, L.M., and Ogawa, M. (1988). Granulocyte colony- 
stimulating factor enhances interleukin-3-dependent proliferation of multipotential hematopoietic 
progenitors. Proceedings Of The National Academy Of Sciences Of The United States Of America 85,
3445-3449.
214
Imai T, Baba M, Nishimura M, Kakizaki M, Takagi S, Yoshie O. (1997). The T cell-directed CC 
chemokine TARC is a highly specific biological ligand for CC chemokine receptor 4. Journal Of 
Biological Chemistry 272: 15036-15042.
Imai T, Chantry D, Raport CJ, Wood CL, Nishimura M, Godiska R, Yoshie O, Gray PW (1998). 
Macrophage-derived chemokine is a functional ligand for the CC chemokine receptor 4. Journal Of 
Biological Chemistry 273(3):1764-1768.
Inaba, K., Inaba, M., Romani, N., Aya, H., Deguchi, M., Ikehara, S., Muramatsu, S., and Steinman, 
R.M. (1992a). Generation of large numbers of dendritic cells from mouse bone-marrow cultures 
supplemented with granulocyte macrophage colony-stimulating factor. Journal of Experimental 
Medicine 1 7 6 ,1693-1702.
Inaba, K., Steinman, R.M., Pack, M.W., Aya, H., Inaba, M., Sudo, T., Wolpe, S., and Schuler, G. 
(1992b). Identification of proliferating dendritic cell precursors in mouse blood. Journal of 
Experimental Medicine 1 7 5 ,1157-1167.
Inge, T.H., Hoover, S.K., Susskind, B.M., Barrett, S.K., and Bear, H.D. (1992). Inhibition of tumour 
specific cytotoxic T-lymphocyte responses by TGF-(3-l. Cancer Research 5 2 ,1386-1392.
Iscove N.N., Till J.E., and McCulloch E.A. (1970). The proliferative status of murine granulopoietic 
progenitor cells. Proceedings of the Society of Experimental Biology 134, 33-36.
Itoh, N., Yonehara, S., Ishii, A., Yonehara, M., Mizushima, S., Sameshima, M., Hase, A., Seto, Y., 
and Nagata, S. (1991). The polypeptide encoded by the cDNA for human cell-surface antigen Fas can 
mediate apoptosis. Cell 66, 233-243.
Itohara S, Farr AG, Lafaille JJ, Bonneville M, Takagaki Y, Haas W, Tonegawa S.(1990). Homing of a 
gamma delta thymocyte subset with homogeneous T-cell receptors to mucosal epithelia. Nature 
343(6260):754-757
Jacobsen, F.W., Stokke, T., and Jacobsen, S.E.W. (1995). TGF-P potently inhibits the viability- 
promoting activity of stem cell factor and other cytokines and induces apoptosis of primitive murine 
haematopoietic progenitor cells. Blood 86, 2957-2966.
Jacobsen, S.E.W., Ruscetti, F.W., Dubois, C.M., and Keller, J.R. (1992). Tumor necrosis factor-a 
directly and indirectly regulates hematopoietic progenitor-cell proliferation - role of colony stimulating 
factor receptor modulation. Journal of Experimental Medicine 175, 1759-1772.
Jiang, Y.L., Valente, A.J., Williamson, M.J., Zhang, L., and Graves, D.T. (1990). Posttranslational 
modification of a monocyte-specific chemoattractant synthesized by glioma, osteosarcoma, and 
vascular smooth-muscle cells. Journal of Biological Chemistry 265, 18318-18321.
Jiang, Y.L., Tabak, L.A., Valente, A.J., and Graves, D.T. (1991). Initial characterization of the 
carbohydrate structure of MCP-1. Biochemical And Biophysical Research Communications 178, 
1400-1404.
Jones, P.H. and Watt, F.M. (1993). Separation of human epidermal stem-cells from transit amplifying 
cells on the basis of differences in integrin function and expression. Cell 73, 713-724.
Jones, P.H., Harper, S., and Watt, F.M. (1995). Stem-cell patterning and fate in human epidermis. Cell 
80, 83-93.
Jones, R.J., Sharkis, S.J., Celano, P., Colvin, O.M., Rowley, S.D., and Sensenbrenner, L.L. (1987). 
Progenitor Cell Assays predict Haematopoietic reconstitution after syngeneic transplantation in mice. 
Blood 70, 1186-1192.
Jones, R.J., Celano, P., Sharkis S.J., and Sensenbrenner, L.L. (1989). Two Phases of Engraftment 
established by Serial Bone Marrow Transplantation in mice. Blood 73, 397-401.
215
Jones, R.J., Wagner, J.E., Celano, P., Zicha, M.S., and Sharkis S.J. (1990). Separation of Pluripotent 
haematopoietic stem cells from multipotent progenitors (CFU-S). Nature 347, 188-189.
Jose, P.J., Griffithsjohnson, D.A., Collins, P.D., Walsh, D.T., Moqbel, R., Totty, N.F., Truong, O., 
Hsuan, J.J., and Williams, T.J. (1994). Eotaxin - a potent eosinophil chemoattractant cytokine detected 
in a guinea-pig model of allergic airways inflammation. Journal of Experimental Medicine 179, 881- 
887.
Kaczmarek, L., Calabretta, B., and Baserga, R. (1985). Expression of cell-cycle-dependent genes in 
phytohemagglutinin-stimulated human lymphocytes. Proceedings Of The National Academy Of 
Sciences Of The United States Of America 82, 5375-5379.
Kam, E., Melville, L., and Pitts, J.D. (1986). Patterns of junctional communication in skin. Journal of 
Investigative Dermatology 87, 748-753.
Kameyoshi, Y., Dorschner, A., Mallet, A.I., Christophers, E., and Schroder, J.M. (1992). Cytokine 
Rantes released by thrombin-stimulated platelets is a potent attractant for human eosinophils. Journal 
of Experimental Medicine 176, 587-592.
Karpus, W.J., Lukacs, N.W., Mcrae, B.L., Strieter, R.M., Kunkel, S.L., and Miller, S.D. (1995). An 
important role for the chemokine macrophage inflammatory protein-la in the pathogenesis of the T- 
cell mediated auto-immune disease, experimental autoimmune encephalomyelitis. Journal of 
Immunology 155, 5003-5010.
Kasama, T., Strieter, R.M., Standiford, T.J., Burdick, M.D., and Kunkel, S.L. (1993). Expression and 
regulation of human neutrophil-derived M IP-la. Journal of Experimental Medicine 178, 63-72.
Kasama, T., Strieter, R.M., Lukacs, N.W., Burdick, M.D., and Kunkel, S.L. (1994). Regulation of 
neutrophil-derived chemokine expression by IL-10. Journal of Immunology 152, 3559-3569.
Katz S.I., Tamaki K., and Sachs D.S. (1979). Epidermal Langerhans' cells are derived from cells 
originating in bone marrow. Nature 282, 324-326.
Kaufman, R.J. (1990). Stable Transfection of CHO cells. Methods in Enzymology. 185, 537-563.
Kawano, Y., Takaue, Y., Hirao, A., Abe, T., Saito, S., Matsunaga, K., Watanabe, T., Hirose, M., 
Ninomiya, T., Kuroda, Y., Yokobayashi, A., and Asano, S. (1991). Synergistic effect of recombinant 
interferon-y and interleukin-3 on the growth of immature human hematopoietic progenitors. Blood 77, 
2118-2121.
Kehrl, J.H., Roberts, A.B., Wakefield, L.M., Jakowlew, S., Spom, M.B., and Fauci, A.S. (1986a). 
Transforming growth factor-(3 is an important immunomodulatory protein for human B lymphocytes. 
Journal of Immunology 137, 3855-3860.
Kehrl, J.H., Wakefield, L.M., Roberts, A.B., Jakowlew, S., Alvarezmon, M., Derynck, R., Spom, 
M.B., and Fauci, A.S. (1986b). Production of TGF-(3 by human T lymphocytes and its potential role in 
the regulation of T cell growth. Journal of experimental medicine 163, 1037-1050.
Kelker, H.C., Oppenheim, J.D., Stonewolff, D., Henriksendestefano, D., Aggarwal, B.B., Stevenson,
H.C., and Vilcek, J. (1985). Characterization of human tumor necrosis factor produced by peripheral- 
blood monocytes and its separation from lymphotoxin. International Journal Of Cancer 36, 69-73.
Keller G. and Snodgrass R. (1990). Lifespan of multipotential haematopoietic stem cells in vivo. 
Journal of experimental medicine 1 7 1 ,1407-1418.
Keller, J.R., Mcniece, I.K., Sill, K.T., Ellingsworth, L.R., Quesenberry, P.J., Sing, G.K., and Ruscetti, 
F.W. (1990). TGF-(3 directly regulates primitive murine hematopoietic-cell proliferation. Blood 75,
596-602.
216
Keller, J.R., Jacobsen, S.E.W., Sill, K.T., Ellingsworth, L.R., and Ruscetti, F.W. (1991). Stimulation 
of granulopoiesis by TGF-(3 - synergy with GM-CSF. Proceedings Of The National Academy Of 
Sciences Of The United States Of America 88, 7190-7194.
Kelner, G.S., Kennedy, J., Bacon, K.B., Kleyensteuber, S., Largaespada, D.A., Jenkins, N.A., 
Copeland, N.G., Bazan, J.F., Moore, K.W., Schall, T.J., and Zlotnik, A. (1994). Lymphotactin - a 
cytokine that represents a new class of chemokine. Science 2 6 6 ,1395-1399.
Kiene, P., Kahlke, B., Menke, M., Christophers, E., and Schroder, J.M. (1993). Expression of Rantes 
mRNA by fibroblasts and endothelial cells. Journal of Investigative Dermatology 100, 445
Kim, J.S., Gautam, S.C., Chopp, M., Zaloga, C., Jones, M.L., Ward, P.A., and Welch, K.M.A. (1995). 
Expression of monocyte chemoattractant protein-1 and macrophage inflammatory protein-1 after focal 
cerebral ischemia in the rat. Journal Of Neuroimmunology 5 6 ,127-134.
Kitamura, T., Sato, N., Arai, K., and Miyajima, A. (1991). Expression cloning of the human IL-3 
receptor cDNA reveals a shared (3-subunit for the human IL-3 and GM-CSF receptors. Cell 66, 1165- 
1174.
Kitaura, M., Nakajima, T., Imai, T., Harada, S., Combadiere, C., Tiffany, H.L., Murphy, P.M., and 
Yoshie, O. (1996). Molecular-cloning of human eotaxin, an eosinophil-selective CC chemokine, and 
identification of a specific eosinophil eotaxin receptor, CCR3. Journal of Biological Chemistry 271, 
7725-7730.
Knapp, A.C., Franke, W.W., Heid, H., Hatzfeld, M., Jorcano, J.L., and Moll, R. (1986). Cytokeratin-9, 
an epidermal type-1 keratin characteristic of a special program of keratinocyte differentiation 
displaying body site specificity. Journal of Cell Biology 103, 657-667.
Kobayashi, K., Rochat, A., and Barrandon, Y. (1993). Segregation of keratinocyte colony-forming 
cells in the bulge of the rat vibrissa. Proceedings Of The National Academy Of Sciences Of The 
United States Of America 90, 7391-7395.
Koch, A.E., Kunkel, S.L., Harlow, L.A., Johnson, B., Evanoff, H.L., Haines, G.K., Burdick, M.D., 
Pope, R.M., and Strieter, R.M. (1992a). Enhanced production of monocyte chemoattractant protein-1 
in rheumatoid arthritis. Journal Of Clinical Investigation 90, 772-779.
Koch, A.E., Polverini, P.J., Kunkel, S.L., Harlow, L.A., Dipietro, L.A., Elner, V.M., Elner, S.G., and 
Strieter, R.M. (199b2). Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 258, 
1798-1801.
Kock, A., Schwarz, T., Kimbauer, R., Urbanski, A., Perry, P., Ansel, J.C., and Luger, T.A. (1990). 
Human keratinocytes are a source for TNF-a - evidence for synthesis and release upon stimulation 
with endotoxin or ultraviolet-light. Journal of Experimental Medicine 172, 1609-1614.
Koeffler, H.P., Gasson, J., Ranyard, J., Souza, L., Shepard, M., and Munker, R. (1987). Recombinant 
human TNF-a stimulates production of granulocyte colony-stimulating factor. Blood 70, 55-59.
Koike, K., Ihle, J.N., and Ogawa, M. (1986). Declining sensitivity to interleukin-3 of murine 
multipotential hematopoietic progenitors during their development - application to a culture system 
that favors blast cell colony formation. Journal Of Clinical Investigation 77, 894-899.
Kolodka TM., Garlick JA., and Taichman LB. (1998). Evidence for keratinocyte stem cells in vitro: 
Long term engraftment and persistence of transgene expression from retrovirus-transduced 
keratinocytes. Proceedings of the National Academy of Science 95 (8) 4356-4361.
Komano H, Fujiura Y, Kawaguchi M, Matsumoto S, Hashimoto Y, Obana S, Mombaerts 
P, Tonegawa S, Yamamoto H, Itohara S. (1995). Homeostatic regulation of intestinal epithelia by 
intraepithelial gamma delta T cells. Proceedings of the National Academy of Science of the U S A .  
92(13):6147-6151.
217
Korfel, A., Vonmarschall, Z., Koenigsmann, M., Oberberg, D., Reufi, B., Thiel, E., and Berdel, W.E. 
(1994). M IP-la/ Stem Cell Inhibitor (SCI) does not affect clonal growth of human solid tumor cell 
lines in vitro. International Journal Of Oncology 4, 353-357.
Krause D.S., Takahito I., Fackler M.J., Smith O.M., Collector M.I., Sharkis S.J., and May W.S.
(1994). Characterization of murine CD34, a marker for haemopoietic progenitor and stem cells. Blood 
84, 691-701.
Krueger, G.G., Daynes, R.A., and Emam, M. (1983). Biology of Langerhans cells - selective migration 
of Langerhans cells into allogeneic and xenogeneic grafts on nude-mice. Proceedings Of The National 
Academy Of Sciences Of The United States Of America-Biological Sciences 8 0 ,1650-1654.
Krystal, G., Lam, V., Dragowska, W., Takahashi, C., Appel, J., Gontier, A., Jenkins, A., Lam, H., 
Quon, L., and Lansdorp, P. (1994).TGF-(31 is an inducer of erythroid differentiation. Journal of 
Experimental Medicine 180, 851-860.
Kuida K, Lippke JA, Ku G, Harding MW, Livingston DJ, Su MS, Flavell RA. (1995). Altered 
cytokine export and apoptosis in mice deficient in interleukin-1 beta converting enzyme. Science 
267(5206):2000-2003.
Kulkami, A.B., Huh, C.G., Becker, D., Geiser, A., Lyght, M., Flanders, K.C., Roberts, A.B., Sporn, 
M.B., Ward, J.M., and Karlsson, S. (1993). TGF-(31 null mutation in mice causes excessive 
inflammatory response and early death. Proceedings Of The National Academy Of Sciences Of The 
United States Of America 90, 770-774.
Laemm, O.D. and Paukovits, W.R. (1984). Inhibitory effects of a synthetic pentapeptide on 
hematopoietic stem- cells in vitro and in vivo. Experimental Hematology 12, 7-17.
Laemm, O.D., Sletvold, O., Bjerknes, R., Eriksen, J.A., Johansen, J.H., Schanche, J.S., Tveteras, T., 
and Paukovits, W.R. (1988). The dimer of hemoregulatory peptide stimulates mouse and human 
myelopoiesis in vitro. Experimental Hematology 16, 274-280.
Laiho, M., Saksela, O., Andreasen, P.A., and Keskioja, J. (1986a). Enhanced production and 
extracellular deposition of the endothelial type plasminogen activator inhibitor in cultured human lung 
fibroblasts by TGF-|3. Journal of Cell Biology 103, 2403-2410.
Laiho, M., Saksela, O., and Keskioja, J. (1986b). Transforming growth factor-P alters the secretion of 
plasminogen activator activity in human skin fibroblasts. Journal Of Cellular Biochemistry 182.
Laiho M., De Caprio J.A., Ludlow J.W., Livingston D.M., and Massague J. (1990). Growth Inhibition 
by TGF-P linked to suppression of retinoblastoma protein phosphorylation. Cell 62, 175-185.
Lajtha, L.G. (1979). Stem Cell Concepts. Differentiation 14, 23-24.
Landmann, L. (1988). The epidermal permeability barrier. Anatomy And Embryology 1 7 8 ,1-13.
Larsen, C.G., Anderson, A.O., Appella, E., Oppenheim, J.J., and Matsushima, K. (1989a). The 
neutrophil-activating protein (NAP-1) is also chemotactic for T lymphocytes. Science 2 4 3 ,1464-1466.
Larsen, C.G., Anderson, A.O., Oppenheim, J.J., and Matsushima, K. (1989b). Production of 
interleukin-8 by human dermal fibroblasts and keratinocytes in response to interleukin-1 or tumor 
necrosis factor. Immunology 68, 31-36.
Lauret, E., Miyanomae, T., Frindel, E., Troalen, F., and Sotty, D. (1989). Abrogation of the biological 
activity of the CFU-S inhibitor acSDKP by a polyclonal antiserum. Leukemia 3, 315-317.
Lavker, R.M. and Sun, T.T. (1982). Heterogeneity in epidermal basal keratinocytes - morphological 
and functional correlations. Science 2 1 5 ,1239-1241.
218
Lavker, R.M. and Sun, T.T. (1983). Epidermal Stem Cells. Journal of Investigative Dermatology. 81 
Supplement, 121s-127s.
Leary, A.G., Ikebuchi, K., Hirai, Y., Wong, G.G., Yang, Y.C., Clark, S.C., and Ogawa, M. (1988). 
Synergism between interleukin-6 and interleukin-3 in supporting proliferation of human hematopoietic 
stem-cells - comparison with IL-la. Blood 7 1 ,1759-1763.
Leblond, C.P. (1964). Classification of cell populations on the basis of their proliferative behaviour. 
National Cancer Institute Monographs 14, 119-150.
Lee, J., Horuk, R., Rice, G.C., Bennett, G.L., Camerato, T., and Wood, W.I. (1992). Characterization 
of 2 high-affinity human interleukin-8 receptors. Journal of Biological Chemistry 267, 16283-16287.
Lee, J., Cacalano, G., Camerato, T., Toy, K., Moore, M.W., and Wood, W.I. (1995). Chemokine 
binding and activities mediated by the mouse il-8 receptor. Journal of Immunology 155, 2158-2164.
Lenfant, M., Wdzieczakbakala, J., Guittet, E., Prome, J.C., Sotty, D., and Frindel, E. (1989). Inhibitor 
of hematopoietic pluripotent stem-cell proliferation -purification and determination of its structure. 
Proceedings Of The National Academy Of Sciences Of The United States Of America 86, 779-782.
Lemer C. and Harrison D.E. (1990). 5-Fluorouracil spares haemopoietic stem cells responsible for 
long term repopulation. Experimental Haematology 18, 114-118.
Letterio, J.J., Geiser, A.G., Kulkami, A.B., Roche, N.S., Spom, M.B., and Roberts, A.B. (1994). 
Maternal rescue of transforming growth-factor-|31 null mice. Science 264, 1936-1938.
Li, J., Ireland, G.W., Farthing, P.M., and Thornhill, M.H. (1996). Epidermal and oral keratinocytes are 
induced to produce Rantes and IL-8 by cytokine stimulation. J. Inv. Derm. 106, 661-666.
Lieschke, G.J., Grail, D., Hodgson, G., Metcalf, D., Stanley, E., Cheers, C., Fowler, K.J., Basu, S., 
Zhan, Y.F., and Dunn, A.R. (1994a). Mice lacking granulocyte-colony-stimulating factor have chronic 
neutropenia, granulocyte and macrophage progenitor-cell deficiency, and impaired neutrophil 
mobilization. Blood 84, 1737-1746.
Lieschke, G.J., Stanley, E., Grail, D., Hodgson, G., Sinickas, V., Gall, J.A.M., Sinclair, R.A., and 
Dunn, A.R. (1994b). Mice lacking both macrophage- and granulocyte-macrophage colony-stimulating 
factor have macrophages and coexistent osteopetrosis and severe lung-disease. Blood 84, 27-35.
Lindley, I., Aschauer, H., Seifert, J.M., Lam, C., Bmnowsky, W., Kownatzki, E., Thelen, M., Peveri, 
P., Dewald, B., Vontscharner, V., Walz, A., and Baggiolini, M. (1988). Synthesis and expression in 
escherichia-coli of the gene encoding monocyte-derived neutrophil-activating factor -biological 
equivalence between natural and recombinant neutrophil-activating factor. Proceedings Of The 
National Academy Of Sciences Of The United States Of America 85, 9199-9203.
Lipes MA, Chang NT, Leonard WJ. (1988). cDNA cloning and characterization of ACT-2, a novel 
activation gene expressed in normal human peripheral blood mononuclear-cells. Clinical Research 36: 
443.
Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Homk R, MacDonald ME, Stuhlmann H, Koup 
RA, Landau NR. (1996). Homozygous defect in HIV-1 coreceptor accounts for resistance of some 
multiply-exposed individuals to HIV-1 infection. Cell 86(3):367-377
Liu, Z.G., Haelens, A., Wuyts, A., Struyf, S., Pang, X.W., Proost, P., Chen, W.F., and Vandamme, J.
(1996). Isolation of a lymphocyte chemotactic factor produced by the murine thymic epithelial-cell 
line mtecl - identification as a 30 kda glycosylated form of MCP-1. European Cytokine Network 7, 
381-388.
219
Locati, M., Zhou, D., Luini, W., Evangelista, V., Mantovani, A., and Sozzani, S. (1994). Rapid 
induction of arachidonic-acid release by monocyte chemotactic protein-1 and related chemokines - 
role of Ca2+ influx, synergism with platelet-activating-factor and significance for chemotaxis. Journal 
of Biological Chemistry 269, 4746-4753.
Lodi, P.J., Garrett, D.S., Kuszewski, J., Tsang, M.L.S., Weatherbee, J.A., Leonard, W.J., Gronenbom, 
A.M., and Clore, G.M. (1994). High-resolution solution structure of the (3-chemokine hMIP-ip by 
multidimensional NMR. Science 263, 1762-1767.
Loetscher, P., Seitz, M., Clarklewis, I., Baggiolini, M., and Moser, B. (1994). Monocyte chemotactic 
proteins MCP-1, MCP-2, and MCP-3 are major attractants for human CD4+ and CD8+ T 
lymphocytes. Faseb Journal 8, 1055-1060.
Lokuta, M.A., Maher, J., Noe, K.H., Pitha, P.M., Shin, M.L., and Shin, H.S. (1996). Mechanisms of 
murine Rantes chemokine gene induction by Newcastle disease virus. Journal of Biological Chemistry 
271, 13731-13738.
Lord B.I., Mori K.J., Wright E.G., and Lajtha L.G. (1976). An inhibitor of stem cell proliferation in 
normal bone marrow. British Journal of Haematology. 34, 441-445.
Lord B.I., Dexter T.M., Clements J.M., Hunter M.A., and Gearing A.J.H. (1992). Macrophage 
inflammatory protein - l a  protects multipotent haematopoietic cells from the cytotoxic effects of 
hydroxyurea in vivo. Blood 79, 2605-2609.
Lord, B.I., Heyworth, C.M., and Woolford, L.B. (1993). Macrophage inflammatory protein - its 
characteristics, biological properties and role in the regulation of hematopoiesis. International Journal 
Of Hematology 57, 197-206.
Lord, B.I., Woolford, L.B., Wood, L.M., Czaplewski, L.G., Mccourt, M., Hunter, M.G., and Edwards, 
R.M. (1995). Mobilization of early hematopoietic progenitor cells with BB-10010 - a genetically- 
engineered variant of human macrophage inflammatory protein-la. Blood 85, 3412-3415.
Lorimore SA, Pragnell IB, Eckmann L, Wright EG. Synergistic interactions allow colony formation in 
vitro by murine haemopoietic stem cells. Leukaemia Research 1990;14(5):481-489.
Lotz, M., Terkeltaub, R., and Villiger, P.M. (1992). Cartilage and joint inflammation - regulation of 
IL-8 expression by human articular chondrocytes. Journal of Immunology 148, 466-473.
Ludewig, B., Graf, D., Gelderblom, H.R., Becker, Y., Kroczek, R.A., and Pauli, G. (1995). 
Spontaneous apoptosis of dendritic cells is efficiently inhibited by trap (CD40-ligand) and TNF-a, but 
strongly enhanced by interleukin-10. European Journal Of Immunology 25, 1943-1950.
Luetteke, N.C., Qiu, T.H., Peiffer, R.L., Oliver, P., Smithies, O., and Lee, D.C. (1993). TGF-a 
deficiency results in hair follicle and eye abnormalities in targeted and waved-1 mice. Cell 73, 263- 
278.
Luo, Y., Laning, J., Devi, S., Mak, J., Schall, T.J., and Dorf, M.E. (1994). Biologic activities of the 
murine (3-chemokine TCA3. Journal of Immunology 153, 4616-4624.
Luo, Y. and Dorf, M.E. (1996). (3-chemokine TCA3 binds to mesangial cells and induces adhesion, 
chemotaxis, and proliferation. Journal of Immunology 156, 742-748.
Luster, A.D., Unkeless, J.C., and Ravetch, J.V. (1985) y-interferon transcriptionally regulates an early- 
response gene containing homology to platelet proteins. Nature 315, 672-676.
Luster, A.D. and Ravetch, J.V. (1987). Genomic characterization of a y-interferon-inducible gene (IP- 
10) and identification of an interferon-inducible hypersensitive site. Molecular and Cellular Biology 7, 
3723-3731.
220
Luster, A.D. and Leder, P. (1993). IP-10, a CXC chemokine, elicits a potent thymus-dependent 
antitumor response in vivo. Journal of Experimental Medicine 178, 1057-1065.
Luster, A.D., Greenberg, S.M., and Leder, P. (1995). The IP-10 chemokine binds to a specific cell- 
surface heparan-sulfate site shared with platelet factor-4 and inhibits endothelial-cell proliferation. 
Journal of Experimental Medicine 182, 219-231.
Lustinarasimhan M, Power CA, Allet B, Alouani S, Bacon KB, Mermod JJ, Proudfoot AEI, Wells 
TNC (1995). Mutation of leu(25) and val(27) introduces CC chemokine activity into interleukin-8. 
Journal Of Biological Chemistry 270: 2716-2721.
Lustinarasimhan, M., Chollet, A., Power, C.A., Allet, B., Proudfoot, A.E.I., and Wells, T.N.C. (1996). 
A molecular switch of chemokine receptor selectivity - chemical modification of the interleukin-8 
leucine(25) to cysteine mutant. Journal of Biological Chemistry 271, 3148-3153.
Lyons, R.M., Keskioja, J., and Moses, H.L. (1988). Proteolytic activation of latent TGF-(31 from 
fibroblast-conditioned medium. Journal of Cell Biology 1 0 6 ,1659-1665.
Lyons R.M., Gentry L.E., Purchio A.F., and Moses H.L. (1990). Mechanism of activation of latent 
recombinant TGF-pi by plasmin. Journal of Cell Biology 110, 1361-1367.
Maciejewski, J., Selleri, C., Anderson, S., and Young, N.S. (1995). Fas antigen expression on CD34+ 
human marrow cells is induced by y-interferon and tumor necrosis factor-a and potentiates cytokine 
mediated hematopoietic suppression in vitro. Blood 85, 3183-3190.
Mack, M., Luckow, B., Nelson, P., Cihak,J., Simmons G., Clapham, P., Signoret, N., Marsh, M., 
Stangassinger M., Borlat, F., Wells, TNC.,Schlondorff D., Proudfoot A. (1998) Aminooxypentane- 
Rantes induces CCR5 internalisation but inhibits recycling: a novel inhibitory mechanism of HIV 
infectivity. Journal of Experimental Medicine 187 (8) 1215-1224.
Maghazachi, A .A , Alaoukaty, A., and Schall, T.J. (1994). CC chemokines induce the chemotaxis of 
NK and IL-2 activated NK cells - role for G proteins. Journal of Immunology 153, 4969-4977.
Magli, M.C., Iscove, N.N., and Odartchenko, N. (1982). Transient nature of early haematopoietic 
spleen colonies. Nature 295, 527-529.
Maione, T.E., Gray, G.S., Petro, J., Hunt, A.J., Donner, A.L., Bauer, S.I., Carson, H.F., and Sharpe, 
R.J. (1990). Inhibition of angiogenesis by recombinant human-platelet factor-4 and related peptides. 
Science 247, 77-79.
Maltman, J., Pragnell, I.B., and Graham, G.J. (1993). TGF-(3 - is it a downregulator of stem-cell
inhibition by M IP-la. Journal of Experimental Medicine 178, 925-932.
Maltman, J., Pragnell, I.B., and Graham, G.J. (1996). Specificity and reciprocity in the interactions
between TGF-(3 and macrophage inflammatory protein-la. Journal of Immunology 1 5 6 ,1566-1571.
Mann, G.B., Fowler, K.J., Gabriel, A., Nice, E.C., Williams, R.L., and Dunn, A.R. (1993). Mice with 
a null mutation of the TGF-a gene have abnormal skin architecture, wavy hair, and curly whiskers and 
often develop comeal inflammation. Cell 73, 249-261.
Mantel, C., Aronica, S., Luo, Z.M., Marshall, M.S., Kim, Y.J., Cooper, S., Hague, N., and Broxmeyer,
H.E. (1995). Macrophage inflammatory protein-la enhances growth factor stimulated 
phosphatidylcholine metabolism and increases cAMP levels in the human growth factor dependent cell 
line M07E - Events associated with growth suppression. Journal of Immunology 154, 2342-2350.
Massague, J. (1990). The transforming growth-factor-(3 family. Annual Review Of Cell Biology 6,
597-641.
221
Masui, T., Wakefield, L.M., Lechner, J.F., Laveck, M.A., Spom, M.B., and Harris, C.C. (1986). Type 
|3 transforming growth factor is the primary differentiation inducing serum factor for normal human 
bronchial epithelial cells. Proceedings Of The National Academy Of Sciences Of The United States Of 
America 83, 2438-2442.
Matsue H., Cruz P., Bergstrasser P.R., and Takashima A. (1992a). Langerhans cells are the major 
source of mRNA for IL-ip and M IP-la among unstimulated mouse epidermal cells. Journal of 
Investigative Dermatology 99, 537-541.
Matsue, H., Cmz, P.D., Bergstresser, P.R., and Takashima, A. (1992b). Cytokine expression by 
epidermal-cell subpopulations. Journal of Investigative Dermatology. 99, S 42-S 45.
Matsue, H., Cmz, P.D., Bergstresser, P.R., and Takashima, A. (1992c). Cytokine expression by 
Langerhans cells - analysis by PCR at the messenger RNA level. J. Inv. Derm. 98, 564
Matsui Y, Zsebo KM, Hogan BL. (1990). Embryonic expression of a haematopoietic growth factor 
encoded by the SI locus and the ligand for c-kit. Nature 347: 667-669.
Matsumoto, K., Hashimoto, K., Hashiro, M., Yoshimasa, H., and Yoshikawa, K. (1990). Modulation 
of growth and differentiation in normal human keratinocytes by transforming growth-factor p. Journal 
of cellular physiology 145, 95-101.
Mccoll, S.R., Hachicha, M., Levasseur, S., Neote, K., and Schall, T.J. (1993). Uncoupling of early 
signal transduction events from effector function in human peripheral-blood neutrophils in response to 
recombinant macrophage inflammatory protein-la and protein-1 p. Journal of Immunology 150, 4550- 
4560.
Mckenzie, I.C. (1969). Ordered structure of the stratum comeum of mammalian skin. Nature 222, 881- 
882.
Mckenzie, I.C. (1970). Relationship between mitosis and the structure of the stratum comeum in 
mouse epidermis. Nature 226, 653-655.
Mckenzie, I.C. and Linder, J.E. (1973). An examination of cellular organisation within the stratum 
comeum by a silver staining method. Journal of Investigative Dermatology. 61, 245-250.
Mckenzie, I.C., Zimmerman, K., and Peterson, L. (1981). The pattern of cellular organisation of 
human epidermis. Journal of Investigative Dermatology. 76, 459-461.
Mckenzie I.C. (1997). Retroviral transduction of murine epidermal stem cells demonstrates clonal 
units of epidermal structure. Journal of Investigative Dermatology 109 (3): 377-383.
Menon, G.K., Feingold, K.R., and Elias, P.M. (1992). Lamellar body secretory response to barrier 
disruption. Journal of Investigative Dermatology. 98, 279-289.
Menton, D.N. and Eisen, A.Z. (1973). Stmcture and organisation of mammalian stratum comeum. 
Journal of Ultrastructural Research. 35, 247-264.
Metcalf D. (1980). Clonal analysis of proliferation and differentiation of paired daughter cells: actions 
of GM-CSF on granulocyte-macrophage precursors. Proceedings of the National Academy of Science 
USA 77, 5327
Metcalf D. (1984). The haemopoietic colony stimulating factors. In 'The haemopoietic colony 
stimulating factors.' Elsevier, ed. (Elsevier),
Metcalf, D. (1993). Hematopoietic regulators - redundancy or subtlety. Blood 82, 3515-3523.
222
Meurer, R., Vanriper, G., Feeney, W., Cunningham, P., Hora, D., Springer, M.S., Maciotyre, D.E., and 
Rosen, H. (1993). Formation of eosinophilic and monocytic intradermal inflammatory sites in the dog 
by injection of human Rantes but not human monocyte chemoattractant protein-1, human macrophage 
inflammatory protein-la, or human interleukin-8. Journal of Experimental Medicine 1 7 8 ,1913-1921.
Miettinen, P.J., Berger, J.E., Meneses, J., Phung, Y., Pedersen, R.A., Werb, Z., and Derynck, R.
(1995). Epithelial immaturity and multiorgan failure in mice lacking epidermal growth-factor receptor. 
Nature 376, 337-341.
Miki, T., Fleming, T.P., Bottaro, D.P., Rubin, J.S., Ron, D., and Aaronson, S.A. (1991). Expression 
cDNA cloning of the KGF receptor by creation of a transforming autocrine loop. Science 251, 72-75.
Miki, T., Bottaro, D.P., Fleming, T.P., Smith, C.L., Burgess, W.H., Chan, A.M.L., and Aaronson, S.A.
(1992). Determination of ligand-binding specificity by alternative splicing - 2 distinct growth-factor 
receptors encoded by a single gene. Proceedings Of The National Academy Of Sciences Of The 
United States Of America 89, 246-250.
Miller M.D. and Krangel M.S. (1992). Biology and biochemistry of the chemokines: a family of 
chemotactic and inflammatory cytokines. Critical Reviews in Immunology 1 2 ,17-46.
Miller S.J., Lavker R.M., and Sun T.T. (1993a). Keratinocyte stem cells of cornea, skin and hair 
follicles: common and distinguishing features. Seminars in Developmental Biology 4, 217-240.
Miller, S.J., Sun, T.T., and Lavker, R.M. (1993b). Hair-follicles, stem-cells, and skin-cancer. Journal 
of Investigative Dermatology 100, S 288-S 294.
Misumi, Y. and Akiyoshi, T. (1991). Epidermal ridge formation in the human fetus - a correlation to 
the appearance of basal-cell heterogeneity and the expression of epidermal growth-factor receptor and 
cytokeratin polypeptides in the epidermis. American Journal Of Anatomy 191, 419-428.
Miyazawa, K., Hendrie, P.C., Mantel, C., Wood, K., Ashman, L.K., and Broxmeyer, H.E. (1991). 
Comparative-analysis of signaling pathways between mast cell growth-factor (c-kit ligand) and
granulocyte macrophage colony-stimulating factor in a human factor-dependent myeloid cell-line 
involves phosphorylation of raf-1, GTPase-activating protein and mitogen-activated protein-kinase. 
Experimental Hematology 19, 1110-1123.
Miyazono, K. and Heldin, C.H. (1991). Latent forms of TGF-|3 - molecular-structure and mechanisms 
of activation. Ciba Foundation Symposia 157, 81-97.
Mohamadzadeh, M., Poltorak, A.N., Bergstresser, P.R., Beutler, B., and Takashima, A. (1996a). 
Langerhans cells produce biologically-active MIP-ly, a new member of the CC chemokine family. 
Journal of Investigative Dermatology. 106, 108
Mohamadzadeh, M., Poltorak, A.N., Bergstresser, P.R., Beutler, B., and Takashima, A. (1996b). 
Dendritic cells produce macrophage inflammatory protein-ly, a new member of the CC chemokine 
family. Journal of Immunology 156, 3102-3106.
Moll, I., Lane, A.T., Franke, W.W., and Moll, R. (1990). Intraepidermal formation of merkel cells in 
xenografts of human fetal skin. Journal of Investigative Dermatology. 94, 359-364.
Moore, M.A.S. (1991). Clinical implications of positive and negative hematopoietic stem cell 
regulators. Blood 7 8 ,1-19.
Moore M.A.S. and Shapiro F. (1994). Regulation and function of haemopoietic stem cells. Current 
Opinion in Haematology 1 , 180-186.
Morris R.J., Fischer S.M., and Slaga T.J. (1985). Evidence that the centrally and peripherally located 
cells in the murine epidermal proliferative unit are two distinct cell populations. Journal of 
Investigative Dermatology. 84, 277-281.
223
Morris, R.J., Fischer, S.M., and Slaga, T.J. (1986). Evidence that a slowly cycling subpopulation of 
adult murine epidermal-cells retains carcinogen. Cancer Research 46, 3061-3066.
Morrison, S.J., Uchida, N., and Weissman, I.L. (1995). The Biology of Haematoopoietic stem cells. 
Annual Reviews of Cellular and Developmental Biology 11, 35-71.
Moser, B., Dewald, B., Barella, L., Schumacher, C., Baggiolini, M., and Clarklewis, I (1993). 
Interleukin-8 antagonists generated by N-terminal modification. Journal of Biological Chemistry 268, 
7125-7128.
Moser, M.H. and Paukovits, W.R. (1991a). Use of hemoregulatory peptide pGlu-Glu-Asp-Cys-Lys 
(pEEDCK) for protection of the long-term marrow repopulating capacity after cytostatic treatment. 
Experimental Hematology 19, 510
Moser, M.H. and Paukovits, W.R. (1991b). Haemoprotection against cytostatic drugs by stem-cell 
inhibition. Trends In Pharmacological Sciences 12, 304-310.
Mullersieburg, C.E. and Deryugina, E. (1995). The stromal cells guide to the stem-cell universe. Stem 
Cells 13, 477-486.
Munker, R., Gasson, J., Ogawa, M., and Koeffler, H.P. (1986). Recombinant human TNF induces 
production of granulocyte monocyte colony-stimulating factor. Nature 323, 79-82.
Murase, T., Hotta, T., Saito, H., and Ohno, R. (1987). Effect of recombinant human tumour necrosis 
factor on the colony growth of human leukemia progenitor cells and normal hematopoietic progenitor 
cells. Blood 69, 467-472.
Murphy, M., Perussia, B., and Trinchieri, G. (1988). Effects of recombinant tumor necrosis factor, 
lymphotoxin, and immune interferon on proliferation and differentiation of enriched hematopoietic 
precursor cells. Experimental Hematology 16, 131-138.
Murphy, P.M. and Tiffany, H.L. (1991). Cloning of complementary-DNA encoding a functional 
human interleukin- 8 receptor. Science 253, 1280-1283.
Murphy, W.J., Taub, D.D., Anver, M., Conlon, K., Oppenheim, J.J., Kelvin, D.J., and Longo, D.L. 
(1994). Human Rantes induces the migration of human T lymphocytes into the peripheral tissues of 
mice with severe combined immune-deficiency. European Journal Of Immunology 24, 1823-1827.
Musashi, M., Yang, Y.C., Paul, S.R., Clark, S.C., Sudo, T., and Ogawa, M. (1991). Direct and 
synergistic effects of interleukin-11 on murine hematopoiesis in culture. Proceedings Of The National 
Academy Of Sciences Of The United States Of America 88, 765-769.
Myers, S.J., Wong, L.M., and Charo, I.F. (1995). Signal-transduction and ligand specificity of the 
human monocyte chemoattractant protein-1 receptor in transfected embryonic kidney cells. Journal of 
Biological Chemistry 270, 5786-5792.
Nagasawa, T., Kikutani, H., and Kishimoto, T. (1994). Molecular-cloning and structure of a pre-B-cell 
growth-stimulating factor. Proceedings Of The National Academy Of Sciences Of The United States 
Of America 91, 2305-2309.
Nagasawa, T., Hirota, S., Tachibana, K., Takakura, N., Nishikawa, S., Kitamura, Y., Yoshida, N., 
Kikutani, H., and Kishimoto, T. (1996). Defects of B cell lymphopoiesis and bone-marrow 
myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 382, 635-638.
Nakahata, T., Gross, A.J., and Ogawa, M. (1982). A stochastic-model of self-renewal and commitment 
to differentiation of the primitive hematopoietic stem-cells in culture. Journal of cellular physiology 
113, 455-458.
Nakao, M., Nomiyama, H., and Shimada, K. (1990). Structures of human genes coding for cytokine 
LD78 and their expression. Molecular and Cellular Biology 10, 3646-3658.
224
Nanney, L.B., Mueller, S.G., Bueno, R., Peiper, S.C., and Richmond, A. (1995). Distributions of 
melanoma growth-stimulatory activity or growth regulated gene and the interleukin receptor-B in 
human wound repair. American Journal of Pathology 147, 1248-1260.
Nathan C.F. (1987). Secretory products of macrophages. Journal of Clinical Investigation. 79, 319- 
326.
Nawroth, P.P., Bank, I., Handley, D., Cassimeris, J., Chess, L., and Stem, D. (1986). Tumour necrosis 
factor/cachectin interacts with endothelial-cell receptors to induce release of interleukin-1. Journal of 
experimental medicine 163, 1363-1375.
Nelson, W.G. and Sun, T.T. (1983). The 50-kdalton and 58-kdalton keratin classes as molecular 
markers for stratified squamous epithelia - cell-culture studies. Journal of Cell Biology 97, 244-251.
Neote K., DIGregorio D., Mak J.Y., Horuk R., and Schall T.J. (1993). Molecular cloning, functional 
expression and signalling characteristics of a CC chemokine. Cell 72, 415-425.
Neote, K., Mak, J.Y., Kolakowski, L.F., and Schall, T.J. (1994). Functional and biochemical analysis 
of the cloned Duffy antigen - identity with the red blood cell chemokine receptor. Blood 84, 44-52.
Nestle, F.O., Zheng, X.G., Thompson, C.B., Turka, L.A., and Nickoloff, B.J. (1993). Characterization 
of dermal dendritic cells obtained from normal human skin reveals phenotypic and functionally 
distinctive subsets. Journal of Immunology 151, 6535-6545.
Neumann, H.A. and Fauser, A.A. (1982). Effect of interferon on pluripotent hematopoietic progenitors 
(CFU- GEMM) derived from human-bone marrow. Experimental Hematology 10, 587-590.
Nibbs RJB, Wylie SM, Pragnell IB, Graham GJ (1997a) Cloning and characterization of a novel 
murine P-chemokine receptor, D6. Comparison to three other related macrophage inflammatory 
protein-la receptors, CCR-1, CCR-3, and CCR-5. Journal of Biological Chemistry 272(19): 12495- 
12504
Nibbs RJ, Wylie SM, Yang J, Landau NR, Graham GJ. (1997b) Cloning and characterization of a 
novel promiscuous human beta-chemokine receptor D6. Journal of Biological Chemistry 
272(51):32078-32083
Nilsson, I. and Vonheijne, G. (1992). A signal peptide with a proline next to the cleavage site inhibits 
leader peptidase when present in a sec-independent protein. Febs Letters 299, 243-246.
Noble, N.A., Harper, J.R., and Border, W.A. (1992). In  vivo interactions of TGF-(3 and extracellular 
matrix. Progress in Growth Factor Research. 4, 369-382.
Noe, KH; Fisher, SN; DhibJalbut, S; Shin, ML. (1996). Induction of cytokine RANTES by vims in 
astrocytes. Journal of Neurochemistry 66 (S1):S71.
Noso, N., Sticherling, M., Bartels, J., Mallet, A.I., Christophers, E., and Schroder, J.M. (1996). 
Identification of an N-terminally truncated form of the chemokine Rantes and granulocyte-macrophage 
colony-stimulating factor as major eosinophil attractants released by cytokine-stimulated dermal 
fibroblasts. Journal of Immunology 1 5 6 ,1946-1953.
Nothwehr SF, Gordon JI. (1990). Targeting of proteins into the eukaryotic secretory pathway: signal 
peptide structure/function relationships. Bioessays 12(10):479-484.
Nourshargh, S., Perkins, J.A., Showell, H.J., Matsushima, K., Williams, T.J., and Collins, P.D. (1992). 
A comparative-study of the neutrophil stimulatory activity in vitro and pro-inflammatory properties in 
vivo of 72 amino-acid and 77 amino acid IL-8. Journal of Immunology 148, 106-111.
Obaru, K., Fukuda, M., Maeda, S., and Shimada, K. (1986). A cDNA clone used to study messenger 
RNA inducible in human tonsillar lymphocytes by a tumor promoter. Journal Of Biochemistry 99, 
885-894.
225
Oberlin, E., Amara, A., Bachelerie, F., Bessia, C., Virelizier, J.L., Arenzanaseisdedos, F., Schwartz,
0 ., Heard, J.M., Clarklewis, I., Legler, D.F., Loetscher, M., Baggiolini, M., and Moser, B. (1996). The 
CXC chemokine SDF-1 is the ligand for lestr/fusin and prevents infection by T cell-line-adapted HIV-
1. Nature 382, 833-835.
Ogawa, M. and Nakahata, T. (1982). Identification in culture of a new class of hematopoietic colony- 
forming-units with extensive capability to self-renew and generate multipotential hematopoietic 
colonies. Experimental Hematology 10, 166
Ogawa, M. (1993). Differentiation and proliferation of hematopoietic stem-cells. Blood 81, 2844- 
2853.
Oppenheim JJ, Zachariae C, Mukaida N, Matsushima K. Properties of the novel proinflammatory 
supergene intercrine cytokine family. (1991). Annual Review of Immunology 9: 617-648.
Orlofsky, A., Berger, M.S., and Prystowsky, M.B. (1991). Novel expression pattern of a new member 
of the MIP-1 family of cytokine-like genes. Cell Regulation 2, 403-412.
Oravecz T., Pall M., Roderiquez G., Gorrell M.D., Ditto M., Nguyen NY., Boykins R., Unsworth E., 
and Norcross M.A. (1997). Regulation of the receptor specificity and function of the chemokine 
RANTES by dipeptidyl peptidase IV (CD-26) mediated cleavage. Journal of experimental medicine 
186 (11) 1865-1872.
Omitz D.M., Yayon A., Flanagan J.G., Svahn K.M., Levi E., and Leder P. (1992). Heparin is required 
for cell-free binding of basic FGF to a soluble receptor and for mitogenesis in whole cells. Molecular 
and Cellular Biology 12, 240-247.
Oster, W., Lindemann, A., Horn, S., Mertelsmann, R., and Herrmann, F. (1987). Tumor necrosis 
factor (TNF)-a but not TNF-|3 induces secretion of colony stimulating factor for macrophages (CSF-1) 
by human monocytes. Blood 70, 1700-1703.
Ozanne, B., Richards, C.S., Hendler, F., Burns, D., and Gusterson, B. (1986). Over-expression of the 
EGF receptor is a hallmark of squamous cell carcinomas. Journal Of Pathology 149, 9-14.
Palombella, V.J., Lin, J.X., Zhang, Y., Feinman, R., Reis, L.F.L., Kelker, H., Le, J., and Vilcek, J. 
(1987). Stimulation of cell growth and gene expression by TNF. Immunobiology 175, 40
Parker, A.N., Sim, A.R., Graham, G.J., Clark, S.C., and Pragnell, J.B. (1995). Macrophage 
inflammatory protein-la has a positive effect on bone-marrow recovery kinetics following treatment 
with cyclophosphamide. Experimental Hematology 23, 874
Parkinson E.K. and Emmerson A. (1982). The effects of tumour promoters on the multiplication and 
morphology of cultured human epidermal keratinocytes. Carcinogenesis 3, 525-531.
Parkinson E.K., Graham G.J., Dauberies P., Bums J.E., Heufler C., Plumb., Schuler G., and Pragnell
I.B. (1993). Haemopoietic stem cell inhibitor (SCI/MIP-la) also inhibits clonogenic epidermal 
keratinocyte proliferation. Journal of Investigative Dermatology. 1 0 1 ,113-117.
Patel V.P., Kreider B.L., Li Y., Li H., Leubg K., Salcedo T., Nardelli B., PippallaV., Gentz S., 
Thotakura R., Parmelee D., Gentz R., and Garotta G. (1997). Molecular and functional 
characterization of two novel human C-C chemokines as inhibitors of two distinct classes of myeloid 
progenitors. Journal of Experimental Medicine 185 (7) 1163-1172.
Paukovits, W.R., Moser, M.H., Binder, K.A., and Paukovits, J.B. (1991). Protection from 
arabinofuranosylcytosine and n-mustard induced myelotoxicity using hemoregulatory peptide pGlu- 
Glu-Asp-Cys-Lys monomer and dimer. Blood 77, 1313-1319.
Paukovits, W.R., Moser, M.H., and Paukovits, J.B. (1993). Pre-CFU-S quiescence and stem-cell 
exhaustion after cytostatic drug treatment- protective effects of the inhibitory pentapeptide pEEDCK. 
Blood 81, 1755-1761.
226
Paukovits, J.B. and Paukovits, W.R. (1995). Stem-cell stimulation in-vitro by the decapeptide 
(pEEDCK2) -a single-factor alternative for multifactor cocktails. Leukemia 9, S 48-S 52.
Paus, R., Stenn, K.S., and Elgjo, K. (1991). The epidermal pentapeptide pyroGLU-GLU-ASP-SER- 
GLYOH inhibits murine hair growth in vivo and in vitro. Dermatologica 1 8 3 ,173-178.
Pennica. D, Nedwin GE, Hayflick JS, Seeburg PH, Derynck R, Palladino MA., Kohr WJ, Aggarwal 
BB and Goeddel DV. (1984). Human-Tumour Necrosis Factor - Precursor structure, expression and 
homology to lymphotoxin. Nature 312: 724-729.
Peters G. (1994). Stifled by Inhibitors. Nature 371, 204-205.
Piepkom, M. (1996). Overexpression of amphiregulin, a major autocrine growth-factor for cultured 
human keratinocytes, in hyperproliferative skin diseases. American Journal Of Dermatopathology 18, 
165-171.
Pietenpol J.A., Stein R.W., Moran E., Yaciuk P., Schlegel R., Lyons R.M., Pittelkow M.R., Munger 
K., Howley P.M., and Moses H.L. (1990). TGF-|31 inhibition of c-myc transcription and growth in 
keratinocytes is abrogated by viral transforming proteins with pRB binding domains. Cell 61, 777-785.
Pillai, S., Bikle, D.D., Eessalu, T.E., Aggarwal, B.B., and Elias, P.M. (1989). Binding and biological 
effects of tumor necrosis factor-a on cultured human neonatal foreskin keratinocytes. Journal of 
Clinical Investigation 83, 816-821.
Pillai, S., Gilliam, L., Conrad, H.E., and Holleran, W.M. (1994). Heparin and its non-anticoagulant 
analogs inhibit human keratinocyte growth without inducing differentiation. Journal of Investigative 
Dermatology. 103, 647-650.
Ploemacher, R.E. and Brons, R.H.C. (1989). Separation of CFU-S from primitive cells responsible for 
reconstitution of the bone marrow haemopoietic stem cell compartment following irradiation: evidence 
for a pre-CFU-S cell. Experimental Haematology 17, 263-266.
Ploemacher, R.E. (1994). Culture of Haemopoietic Cells. In I. Freshney, I. Pragnell, and M. Freshney, 
eds. (Wiley-Liss), pp. 1-23.
Plumb, M., Graham, G.J., Grove, M., Reid, A., and Pragnell, I.B. (1991). Molecular aspects of a 
negative regulator of hematopoiesis. British Journal Of Cancer 64, 990-992.
Poltorak, A.N., Bazzoni, F., Smirnova, I.I., Alejos, E., Thompson, P., Luheshi, G., Rothwell, N., and 
Beutler, B. (1995). Mip-ly - molecular cloning, expression, and biological activities of a novel CC 
chemokine that is constitutively secreted in vivo. Journal Of Inflammation 45, 207-219.
Ponath PD, Qin S, Ringler DJ, Clark-Lewis I, Wang J, Kassam N, Smith H, Shi X, Gonzalo JA,
Newman W, Gutierrez-Ramos JC, Mackay CR. (1996a) Cloning of the human eosinophil 
chemoattractant, eotaxin. Expression, receptor binding, and functional properties suggest a mechanism 
for the selective recruitment of eosinophils. Journal of Clinical Investigation 97(3):604-612.
Ponath, P.D., Qin, S.X., Post, T.W., Wang, J., Wu, L., Gerard, N.P., Newman, W., Gerard, C., and 
Mackay, C.R. (1996b). Molecular cloning and characterization of a human eotaxin receptor expressed 
selectively on eosinophils. Journal of Experimental Medicine 183, 2437-2448.
Popliker, M., Shatz, A., Avivi, A., Ullrich, A., Schlessinger, J., and Webb, C.G. (1987). Onset of 
endogenous synthesis of epidermal growth-factor in neonatal mice. Developmental Biology 119, 38- 
44.
Porreca, E., Difebbo, C., and Bertini, R. (1996). Monocyte chemotactic protein-1 (MCP-1) - a 
possible target for therapeutic agents in atherosclerosis. International Journal Of Immunopathology 
And Pharmacology 9, 67-72.
Potten C.S. and Hendry J.M. (1973). Clonogenic cells and stem cells in epidermis. International 
Journal of Radiation Biology 24, 537-540.
227
Potten C.S. (1974). The epidermal proliferative unit: the possible role of the central basal cell. Cell 
and tissue kinetics 7, 77-88.
Potten C.S. and Allen T.D. (1976). A model implicating the Langerhans cell in keratinocyte 
proliferation control. Differentiation 5, 43-47.
Potten C.S. (1981). Cell replacement in epidermis (keratopoiesis) via disrete units of proliferation. 
International review of cytology 69, 271-318.
Potten, C.S. and Morris, R.J. (1988). Epithelial stem cells in vivo. Journal of Cell Science 10, 45-62.
Power CA, Meyer A, Nemeth K, Bacon KB, Hoogewerf AJ, Proudfoot AE, Wells TN.(1995). 
Molecular cloning and functional expression of a novel CC chemokine receptor cDNA from a human 
basophilic cell line. Journal of Biological Chemistry 270(33): 19495-19500.
Pragnell, I.B., Wright, E.G., Lorimore, S.A., Adam, J., Rosendaal, M., DeLamarter, J.F., Freshney, 
M., Eckmann, L., Sproul, A., and Wilkie, N. (1988). The effect of Stem Cell Proliferation Regulators 
demonstrated with an in vitro assay. Blood 72,196-201.
Prigent, S.A. and Lemoine, N.R. (1992). The type 1 (EGFR-related) family of growth-factor receptors 
and their ligands. Progress in Growth Factor Research. 4 , 1-24.
Proost, P., Dewolfpeeters, C., Conings, R., Opdenakker, G., Billiau, A., and Vandamme, J. (1993). 
Identification of a novel granulocyte chemotactic protein (GCP-2) from human tumour cells - in vitro 
and in vivo comparison with natural forms of GRP, IP-10, and IL-8. Journal of Immunology 150, 
1000-1010.
Proost, P., Wuyts, A., and Vandamme, J. (1996). Human monocyte chemotactic protein-2 and protein- 
3 - structural and functional comparison with MCP-1. Journal Of Leukocyte Biology 59, 67-74.
Proost P., Struyf S., Couvreur M., Lenaerts J.P., Conings R., Menten P., Verhaert P., Wuyts A., Van 
Damme J. (1998) Post-translational modifications affect the activity of the human monocyte 
chemotactic proteins MCP-1 and MCP-2. Identification of MCP-2 (6-76) as a natural chemokine 
inhibitor. Journal of Immunology 160(8):4034-4041
Proudfoot, A.E.I., Power, C.A., Hoogewerf, A.J., Montjovent, M.O., Borlat, F., Offord, R.E., and 
Wells, T.N.C. (1996). Extension of recombinant human Rantes by the retention of the initiating 
methionine produces a potent antagonist. Journal of Biological Chemistry 271, 2599-2603.
Quesniaux, V.F.J., Graham, G.J., Pragnell, I., Donaldson, D., Wolpe, S.D., Iscove, N.N., and Fagg, B.
(1993). Use of 5-fluorouracil to analyze the effect of macrophage inflammatory protein-la on long­
term reconstituting stem-cells in vivo. Blood 8 1 ,1497-1504.
Rajarathnam, K., Sykes, B.D., Kay, C.M., Dewald, B., Geiser, T., Baggiolini, M., and Clarklewis, I
(1994). Neutrophil activation by monomeric interleukin-8. Science 264, 90-92.
Rajarathnam, K., Clarklewis, I., and Sykes, B.D. (1995). H-l NMR solution structure of an active 
monomeric interleukin-8. Biochemistry 34, 12983-12990.
Rajarathnam, K., Kay, C.M., Dewald, B., Wolf, M., Baggiolini, M., Clarklewis, I., and Sykes, B.D.
(1997). Neutrophil-activating peptide-2 and melanoma growth-stimulatory activity are functional as 
monomers for neutrophil activation. Journal of Biological Chemistry 272, 1725-1729.
Rail, L.B., Scott, J., Bell, G.I., Crawford, R.J., Penschow, J.D., Niall, H.D., and Coghlan, J.P. (1985). 
Mouse prepro-epidermal growth-factor synthesis by the kidney and other tissues. Nature 313, 228-231.
Ramage P, Cheneval D, Chvei M, Graff P, Hemmig R, Heng R, Kocher HP, Mackenzie A, Memmert 
K, Revesz L, and William Wishart. (1995). Expression, refolding, and autocatalytic proteolytic 
processing of the interleukin-1 beta-converting enzyme precursor. Journal of Biological Chemistry 
270(16):9378-9383.
228
Ranges, G.E., Figari, I.S., Espevik, T., and Palladino, M.A. (1987). Inhibition of cytotoxic T cell 
development by transforming growth factor-(3 and reversal by recombinant tumor necrosis factor-a. 
Journal of Experimental Medicine 166, 991-998.
Ransohoff, R.M., Hamilton, T.A., Tani, M., Stoler, M.H., Shick, H.E., Major, J.A., Estes, M.L., 
Thomas, D.M., and Tuohy, V.K. (1993). Astrocyte expression of mRNA encoding cytokines IP-10 
and JE/ MCP-1 in experimental autoimmune encephalomyelitis. Faseb Journal 7, 592-600.
Raport, C.J., Gosling, J., Schweickart, V.L., Gray, P.W., and Charo, I.F. (1996a). Molecular-cloning 
and functional-characterization of a novel human CC chemokine receptor (CCR5) for Rantes, MIP-ip, 
and M IP-la. Journal of Biological Chemistry 2 7 1 ,17161-17166.
Raport, C.J., Schweickart, V.L., Chantry, D., Eddy, R.L., Shows, T.B., Godiska, R., and Gray, P.W. 
(1996b). New members of the chemokine receptor gene family. Journal Of Leukocyte Biology 59, 18- 
23.
Rawles, M.E. (1947). Origin of pigment cells from neural crest in mouse embryo. Physiology and 
Zoology. 20, 248-266.
Reeves JD, McKnight A, Potempa S, Simmons G, Gray PW, Power CA, Wells T, Weiss RA, Talbot 
SJ. (1997). CD4-independent infection by HIV-2 (ROD/B): use of the 7-transmembrane receptors 
CXCR-4, CCR-3, and V28 for entry. Virology 231(1):130-134.
Reibman, J., Meixler, S.M., Lee, T.C., Cronstein, B.N., Gold, L.I., and Weissmann, G. (1990). 
Transforming growth fact or-(31 - the most potent chemoattractant for human neutrophils. Clinical 
Research 38, A 406
Reinartz, J., Bechtel, M.J., and Kramer, M.D. (1996). Tumor necrosis factor-a-induced apoptosis in a 
human keratinocyte cell-line (Hacat) is counteracted by transforming growth-factor-a. Experimental 
Cell Research 228, 334-340.
Reusch, M.K., Studtmann, M., Schroder, J.M., Sticherling, M., and Christophers, E. (1990). 
NAP/Interleukin-8 is a potent mitogen for human keratinocytes in vitro. Journal of Investigative 
Dermatology. 95, 485
Rheinwald, J.G. and Green, H. (1977). Epidermal Growth Factor and the multiplication of cultured 
human epidermal keratinocytes. Nature 265, 421-424.
Rice, R.H. and Green, H. (1979). Presence in epidermal cells of a soluble protein precursor of the 
cross-linked envelope: activation of the cross-linking by calcium ions. Cell 18, 681-694.
Richmond, A., Balentien, E., Thomas, H.G., Flaggs, G., Barton, D.E., Spiess, J., Bordoni, R., Francke, 
U., and Derynck, R. (1988). Molecular characterization and chromosomal mapping of melanoma 
growth stimulatory activity, a growth-factor structurally related to (3- thromboglobulin. Embo Journal 
7, 2025-2033.
Rigby, W.F.C., Ball, E.D., Guyre, P.M., and Fanger, M.W. (1985). The effects of recombinant DNA 
derived interferons on the growth of myeloid progenitor cells. Blood 65, 858-861.
Roberts, A.B., Anzano, M.A., Lamb, L.C., Smith, J.M., and Spom, M.B. (1981a). New class of 
transforming growth factors potentiated by epidermal growth-factor - isolation from non-neoplastic 
tissues. Proceedings Of The National Academy Of Sciences Of The United States Of America- 
Biological Sciences 78, 5339-5343.
Roberts, A.B., Spom, M.B., Assoian, R.K., Smith, J.M., Roche, N.S., Wakefield, L.M., Heine, U.I., 
Liotta, L.A., Falanga, V., Kehrl, J.H., and Fauci, A.S. (1986b). Transforming growth-factor type (3 - 
rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. 
Proceedings Of The National Academy Of Sciences Of The United States Of America 83, 4167-4171.
229
Roberts, R., Gallagher, J., Spooncer, E., Allen, T.D., Bloomfield, F., and Dexter, T.M. (1988). 
Heparan sulfate bound growth-factors - a mechanism for stromal cell mediated haemopoiesis. Nature 
332, 376-378.
Robinson, EA; Yoshimura, T; Leonard, EJ; Tanaka, S; Griffin, PR; Shabanowitz, J; Hunt, DF; 
Appella, E. (1989). Complete amino-acid sequence of a human monocyte chemoattractant, a putative 
mediator of cellular immune-reactions. Proceedings of the National Academy of Sciences of the 
United States of America.
Robinson, S., Lenfant, M., Wdzieczakbakala, J., and Riches, A. (1993). The molecular specificity of 
action of the tetrapeptide acetyl-n-SDKP. Stem Cells 11, 422-427.
Rochat, A., Kobayashi, K., and Barrandon, Y. (1994). Location of stem-cells of human hair-follicles 
by clonal analysis. Cell 7 6 ,1063-1073.
Rollins, B.J., Stier, P., Ernst, T., and Wong, G.G. (1989). The human homolog of the JE gene encodes 
a monocyte secretory protein. Molecular and Cellular Biology 9, 4687-4695.
Romani, N., Gruner, S., Brang, D., Kampgen, E., Lenz, A., Trockenbacher, B., Konwalinka, G., 
Fritsch, P.O., Steinman, R.M., and Schuler, G. (1994). Proliferating dendritic cell progenitors in 
human blood. Journal of Experimental Medicine 180, 83-93.
Roodman, G.D., Bird, A., Hutzler, D., and Montgomery, W. (1987). Tumor necrosis factor-a and 
hematopoietic progenitors - effects of tumor necrosis factor on the growth of erythroid progenitors 
CFU-E and BFU-E and the hematopoietic-cell lines K562, HL60, and HEL cells. Experimental 
Hematology 15, 928-935.
Rook, A.H., Kehrl, J.H., Wakefield, L.M., Roberts, A.B., Spom, M.B., Burlington, D.B., Lane, H.C., 
and Fauci, A.S. (1986). Effects of transforming growth factor-p on the functions of natural-killer cells 
- depressed cytolytic activity and blunting of interferon responsiveness. Journal of Immunology 136, 
3916-3920.
Rosendaal, M., Hodgson, G.S., and Bradley, T.R. (1976). Haematopoietic Stem Cells are organised 
for use on the Basis of their Generation Age. Nature 264, 68-69.
Rot, A., Krieger, M., Brunner, T., Bischoff, S.C., Schall, T.J., and Dahinden, C.A. (1992). Rantes and 
macrophage inflammatory protein-la induce the migration and activation of normal human eosinophil 
granulocytes. Journal of Experimental Medicine 1 7 6 ,1489-1495.
Rothenberg, M.E., Luster, A.D., and Leder, P. (1995a). Murine eotaxin - an eosinophil 
chemoattractant inducible in endothelial-cells and in interleukin 4 induced tumour suppression. 
Proceedings Of The National Academy Of Sciences Of The United States Of America 92, 8960-8964.
Rothenberg, M.E., Luster, A.D., Lilly, C.M., Drazen, J.M., and Leder, P. (1995b). Constitutive and 
allergen-induced expression of eotaxin mRNA in the guinea-pig lung. Journal of Experimental 
Medicine 1 8 1 ,1211-1216.
Rothenberg, M.E., Ownbey, R., Mehlhop, P.D., Loiselle, P.M., Vanderijn, M., Bonventre, J.V., 
Oettgen, H.C., Leder, P., and Luster, A.D. (1996). Eotaxin triggers eosinophil-selective chemotaxis 
and calcium flux via a distinct receptor and induces pulmonary eosinophilia in the presence of 
interleukin-5 in mice. Molecular Medicine 2, 334-348.
Rothenberg, M.E., MacLean, J.A., Pearlman, E., Luster, A.D., and Leder, P. (1997). Targeted 
disruption of the chemokine eotaxin partially reduces antigen-induced tissue eosinophilia. Journal of 
Experimental Medicine 185, 785-790.
Rubin, B.Y., Anderson, S.L., Sullivan, S.A., Williamson, B.D., Carswell, E.A., and Old, L.J. (1985). 
Purification and characterization of a human tumor necrosis factor from the lukii cell-line. Proceedings 
Of The National Academy Of Sciences Of The United States Of America 82, 6637-6641.
230
Rubin, J.S., Osada, H., Finch, P.W., Taylor, W.G., Rudikoff, S., and Aaronson, S.A. (1989). 
Purification and characterization of a newly identified growth-factor specific for epithelial-cells. 
Proceedings Of The National Academy Of Sciences Of The United States Of America 86, 802-806.
Rucinski B., Niewiarowski S., James P., Walz D.A., and Budzynski A.Z. (1979). Antiheparin proteins 
secreted by human platelets. Purification, characterisation and radioimmunoassay. Blood 53, 47
Ruoslahti E. and Yamaguchi Y. (1991). Proteoglycans as modulators of growth factor activity. Cell 
64, 867-869.
Russell, E.S. (1997). Hereditary Anaemias of the mouse: A review for Geneticists. Advances in 
Genetics 20, 357-459.
Rutledge, B.J., Rayburn, H., Rosenberg, R., North, R.J., Gladue, R.P., Corless, C.L., and Rollins, B.J.
(1995). High-level monocyte chemoattractant protein-1 expression in transgenic mice increases their 
susceptibility to intracellular pathogens. Journal of Immunology 155, 4838-4843.
Sachs L (1992) The molecular control of hematopoiesis: from clonal development in culture to therapy 
in the clinic. International Journal of Cell Cloning 10:196-204.
Salomon B., Lores P., Pioche C., Racz P., Jami J., and Klatzman D. (1994). Conditional ablation of 
dendritic cells in transgenic mice. Journal of Immunology 537-548.
Salomon, D., Saurat, J.H., and Meda, P. (1988). Cell-to-cell communication within intact human-skin. 
Journal Of Clinical Investigation 82, 248-254.
Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, Saragosti S, Lapoumeroulie C, 
Cognaux J, Forceille C, Muyldermans G, Verhofstede C, Burtonboy G, Georges M, Imai T, Rana S, 
Yi Y, Smyth RJ, Collman RG, Doms RW, Vassart G, Parmentier M. (1996) Resistance to HIV-1 
infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. 
Nature 382:722-725.
Sanchez, A., Alvarez, A.M., Benito, M., and Fabregat, I (1996). Apoptosis induced by transforming 
growth-factor-p in fetal hepatocyte primary cultures - involvement of reactive oxygen intermediates. 
Journal of Biological Chemistry 271, 7416-7422.
Sawyers C.L., Denny T.C., and Witte O.N. (1991). Leukaemia and the disruption of normal 
haemopoiesis. Cell 64, 337-350.
Schagger, H. and Vonjagow, G. (1987). Tricine sodium dodecyl-sulfate polyacrylamide-gel 
electrophoresis for the separation of proteins in the range from 1-kda to 100-kda. Analytical 
Biochemistry 166, 368-379.
Schall, T.J., Jongstra, J., Dyer, B.J., Clayberger, C., Davis, M.M., and Krensky, A.M. (1988). 
Molecular characterization of a novel T cell secreted factor and predicted structural similarities with 
other lymphokine-like molecules - a new gene family. Faseb Journal 2, A1447
Schall, T.J., Bacon, K., Toy, K.J., and Goeddel, D.V. (1990). Selective attraction of monocytes and T 
lymphocytes of the memory phenotype by cytokine Rantes. Nature 347, 669-671.
Schall, T.J. (1991). Biology of the Rantes/sis cytokine family. Cytokine 3 , 165-183.
Schall, T.J., Bacon, K., Camp, R.D.R., Kaspari, J.W., and Goeddel, D.V. (1993). Human macrophage 
inflammatory protein-la (M IP-la) and M IP-ip chemokines attract distinct populations of 
lymphocytes. Journal of Experimental Medicine 1 7 7 ,1821-1825.
Schall TJ, Bacon KB (1994). Chemokines, leukocyte trafficking, and inflammation. Current Opinion 
in Immunology 6(6):865-873.
231
Schmid, J. and Weissmann, C. (1987). Induction of mRNA for a serine protease and a (3- 
thromboglobulin-like protein in mitogen-stimulated human leukocytes. Journal of Immunology 139, 
250-256.
Schmidt, G.H., Blount, M.A., and Ponder, B.A.J. (1987). Immunochemical demonstration of the 
clonal organization of chimaeric mouse epidermis. Development 100, 535
Schneider, J.G., Iwata, K.K., Haley, J.D., and Moore, M.A.S. (1993). Transforming growth-factor - |33 
(TGF-|33) protects normal hematopoietic and intestinal mucosal cells from chemotherapy-induced 
cytotoxicities. Blood 82, A 370
Schofield R. (1978). The relationship between the spleen colony forming cell and the haemopoietic 
stem cell. Blood Cells 4, 7-28.
Schofield R. (1983). Microenvironmental control of stem-cell maintenance. Journal of Anatomy 
136:444-445.
Schraufstatter LU, Ma M, Oades Zg, Barritt DS, Cochrane CG. (1995). The role of Tyr(13) and 
Lys(15) of Interleukin-8 in the high-affinity interaction with the Interleukin-8-Receptor type-A. 
Journal Of Biological Chemistry 270: 10428-10431.
Schroder, J.M., Mrowietz, U., Morita, E., and Christophers, E. (1987). Purification and partial 
biochemical-characterization of a human monocyte-derived, neutrophil-activating peptide that lacks 
interleukin-1 activity. Journal of Immunology 139, 3474-3483.
Schroder, J.M., Persoon, N.L.M., and Christophers, E. (1990a). Lipopolysaccharide-stimulated human 
monocytes secrete, apart from neutrophil-activating peptide-l/interleukin-8, a second neutrophil 
activating protein- amino-terminal identity with MGSA. Journal of Experimental Medicine 171, 1091- 
1100 .
Schroder, J.M., Sticherling, M., Henneicke, H.H., Preissner, W.C., and Christophers, E. (1990b). I l- la  
or tumor necrosis factor-a stimulate release of three NAP-l/IL-8 related neutrophil chemotactic 
proteins in human dermal fibroblasts. Journal of Immunology 144, 2223-2232.
Schroder, J.M. and Christophers, E. (1992). 11-8 and gro-like neutrophil attractants in psoriasis. 
Journal of Investigative Dermatology. 98, 505
Schuhmachers, G., Xu, S., Bergstresser, P.R., and Takashima, A. (1995). Identity and functional 
properties of novel skin-derived fibroblast lines (NS series) that support the growth of epidermal- 
derived dendritic cell-lines. Journal of Investigative Dermatology. 105, 225-230.
Schuler, G. (1991). Epidermal Langerhans Cells. In Epidermal Langerhans Cells. G. Schuler, ed. 
(Boca Raton: CRC Press),
Schultzcherry, S. and Murphyullrich, J.E. (1993). Thrombospondin causes activation of latent TGF-J3. 
Journal of Cell Biology 122, 923-932.
Schultzcherry, S., Lawler, J., and Murphyullrich, J.E. (1994a). The type-1 repeats of thrombospondin- 
1 activate latent transforming growth-factor-(3. Journal of Biological Chemistry 269, 26783-26788.
Schultzcherry, S., Ribeiro, S., Gentry, L., and Murphyullrich, J.E. (1994b). Thrombospondin binds 
and activates the small and large forms of latent transforming growth-factor |3 in a chemically-defined 
system. Journal of Biological Chemistry 269, 26775-26782.
Schulzknappe, P., Magert, H.J., Dewald, B., Meyer, M., Cetin, Y., Kubbies, M., Tomeczkowski, J., 
Kirchhoff, K., Raida, M., Adermann, K., Kist, A., Reinecke, M., Sillard, R., Pardigol, A., Uguccioni, 
M., Baggiolini, M., and Forssmann, W.G. (1996). HCC-1, a novel chemokine from human plasma. 
Journal of Experimental Medicine 183, 295-299.
232
Selleri, C., Sato, T., Anderson, S., Young, N.S., and Maciejewski, J.P. (1995). Interferon-y and tumor 
necrosis factor-a suppress both early and late stages of hematopoiesis and induce programmed cell 
death. Journal of Cellular Physiology 165, 538-546.
Selleri, C., Maciejewski, J.P., Sato, T., and Young, N.S. (1996). Interferon-y constitutively expressed 
in the stromal microenvironment of human marrow cultures mediates potent hematopoietic inhibition. 
Blood 87, 4149-4157.
Sellheyer, K., Bickenbach, J.R., Rothnagel, J.A., Bundman, D., Longley, M.A., Krieg, T., Roche, 
N.S., Roberts, A.B., and Roop, D.R. (1993). Inhibition of skin development by overexpression of 
transforming growth-factor-(31 in the epidermis of transgenic mice. Proceedings Of The National 
Academy Of Sciences Of The United States Of America 9 0 ,5237-5241.
Senior, R.M., Griffin, G.L., Huang, J.S., Walz, D.A., and Deuel, T.F. (1983). Chemotactic activity of 
platelet a-granule proteins for fibroblasts. Journal of Cell Biology 96, 382-385.
Seyedin, S.M., Thomas, T.C., Thompson, A.Y., Rosen, D.M., and Piez, K.A. (1985). Purification and 
characterization of 2 cartilage-inducing factors from bovine demineralized bone. Proceedings Of The 
National Academy Of Sciences Of The United States Of America 82, 2267-2271.
Seyedin, S.M., Segarini, P.R., Rosen, D.M., Thompson, A.Y., Bentz, H., and Graycar, J. (1987). 
Cartilage-inducing factor-b is a unique protein structurally and functionally related to transforming 
growth factor-p Journal of Biological Chemistry 2 6 2 ,1946-1949.
Seymour JF.,Lieschke GJ., Grail D., Quilici C., Hodgson G., Dunn AR.(1997) Mice lacking both G- 
CSF and GM-CSF have impaired reproductive capacity, perturbed neonatal granulopoiesis, lung 
disease, amyloidosis, and reduced long-term survival. Blood 90 (8): 3037-3049.
Shah, P.D., Keij, J., Gilbertson, S.M., and Rowley, D.A. (1986). Thy-1 and thy-1- natural-killer cells - 
only thy-l-natural killer cells suppress dendritic cells. Journal of Experimental Medicine 163, 1012- 
1017.
Sherry, B., Tekampolson, P., Gallegos, C., Bauer, D., Davatelis, G., Wolpe, S.D., Masiarz, F., Coit, 
D., and Cerami, A. (1988). Resolution of the 2 components of macrophage inflammatory protein-1, 
and cloning and characterization of one of those components, macrophage inflammatory protein-1 p. 
Journal of Experimental Medicine 168, 2251-2259.
Shibaki, A., Meunier, L., Ra, C.S., Shimada, S., Ohkawara, A., and Cooper, K.D. (1995). Differential 
responsiveness of Langerhans cell subsets of varying phenotypic states in normal human epidermis. 
Journal of Investigative Dermatology. 104, 42-46.
Shieh, J.H., Peterson, R.H.F., and Moore, M.A.S. (1991). Modulation of granulocyte colony- 
stimulating factor receptors on murine peritoneal-exudate macrophages by tumor-necrosis-factor-a. 
Journal of Immunology 146, 2648-2653.
Shipley, G.D., Pittelkow, M.R., Wille, J.J., Scott, R.E., and Moses, H.L. (1986). Reversible inhibition 
of normal human prokeratinocyte proliferation by type-P transforming growth factor-growth inhibitor 
in serum-free medium. Cancer Research 46, 2068-2071.
Shoyab, M., Mcdonald, V.L., Bradley, J.G., and Todaro, G.J. (1988). Amphiregulin - a bifunctional 
growth-modulating glycoprotein produced by the phorbol 12-myristate 13-acetate-treated human- 
breast adenocarcinoma cell-line MCF-7. Proceedings Of The National Academy Of Sciences Of The 
United States Of America 85, 6528-6532.
Shoyab, M., Plowman, G.D., Mcdonald, V.L., Bradley, J.G., and Todaro, G.J. (1989). Structure and 
function of human amphiregulin - a member of the epidermal growth-factor family. Science 2 4 3 ,1074- 
1076.
233
Shull, M.M., Ormsby, I., Kier, A.B., Pawlowski, S., Diebold, R.J., Yin, M.Y., Allen, R., Sidman, C., 
Proetzel, G., Calvin, D., Annunziata, N., and Doetschman, T. (1992). Targeted disruption of the 
mouse transforming growth fact or-pi gene results in multifocal inflammatory disease. Nature 359, 
693-699.
Sillaber, C., Geissler, K., Scherrer, R., Kaltenbrunner, R., Bettelheim, P., Lechner, K., and Valent, P. 
(1992). Type-P transforming growth-factors promote interleukin-3 (IL-3) dependent differentiation of 
human basophils but inhibit IL-3 dependent differentiation of human eosinophils. Blood 80, 634-641.
Siminovitch, L., McCulloch, E.A., and Till, J.E. (1963). The Distribution of Colony Forming Cells 
among Spleen Colonies. Journal of Cellular and Comparative physiology 327-336.
Simmons G., Clapham PR., Picard L., Offord RE., Rosenkilde MM., Schwartz TW., Buser R., Wells 
TNC., Proudfoot AEI. (1997). Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes 
by a novel CCR5 antagonist. Science 276: 276-279.
Simonet, W.S., Hughes, T.M., Nguyen, H.Q., Trebasky, L.D., Danilenko, D.M., and Medlock, E.S.
(1994). Long-term impaired neutrophil migration in mice overexpressing human interleukin-8. Journal 
Of Clinical Investigation 9 4 ,1310-1319.
Sing, G.K., Keller, J.R., Ellingsworth, L.R., and Ruscetti, F.W. (1988). Transforming growth factor-(3 
selectively inhibits normal and leukemic human-bone marrow cell-growth in vitro. Blood 72, 1504- 
1511.
Sitnicka, E., Ruscetti, F.W., Priestley, G.V., Wolf, N.S., and Bartelmez, S.H. (1996). Transforming 
growth-factor-pi directly and reversibly inhibits the initial cell divisions of long-term repopulating 
hematopoietic stem-cells. Blood 88, 82-88.
Siuzdak G. The emergence of mass spectrometry in biochemical research. (1994). Proceedings of the 
National Academy of Science 91: 11290-11297.
Skelton, N.J., Aspiras, F., Ogez, J., and Schall, T.J. (1995). Proton NMR assignments and solution 
conformation of Rantes, a chemokine of the CC type. Biochemistry 34, 5329-5342.
Sleath PR, Hendrickson RC, Kronheim SR, March CJ, Black RA. (1990). Substrate specificity of the 
protease that processes human interleukin-1 beta. Journal of Biological Chemistry 265(24): 14526- 
14528.
Snodgrass R. and Keller G. (1987). Clonal fluctuation within the haemopoietic system of mice 
reconstituted with retrovirus infected cells. EMBO 6, 3955-3960.
Soma, T., Yu, J.M., and Dunbar, C.E. (1996). Maintenance of murine long-term repopulating stem- 
cells in ex-vivo culture is affected by modulation of transforming growth-factor-13 but not macrophage 
inflammatory protein-l-a activities. Blood 87, 4561-4567.
Spangrude G.J., Heimfeld S., and Weissman I.L. (1988). Purification and characterisation of mouse 
haematopoietic stem cells. Science 241, 58-62.
Spangrude, G.J. and Johnson, G.R. (1990). Resting and Activated Subsets of Mouse Pluripotent 
Haematopoietic Stem Cells. Proceedings of the National Academy of Science USA 87, 7433-7437.
Spom, M.B. and Roberts, A.B. (1988). Peptide growth-factors are multifunctional. Nature 332, 217- 
219.
Spom, M.B. and Roberts, A.B. (1992). Transforming growth-factor-(3- recent progress and new 
challenges. Journal of Cell Biology 119, 1017-1021.
234
Standiford, T.J., Kunkel, S.L., Liebler, J.M., Burdick, M.D., Gilbert, A.R., and Strieter, R.M. (1993a). 
Gene-expression of macrophage inflammatory protein-la from human blood monocytes and alveolar 
macrophages is inhibited by interleukin-4. American Journal Of Respiratory Cell And Molecular 
Biology 9, 192-198.
Standiford, T.J., Rolfe, M.W., Kunkel, S.L., Lynch, J.P., Burdick, M.D., Gilbert, A.R., Orringer, 
M.B., Whyte, R.I., and Strieter, R.M. (1993b). Macrophage inflammatory protein-la expression in 
interstitial lung-disease. Journal of Immunology 151, 2852-2863.
Stanley, E., Lieschke, G.J., Grail, D., Metcalf, D., Hodgson, G., Gall, J.A.M., Maher, D.W., Cebon, J., 
Sinickas, V., and Dunn, A.R. (1994). Granulocyte/macrophage colony-stimulating factor-deficient 
mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. 
Proceedings Of The National Academy Of Sciences Of The United States Of America 91, 5592-5596.
Stanley, J.R., Foidart, J.M., Murray, J.C., Martin, G.R., and Katz, S.I. (1980). The epidermal cell 
which selectively adheres to a collagen substrate is the basal cell. Journal of Investigative 
Dermatology. 74, 54-58.
St Charles, R., Walz, D.A., and Edwards, B.F.P. (1989). The 3-dimensional structure of bovine 
platelet factor-4 at 3.0A resolution. Journal of Biological Chemistry 264, 2092-2099.
Steinman, R., Hoffman, L., and Pope, M. (1995). Maturation and migration of cutaneous dendritic 
cells. Journal of Investigative Dermatology. 105, S 2-S 7.
Sticherling, M., Schroder, J.M., and Christophers, E. (1989). Production and characterization of 
monoclonal-antibodies against the novel neutrophil activating peptide NAP/IL-8. Journal of 
Immunology 143, 1628-1634.
Sticherling, M., Bomscheuer, E., Schroder, J.M., and Christophers, E. (1994). Rantes peptide is 
produced and released by human dermal fibroblasts and hematopoietic cell-lines. Journal of 
Investigative Dermatology. 103, 425
Stoeckle MY, Barker KA. (1990). Two burgeoning families of platelet factor 4-related proteins: 
mediators of the inflammatory response. New Biologist. 2(4):313-323.
Strieter, R.M., Kunkel, S.L., Showell, H.J., Remick, D.G., Phan, S.H., Ward, P.A., and Marks, R.M. 
(1989a). Endothelial-cell gene-expression of a neutrophil chemotactic factor by TNF-a, LPS, and IL- 
ip . Science 243, 1467-1469.
Strieter, R.M., Phan, S.H., Showell, H.J., Remick, D.G., Lynch, J.P., Genord, M., Raiford, C., 
Eskandari, M., Marks, R.M., and Kunkel, S.L. (1989b). Monokine-induced neutrophil chemotactic 
factor gene-expression in human-fibroblasts. Journal of Biological Chemistry 2 6 4 ,10621-10626.
Strieter, R.M., Wiggins, R., Phan, S.H., Wharram, B.L., Showell, H.J., Remick, D.G., Chensue, S.W., 
and Kunkel, S.L. (1989c). Monocyte chemotactic protein gene-expression by cytokine-treated human- 
fibroblasts and endothelial-cells. Biochemical And Biophysical Research Communications 162, 694- 
700.
Suda, T., Suda, J., and Ogawa, M. (1983). Proliferative kinetics and differentiation of murine blast cell 
colonies in culture - evidence for variable GO-periods and constant doubling rates of early pluripotent 
hematopoietic progenitors. Journal of cellular physiology 117, 308-318.
Sugarman, B.J., Aggarwal, B.B., Hass, P.E., Figari, I.S., Palladino, M.A., and Shepard, H.M. (1985). 
Recombinant human TNF-a - effects on proliferation of normal and transformed-cells in vitro. Science 
230, 943-945.
Tachibana, T. (1995). The merkel cell - recent findings and unresolved problems. Archives of 
Histology And Cytology 58, 379-396.
235
Taipale J., Miyazono K., and Keski-Oja J. (1994). Latent Transforming Growth Factor-(31 associates 
to fibroblast extracellular matrix via latent TGF-|3 binding protein. Journal of Cell Biology 124, 171- 
181.
Takashima A., and Bergstresser PR. (1996). Cytokine-mediated communication by keratinocytes and 
Langerhans cells with Dendritic epidermal T-cells. Seminars in Immunology 8: 333-339.
Tang, A.M., Amagai, M., Granger, L.G., Stanley, J.R., and Udey, M.C. (1993). Adhesion of epidermal 
Langerhans cells to keratinocytes is mediated by E-cadherin. Nature 361, 82-85.
Tashiro, K., Tada, H., Heilker, R., Shirozu, M., Nakano, T., and Honjo, T. (1993). Signal sequence 
trap - a cloning strategy for secreted proteins and type-1 membrane-proteins. Science 261, 600-603.
Taub, D.D., Lloyd, A., Conlon, K., Matsushima, K., Oppenheim, J., and Kelvin, D. (1993). 
Chemoattraction of T cell subsets by chemokine family members. Journal Of Cellular Biochemistry 99
Taub, D.D., Proost, P., Murphy, W.J., Anver, M., Longo, D.L., Vandamme, J., and Oppenheim, J.J. 
(1995a). Monocyte chemotactic protein-1 (MCP-1), protein-2, and protein-3 are chemotactic for 
human T lymphocytes. Journal Of Clinical Investigation 9 5 ,1370-1376.
Taub, D.D., Sayers, T.J., Carter, C.R.D., and Ortaldo, J.R. (1995b). a-chemokine and |3-chemokine 
induce NK cell-migration and enhance NK-mediated cytolysis. Journal of Immunology 155, 3877- 
3888.
Taub, D.D., Turcovskicorrales, S.M., Key, M.L., Longo, D.L., and Murphy, W.J. (1996). Chemokines 
and T lymphocyte activation. 1. |3 chemokines costimulate human T lymphocyte activation in vitro. 
Journal of Immunology 156, 2095-2103.
Teixido, J., Gilmore, R., Lee, D.C., and Massague, J. (1987). Integral membrane glycoprotein 
properties of the prohormone pro-TGF-a. Nature 326, 883-885.
Tekampolson, P., Gallegos, C., Bauer, D., Mcclain, J., Sherry, B., Fabre, M., Vandeventer, S., and 
Cerami, A. (1990). Cloning and characterization of cDNAs for murine macrophage inflammatory 
protein-2 and its human homologs. Journal of Experimental Medicine 172, 911-919.
Thornton, A.J., Strieter, R.M., Lindley, I., Baggiolini, M., and Kunkel, S.L. (1990). Cytokine-induced 
gene-expression of a neutrophil chemotactic factor IL-8 in human hepatocytes. Journal of Immunology 
144, 2609-2614.
Tiffany HL, Lautens LL, Gao JL, Pease J, Locati M, Combadiere C, Modi W, Bonner TI, Murphy 
PM. (1997). Identification of CCR8: a human monocyte and thymus receptor for the CC chemokine I- 
309. Journal of Experimental Medicine 186(1): 165-170
Tigelaar RE., and Lewis JM. (1995). Immunobiology of mouse dendritic epidermal T-cells: A decade 
later, some answers, but still more questions. Journal of Investigative Dermatology 105: 43S-49S.
Till J.E. and McCulloch E.A. (1961). A direct measurement of the radiation sensitivity of normal 
murine bone marrow cells. Radiation Research 14, 213-222.
Todaro, G.J., Fryling, C., and DeLarco, J.E. (1980). Transforming Growth Factor produced by certain 
human tumour cells: polypeptides that interact with epidermal growth factor receptors. Proceedings Of 
The National Academy Of Sciences Of The United Of America 77, 5258-5262.
Todaro, G.J., Rose, T.M., Spooner, C.E., Shoyab, M., and Plowman, G.D. (1990). Cellular and viral 
ligands that interact with the EGF receptor. Seminars in Cancer Biology. 1, 257-263.
236
Toksoz, D., Zsebo, K.M., Smith, K.A., Hu, S., Brankow, D., Suggs, S.V., Martin, F.H., and Williams, 
D.A. (1992). Support of human hematopoiesis in long-term bone-marrow cultures by murine stromal 
cells selectively expressing the membrane-bound and secreted forms of the human homolog of the 
steel gene-product, st. Proceedings Of The National Academy Of Sciences Of The United States Of 
America 89, 7350-7354.
Tsuji, K., Zsebo, K.M., and Ogawa, M. (1991). Enhancement of murine blast cell colony formation in 
culture by recombinant rat stem-cell factor, ligand for c-kit. Blood 7 8 ,1223-1229.
Tsunawaki, S., Spom, M., Ding, A., and Nathan, C. (1988). Deactivation of macrophages by 
transforming growth factor-(3. Nature 334, 260-262.
Turksen, K., Kupper, T., Degenstein, L., Williams, I., and Fuchs, E. (1992). Interleukin-6 - insights to 
its function in skin by overexpression in transgenic mice. Proceedings Of The National Academy Of 
Sciences Of The United States Of America 89, 5068-5072.
Ueno, H., Gunn, M., Dell, K., Tseng, A., and Williams, L. (1992). A tmncated form of fibroblast 
growth-factor receptor-1 inhibits signal transduction by multiple types of fibroblast growth-factor 
receptor. Journal of Biological Chemistry 2 6 7 ,1470-1476.
Uguccioni, M., Loetscher, P., Forssmann, U., Dewald, B., Li, H.D., Lima, S.H., Li, Y.L., Kreider, B., 
Garotta, G., Thelen, M., and Baggiolini, M. (1996). Monocyte chemotactic protein-4 (MCP-4), a 
novel structural and functional analog of MCP-3 and eotaxin. Journal of Experimental Medicine 183, 
2379-2384.
Unemori, E.N., Homk, R., and Amento, E.P. (1993). A potentially novel melanoma growth 
stimulatory activity (MGSA)/gro receptor on rheumatoid synovial but not normal fibroblasts 
modulates interstitial collagen expression in response to MGSA/gro. Journal Of Cellular Biochemistry 
155
Valente, A.J., Graves, D.T., Viallevalentin, C.E., Delgado, R., and Schwartz, C.J. (1988). Purification 
of a monocyte chemotactic factor secreted by nonhuman primate vascular cells in culture. 
Biochemistry 27, 4162-4168.
Vandamme, J., Vanbeeumen, J., Conings, R., Decock, B., and Billiau, A. (1989). Purification of 
granulocyte chemotactic peptide interleukin-8 reveals N-terminal sequence heterogeneity similar to 
that of P-thromboglobulin. European Journal Of Biochemistry 181, 337-344.
Van Damme J, Rampart M, Conings R, Decock B, Van Osselaer N, Willems J, Billiau A. (1990). The 
neutrophil-activating proteins interleukin 8 and beta-thromboglobulin: in vitro and in vivo comparison 
of NH2-terminally processed forms. European Journal of Immunology 20(9):2113-2118.
Van Damme J. (1991). Interleukin 8 and related molecules. The Cytokine Handbook, Academic Press 
Limited.
Vandamme, J., Proost, P., Lenaerts, J.P., and Opdenakker, G. (1992). Structural and functional 
identification of 2 human, tumour-derived monocyte chemotactic proteins (MCP-2 & MCP-3) 
belonging to the chemokine family. Journal of Experimental Medicine 176, 59-65.
Vassar, R. and Fuchs, E. (1991). Transgenic mice provide new insights into the role of TGF-a 
during epidermal development and differentiation. Genes & Development 5, 714-727.
Verfaillie, C.M. (1993). Soluble factor(s) produced by human bone-marrow stroma increase cytokine- 
induced proliferation and maturation of primitive hematopoietic progenitors while preventing their 
terminal differentiation. Blood 82, 2045-2053.
Verfaillie C.M., Catanzarro P.M., and Wen-na Li. (1994). Macrophage inflammatory product-la, 
interleukin 3 and diffusible marrow stromal factors maintain haematopoietic stem cells for at least 
eight weeks in vitro. Journal of Experimental Medicine 179, 643-649.
237
Vieira, K.B.L., Goldstein, D.J., and Villa, L.L. (1996). Tumor-necrosis-factor-a interferes with the 
cell-cycle of normal and papillomavirus-immortalized human keratinocytes. Cancer Research 56, 
2452-2457.
Vilcek, J., Palombella, V.J., Henriksendestefano, D., Swenson, C., Feinman, R., Hirai, M., and 
Tsujimoto, M. (1986). Fibroblast growth enhancing activity of tumor necrosis factor and its 
relationship to other polypeptide growth-factors. Journal of Experimental Medicine 163, 632-643.
Visser, J.W., Bauman, J.G.J., Mulder, A.H., Eliason, J.F., and de Leeuw, A.M. (1984). Isolation of 
Murine Pluripotent Haematopoietic Stem Cells. Journal of Experimental Medicine 1 5 9 ,1576-1590.
Vonheijne, G. (1986). A new method for predicting signal sequence cleavage sites. Nucleic Acids 
Research 14, 4683-4690.
Wakefield, L.M., Smith, D.M., Flanders, K.C., and Spom, M.B. (1988). Latent transforming growth 
factor-p from human-platelets - a high molecular-weight complex containing precursor sequences. 
Journal of Biological Chemistry 263, 7646-7654.
Wakefield, P.E., James, W.D., Samlaska, C.P., and Meltzer, M.S. (1991). Tumor-necrosis-factor. 
Journal Of The American Academy Of Dermatology 24, 675-685.
Walz, A., Peveri, P., Aschauer, H., and Baggiolini, M. (1987). Purification and amino-acid sequencing 
of naf, a novel neutrophil activating factor produced by monocytes. Biochemical And Biophysical 
Research Communications 149, 755-761.
Walz, A., Dewald, B., Vontschamer, V., and Baggiolini, M. (1989). Effects of the neutrophil- 
activating peptide (NAP-2), platelet basic protein (PBP), connective tissue activating peptide III 
(CTAP-III) and platelet factor-4 (PF4) on human neutrophils. Journal of Experimental Medicine 170, 
1745-1750.
Walz A. and Baggiolini M. (1990). Generation of the neutrophil activating peptide NAP-2 from 
platelet basic protein or connective tissue-activating peptide III through monocyte proteases. Journal 
of Experimental Medicine 171, 449-454.
Walz, A., Burgener, R., Car, B., Baggiolini, M., Kunkel, S.L., and Strieter, R.M. (1991). Structure and 
neutrophil-activating properties of a novel inflammatory peptide (Ena-78) with homology to 
interleukin-8. Journal of Experimental Medicine 174, 1355-1362.
Wang XJ., Greenhalgh DA., Bickenbach JR., Jiang A., Bundman DS., Krieg T., Derynck R. and Roop 
DR. (1997). Expression of a dominant negative type II TGF-(3 receptor in the epidermis of transgenic 
mice blocks TGF-|3 mediated growth inhibition. Proceedings of the National Academy of Science 
USA 94: 2386-2391.
Watt, F.M., Jordan, P.W., and O'Neill, C.H. (1988). Cell shape controls terminal differentiation of 
human epidermal keratinocytes. Proceedings of the National Academy of Science USA 85, 5576- 
5580.
Webb, L.M.C., Ehrengruber, M.U., Clarklewis, I., Baggiolini, M., and Rot, A. (1993). Binding to 
heparan-sulfate or heparin enhances neutrophil responses to interleukin-8. Proceedings Of The 
National Academy Of Sciences Of The United States Of America 90, 7158-7162.
Weber, M., Uguccioni, M., Baggiolini, M., Clarklewis, I., and Dahinden, C.A. (1996). Deletion of the 
NH2-terminal residue converts monocyte chemotactic protein-1 from an activator of basophil mediator 
release to an eosinophil chemoattractant. Journal of Experimental Medicine 183, 681-685.
Wells T.N.C., Guyecoulin F, Bacon KB. (1995). Peptides from the amino-terminus of Rantes cause 
chemotaxis of human T-lymphocytes. Biochemical And Biophysical Research Communications 211: 
100-105.
238
Wells, T.N.C., Power, C.A., Lustinarasimhan, M., Hoogewerf, A.J., Cooke, R.M.,. Chung, C.W., 
Peitsch, M.C., and Proudfoot, A.E.I. (1996). Selectivity and antagonism of chemokine receptors. 
Journal Of Leukocyte Biology 59, 53-60.
Werner, S., Peters, K.G., Longaker, M.T., Fullerpace, F., Banda, M.J., and Williams, L.T. (1992). 
Large induction of keratinocyte growth-factor expression in the dermis during wound-healing. 
Proceedings Of The National Academy Of Sciences Of The United States Of America 89, 6896-6900.
Werner S, Smola H, Liao X, Longaker MT, Krieg T, Hofschneider PH, Williams LT. (1994). The 
function of KGF in morphogenesis of epithelium and reepithelialization of wounds. Science 
266(5186):819-822.
Whyte, A. and Binns, R.M. (1994). Rantes and chemokines in rheumatoid-arthritis. Lancet 343, 1291- 
1292.
Wille J.J.Jr, Pittelkow M.R., Shipley G.D., and Scott R.E. (1984). Integrated control of growth and 
differentiation of normal human prokeratinocytes cultured in serum free medium: clonal analyses, 
growth kinetics, and cell cycle studies. Journal of cellular physiology 121, 31-44.
Williams GT, Smith CA, Spooncer E, Dexter TM, Taylor DR (1990). Haemopoietic colony 
stimulating factors promote cell survival by suppressing apoptosis. Nature 343:76-79.
Williams, M.L. (1991). Lipids in normal and pathological desquamation. In Advances in Lipid 
Research. P.M. Elias, ed. (New York: Academic Press), pp. 211-252.
Wilm M., Shevchenko A., Houthaeve T., Breit S., Schweigerer L., Fotsis T., and Mann M. Femtomole 
sequencing of proteins from polyacrylamide gels by nano-electrospray mass spectrometry. (1996). 
Nature 379: 466-469.
Wilson I.B., Gavel Y., and Heijne G. (1991). Amino acid distribution around O-linked glycosylation 
sites. Biochemical Journal 275, 529-534.
Wilson KP, Black JA, Thomson JA, Kim EE, Griffith JP, Navia MA, Murcko MA, Chambers SP, 
Aldape RA, Raybuck SA. (1994). Structure and mechanism of interleukin-1(3 converting enzyme. 
Nature 370(6487):270-275.
Wilson, S.D., Kuchroo, V.K., Israel, D.I., and Dorf, M.E. (1990). Expression and characterization of 
TCA3 - a murine inflammatory protein. Journal of Immunology 145, 2745-2750.
Wineman, J., Moore, K., Lemischka, I., and Mullersieburg, C. (1996). Functional-heterogeneity of the 
hematopoietic microenvironment -rare stromal elements maintain long-term repopulating stem-cells. 
Blood 87, 4082-4090.
Witt DP, Lander AD. (1994). Differential binding of chemokines to glycosaminoglycan 
subpopulations. Current Biology 4(5):394-400.
Wolfe N.S. and Priestley G.V. (1986). Kinetics of early and late spleen colony development. 
Experimental Haematology 14, 676-682.
Wolpe, S.D., Davatelis, G., Sherry, B., Beutler, B., Hesse, D.G., Nguyen, H.T., Moldawer, L.L., 
Nathan, C.F., Lowry, S.F., and Cerami, A. (1987). Macrophages secrete a novel heparin-binding 
protein with inflammatory and neutrophil chemokinetic properties. Journal Of Leukocyte Biology 42, 
618
Wolpe, S.D., Davatelis, G., Sherry, B., Beutler, B., Hesse, D.G., Nguyen, H.T., Moldawer, L.L., 
Nathan, C.F., Lowry, S.F., and Cerami, A. (1988). Macrophages secrete a novel heparin-binding 
protein with inflammatory and neutrophil chemokinetic properties. Journal of experimental medicine 
167, 570-581.
Wright, N. and Allison, M. (1984). The Biology of Epithelial Stem Cells. In "The Biology of 
Epithelial Cell Populations." OUP
239
Wu, A.M., Till, J.E., Siminovitch, L., and McCulloch, E.A. (1967). A Cytological Study of the 
Capacity for Differentiation of Normal Hemopoietic colony-forming cells. Journal of Cellular 
Physiology 69, 177-184.
Wu, J., Dent, P., Jelinek, T., Wolfman, A., Weber, M.J., and Sturgill, T.W. (1993). Inhibition of the 
EGF-activated map kinase signaling pathway by adenosine-3',5'-monophosphatc. Science 262, 1065- 
1069.
Xu, S., Ariizumi, K., Edelbaum, D., Bergstresser, P.R., and Takashima, A. (1995a). Cytokine- 
dependent regulation of growth and maturation in murine epidermal dendritic cell-lines. European 
Journal Of Immunology 25, 1018-1024.
Xu, S., Bergstresser, P.R., and Takashima, A. (1995b). Phenotypic and functional-heterogeneity 
among murine epidermal derived dendritic cell clones. Journal of Investigative Dermatology. 105, 
831-836.
Yamamura, Y., Hattori, T., Obam, K., Sakai, K., Asou, N., Takatsuki, K., Ohmoto, Y., Nomiyama, H., 
and Shimada, K. (1989). Synthesis of a novel cytokine and its gene (LD78): expression in 
hematopoietic fresh tumour-cells and cell-lines. Journal Of Clinical Investigation 8 4 ,1707-1712.
Yayon A., Klagsbrun M., Esko J.D., Leder P., and Omitz D.M. (1991). Cell surface heparin like 
molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 
64, 841-848.
Ying, S., Meng, Q., Tabordabarata, L., Corrigan, C.J., Barkans, J., Assoufi, B., Moqbel, R., Durham, 
S.R., and Kay, A.B. (1996). Human eosinophils express mRNA encoding Rantes and store and 
release biologically-active Rantes protein. European Journal Of Immunology 26, 70-76.
Yoshida, H., Hayashi, S.I., Kunisada, T., Ogawa, M., Nishikawa, S., Okamura, H., Sudo, T., Shultz, 
L.D., and Nishikawa, S.I. (1990). The murine mutation osteopetrosis is in the coding region of the 
macrophage colony stimulating factor gene. Nature 345, 442-444.
Yoshimura, T., Matsushima, K., Appella, E., Oppenheim, J.J., and Leonard, E.J. (1987). Purification 
of human neutrophil chemotactic factor produced by lipopolysaccharide (LPS)-stimulated human- 
monocytes. Journal Of Leukocyte Biology 42, 363
Yoshimura, T; Robinson, EA; Tanaka, S; Appella, E; Leonard, EJ. (1989a). Purification and amino- 
acid analysis of 2 human monocyte chemoattractants produced by phytohemagglutinin-stimulated 
human blood mononuclear leukocytes. Journal of Immunology. 142: 1956-1962.
Yoshimura, T; Robinson, EA; Tanaka, S; Appella, E; Kuratsu, JI; Leonard, EJ. (1989b). Purification 
and amino-acid analysis of 2 human glioma-derived monocyte chemoattractants. Journal of 
Experimental Medicine 169: 1449-1459.
Yoshimura, T. and Leonard, E.J. (1990). Secretion by human fibroblasts of monocyte chemoattractant 
protein-1, the product of gene JE. Journal of Immunology 144, 2377-2383.
Youn BS, Zhang SM, Broxmeyer HE, Cooper S, Antol K, Fraser M Jr, Kwon BS
(1998).Characterization of CK|3 8 and CK|3 8-1: two alternatively spliced forms of human beta- 
chemokine, chemoattractants for neutrophils, monocytes, and lymphocytes, and potent agonists at CC 
chemokine receptor 1. Blood 91(9):3118-3126.
Zagury D, Lachgar A, Chams V, Fall LS, Bernard J, Zagury JF, Bizzini B, Gringeri A, Santagostino E, 
Rappaport J, Feldman M, O'Brien SJ, Bumy A, Gallo RC. (1998). C-C chemokines, pivotal in 
protection against HIV type 1 infection. Proceedings of the National Academy of Science 95(7):3857- 
3861
Zhang, K., Gharaeekermani, M., Jones, M.L., Warren, J.S., and Phan, S.H. (1994). Lung monocyte 
chemoattractant protein-1 gene-expression in bleomycin induced pulmonary fibrosis. Journal of 
Immunology 153, 4733-4741.
240
Zhang, Y.J., Rutledge, B.J., and Rollins, B.J. (1994). Structure/activity analysis of human monocyte 
chemoattractant protein-1 (MCP-1) by mutagenesis - Identification of a mutated protein that inhibits 
MCP-1-mediated monocyte chemotaxis. Journal of Biological Chemistry 269, 15918-15924.
Zhang, Y.J. and Rollins, B.J. (1995). A dominant-negative inhibitor indicates that monocyte 
chemoattractant protein-1 functions as a dimer. Molecular and Cellular Biology 15, 4851-4855.
Zipfel, P.F., Balke, J., Irving, S.G., Kelly, K., and Siebenlist, U. (1989). Mitogenic activation of 
human T-cells induces 2 closely related genes which share structural similarities with a new family of 
secreted factors. Journal of Immunology 142, 1582-1590.
Zoumbos, N.C., Gascon, P., Djeu, J.Y., and Young, N.S. (1985). Interferon is a mediator of 
hematopoietic suppression in aplastic anaemia. Proceedings Of The National Academy Of Sciences Of 
The United States Of America 8 2 ,188-192.
